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Summary 
 
Summary 
 
Overexpression of the transmembrane heparan sulfate proteoglycan Syndecan-1 (Sdc-1) 
and the HGF receptor c-Met in breast cancer correlates with poor clinical outcome. We 
investigated a potential coreceptor requirement of Sdc-1 for HGF/c-Met -signaling using 
an in vitro siRNA approach. In human MDA-MB-231 breast cancer cells, HGF-induced 
c-Met-, p44/42 MAPK-, p38 MAPK- and AKT/PKB-phosphorylation were reduced 
following Sdc-1 siRNA-mediated knockdown, resulting in decreased HGF-specific cell 
proliferation and migration. Similarly, HGF-treated control cells showed a significant 
acceleration of wound closure compared to Sdc-1-depleted cells. Surprisingly, Sdc-1 
depletion massively increased cancer cell invasiveness in Matrigel chamber assays 
independent of HGF. Adhesion to fibronectin and laminin and basal cell proliferation 
were increased upon Sdc-1 depletion. In vitro adhesion of Sdc-1 siRNA-transfected cells 
to fibronectin and laminin was significantly enhanced sompared to controls. Sdc-1 
cytoplasmic domain-specific antibodies co-immunoprecipitated FAK, and FAK 
phoshorylation was increased in Sdc-1-deficient cells. Affymetrix gene array screening 
and confirmatory qPCR and Western blot analysis revealed upregulation of ATF-2, 
COX-2, cadherin-11, vinculin, ACTG2, MYL9, TAGLN, RhoA/C, MMP-2 and HPSE, 
and downregulation of RUNX1/AML1, E-cad, Claudin-1, p21 Waf1/Cip1, CDK6, TLR-4, 
PAI-1/2, COL1A2, JHDM1D, MPP4, MMP-9, matrilin-2 and ANXA3/A10. Expression 
changes of of p21 Waf1/Cip1 and COX-2 were linked to Sdc-1-dependent Rho GTPase 
activation, since their expression levels were extremely inhibited in Sdc-1-depleted cells 
post Y27632 treatment. Time-lapse video microscopy revealed massively increased Rho 
kinase-dependent motility of Sdc-1-depleted cells, which displayed increased filopodia 
formation. Ectopic expression of the microRNA miR-10b induced posttranscriptionally 
downregulation of Sdc-1 expression as confirmed by 3’UTR luciferase activation assays, 
and generated a phenocopy of the invasive and migratory phenotype of Sdc-1-depleted 
cells. Finally, our data implicate Sdc-1 as a potential modulator of E-cad and TAGLN 
expression in MDA-MB-231 cells overexpressing miR-10b, which negatively regulates 
Sdc-1 expression. Our results establish a coreceptor function of the novel miR-10b target 
Sdc-1 for HGF/c-Met signaling in breast cancer, and identify a novel HGF-independent 
Sdc-1 pathway. Altered FAK and Rho-pathway activation are associated with differential 
expression of the transcription factors ATF-2 and RUNX1/AML1, thus modulating 
expression of multiple key regulators and effector molecules of cell cycle progression and 
metastasis. Our results also underscore the multitude of Sdc-1 functions in breast cancer 
Summary 
 
pathogenesis that substantially depend on the coexpression pattern of receptor tyrosine 
kinases, matrix substrates, proteases and heparanase. Taken together, this study provides 
new molecular insights into the mechanisms underlying Sdc-1-mediated HGF-dependent 
and -independent cancer metastasis and could establish Sdc-1 based breast cancer 
therapeutic approaches. 
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 1 
1 Introduction 
1.1 c-Met 
Receptor tyrosine kinases (RTKs) are key regulators of multiple processes relevant to 
breast cancer progression, including cell proliferation, cell adhesion, migration, 
angiogenesis, and gene expression (Lemmon and Schlessinger, 2010; Menashe et al., 
2010; Peruzzi and Bottaro, 2006).  c-Met, a cell surface RTK for hepatocyte growth factor 
(HGF), is expressed on epithelial cells of many organs, including breast epithelium 
(Bottaro et al., 1991; Cooper et al., 1984).  
 
 1.1.1 c-Met molecular structure 
c-Met is synthesized as a single-chain precursor protein (Bottaro et al., 1991; Naldini et 
al., 1991). This precursor receptor is proteolytically cleaved to produce a glycosylated 
alpha-chain subunit (50 kDa) and a transmembrane beta- chain subunit (145 kDa), which 
are linked by a disulfide bond to form the mature receptor (Rodrigues et al., 1991) (Fig. 
1.1). The extracellular portion of c-Met, which is responsible for binding to HGF, 
contains a Sema domain (homologous to semaphorins), a cysteine-rich 
Met-related-sequence (MRS) domain, and four immunoglobulin-like structures (IgG 
domain) (Rodrigues et al., 1991). The intracellular portion of c-Met, which is responsible 
for signal transduction, is composed of a juxtamembrane domain, a tyrosine kinase 
domain, and a C-terminal regulatory tail (Bardelli et al., 1994). 
 
1.1.2 The c-Met signaling pathway in cancer 
HGF binding induces c-Met receptor homodimerization and autophosphorylation of two 
critical tyrosine residues (Y1234 and Y1235) within the catalytic site, regulating kinase 
activity (Longati et al., 1994). Autophosphorylation of tyrosines Y1349 and Y1356, 
docking sites located within the carboxyl terminal tail, recruits the intracellular adaptor 
proteins leading to downstream signaling (Ponzetto et al., 1993; Ponzetto et al., 1994). As 
a consequence of c-Met activation, a multiple of physiological processes including 
proliferation, invasion, and angiogenesis are induced. Invasive growth occurs under 
normal physiological conditions during embryonic development, postnatal hepatic and 
cardiac injury repair, while it occurs pathologically during oncogenesis. Activation of the 
c-Met receptor augments proliferation and survival through a variety of downstream 
signaling pathways. The RAS-mitogen-activated protein kinase (MAPK) signaling 
pathway is responsible for mitogenesis, growth and plays a critical role in morphogenesis, 
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the epithelial-to-mesenchymal transition (EMT) through loss of intracellular adhesion via 
cadherins, focal adhesion kinase (FAK), and integrins, resulting in changes in cell shape 
(Boccaccio and Comoglio, 2006). Moreover, activation of phosphatidylinositol-3-kinase 
(PI3 kinase) and subsequent AKT pathway activation inhibits apoptosis (Derksen et al., 
2003; Fan et al., 2000; Xiao et al., 2001). Mechanistically, c-Met inhibits apoptosis via 
the integration between PI3 kinase-AKT pathway and the RAS-MAPK pathway (Tulasne 
and Foveau, 2008; Zeng et al., 2002).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.1 Mature c-Met is composed of a glycosylated alpha subunit and a transmembrane 
beta subunit. The extracellular region of mature c-Met contains a Sema domain, a 
cysteine-rich Met-related sequence (MRS) domain, and four immunoglobulin-like 
structure domain (IgG). The intracellular region is composed of a juxtamembrane domain, 
a tyrosine kinase domain, and a C-terminal regulatory tail (modified from You and 
McDonald, 2008). 
 
It has been reported that c-Met crosstalks to epidermal growth factor receptor (EGFR) 
and interacts with the laminin receptor α6β4 integrin, the semaphorin receptors of the 
plexin B family, and the v6 splice variant of the hyaluronan receptor CD44 (Comoglio et 
al., 2008; Guo et al., 2008; Knudsen and Vande, 2008). Crosstalk and interaction of c-Met 
and membrane partners facilitate the activation of c-Met and allow for the integration of 
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signals present in the extracellular environment (Migliore and Giordano, 2008). Data 
from cellular and animal tumor models demonstrates that c-Met mediates tumorgenicity 
by different mechanisms: (1) establishment of HGF/c-Met autocrine loops; (2) 
overexpression of HGF or c-Met; and (3) constitutive c-Met activation by its tyrosine 
kinase domain mutations (Benvenuti and Comoglio, 2007; Gentile et al., 2008; Schmidt 
et al., 1997). Overexpression of HGF and c-Met is associated with poor prognosis in 
cancer and an indicator of increased invasiveness (Boccaccio and Comoglio, 2006). 
Angiogenesis is promoted by HGF/c-Met signaling by inducing proliferation and 
migration in endothelial cells, expression of vascular endothelial growth factor (VEGF), 
and massive downregulation of thrombospondin-1 (TSP-1), a negative regulator of 
angiogenesis (Rosen and Goldberg, 1995; Zhang et al., 2003). Altered c-Met signaling 
has been reported in a wide range of human malignancies, including bladder, breast, 
cervical, colorectal, gastric, head and neck, liver, lung, ovarian, pancreatic, prostrate, 
renal, and thyroid cancers, as well as in various sarcomas, hematopoietic malignancies, 
and melanoma (Birchmeier et al., 2003; Peruzzi and Bottaro, 2006; Trusolino and 
Comoglio, 2002). Of particular relevance for this thesis are reports which demonstrated 
that cell surface heparan sulfate proteoglycan (HSPG) facilitates HGF signaling via 
interaction with c-Met (Rubin et al., 2001). 
 
1.2 Glycosaminoglycans  
Glycosaminoglycans (GAGs) are linear sulfated heterogeneous negatively charged 
carbohydrates called mucopolysaccarides because of their viscous and lubricating 
properties. They have molecular weights of roughly 10–100 kDa (Gandhi and Mancera, 
2008) and interact with a wide range of proteins involved in physiological and 
pathological processes (Casu and Lindahl, 2001; Jackson et al., 1991). Proteoglycans 
(PGs) are composed of GAGs covalently attached to core proteins. Virtually all 
mammalian cells produce PGs and either secrete them into the extracellular matrix 
(ECM), insert them into the plasma membrane, or store them in secretory granules 
(Bernfield et al., 1999). GAGs and PGs are ubiquitously expressed in the ECM, and some 
are known to bind and regulate the function of a number of discrete proteins, including 
chemokines, cytokines, growth factors, and adhesion molecules (Gandhi and Mancera, 
2008). GAGs chains consists of disaccharide repeating units that are composed of uronic 
acid (D-glucoronic acid or L-iduronic acid) and amino sugars (D-galactosamine or 
D-glucosamine). Hence, GAGs are varied according to the type of hexosamine, hexose or 
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hexuronic acid unit that they contain, as well as the geometry of the glycosidic linkage 
between these units (Capila and Linhardt, 2002; Sasisekharan and Venkataraman, 2000). 
 
1.2.1 Nomenclature of glycosaminoglycans 
Most of the monosaccharides are in the d-configuration, except for iduronic acid (IdoA) 
and all of them are assumed to be in the pyranose (p) form (six-membered ring), while all 
glycosidic linkages are assumed to originate from the anomeric C1 hydroxyl group. 
These monosaccharides are further classified according to the substitution position and 
the substituent (such as O-sulfate). The amino sugar may be sulfated on carbons 4 or 6 or 
on the non-acetylated nitrogen. However, the sugar backbone of GAGs can be sulfated at 
various positions. If sulfate is attached to the C2 carbon of iduronic acid, it is referred to 
as IdoA2S. Sulfation at positions 2 and 6 in N-acetylglucosamine can be written as 
GlcNS6S. The glycosidic linkage between the monosaccharides is in either α or β 
configuration, involving the anomeric hydroxyl of one monosaccharide and any available 
hydroxyl group in a second monosaccharide. For example, α (1→4) refers to the α 
linkage in a disaccharide between the anomeric carbon of the first monosaccharide and 
the hydroxyl at position 4 of the other monosaccharide. The name begins at the 
non-reducing end (which is usually highly sulfated) proceeding towards the reducing end 
(the sugar with the free anomeric carbon that can be oxidized) (Sharon, 1986). In addition, 
all carboxylic acid and sulfate groups are deprotonated at physiological pH, giving GAGs 
very high negative charge densities (heparin has the highest negative charge density of 
any known biomolecule) (Bulow and Hobert, 2006; Esko and Lindahl, 2001; Gandhi and 
Mancera, 2008; Iozzo, 1998; Kjellen and Lindahl, 1991; Lander and Selleck, 2000; 
Oldberg et al., 1990; Perrimon and Bernfield, 2001; Seidler and Dreier, 2008). 
 
1.2.2 Types of glycosaminoglycans  
1.2.2.1 Non-sulfated glycosaminoglycans 
Hyaluronic acid (HA) (Fig. 1.2) is the only GAG which is not sulfated and not covalently 
linked to a core protein. It is composed of repeating disaccharides in which 
N-acetylglucosamine and glucuronic acid are combined by β-1,3 and β-1,4 linkage (Itano, 
2008; McDonald and Hascall, 2002). It is found in the ECM and intracellularly (Hascall 
et al., 2004). HA binds to a variety of proteins and PGs, denoted as hyalectans (see below) 
(Day and Prestwich, 2002). HA acts as a signaling molecule by interaction with CD44, 
RHAMM (receptor for HA mediated motility expressed protein), LYVE-1 (lymphatic 
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vessel endothelial HA receptor-1, and HARE (HA receptor for endocytosis, stabillin-2) 
eliciting diverse signaling pathways, such as Ras, MAPK, c-Src, PI3kinase/AKT, thereby 
modulating cell growth, differentiation, adhesion, and motility and influencing 
embryonic development, tumorigenesis, atherosclerosis, and lung and kidney injury 
(Itano, 2008; Jiang et al., 2007; Wight, 2008). 
 
1.2.2.2 Sulfated glycosaminoglycans 
These types of GAGs can be divided into (Gandhi and Mancera, 2008): 
 
a) Galactosaminoglycans 
These include chondroitin sulfate (CS), dermatan sulfate (DS) (Fig. 1.2). The repeating 
disaccharide units are composed of glucuronic acid or its epimer, iduronic acid, linked to 
an amino sugar galactosamine. 
 
b) Glucosaminoglycans 
These include heparin and heparan sulfate (HS) (Fig. 1.2). The repeating disaccharide 
units are composed of glucuronic acid or its epimer, iduronic acid, linked to an amino 
sugar, glucosamine. 
Galactosaminoglycans and Glucosaminoglycans are linked to their respective protein 
cores via serine residues and a linkage tetrasaccharide 
(Serine->Xylose-Galactose-Galactose-Uronic acid). 
 
c) Keratan sulfate  
Keratan sulfate (KS) consists of Galactose (Gal) and N-acetylglucosamine (GlcNAc) and 
can be synthesized on N-linked oligosaccharides and on serine/ threonine O-linked 
oligosaccharides, which are distinct from the linkage regions of all other GAGs (Fig. 1.2). 
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1.3 Proteoglycans classification 
1.3.1 Small leucine-rich proteoglycans  
Small leucine-rich proteoglycans (SLRPs) are charactrized by a protein core with 
leucine-rich repeats (LRRs), the presence of N-terminal cysteine clusters and “ear 
repeats” (classes I–III), and at least one GAG side chain (Huxley-Jones et al., 2007; Iozzo, 
1998; Iozzo, 1999; McEwan et al., 2006; Schaefer and Iozzo, 2008). Based on 
conservation and homology at the protein and genomic level, cysteine-rich regions, and 
chromosomal organization, the family of SLRPs is divided into five sub-families, 
including the traditionally defined classes I–III and the non-canonical classes IV and V 
(Schaefer and Iozzo, 2008). SLRPs comprise the dermatan/chondroitin 
sulfate-substituted decorin and biglycan; and the keratan sulfate-substituted fibromodulin 
and lumican. Decorin, biglycan and fibromodulin are capable of binding, albeit with low 
affinity, different isoforms of transforming growth factor-β (TGF-β) (Hildebrand et al., 
1994). Biglycan acts as an endogenous ligand of Toll-like receptor 2 (TLR2) and TLR4 
(Schaefer et al., 2005) upon its release from the ECM or by secretion from macrophages, 
whereas lumican (KS PG) is involved in the presentation of bacterial lipopolysaccharides 
to TLR4/CD14, hence SLRPs are considered as a part of innate immune response. 
Mutations in SLRP genes are mostly associated with abnormalities of the eye, the ear 
repeat lacking decorin cause congenital dystrophy of the cornea (Bredrup et al., 2010). 
On the other hand, decorin deficiency in mice leads to enhanced skin fragility similar to 
that in Ehlers-Danlos syndrome in humans  (Danielson et al., 1997),whereas lack of 
biglycan causes osteoporosis and spontaneous aortic dissection (in male animals only). 
Moreover, disruption of the fibromodulin gene is associated with ectopic tendon 
ossification and osteoarthritis (Ameye et al., 2002). 
 
1.3.2 Modular proteoglycans or the large molecular weight 
proteoglycans  
The modular PGs are a heterogeneous group characterized by the assembly of various 
protein modules in an elongated and often highly glycosylated structure that are divided 
into two subfamilies of hyalectans (HA- and lectin-binding PGs) and the non-HA-binding 
PGs (Iozzo, 1998; Iozzo and Murdoch, 1996; Schaefer and Schaefer, 2010). This group is 
further divided into two subfamilies of hyalectans (HA- and lectin-binding PGs) and the 
non-HA-binding PGs (Iozzo, 1998; Schaefer and Schaefer, 2010). The members of this 
family with their tissue distribution and functions are summarized in Table 1. 
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Table 1.1 Modular proteoglycans (taken from Schaefer and Schaefer, 2010). 
 
 
Modular PGs 
 
 
Proteoglycans 
(GAGs) 
 
Tissue distribution 
 
Major functions 
Hyalectans/ 
Lecticans 
a.Versican (CS/ 
DS) 
 
Blood vessels, 
CNS, 
skin, cartilage 
 
 
Regulation of cell 
(mainly ASMC) 
adhesion, migration 
and proliferation, 
ECM assembly, 
fibrillogenesis of 
elastic fibers; 
endogenous ligand 
of 
TLR2 
 
 b. Aggrecan (CS/ 
KS) 
 
Cartilage, CNS, 
blood vessels 
 
Regulation of 
cartilage 
development, 
growth and 
homeostasis 
 
 c. Neurocan (CS) 
 
CNS 
 
Inhibition of 
neuronal 
attachment and 
neurite outgrowth 
 
 d. Brevican 
 
CNS 
 
Inhibition of 
neurite outgrowth 
 
Non-hyaluronan 
binding PGs 
a. Perlecan (HS/ 
CS) 
 
BM, cartilage, 
connective tissue 
stromas 
Signaling, 
pro-angiogenic 
(proliferative 
and migratory 
pathways), 
collagen 
fibrillogenesis, 
apoptosis; 
C-terminal 
domain: 
Endorepellin, 
anti-angiogenic 
 
 b. Agrin (HS) 
 
BM, 
neuro-muscular 
junctions, immune 
system, 
chondrocytes 
Modulator of 
synaptogenesis, 
AChR aggregation, 
T-cell signaling, 
skeletogenesis 
 
 c. Testicans (1–3), 
BM-40/ 
Seminal fluid, 
brain, 
Neuronal 
attachment, MMP 
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SPARC/osteonectin 
family 
(CS/HS) 
 
cartilage 
 
and 
cathepsin L 
inhibition 
 
 
 d. Phosphacan 
(CS/KS) 
 
CNS 
 
Cell-specific 
regulation of 
neurite 
Outgrowth 
 
 e. Collagen IX 
(CS/DS) 
 
Cartilage, 
intervertebral disc, 
embryonic tissue 
(corneal stroma, 
skin, CNS) 
 
Regulation of 
cartilage collagen 
fibril formation, 
stabilization of 
cartilage 
 
 f. Collagen XV 
(CS) 
 
 
Vascular, neuronal, 
mesenchymal, BM 
Zone 
Responsible for 
capillary integrity; 
NC1 domain: 
Endostatin-like 
(Restin), 
anti-angiogenic 
 
 g. Collagen XVIII 
(HS) 
 
BM zone Effects on growth 
factors and 
angiogenesis, cell 
adhesion, motility, 
apoptosis; NC1 
domain: 
Endostatin, 
anti-angiogenic 
 
 
(AChR acetylcholine receptor, ASMC arterial smooth muscle cell, BM basement 
membrane, CNS central nervous system, CS chondroitin sulfate, DS dermatan sulfate, 
ECM extracellular matrix, HS heparan sulfate, MMP matrix metalloproteinase, PG 
proteoglycan, SPARC secreted protein, acidic and rich in cysteine, TLR Toll-like 
receptor. (reviewed by Bix and Iozzo, 2008; Carter and Raggio, 2009; Farach-Carson and 
Carson, 2007; Iozzo, 1998, 2005; Iozzo and Murdoch, 1996; Lin, 2004; Myers et al., 
2007; Rodgers et al., 2008). 
 
1.3.3 Cell-surface heparan sulfate proteoglycans  
HSPGs are common constituents of cell surfaces and ECM (Bernfield et al., 1999). HS 
are absent in protista, plantae and fungi, and their appearance in the animal kingdom 
coincides with the emergence of eumetazoa, which are animals that display true tissues, 
being ubiquitously found in all tissues and species analyzed (Cassaro and Dietrich, 1977; 
Dietrich et al., 1977, 1980; Gomes and Dietrich, 1982; Nader et al., 1984; Toledo and 
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Dietrich, 1977). At the cell surface, HSPGs could be classified into two families 
(Bernfield et al., 1999; Nader et al., 1984) (Fig. 1.3): 
 
1.3.3.1 Glycosylphosphatidylinositol-anchored glypicans  
Glycosylphosphatidylinositol-anchored glypicans (GPCs) are HSPGs anchored to the 
cell surface via a glycosylphosphatidylinositol (GPI). In mammals, GPCs are divided into 
six families (GPC1 to GPC6) (Fico et al., 2007; Filmus and Selleck, 2001). The main 
function of GPCs is to modulate the signaling of fibroblast growth factor (FGF), Wnts, 
Hedgehogs and bone morphogenetic proteins (BMPs). (Lin and Perrimon, 1999; 
Ohkawara et al., 2003; Topczewski et al., 2001; Yan and Lin, 2007).  
 
Interestingly, GPCs have paradox activity depending on the context. It has been reported 
that GPCs have stimulatory mechanism through facilitating and/or stabilizing the 
interaction of Wnts with their signaling receptors, the Frizzled proteins (Capurro et al., 
2005). On the other hand, the inhibitory mechanism of GPC3 was elucidated for 
Hedgehog protein signaling during development by competing with Patched, the 
Hedgehog receptor (Capurro et al., 2008). Intriguingly, the regulatory activity of 
glypicans in the Wnt, Hedgehog and BMPs signaling pathways is only partially 
dependent on the HS chains. GPCs can be shed (see below) and released from the cell 
surface into ECM by a lipase, Notum, which cleaves the GPI anchor (Kreuger et al., 2004; 
Traister et al., 2008) and most of them are endoproteolytic cleaved by furin-like 
convertases (De Cat et al., 2003). 
 
1.3.3.2 Membrane- spanning syndecans 
The syndecans are type I transmembrane cell surface HSPGs and are ubiquitous in 
metazoans. A single syndecan gene was identified in invertebrates and primitive 
chordates whereas four syndecan genes are expressed in mammals and are divided into 
two subfamilies consisting of syndecan-1 (Sdc-1) and -3 (Sdc-3), and -2 (Sdc-2) and -4 
(Sdc-4), respectively (Bernfield et al., 1999; Chakravarti and Adams, 2006; Couchman et 
al., 2001). The classification is based on the presence of GAG substitution sites situated 
close to the transmembrane domain of Sdc-1 and Sdc-3. Syndecan family members have 
distinct expression patterns; Sdc-1 occurs principally in epithelial cells, Sdc-2 in 
mesenchymal cells including endothelia and Sdc-3 in neuronal cells, while Sdc-4 is 
exceptional in that it is expressed on virtually on all cell types (albeit at low levels) (Kim 
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et al., 1994). Invertebrate syndecans are associated with the formation of neural networks 
and function principally as regulators of growth factor signaling (Rawson et al., 2005; 
Rhiner et al., 2005).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.3 Schematic depiction of cell surface heparan sulfate proteoglycans (HSPGs). 
Syndecans are transmembrane proteins that bear HS chains distal from the plasma 
membrane. Some syndecans also contain chondroitin sulfate (CS) chains, which, as in the 
case of syndecan-1, are close to the plasma membrane. Based on their high proline 
content, the syndecan ectodomains are likely extended proteins. Glypicans are covalently 
linked to a phosphatidyl inositol in the outer leaflet of the plasma membrane. The HS 
chains are located on a likely extended protein domain near the plasma membrane. The 
glypican ectodomains are presumably compact and globular proteins due to their 
characteristic 14 conserved cysteine residues. The disulfide bonds shown here are 
arbitrary (modified from Bernfield et al., 1999). 
 
a) Syndecan structure 
All syndecans have a short cytoplasmic domain, a transmembrane domain and a longer 
extracellular domain, and each domain contributes to syndecan function (Fig. 1.4). 
 
The extracellular domain (ectodomain) 
The ectodomains of syndecans are sequence-divergent except for GAG attachment, cell 
interaction, proteolytic cleavage and oligomerization. The saccharide units are attached to 
the core protein, at a serine- glycine sequence located within consensus regions rich in 
acidic residues (Esko and Zhang, 1996), through a tetrasaccharide linker of 
xylose-galactose-galactose-uronic acid. Sdc-1, -3 and -4 also contain ser-gly sequences 
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close to the plasma membrane that may serve as attachment sites for CS. All syndecans 
can be shed from the cell surface by proteolytic cleavage near the plasma membrane (see 
below). It was assumed that the syndecan core protein had a few functions but it has been 
recently shown that unglycosylated ectodomains of Sdc-1,-3 and-4 can modulate integrin 
mediated cell adhesion (Whiteford and Couchman, 2006). In contrast, the interaction 
between β1 integrin and the Sdc-2 and -4 ectodomains is indirect and occurs through 
distinct receptors (Whiteford et al., 2007). Clustering of Sdc-1 with cognate antibodies 
results in αVβ3 and αVβ5 integrin-mediated attachment and spreading in MDA-MB-231 
cells and B82L fibroblasts, respectively. This can be compromised via deletion of 
residues 88–252 within the Sdc-1 ectodomain and is HS-independent (Beauvais et al., 
2004; McQuade et al., 2006). 
 
Transmembrane domain 
The transmembrane region of syndecans is highly conserved between the four members 
of the syndecan family. It contains a GXXXG motif that strongly promotes dimerization 
that is substantially SDS-resistant in solution (Choi et al., 2005; Dews and Mackenzie, 
2007). The valency of syndecans is increasesd by multimerisation, hence enhancing their 
interaction with the ECM ligands and may modulate signaling through the cytoplasmic 
domain (Xian et al., 2010). 
 
Cytoplasmic domain 
The small cytoplasmic domains of the syndecans are composed of two highly conserved 
subdomains (C1 and C2) separated by a variable region (V), which is unique to each 
family member and is a major determinant of the functional differences between 
Sdc-1,-2,-3 and -4.. The C1 and C2, characteristic signature regions, are proximal and 
distal to the transmembrane domain respectively (Fig. 1.4) (Couchman, 2003; Couchman 
et al., 2001). Well-characterized interactions occur between the C-terminal part of C2 
region of syndecans and a number of PDZ-domain-containing proteins through PDZ 
protein-binding motif FXF (where F is a hydrophobic residue and X can be any amino 
acid (Fanning and Anderson, 1996; Maday et al., 2008). PDZ domains are protein 
interaction modules that form submembranous complexes and regulate targeting and 
trafficking of syndecans to and from the membrane (Zimmermann et al., 2005).  
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Fig. 1.4 The structure of syndecan-1. (A) Syndecans are membrane-spanning with a short 
cytoplasmic domain and an ectodomain, which is substituted with predominantly heparan 
sulfate sugar chains. The number and position of GAG substitution sites varies between 
family members. Multiple sequence alignment of the human syndecan family 
cytoplasmic domains. Conserved residues within the C1 and C2 regions are highlighted 
in blue flanked by a variable region (V). The intact ectodomains of the syndecans can be 
cleaved at a site close to the plasma membrane (juxtamembrane domain JMD), thus 
forming a soluble effector molecule in a process called shedding (see text). (B) 
Conserved residues within the C1 and C2 regions are highlighted in red. The sequence 
variant V region is shown in black text on a white background. (Bernfield et al., 1999; 
Fitzgerald et al., 2000; Okina et al., 2009). 
 
The domain takes its name from PSD-95, a postsynaptic protein; Discs-large, a 
Drosophila septate junction protein; and ZO-1, a tight junction protein (Hung and Sheng, 
2002). The most well-known PDZ proteins are syntenin, GIPC (Gα-interacting protein 
(GAIP)-interacting protein C terminus)/synectin and calcium/calmodulin-associated 
serine kinase (CASK) (Multhaupt et al., 2009). The C2 regions possess an EFYA 
sequence at their C terminus that can bind to PDZ domain-containing proteins (Bernfield 
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et al., 1999). In contrast, current studies suggests that the C1 region contains a sequence 
that is known to interact with ezrin, radixin, moesin proteins (ERM), which are 
cortical-membrane- and actin associated (Granés et al., 2003). However, the functional 
role of this interaction remains unclear. Moreover, it has been elucidated that the C1 
region of Sdc-3 interacts with a cSrc/cortactin complex in response to the heparin-binding 
ligand pleiotrophin (Kinnunen et al., 1998).  
 
The syndecan cytoplasmic domains are too small to contain intrinsic enzymatic activity 
and therefore require interactions to be able to signal. Interactional and functional 
specificity of syndecan are attributed to the V regions, as these regions are specific to 
each syndecan, but conserved across species (Xian et al., 2010). Sdc-4 is the only 
extensively studied one that possesses a significant amount of data concerning interaction 
partners and signaling capacity. Its V region is highly cationic and provides the structural 
basis for the twisted clamp motif (Shin et al., 2001). This structure undergoes a 
conformational change in the presence of PI4,5P2 that interacts primarily with some of 
the eight lysine residues present in each V region dimer (Lee et al., 1998; Whiteford et al., 
2008). This combination is proposed to provide a platform for PI4,5P2 and Sdc-4 to 
interact with protein kinase Cα (PKCα) in a ternary complex resulting in persistently 
activated PKCα (Couchman, 2003; Keum et al., 2004; Morgan et al., 2007). A long with 
α5β1, Sdc-4 can promote cell adhesion and, particularly the assembly of microfilament 
bundles (stress fibers) terminating at focal adhesions. Hence, Sdc-4 may regulate G 
proteins (Bass et al., 2007, 2008; Dovas et al., 2006). Specifically, Rac and ras 
homologue gene family member A (RhoA) lie downstream of Sdc-4/PKCα, which 
suggests that PKCα may directly or indirectly affect a regulator such as a guanine 
exchange factor (GEF), GTPase-activating factor protein (GAP), or guanine dissociation 
inhibitor (GDI). RhoGDIα, a target of PKCα that causes release of RhoA (Knezevic et al., 
2007), can sequester several members of the Rho family, Rac, Rho, and CDC42. It has 
been reported, upon phosphorylation of RhoGDIα on serine 96 in endothelial cells either 
RhoA or RhoG, a close relative of Rac, are released (Elfenbein et al., 2009; Knezevic et 
al., 2007). Indeed, a Sdc-4-synectin-RhoGDI1 complex inhibits the activity of RhoG 
(Elfenbein et al., 2009). Ultimately, direct interactions with cytoskeletal proteins, in 
particular α-actinin, have been elucidated for the Sdc-4 V region (Greene et al., 2003). 
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b) Syndecan biosynthesis 
The biosynthestic pathway of HS is a complex process resulting in heterogeneous 
sulfation of sugar chains (Bernfield et al., 1999; Häcker et al., 2005; Nadanaka and 
Kitagawa, 2008). While synthesis of the core protein resembles the common biosynthetic 
pathway of transmembrane proteins, the biosynthesis of HS is highly complex and can be 
divided into 3 phases (Fig. 1.5): 
 
Chain initiation 
 In mammals, as many as 26 enzymes participate in the formation of HS chains. HSPG 
core proteins are xylosylated form UDP-xylose co-translationally at specific serine 
residues (by XYLT1 and XYLT2). A tetrasaccharide primer (GlcA-Gal-Gal-Xyl, where 
Gal is galactose and Xyl is xylose) is assembled in the Golgi by galactosyltransferases 
(GALT1 and GALT2), and by glucuronyltransferase 1 (GLCAT1). The chain initiation is 
terminated by addition of the first GlcNAc unit by EXTL3, a relative of the hereditary 
multiple exostoses (EXT) gene family of tumor suppressors (Esko and Zhang, 1996; 
Sugahara and Kitagawa, 2000). 
 
Chain polymerization 
Chain elongation proceeds with sequential addition of GlcNAc and GlcA disaccharides 
from their respective UDP-sugar nucleotide precursors by the action of a heterodimeric 
complex of two glycosyl transferases (EXTI and EXT2), within the Golgi apparatus in a 
synergistic manner (Bernfield et al., 1999; Nadanaka and Kitagawa, 2008). 
 
Chain modification 
 As chain elongation progresses and once the HS chain is assembled, generally 50-150 
disaccharides, the individual saccharide units are subjected to a series of sequential 
enzymatic modification reactions. Some, but not all, of the GlcNAc residues are 
N-deacetylated and N-sulfated via the action of N-deacetylase/N-sulfotransferases 
(NDST), the initial modification enzyme, that replaces the N-acetyl group of Glc-NAc 
residues with a sulfate group. Further modification of HS chains usually occurs on 
regions of the chains that have been modified by NDSTs. D-glucuronic acid residues 
adjacent to GlcNSO3 residues are epimerized to L-iduronic acid units by glucuronyl C-5 
epimerase. An iduronosyl 2-O-sulfotransferase (2-OST) acts, then a glucosaminyl 
6-O-sulfotransferase (6-OST) acts, and finally sulfation modification reactions of a few 
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residues are completed by glucosaminyl 3-Osulfotransferase (3-OST). The 
sulfotransferases utilize 3’-phosphoadenosine 5’-phosphosulfate as a sulfate donor. The 
3’-phosphoadenosine 5’-phosphosulfate is synthesized from ATP and SO3 via a single 
enzyme having both ATP sulfurylase and adenosine 5’-phosphosulfate kinase activities 
(Bernfield et al., 1999; Nadanaka and Kitagawa, 2008). 
 
The length of the HS chains can vary over 10-fold with cell type and core protein, but 
none of these chain modifications goes to completion, resulting in the potential for 
considerable heterogeneity in structure (Murphy et al., 2004; Skidmore et al., 2008). 
Structural heterogeneity arises from five potential modifications that can occur to each 
disaccharide: N-sulfation, 6-O sulfation to glucosamine, 3-O sulfation to glucosamine, 
2-O sulfation to uronic acid, and epimerization of D-glucuronic acid to L-glucuronic acid. 
These five different modifications give rise to 25 = 32 possible structural combinations 
for each disaccharide along the chain. Thus, even a short HS such as an octasaccharide 
can have over a million possible sequences, thereby making HS the most information 
dense biopolymer found in nature (Sasisekharan and Venkataraman, 2000). This could be 
the rationale behind the ability of HS to interact with many ligands, since sulfation 
patterns impact HS/ligand interactions. Although the process is not random, and poorly 
understood, HS chain synthesis and fine structure are tightly controlled (Skidmore et al., 
2008). 
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Fig. 1.5 A representative diagram of heparan sulfate biosynthesis. (A) The biosynthesis 
of HS is initiated by the formation of a linkage region tetrasaccharide. The addition of the 
first N-acetylglucosamine residue is catalyzed by an enzyme called EXTL3, which differs 
from the transferases involved in heparan polymerization (called EXT1 and EXT2). (B) 
Chain polymerization and modification begins by a sequential addition of 
N-acetylglucosamine and glucuronic acid (GlcA) residues via EXT1 and EXT2 to a 
tetrasaccharide linker region, which is covalently linked to the serine residue contained 
within the core protein GAG attachment site. The chain then undergoes stepwise 
modifications beginning with N-deacetylation and sulfation of some but not all 
glucosamine residues. Some GlcA residues are epimerized into iduronic acid residues. 
Iduronate may then be 2-O-sulfated, with further sulfation at the 6-O and 3-O positions 
on glucosamine residues (modified from Okina et al., 2009). 
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c) Syndecan remodeling 
Once HSPGs are expressed on the cell surface or secreted into ECM, they don’t remain 
static but rather subjected to remodeling by a number of enzymes that degrade either the 
core proteins or HS chains. As matrix metalloptroteases (MMPs) hydrolyze specific sites 
of HSPG protein cores in ECM, heparanase І (HPSE) and sulfatases (Sulfs) hydrolyze 
specific sites of HS chains (Sanderson and Yang Y, 2008). 
 
1.3.3.2.c.1 Syndecan remodeling by Heparanase I  
 HPSE І is an endo-beta-D-glucuronidase cleaving between glucuronosyl and N-sulfated 
acetylglucosaminyl residues in HS chains. Less modified, low-sulfated regions of HS 
chains are restricted motifs that are recognized by HPSE І; hence its acivity is in between 
regions active in protein binding (Gong et al., 2003). Furthermore, specific sulfation 
patterns such as 3-O-sulfation of the glucosamine residue on the reducing side of the 
target inhibit HPSE І when present in highly sulfated domains (Okada et al., 2002). It is 
highly expressed by endothelial cells (Elkin et al., 2001), various tumor cells (Vlodavsky 
and Friedmann, 2001), trophoblast (Goshen et al., 1996) and decidual cells of mouse 
embryo implantation sites (D’Souza et al., 2007). Its patterns of expression are consistent 
with a role in ECM remodeling as well as growth factor release. HPSE expression is 
significantly increased in cancer, thereby potentiating both the angiogenic and metastatic 
potential of tumor cells (Götte and Yip 2006; Ilan et al., 2006; Vlodavsky et al., 2002). 
 
Notably, several distinct mechanistic activities are revealed, thereby HPSE facilitates 
cancer progression. First, cleavage of HS within the ECM is essential for migration of 
metastasizing tumor cells and for remodeling of the vasculature during angiogenesis. 
Second, HPSE directly promotes angiogenesis by releasing heparin binding angiogenic 
growth factors such as FGF-2 and VEGF that are trapped within the ECM (Götte and Yip, 
2006; Iozzo and San Antonio, 2001; Whitelock et al., 1996). Third, there is emerging 
evidence that HPSE generates biologically active fragments of HS more than the native 
HS chain from which they are derived (Elkin et al., 2001). For example, degradation of 
Sdc-1 with HPSE yields fragments that activate FGF-2 mitogenicity better than does 
intact Sdc-1 (Kato et al., 1998). There is a substantial evidence that inactive HPSE 
(proHPSE) is secreted by cells and then can be taken back up by cells via cell surface 
receptors (lipoprotein related receptor protein, mannose-6-phosphate receptor, HSPGs) 
where it is transported to the lysosomal compartment and activated (Vreys et al., 2005).  
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1.3.3.2.c.2 Syndecan remodeling by sulfatases 
Sulfs are secreted enzymes, Sulf1 and Sulf2, that remove 6-O-sulfates from glucosaminyl 
residues in HS chains (Lamanna et al., 2007). Post 6-O- sulfate removal, Sulfs do not alter 
the physical structure of ECM, rather they substantially modify the biological properties 
of ECM. Thus, Sulf function may both destroy binding sites in HS and prevent 
subsequent HS binding protein interaction or cause release of HS-bound growth factors. 
Destruction of HS-binding growth factor binding sites would be expected to increase 
growth factor diffusion and reduce local concentrations of these proteins (Lai et al., 2008; 
Narita et al., 2007). In fact, Sulfs are expressed in diverse cell types in developing and 
adult tissues as well as various tumors (Backen et al., 2007; Lum et al., 2007). 
Contradictory results have been reported for Sulfs function in cancer. In some cases, Sulfs 
enhance tumor progression while in others tumor progression is inhibited (Lai et al., 2008; 
Narita et al., 2007). This could be attributed to differences in tumor types or responses to 
individual HS-binding growth factors. 
 
In this study we aimed at studying the functional role of Sdc-1 in breast cancer 
progression, hence we will focus in more detail on Sdc-1 in the following chapters.  
 
1.4 Syndecan-1 
1.4.1 Syndecan-1 history 
Sdc-1 (CD138), the prototype member of cell surface HSPGs, was first identified as a 
developmentally regulated type-I transmembrane protein that anchors ECM components 
to epithelial cells (Bernfield et al., 1999; Rapraeger and Bernfield, 1983;). The syndecan 
name was originated from the Greek “syndein,” to bind together, because it was thought 
to link the ECM components to the cytoskeleton (Saunders et al., 1989). Structurally, 
Sdc-1 is a hybrid PG, containing both HS and CS chains attached to core protein 
(Rapraeger et al., 1985), but later it was found that Sdc-1 may also carry HS alone, 
depending on the cell type and tissue expressing Sdc-1 (Salmivirta et al., 1991; Sanderson 
et al., 1989). The human Sdc-1 gene was mapped to chromosome 2p23 (Ala-Kapee et al., 
1990). 
 
1.4.2 Syndecan-1 tissue expression 
The expression of Sdc-1 is modified during development, carcinogenesis, and tissue 
regeneration. Sdc-1 is constitutively expressed by several epithelial cells, but expression 
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is also induced during many biological phenomena, such as tissue regeneration and the 
epithelial-mesenchymal interactions during organ development (Bernfield et al., 1999; 
Nikolova et al., 2009). Moreover, Sdc-1 expression is induced by growth factors. For 
example, in fibroblasts Sdc-1 is induced by FGF-2 and in keratinocytes by EGF and 
keratinocyte growth factor (Jaakkola and Jalkanen, 1999). At certain differentiation 
stages of the hemopoietic cells, Sdc-1 is expressed only in B cells (pre-B and plasma cells) 
(Kopper and Sebestyén, 2000) and is regulated by interleukin-6 (Götte, 2003; Götte et al., 
2002; Sneed et al., 1994). During tooth development, Sdc-1 is involved morphogenesis 
and modulates the differentiation of ameloblast and odontoblast (Gao and Lesot, 2008). 
Immunohistochemical studies showed intense staining of Sdc-1 in the basal cell layer of 
vaginal and ectocervical epithelium in the proliferative phase, and minimal staining in the 
secretory phase in growth factor-dependent manner (Inki, 1997). During cutaneous 
wound healing, Sdc-1 expression is transiently induced in endothelial cells of granulation 
tissue as well as in proliferating keratinocytes. Upon tumor necrosis factor-alpha (TNF-α) 
stimulation, Sdc-1 expression is downregulated in endothelial cells in vitro and in vivo 
(Kainulainen et al., 1996). Interestingly, the amount and the structure of Sdc-1 are 
changed during keratinocytes stratification (Sanderson et al., 1992). Downregulation of 
Sdc-1 expression is observed during myogenesis and upon retinoic acid treatment of 
differentiating muscle cells. On the other hand, the expression of Sdc-1 is restored by 
growth factors in a myogenin-independent mechanism (Larraín et al., 1997). During 
embryonic development, Sdc-1 is expressed at sites of early matrix accumulation, like in 
basement membranes of epithelial-mesenchymal boundaries and in condensing 
mesenchymes (Salmivirta et al., 1994). The Wilms' tumor suppressor gene (WT1),  
encoding a zinc finger DNA binding protein, acts as a transcriptional activator of Sdc-1 
expression which may potentiate epithelial differentiation and maintenance in the 
developing kidney (Cook et al., 1996). In vascular smooth muscle, thrombin augments 
the expression of Sdc-1 which inhibits the antithrombin III activity (Cizmeci-Smith  and 
Carey, 1997). 
 
1.4.3 Syndecan-1 shedding 
Some transmembrane PGs can be proteolytically clipped from the cell surface in a 
process called shedding, resulting in release of the intact extracellular domain with the 
attached HS chains. This released form of the PGs can remain soluble within the stromal 
compartment and retain its biological activity via binding to the stromal matrix by HS 
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interactions with molecules such as fibronectin and collagens. They may also facilitate 
growth factor interactions, or act as competitive inhibitors of the membrane-bound form. 
Thus, HSPGs shed by tumor cells can act as reservoirs by holding and concentrating 
effector molecules within a defined area adjacent to tumor cells (Choi et al., 2010; 
Nikolova et al., 2009; Sanderson et al., 2004) or provide a mechanism for conditioning 
the tumor microenvironment to support growth (Sanderson  and Yang, 2008). 
Furthermore, shed PGs can be utilized as serum markers for tumor load and prognosis 
suggesting their potential functions for early detection of some cancers (Seidel et al., 
2000). Shedding can occur constitutively in cultured cells or in response to external 
triggers (Fitzgerald et al., 2000).  
 
Sdc-1 shedding is a highly physiologically regulated process orchestrated by many 
effectors that involves the cleavage of the extracellular core protein at a specific 
juxtamembrane site called the juxtamembrane domain (JMD) (Fig. 1.4A) (Wang et al., 
2005). Shedding of Sdc-1 could be accelerated by phorbol myristate acetate (PMA) 
activation of protein kinase C, ligand activation of the thrombin (G-protein-coupled) and 
EGF (protein tyrosine kinase) receptors (Subramanian et al., 1997). Multiple signaling 
pathways regulate accelerated and constitutive shedding of Sdc-1 mediated by tissue 
inhibitor of metalloproteinase-3 (TIMP-3) (Fitzgerald et al., 2000). It has been shown that 
Sdc-1 shedding is mediated by MMP-9, MMP-7 and accelerated by stromal cell-derived 
factor-1 (SDF-1/CXCL12) in cancer and additional cell types (Brule et al., 2006; Ding et 
al., 2005). Additionally, HPSE enhances upregulation and shedding of Sdc-1, and high 
levels of heparanase and shed Sdc-1 in the tumor microenvironment facilitate the growth, 
angiogenesis, and metastasis of tumors and are associated with poor prognosis in 
myeloma and other cancers (Purushothaman et al., 2010; Yang et al., 2007). Treatment of 
the bladder carcinoma epithelial cell line ECV304, the lung epithelial cell line A459 and 
primary alveolar epithelial with PMA, thrombin, or proinflammatory cytokines (TNF-α) 
activates a disintegrin-like and metalloproteinase (ADAM17) concomitant with Sdc-1 
shedding (Pruessmeyer et al., 2010).  Furthermore, in lungs, MMP-7 expression 
modulates the migration and wound closure and facilitates re-epithelization by Sdc-1 
shedding induced-change of the activation state of the α2β1 integrin (Chen et al., 2009). 
Insulin has been shown that could increase shedding of Sdc-1 to the serum of type 2 
diabetes mellitus patients in a time-dependent manner (Wang et al., 2009).  The 
resolution of neutrophilic inflammation is mediated by Sdc-1 shedding by removal of 
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proinflammatory chemokines in a HS-dependent manner (Hayashida et al., 2009). The 
stromal shedding of Sdc-1 from human mammary fibroblasts mediated by membrane 
type 1 matrix metalloproteinase (MT1-MMP) is pre-requisite to stimulate the 
proliferation of T47D breast carcinoma cells in a co culture model (Su et al., 2008). On 
the other hand, the shed Sdc-1 ectodomain may enhance proteolytic activity and inhibit 
cell proliferation during cutaneous wound repair in mice (Elenius et al., 2004). 
Interestingly, stress due to changes in the mechanical microenvironment of the vascular 
wall induced Sdc-1 expression and shedding in smooth muscle cells (Julien et al., 2007). 
Rab5, a small GTPase that regulates intracellular trafficking and signaling events, is a 
critical modulator of Sdc-1 shedding and acts as an on-off molecular switch through its 
exchange between the GDP-bound and GTP-bound forms (Hayashida et al., 2008). In 
Hela cells, chemokine (C-C motif) ligand 5 (CCL5/RANTES) induces a chemokine (C-C 
motif) receptor 5 (CCR5) -dependent accelerated shedding of Sdc-1 forming complexes 
with the shed ectodomains (Charnaux et al., 2005). Exploitation of Sdc-1 shedding by 
Pseudomonas aeruginosa enhances virulence. For example, it has been demonstrated that 
Sdc1-/- newborn mice showed a considerable resistance to microbial lung infection due 
to the lack of Sdc1 shedding and the absence of HS chains on epithelial cell surfaces (Park 
et al., 2001). Interestingly, the same proteolytic cleavage site of Sdc-1, amino acids A243 
and S244, are generated by constitutive and PMA-induced shedding both in vitro from 
NMuMG and CHO cells and in vivo (Jalkanen et al., 1987; wang  et al., 2005). On other 
hand, MT1-MMP promotes shedding of Sdc-1 through the preferential cleavage of 
Gly245-Leu246 peptide bond stimulates HT1080 fibrosarcoma cell migration on 
collagen (Endo et al., 2003).  
 
1.4.4 Biological functions of Syndecan-1 
1.4.4.1 Developmental roles of Syndecan-1 
Genetic ablation studies in several model organisms have been conducted to investigate 
the roles of Sdc-1. Mice in which Sdc-1 has been deleted develop normally and are fertile 
(Stepp et al., 2002). The relevance role of Sdc-1 for normal neural crest migration and 
convergent and extension movements has been unveiled by downregulation of its 
expression using morpholinos in zebrafish and Xenopus (Matthews et al., 2008; Mun˜ oz 
et al., 2006). 
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1.4.4.2 Molecular functions of Syndecan-1 in tumor progression 
Experimental studies have shown that the dysregulation of Sdc-1 expression can affect 
the tumor cell behaviour. 
 
a) Syndecan-1-dependent regulation of tumour growth 
1.4.4.2.a.1 Syndecan-1 as a modulator of tumor cell proliferation 
Many growth factors bind not only to their cognate high affinity receptors, but also to the 
HSPGs as low affinity receptors on the cell surface or within the ECM (Yayon et al., 
1991). Numerous studies demonstrate that signal transmission through the FGF 
high-affinity receptors is mediated by binding of HSPGs to FGFs (Rapraeger et al., 1991; 
Yayon et al., 1991). Signaling through FGFR typically involves homodimerization of 
receptors which is facilitated by a scaffold function of HS forming a ternary complex of 
receptor, ligand and HSPG (Spivak-Kroizman et al., 1994). Consequently, HS on breast 
cancer cells regulates the differential mitogenic activity of FGF-1 and FGF-2 (Fernig et 
al., 2000). However, it was found that HS can also bind directly to FGFR even in absence 
of FGF forming a complex that is able to discriminate between various FGFs and to 
prevent autodimerization and activation of the receptor in the absence of ligand (Kan et 
al., 1993; Kan et al., 1996).  
 
The interaction between Sdc-1 and growth factors is most extensively studied in the 
context of FGFs. siRNA-mediated knockdown of Sdc-1 results in reduced 
FGF-2-dependent activation of the MAPK pathway in MCF-7 breast cancer and Caco 2 
colon carcinoma cells (Floer et al., 2010; Nikolova et al., 2009). Furthermore, Sdc-1 
modulates multiple myeloma cell responses to EGF-family ligands of ErbB receptors 
(Mahtouk et al., 2006). A coreceptor role for Sdc-1 in HGF-mediated mitogenic and 
angiogenic signaling via the c-Met RTK has been established in multiple myeloma 
(Derksen et al., 2002). Interestingly, soluble and membrane-bound forms of Sdc-1 appear 
to have opposing effects on breast cancer cell proliferation, as overexpression of the 
soluble form of Sdc-1 inhibited proliferation of MCF-7 breast cancer cells, possibly due 
to competitive binding to growth factors (Nikolova et al., 2009). Transfection of 
mesenchymal tumor cell with a full-length and truncated Sdc-1 construct inhibits 
proliferation (Zong et al., 2010). In contrast, overexpression of Sdc-1 promoted tumor 
cell proliferation through activation of nuclear factor kappaB (NFkB) in endometrial 
cancer cells (Oh et al., 2009). Sdc-1 null mice showed reduction of Wnt-1-mediated 
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mammary hyperplasia which denotes that Sdc-1 modulates Wnt signaling (Alexander et 
al., 2000). 
 
1.4.4.2.a.2 Syndecan-1 as a modulator of tumour cell apoptosis 
Acquired or inherent resistance to apoptosis, the mechanism of programmed cell death, is 
a hallmark of human cancers (Fulda, 2009). The addition of purified Sdc-1 ectodomain 
leads to apoptosis induction, dose-dependent growth inhibition and concurrent 
downregulation of cyclin D1 in multiple myeloma cell lines (Dhodapkar et al., 1998). In 
MCF-7 breast cancer cell lines, treatment with n-3 fatty acid docosahexaenoic acid 
promotes Sdc-1 upregulation mediated apoptosis via peroxisome proliferator-activated 
receptor gamma activation (Sun et al., 2008). On the other hand, siRNA-mediated 
knockdown of Sdc-1 expression in human multiple myeloma cells reduces growth rates 
and a strong increase of apoptosis (Reijmers et al., 2010). Similarly, silencing of Sdc-1 in 
the androgen-independent prostate cancer cell lines downregulates NADPH oxidase 2 
and induces apoptosis (Shimada et al., 2009). Additionally, Sdc-1 depletion in urothelial 
carcinoma cell lines leads to a downregulation of the transcription factor junB and the 
long isoform of FLICE-inhibitory protein (FLIP long), resulting in an induction of 
apoptosis which could be blocked by pan-caspase inhibitors (Shimada et al., 2010). 
Furthermore, aggregation and apoptosis-induction of HT58 lymphoma cells were found 
to depend on Sdc-1 and HS (Sebestyén et al., 2000). Intriguingly, Sdc-1-mediated 
apoptosis appear to depend on its core protein, as association of Sdc-1 with the 
cytoplasmic domain of alpha6beta4 integrin regulated AKT-dependent anti-apoptotic 
pathways in a human squamous carcinoma cell line (Wang et al., 2010). 
 
b) Invasion and metastasis of tumor cells 
1.4.4.2.b.1 Syndecan-1-dependent modulation of cell adhesion and 
motility 
The acquisition of migratory and invasive potential by tumor cells is crucial in the 
progression of a solid, local primary tumor to metastasis.  In a first step, transformed cells 
within the primary tumor need to loosen cell-cell and cell-matrix contacts in order to 
migrate through the surrounding tissue. This process orchestrated by changes in the 
expression of cell surface molecules and an aberrant reactivation of developmental 
processes such as EMT (Egeblad and Werb, 2002; Micalizzi et al., 2010). Syndecans 
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have been suggested to play a role in cell-cell adhesion based on the finding that several 
well-characterized cell-adhesion molecules bind to HS (Couchman et al., 2001). Certain 
myeloma cell lines have lost the ability to synthesize Sdc-1 concomitantly with loss 
adhesion to each other (Sanderson et al., 1992). Furthermore, stable transfection of these 
cells with Sdc-1 restores the cell-to-cell adhesion activity (Stanley et al., 1995). In 
contrast, Raji cells do not undergo cell-cell adhesion following their transfection with 
Sdc-1 (Rapraeger, 1993). Expression of the homotypic cell adhesion molecule 
E-cadherin (E-cad) which is frequently downregulated in invasive cancers (Graff et al., 
1995; Lind et al., 2004) appears to be linked to the expression of cell surface HSPG. 
Synchronous regulation of Sdc-1 and E-cad has been described in colon carcinoma, 
prostate cancer, and in breast cancer cell lines (Bernfield et al., 1999; Contreras et al., 
2010; Nikolova et al., 2009). In fact, Sdc-1 expression is necessary for maintaining 
epithelial morphology, and when it is lost, the epithelial cell becomes fusiform and 
fibroblastic in appearance and exhibit characteristics of neoplastically transformed cells 
including anchorage-independent growth, the presence of elongated filopodial extensions 
and an absence of stress fibers and focal adhesions (reviewed in Bernfield et al., 
1999).Transfection of Sdc-1 into COS-7 cells stimulates cell migration (Adams et al., 
2001). Ectopic expression of Sdc-1 in Schwann cells results in enhanced migration of the 
cells on fibronectin and laminin-coated substrata, and in a striking reorganization of 
Schwann cell microfilaments (Carey et al., 1994).  
 
Upon acquiring a migratory phenotype, differential adhesion to interstitial ECM 
molecules, activation of integrins and FAK signaling pathways lead to 
Rho-GTPase-dependent rearrangements of the cytoskeleton in tumor cells. For example, 
in squamous carcinoma cells, Sdc-1 silencing lead to reduced focal adhesion formation 
and enhanced cell spreading and motility on collagen I substrates (Ishikawa and Kramer, 
2010). While adhesion-induced RhoA activation was ablated in the Sdc-1-deficient cells, 
Rac1 was strongly activated, leading the authors to suggest that Sdc1 may mediate the 
link between integrin-induced actin remodeling and motility (Ishikawa and Kramer, 
2010). In contrast, in endometrial carcinoma cells, Sdc-1 overexpression conferred a 
more mobile and invasive phenotype, possibly via regulating its association with αvβ5 
integrin and focal adhesion kinase-mediated signaling (Oh et al., 2009). Sdc-1 expression 
is necessary for human hepatoma cells migration induced by CCL5/ RANTES (Charni et 
al., 2009) and regulates alphaVbeta3 integrin-dependent breast cancer cell adhesion and 
Introduction 
 27 
motility (Beauvais et al., 2004). Laminin-derived peptide AG73 treatment induced 
squamous cell carcinoma migration mediated by Sdc-1 and beta1 integrin signaling 
suggesting the receptor role of Sdc-1 for laminin alpha 1 (Siqueira et al., 2010). Sdc-1 
positive expression along with fascin-1 overexpression may act in concert to enhance gall 
bladder cancer cell motility (Roh et al., 2009). Notably, wound-healing defects are 
associated with impaired keratinocyte migration due to dysregulated integrin expression 
in Sdc-1 knockout mice (Alexander et al., 2000; Stepp et al., 2002). 
 
1.4.4.2.b.2 Syndecan-1 as a target and a regulator of protease and 
heparanse activity 
HSPGs are integral components of the basement membrane and ECM, hence any changes 
in their expression or increase MMPs expression that degrade the surrounding ECM may 
reduce the cell adhesion and promote cancer cell invasion (Fig. 1.6) (Egeblad and Werb, 
2002). There is ample evidence for a HSPG-dependent regulation of MMP expression: 
For example, crosstalk between Sdc-1 and α2β1 integrin signaling enhances MMP-1 
transcription in response to collagen binding (Vuoriluoto et al., 2008), and 
overexpression of Sdc-1 in endometrial carcinoma cells results in an NFkB-dependent 
upregulation of MMP-9 expression (Oh et al., 2009). In squamous cell carcinoma, Sdc-1 
and beta 1 integrin modulate the cell invasion by interaction with laminin alpha1 chain 
peptide AG73 in MMP-9-dependent mechanism (Siqueira et al., 2010). It has been 
indicated that Wnt5A signaling activation increases the metastasis of melanoma. A recent 
study has demonstrated that silencing of Sdc-1 decreased cellular Wnt5A levels 
accompanied by ablation of invasion which could be restored by treating the cells with 
recombinant Wnt5A (O'Connell et al., 2009). Interestingly, our research group could 
recently show that overexpression of a constitutively membrane-bound form of Sdc-1 
increased secreted amounts of the endogenous MMP inhibitor TIMP-1, whereas 
overexpression of soluble Sdc-1 reduced TIMP-1 expression, resulting in increased 
invasiveness of human MCF-7 breast cancer cells (Nikolova et al., 2009). 
MMP-mediated shedding of Sdc-1 may therefore mark a switch from a proliferative to an 
invasive phenotype in breast cancer cells. Increased activity and expression of heparanase 
promotes metastasis in vitro and in vivo (Casu et al., 2008; Fux et al., 2009; Götte and Yip, 
2006) and its expression correlates with tumor metastasis in clinical specimens (Lerner et 
al., 2008; Maxhimer et al., 2002). Degradation of HS by HPSE promotes metastasis via 
several molecular mechanisms, including physical removal of sterical hindrances upon 
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basement membrane HSPG degradation, release of biologically active HS fragments 
capable of activating growth factor signaling, release of cytokines and angiogenic factors, 
and direct induction of signaling, possibly even via regulation of transcriptional activity 
in the nucleus (Fux et al., 2009; Götte and Yip, 2006; Zong et al., 2009). Metastasis also 
depends on the dissemination of invasive tumor cells into the circulation and 
encompasses adhesive interactions with endothelial cells, leukocytes and platelets, 
ultimately resulting in the colonization of distant tissues and organs by the tumor cells 
(Bacac and Stamenkovic, 2008).  Our research group has shown that a loss of Sdc-1, an 
important modulator of chemokine function (Götte, 2003; Götte and Echtermeyer, 2003), 
results in increased leukocyte-endothelial interactions both in vitro and in vivo, due to a 
HS-dependent modulation of integrin-intercellular adhesion molecule 1 (ICAM-1) 
interactions (Floer et al., 2010; Kharabi Masouleh et al., 2009). Therefore, Sdc-1 may 
regulate adhesion of tumor cells to blood and lymphatic vessel endothelium, or promote 
the association with different host cells during metastatic seeding.   
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Fig. 1.6 Principal steps of cancer cell invasion and metastasis. Tumor cells loss cell-cell 
and cell-matrix contact to invade the surrounding stroma and need to regain adhesiveness 
by glycosaminoglycans and proteoglycans. Glycosaminoglycans and proteoglycans in 
the basement membranes of epithelia and endothelia and ECM are degraded by matrix 
metalloproteinases (MMP), heparanase (HPSE), and hyaluronidases (HYAL). Cell 
adhesion and migration are modulated by glycosaminoglycans and proteoglycans such as 
versican, CD44/hyaluronan, and syndecans. Disseminated tumor cells aggregate with 
leukocytes and platelets and adhere to the vessel wall to escape from the circulation, a 
process involving heparan sulfate (HS) proteoglycan and chondroitin sulfate 
proteoglycan via direct interactions with and modulation of chemokine signaling. These 
functions also promote tumor angiogenesis (Modified from Yip et al., 2006). 
 
 
c) Syndecan-1 as a modulator of angiogenesis 
Angiogenesis is a tightly controlled fundamental multi-step process which involves 
localized breakdown of the basement membrane and the ECM. This process precedes the 
proliferation and migration of capillary endothelial cells into the surrounding tissue, and 
formation of new vessels arising from pre-existing blood vessels (Carmeliet and Jain, 
2000; Folkman, 2007). The switch from normal quiescent vasculature to angiogenesis is 
induced by a change in the balance of many pro- and anti-angiogenic factors that are 
released predominantly by surrounding pericytes and lymphocytes. A large number of 
these factors have been found to bind to HS or the structurally related heparin, including 
key angiogenic growth factors such as the FGFs and VEGFs (Götte, 2003; Iozzo and San 
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Antonio, 2001). However, the only growth factor observed almost ubiquitously at sites of 
angiogenesis and whose levels correlate most closely with the spatial and temporal events 
of blood vessel growth is VEGF ( Ferrara and Gerber, 2001). 
 
Sdc-1 expression has been correlated to tumor angiogenesis in clinical samples and 
xenograft studies (Götte et al., 2007; Maeda et al., 2006; Purushothaman et al., 2010). 
Expression of Sdc-1 has an apparent paradoxical function in angiogenesis. A human 
Sdc-1 transfectant has been documented in enabling the promotion of angiogenesis in an 
endometrial cancer xenograft model (Oh et al., 2010). Sdc-1 appears to play an important 
role as a coreceptor and storage factor for many cytokines and angiogenic factors during 
decidualization and implantation period, supporting proper implantation and 
angiogenesis by regulation of chemokine and angiogenic factor secretion supporting the 
implanting embryo (Baston-Büst et al., 2010). However, induction of Sdc-1 expression in 
the tumor stroma has also been postulated to promote tumor angiogenesis via its binding 
to growth factors such as basic FGF (bFGF) (Mukunyadzi et al., 2003). Moreover, 
stromal fibroblast-derived Sdc1 stimulates breast carcinoma growth and angiogenesis in 
vivo (Maeda et al., 2006). On the contrary, ephrinB2 inhibits in vitro the angiogenic 
effects of bFGF on ephrin receptor EphB4-positive endothelial cells. EphrinB2 
upregulates Sdc-1 expression, thereby competing with FGFR for bFGF on endothelial 
cells. In contrast, the in vivo suppressive effect of ephrinB2 was reversed into activator by 
HPSE which is responsible for degradation of sulfate groups in Sdc-1 HS chains (Yuan et 
al., 2004). In myeloma, tumor cells express high levels of Sdc-1, which are associated 
with increased growth, metastasis, and angiogenesis concomitant with high HPSE 
expression (Kelly et al., 2003). Mechanistically, HPSE expression increases VEGF levels, 
which along with Sdc-1 shedding form matrix-anchored complexes, thereby activating 
integrin and VEGF receptors on adjacent endothelial cells and stimulating tumor 
angiogenesis (Purushothaman et al., 2010). It has been elucidated that the core protein of 
Sdc-1 regulates alphavbeta3 and alphavbeta5 integrin activation during tumor 
angiogenesis in vivo, with implications for Sdc-1-peptide inhibitor-based anti-angiogenic 
therapy (Beauvais et al., 2009; Purushothaman et al., 2010). Moreover, in a retina 
perfusion model, Sdc1(-/-) mice showed increased inflammation-mediated corneal 
angiogenesis, thereby promoting leukocyte adhesion which is massively increased via 
TNF-α stimulation (Götte et al., 2002). Clinically, the coexpression of Sdc-1, E-cad and 
c-Met represents a marker signature associated with angiogenic and lymphangiogenic 
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factors in ductal breast carcinoma in situ (DCIS) which points to the parallel activation of 
different signal transduction pathways promoting tumor cell proliferation and 
angiogenesis (Götte et al., 2007). 
 
1.5 MicroRNAs  
MicroRNAs (miRNAs) are a conserved class of small, approximately 22-nucleotide 
non-coding RNAs that decrease gene expression post-transcriptionally in a 
sequence-specific manner. Most miRNAs are transcribed in the nucleus by RNA 
polymerase II (although some miRNAs are also transcribed by RNA polymerase III 
(Borchert et al., 2006) as long primary transcripts (primiRNAs) that undergo processing 
by Drosha and DGCR8, resulting in an approximately 70-nucleotide stem-loop RNA 
(pre-miRNA). Pre-miRNAs are subsequently exported to the cytoplasm via Exportin 5 
and cleaved by Dicer, resulting in approximately 22-nucleotide RNA duplexes. The 
strand with decreased base-pairing at its 5' end is then selected to function as a mature 
miRNA, while the other strand (also referred to as the passenger strand) is typically 
degraded (Filipowicz et al., 2008; Tomari and Zamore, 2005). The mature miRNA 
associates with Argonautes and other proteins to form the RNA-induced silencing 
complex (miRISC), which then binds to target mRNAs via partial complementarity. 
Mammalian miRNAs predominantly act by binding to the 3' untranslated region (UTR) 
of cognate mRNAs. However, there is growing evidence that they can also downregulate 
the expression of some genes by base-pairing to the coding region (Abdelmohsen et al., 
2008; Forman et al., 2008; Lal et al., 2008; Tay et al., 2008) or the 5' UTR of some 
mRNAs (Lytle et al., 2007). Initially, miRNAs were thought to function mainly by 
suppressing mRNA translation (Olsen and Ambros, 1999). However, two recent studies 
combined proteomics and microarrays revealed that changes in protein expression 
mediated by a miRNA are usually associated with altered mRNA expression, suggesting 
that mRNA degradation may be the major component of mammalian miRNA repression 
(Baek et al., 2008; Selbach et al., 2008). Although most studies suggest that miRNAs 
negatively regulate gene expression by base-pairing to the 3' UTR, a few recent examples 
have shown that miRNAs can also upregulate the translation of their target mRNAs 
(Vasudevan et al., 2007). More than 700 human miRNAs have been identified that can 
potentially regulate the expression of hundreds of genes and a single transcript can be 
targeted by multiple miRNAs to concurrently downregulate multiple proteins in the same 
pathway (Bartel, 2009). In normal cells, miRNAs control normal rates of cellular growth, 
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proliferation, differentiation and apoptosis. Since miRNAs inhibit cell cycle progression 
and drive terminal differentiation, downregulation of some miRNAs may play an 
important role in the development or progression of cancer (Croce, 2009). Over the past 
few years, miRNA profiling studies have led to the identification of miRNAs that are 
aberrantly expressed in human breast cancer. As in other cancers, some miRNAs can 
function as tumor suppressors and other miRNAs as oncogenes. Thus, tumor formation 
may arise from a reduction or deletion of a tumor suppressor miRNA and/or amplification 
or overexpression of an oncogenic miRNA. The biosynthesis and action of miRNAs are 
summarized in Fig. 1.7. 
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Fig. 1.7 (A) Synthesis and maturation pathway of miRNAs. (B) Mechanism of miRNA 
action. ORF: open reading frame (taken from Le Quesne and Caldas, 2010).  
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1.6 Role of Syndecan-1, c-Met and miR-10b in breast cancer 
pathogenesis 
Breast cancer is the most prevalent cancer among women, with around 1 million newly 
diagnosed cases each year worldwide (Bray et al., 2004). According to histopathology, 
primary breast tumors can be subclassified based on tumor stage (size, invasiveness, and 
metastatic status), grade (differentiation state), origins (ductal or lobular), and 
immunohistochemical staining. Standard immunohistochemical stainings include 
estrogen receptor (ER), progesterone receptor (PR) (as a marker for functional ER, 
because PR is an estrogen–ER-regulated target gene), and human epidermal growth 
factor receptor (HER2/ERBB2) levels (Onitilo et al., 2009). Two different models have 
been proposed for human breast cancer progression. For the ductal subtype, a normal 
epithelium progress to flat epithelial atypia, advances to atypical ductal hyperplasia, 
evolves to DCIS and ultimately forms invasive ductal carcinoma (IDC) (Wellings and 
Jensen, 1973). The model of lobular neoplasia proposes a multi-step progression from 
normal epithelium to atypical lobular hyperplasia, lobular carcinoma in situ (LCIS) and 
invasive lobular carcinoma (ILC) (reviewed in Bombonati and Sgroi, 2011). The ER, a 
transcription factor, appears to have essential role in bone integrity and neuronal tissues 
in both sexes concomitant with the main function to develop and maintain the female 
reproductive organs. It has been discovered a function a link between estrogen, a ligand to 
ER, and progression of breast cancer. Since removal of the ovaries in patients with 
advanced breast cancer resulted in a delayed disease progression (Zwart et al., 2010). 
Based on microarray-based expression profiling, breast tumors subtypes includes normal 
breast-like, basal, luminal A, luminal B, and HER2/ERBB2 amplified/overexpressing 
breast cancers (Perou et al., 2000; Sorlie et al., 2001). According to receptor status, the 
breast cancer could be subdivided into ER-positive tumors, HER2-positive tumors, PR- 
positive tumors and triple negative (negative for ER, PR, and HER2) (Zwart et al., 2010). 
Luminal breast cancers are typically ER-positive that are molecular classified into a 
luminal A subtype and a more aggressive luminal B subtype which exhibits a stronger 
proliferative signature (Ibrahim et al., 2009; Sotiriou et al., 2003). Breast cancer 1, early 
onset (BRCA1) tumors are more frequently triple negative. However, not all 
triple-negative tumors are basal tumors or harbor BRCA1 mutations (Turner and 
Reis-Filho, 2006; Turner et al., 2007). The identified risk factors for breast cancer mostly 
were body mass index, menarche, menopause, family history, age at first birth, parity, 
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breastfeeding, alcohol use, smoking habits, diet, use of oral contraceptives and stress 
(Kluttig and Schmidt-Pokrzywniak, 2009). 
 
The diverse consequences of aberrant Sdc-1 expression are reflected by its prognostic 
value in breast cancer. High expression levels of Sdc-1 was associated with high 
histological grade, high mitotic count, large tumor size, ER- and PR-negative status in a 
study on 254 breast cancer patients with long term follow-up (Barbareschi et al., 2003). 
Additional investigations revealed a reduction of ten-year breast cancer-specific overall 
survival in patients displaying epithelial or stromal Sdc-1 expression, respectively 
(Leivonen et al., 2004). From a therapeutic perspective, it is noteworthy that stromal 
Sdc-1 expression is significantly downregulated upon preoperative systemic therapy of 
breast cancer (Tokes et al., 2009) consistent with the potential predictive value of Sdc-1 
expression in neoadjuvant chemotherapy (Götte et al., 2006).  
 
Similar to Sdc-1, high c-Met expression has a prognostic value in breast cancer, 
particularly in lymph node negative breast cancer patients (Ghoussoub et al., 1998; 
Lengyel et al., 2005; Peruzzi and Bottaro, 2006). Ribozyme targeting of c-Met in breast 
cancer cells reduced mammary cancer and tumor-associated angiogenesis in a xenograft 
study, demonstrating its relevance for tumor progression in vivo (Jiang et al., 2003). A 
coreceptor function of Sdc-1 for c-Met-mediated signaling has been proposed in multiple 
myeloma (Derksen et al., 2002), and it was recently shown that HGF binds to Sdc-1 and 
enhances its bioactivity in a HPSE-dependent manner in this tumor entity (Ramani et al., 
2010). However, little is known about the functional interplay of Sdc-1 and c-Met in 
breast cancer pathogenesis. 
 
miR-10b is one of the oncogenic miRNAs which was the first miRNA found to influence 
the metastatic potential of human breast cancer cells (O'Day and Lal, 2010). miR-10b was 
highly expressed only in metastatic cancer cells and was found to promote cell migration 
and invasion in vitro and initiate tumor invasion and metastasis in vivo. Expression of 
miR-10b was found to be induced by the transcription factor Twist; in turn, miR-10b 
inhibits the translation of the transcription factor homeobox D10 (HOXD10), resulting in 
a cascade of cellular alterations that include expression of the prometastatic gene RhoC, a 
gene that promotes cancer cell migration and invasion (Ma et al., 2007). A DIANA 
miRGen database (Megraw et al., 2007) search identified miR-10b, as a potential 
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regulator of Sdc-1 expression, as predicted by the TargetScanS (Lewis et al., 2005) and 
PicTar (4 way) (Krek et al., 2005) algorithms.  
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1.7 Aims of the present study 
GAGs and PGs are key players in all stages of cancer progression (Floer et al., 2010; 
Nikolova et al., 2009). Importantly, changes in expression of GAGs and PGs have 
diagnostic and prognostic values in several cancers (Götte et al., 2007). Owing to 
multifaceted functions of GAGs and PGs in cancer pathobiology, interference with their 
function frequently results in inhibition of the malignant process at multiple stages. 
Targeting of GAGs and PGs and the use of GAGs and PGs, and their mimetics are highly 
promising and increasingly become amenable in planning of targeted cancer 
glycotherapies, including breast cancer (Koo et al., 2008; Yip et al., 2006). Sdc-1 is a 
tumor marker for a number of cancers and was recently exploited as a target for 
antibody-mediated toxin-delivery to cancer cells (Tassone et al., 2004). However, the 
diverse functions of Sdc-1 require careful, context-dependent therapeutic application. For 
instance, proteolytic conversion of Sdc1 from a membrane-bound into a soluble molecule 
marks a switch from a proliferative to an invasive phenotype (Nikolova et al., 2009). 
From a therapeutic perspective, this functional diversity constitutes a major challenge. 
 
c-Met RTK is a key regulator of multiple processes relevant to breast cancer progression, 
including cell proliferation, adhesion, migration, angiogenesis, and gene expression 
(Lemmon and Schlessinger, 2010; Menashe et al., 2010; Peruzzi and Bottaro, 2006). It 
has been reported that Sdc-1 and c-Met are coexpressed in DCIS (Götte et al., 2007). 
Sofar, the molecular mechanism through which Sdc-1 and c-Met may act as effector 
partner molecules regulating breast cancer behavior is still poorly understood. Small 
interfering RNA technology in breast carcinoma cells was applied in this study to answer 
the following intriguing questions: 
 
(1) To better delineate the functional interplay of Sdc-1 and c-Met and to test whether 
Sdc-1 has a coreceptor function for HGF/c-Met signaling and its downstream 
signaling in breast cancer.  
(2) To elucidate the functional consequences of Sdc-1 depletion on breast cancer 
proliferation. 
(3) To determine the influence of Sdc-1 depletion on in vitro breast cancer cell 
motility utilizing an in vitro wound healing assay and time-lapse video 
microscopy. 
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(4) To investigate the impact of Sdc-1 depletion on in vitro invasive phenotype of 
breast cancer cells. 
(5) To screen whether Sdc-1 loss differentially regulates gene expression, which 
could modulate the breast cancer phenotype and aids to unveil the mechanistic 
clue(s) of breast cancer pathogenesis employing Affymetrix microarray 
technology. 
(6) To identify transcriptional regulators capable of downregulating Sdc-1 expression 
as mimicked by our siRNA approach - under physiological conditions. 
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2 Materials  
2.1 Cell lines 
All human breast cancer cell lines were purchased from ATCC/LGC Promochem (Wesel, 
Germany). 
MCF-7 
Type: Mammary carcinoma, invasive ductal 
Species:  human 
Origin: Pleural effusion (Brooks, 1973) 
Culture medium: RPMI 1640 supplemented with 1% Glutamine, 1% 
Penicillin/Streptomycin and 10% FCS  
Culture conditions:  37 °C, 5% CO2, 100% relative humidity 
 
MDA-MB-231 and MDA-MB-468 
Type: Adenocarcinoma  
Species:  human 
Origin: Pleural effusion (Cailleau, 1974) 
Culture medium: DMEM high glucose supplemented with 1% Glutamine, 1% 
Penicillin/Streptomycin and 10% FCS  
Culture conditions:  37 °C, 8% CO2, 100% relative humidity  
 
2.2 Cell culture media und supplements 
 
BMCyclin® Hoffmann-La Roche, Basel, CH 
DMEM High Glucose (4,5 g/l)  Gibco Invitrogen, Paisley, GB 
DMEM High Glucose (4,5 g/l) without 
phenol red  
PAA Laboratories GmbH, Pasching, A 
DPBS 10X Gibco Invitrogen, Paisley, GB 
Fetal calf serum (FCS)  PAA Laboratories GmbH, Pasching, A 
Freezing medium  70% culture medium, 20% FCS, 10% 
DMSO 
HEPES-reagent (1 M)  Gibco Invitrogen, Karlsruhe 
Insulin 10 mg/ml Sigma-Aldrich, Steinheim 
L-Glutamine (200 mM)  PAA Laboratories GmbH, Pasching, A 
OPTI-MEM I Gibco Invitrogen, Paisley, GB 
Penicillin/Streptomycin (100X)  PAA Laboratories GmbH, Pasching, A 
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RPMI 1640  PAA Laboratories GmbH, Pasching, A 
Trypsin/EDTA (0.05%, 1X) Gibco Invitrogen, Paisley, GB 
Kanamycin Biochrom AG, Berlin 
 
2.3 Bacterial media 
 
Luria-Bertina (LB) 
medium 
 
1% (w/v) Tryptone  
0.5% (w/v) Yeast extract  
1% (w/v) NaCl  
 
Luria-Bertina (LB) 
agar 
1% (w/v) Pancreatic digest of casein  
0.5% (w/v) Yeast extract  
1% (w/v) NaCl 
1.5% (w/v) Agar 
 
 
2.4 Chemicals and Chemokines 
 
1,4-Dithiothreit (DTT) Merck KGaA, 
Darmstadt 
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl-tetrazoliumbromid 
(MTT) 
Sigma-Aldrich, 
Steinheim 
Acetic acid 100% (Glacial) Merck KGaA, 
Darmstadt 
Agar  AppliChem, Darmstadt 
Agarose  Sigma-Aldrich, 
Steinheim 
Ammonium persulfate (APS) Bio-Rad Laboratories 
Inc., Hercules, USA 
Bidistilled water Clinic Pharmacy of the 
University Hospital 
Münster, Münster 
 
Boric acid (Crystalline)  Merck KGaA, 
Darmstadt 
Bovine serum abumin (BSA)  Sigma-Aldrich, 
Steinheim 
Bromophenol blue Merck KGaA, 
Darmstadt 
Dimethylsulfoxide (DMSO)  Carl Roth GmbH & Co. 
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KG, Karlsruhe 
Ethanol absolute Merck KGaA, 
Darmstadt 
Ethylendiamintetracetic acid (EDTA)  AppliChem, Darmstadt 
Gelatin Type A: porcine skin, G-2625 Sigma-Aldrich, 
Steinheim 
Glycerol Merck KGaA, 
Darmstadt 
Glycine Merck KGaA, 
Darmstadt 
HGF R&D Systems GmbH, 
Wiesbaden 
Human fibronectin BD, Becton & 
Dickinson Biosciences, 
Heidelberg 
Hydrochloric acid (HCl) fumed 37% Merck KGaA, 
Darmstadt  
Laminin Sigma-Aldrich, 
Steinheim 
Methanol Merck KGaA, 
Darmstadt 
Methylene blue Sigma-Aldrich, 
Steinheim 
N,N-Dimethylformamide 99% Sigma-Aldrich, 
Steinheim 
PMA Fluka, Buchs, 
Switzerland 
Potssium chloride (KCl) Merck KGaA, 
Darmstadt 
ProMMP-2, ProMMP-9 Merck KGaA, 
Darmstadt 
Skimmed milk powder Sigma-Aldrich, 
Steinheim 
Sodium bicarbonate (NaHCO3) Merck KGaA, 
Darmstadt 
Sodium carbonate (Na2CO3) Merck KGaA, 
Darmstadt 
Sodium Chloride (NaCl) J.T. Baker, 
Phillipsburg, NJ, USA 
Sodium dodecyl sulfate (SDS) Sigma-Aldrich, 
Steinheim 
Sodium Fluoride (NaF) Sigma-Aldrich, 
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Steinheim 
Sodium hydroxide (NaOH) Merck KGaA, 
Darmstadt 
Sodium orthovandate (NaVO3) Sigma-Aldrich, 
Steinheim 
Tris (Tris-(hydroxymethyl)-aminomethane)  Carl Roth GmbH & Co. 
KG 
Tris-Hcl Merck KGaA, 
Darmstadt 
Triton X-100 Sigma-Aldrich, 
Steinheim 
Triton X-114 Sigma-Aldrich, 
Steinheim 
Tryptone AppliChem, Darmstadt 
Tween 20  Fluka, Buchs, 
Switzerland 
Xylol  Merck KGaA, 
Darmstadt 
Y-27632 dihydrochloride monohydrate Sigma-Aldrich, 
Steinheim 
Yeast extract AppliChem, Darmstadt 
β-Glycerophosphate Sigma-Aldrich, 
Steinheim 
 
2.5 Buffers and solutions 
2.5.1 Buffers 
Unless stated, all buffers were diluted with bidistilled water. Stock solutions (10X or 5X) 
of the buffers were prepared and immediately diluted before using. The required pH was 
adjusted, if necessary, by adding appropriate volume of HCl or NaOH. 
 
Protein chemistry and Western blot 
 
Blocking buffer (diluting buffer of the 
secondary antibody) 
5% (w/v) Skimmed milk powder 
0.1% (v/v) Tween 20 
in TBS 1X 
 
Blotting buffer, 10X 0.25 M Tris 
1.92 M Glycine 
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Blotting buffer, 1X 10% (v/v) Blotting buffer, 10X 
20% (v/v) Methanol 
 
Diluting buffer of the primary antibody 5% (w/v) BSA in PBS 
 
Fractionation lysis buffer 50 mM HEPES pH 7.5 
50 mM NaCl  
1 mM MgCl2  
2 mM EDTA  
10 mM NaF  
1 mM DTT 
1% (v/v) Protease Inhibitor Cocktail 
10 mM β-Glycerophosphate 
10 mM NaF 
1 mM NaVO3 
 
Resolving buffer, 2.5X, pH 6.7 1.875 M Tris 
0.5% (w/v) SDS 
 
RIPA buffer 20 mM Tris-HCl pH 7.4 
137 mM NaCl 
1% (v/v) Triton X-100 
2 mM EDTA 
1% (v/v) Protease Inhibitor Cocktail 
10 mM β-Glycerophosphate 
10 mM NaF 
1 mM NaVO3 
 
Running buffer, 5X 0.5 M Tris 
1.92 M Glycine 
0.5% (w/v) SDS 
 
Sample buffer, 5X 1 M Tris-HCl pH 6.8 
25% (v/v) Glycerol  
5% (w/v) SDS 
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0.1% (w/v) Bromophenol blue 
 
Stacking buffer, 5X, pH 8.9 0.3 M Tris 
0.25% (w/v) SDS 
 
Stopping solution (Developing of the film) 1% (v/v) Acetic acid 
 
Stripping buffer, pH 2.5 0.1 M Glycine 
0.15 M NaCl 
 
TBS, 10X, pH 7.6 0.15 M Tris-HCl 
1.37 M NaCl 
 
Washing buffer 0.1% (v/v)Tween 20 in TBS, 1X 
 
 
Cell viability assay (MTT) 
 
MTT ((3-(4, 5-dimethylthiazolyl-2)-2, 
5-diphenyltetrazolium bromide) solution 
0.5% (w/v) MTT in PBS 
sterile filterd (0.22 µm) 
 
Stopping buffer, pH 4.7 10% (w/v) SDS 
50% (v/v) N,N-Dimethyl formamide 
 
 
Cell adhesion assay 
 
Blocking buffer 0.5% BSA in DMEM without FCS 
 
Borate buffer, pH 8.5 0.01 M Boric acid 
 
Fixative 3.7% (v/v) PBS-buffered formaldehyde 
 
Washing buffer 0.1% BSA in DMEM without FCS 
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Immunofluorescence microscopy 
 
Blocking buffer 10% (v/v) Aurion BSA in PBS 
 
Diluting solution of primary and secondary 
antibodies 
1% (w/v) BSA in PBS 
Fixative Ice cold methanol or 3.7% (v/v)   
PBS-buffered formaldehyde 
 
Permeabilization solution 0.1% (v/v) Triton-X100 in PBS 
 
 
Zymography 
 
Destaining solution Acetic acid/Isopropanol/Bidistilled water. 
1:3:6 
 
Resolving bufffer, 2.5X, pH 6,7 1.875 M Tris 
0.5% (w/v) SDS 
 
Running buffer, 5X 0.5 M Tris 
1.92 M Glycine 
0.5% (w/v) SDS 
 
SDS-Loading buffer 20 mM Tris-HCl 
20% (v/v) Glycerin 
2% (w/v) SDS 
0.01% (w/v) Bromo phenol blue 
 
Stacking buffer, 5X, pH 8.9 0.3 M Tris 
0.25% (w/v) SDS 
 
Staining solution 0.5% (w/v) Coomassie-Brilliant-Blue R250 
in destaining solution 
 
Substrate buffer, pH 8.5 50 mM Tris-HCl 
5 mM CaCl2 
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Molecular biology 
 
TBE, 10X 0.9 M Tris 
25 mM EDTA 
0.9 M Boric acid 
 
Buffer E1 50 mM Tris-HCl (pH 8.0) 
10 mM EDTA 
100 µg/ml RNase 
 
Buffer E2 200 mM NaOH 
1% (w/v) SDS 
 
Buffer E3 3.1 M Potassium acetate (pH 5.5 with acetic 
acid) 
 
Buffer E4 100 mM Sodium acetate (pH 5.0 with 
acetic acid) 
600 mM NaCl 
0.15%  (v/v) Triton X-100 
 
Buffer E5 100 mM Sodium acetate (pH 5.0 with 
acetic acid) 
800 mM NaCl 
 
Buffer E6 100 mM Sodium acetate (pH 5.0 with 
acetic acid) 
1.5 M NaCl 
 
2.5.2 Solutions ready to use 
 
4', 6'-diamidino-2-phenylindole (DAPI) Molecular Probes, Karlsruhe 
Acrylamide/Bis Solution 30% Bio-Rad Laboratories Inc., Hercules, 
USA 
Aurion BSA-c® (10%) AURION Immuno Gold Reagents & 
Accessories, Wageningen, NL 
DNA Ladder 100bp 500µg/mL New England Biolabs, Inc., Ipswich, 
USA 
DPBS 10x Gibco Invitrogen, Paisley, GB 
Ethidium bromide solution 1%  AppliChem, Darmstadt 
Formaldehyde solution 37%  Merck, Darmstadt 
G150 (Developer)  AGFA, Dübendorf, CH 
G354 (Fixative)  AGFA, Dübendorf, CH 
Goat serum (Normal) DakoCytomation, Glostrup, Denmark 
PageRuler™ Prestained Protein Ladder Fermentas GmbH, St. Leon-Rot 
Materials 
 47 
Ponceau S solution Sigma-Aldrich, Steinheim 
Prestained SDS-PAGE Standard High Range Bio-Rad Laboratories Inc., Hercules, 
USA 
Prestained SDS-PAGE Standard Low Range Bio-Rad Laboratories Inc., Hercules, 
USA 
Protease Inhibitor Cocktail 100x Sigma-Aldrich, Steinheim 
Protein A/G PLUS-Agarose 
Immunoprecipitation Reagent 
Santa Cruz Biotechnology Inc., Santa 
Cruz, USA 
TaqMan Universal PCR Master Mix, No 
AmpErase®UNG 
Applied Biosystems, Foster City, USA 
N,N,N,N-tetra methylene diamine (TEMED) Bio-Rad Laboratories Inc., Hercules, 
USA 
Transfection reagent DharmaFECT® 1 Dharmacon, Lafayette, USA 
Trypan blue solution 0.4%  Sigma-Aldrich, Steinheim 
VECTASHIELD® Mounting Medium Vector Laboratories, Burlingame, CA, 
USA 
 
2.6 Antibodies 
 
Alexa-Flour 488 anti-mouse IgG, Goat Invitrogen Corporation, Carlsbad, USA 
Alexa-Flour 555 anti-mouse IgG, Rabbit Invitrogen Corporation, Carlsbad, USA 
anti-goat-IgG, H&L-Chain, HRP-Conj., 
Rabbit 
Merck KGaA, Darmstadt 
anti-human-Akt, polyclonal, Rabbit Cell Signaling Technology, Inc., Danvers, 
USA 
anti-human-AML1, polyclonal, Rabbit Cell Signaling Technology, Inc., Danvers, 
USA 
anti-human-Annexin A3, polyclonal, 
Rabbit 
Eurogentec, Cologne 
anti-human-ATF-2 (20F1), monoclonal, 
Rabbit 
Cell Signaling Technology, Inc., Danvers, 
USA 
anti-human-Cadherin11, clone 5B2H5, 
Mouse  
Invitrogen Corporation, Carlsbad, USA 
anti-human-Cdc42, polyclonal, Rabbit Cell Signaling Technology, Inc., Danvers, 
USA 
anti-human-CDK6 (DCS83), Mouse mAb Cell Signaling Technology, Inc., Danvers, 
USA 
anti-human-COL1A2 (M-19), polyclonal, 
Goat 
Santa Cruz Biotechnology Inc., Santa Cruz, 
USA 
anti-human-COX-2 (C-20), polyclonal, 
Goat 
Santa Cruz Biotechnology Inc., Santa Cruz, 
USA 
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anti-human-E-Cadherin, clone 36, Mouse BD, Becton & Dickinson Biosciences, 
Heidelberg 
anti-human-EMP-2 (M-21), polyclonal, 
Rabbit 
Santa Cruz Biotechnology Inc., Santa Cruz, 
USA 
anti-human-Fascin-1 (55K-2), monoclonal, 
Mouse 
Santa Cruz Biotechnology Inc., Santa Cruz, 
USA 
anti-human-JAM-1, monoclonal, Mouse BD, Becton & Dickinson Biosciences, 
Heidelberg 
Anti-human-Met (C-12), polyclonal, 
Rabbit 
Santa Cruz Biotechnology Inc., Santa Cruz, 
USA 
anti-human-MPP4 (H10), monoclonal, 
Mouse  
Described by Stöhr et al., 2005 
anti-human-p21 Waf1/Cip1 (12D1), 
monoclonal, Rabbit 
Cell Signaling Technology, Inc., Danvers, 
USA 
anti-human-p38 MAP Kinase, polyclonal, 
Rabbit 
Cell Signaling Technology, Inc., Danvers, 
USA 
anti-human-p44/42 MAP Kinase, 
polyclonal, Rabbit 
Cell Signaling Technology, Inc., Danvers, 
USA 
anti-human-PAI-1 (3A120), monoclonal, 
Mouse 
Santa Cruz Biotechnology Inc., Santa Cruz, 
USA 
anti-human-phosho-Akt (ser473), 
polyclonal, Rabbit 
Cell Signaling Technology, Inc., Danvers, 
USA 
anti-human-phospho -FAK (Tyr925), 
polyclonal, Rabbit 
Cell Signaling Technology, Inc., Danvers, 
USA 
anti-human-phospho p44/42 MAP Kinase 
(Thr202/Tyr204), polyclonal, Rabbit 
Cell Signaling Technology, Inc., Danvers, 
USA 
anti-human-phospho-Met (Tyr1234/1235), 
polyclonal, Rabbit 
Cell Signaling Technology, Inc., Danvers, 
USA 
anti-human-phospho-p38 MAP Kinase 
(Thr180/Tyr182), polyclonal, Rabbit  
Cell Signaling Technology, Inc., Danvers, 
USA 
anti-human-Phospho-Tyrosine 
(P-Tyr-100), monoclonal, Mouse  
Cell Signaling Technology, Inc., Danvers, 
USA 
anti-human-Rho A/B/C (H-70), polyclonal, 
Rabbit 
Santa Cruz Biotechnology Inc., Santa Cruz, 
USA 
anti-human-Rho B (119), polyclonal, 
Rabbit 
Santa Cruz Biotechnology Inc., Santa Cruz, 
USA 
anti-human-Syndecan-1 (C-20), 
polyclonal, Goat 
Santa Cruz Biotechnology Inc., Santa Cruz, 
USA 
anti-human-Syndecan-1 (DL-101), 
monoclonal Mouse 
Santa Cruz Biotechnology Inc., Santa Cruz, 
USA 
anti-human-Syndecan-1, clone BB4, 
monoclonal, Mouse 
Serotec, Düsseldorf 
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anti-human-Syndecan-1, polyclonal, Goat 
(AF2780) 
R&D Systems GmbH, Wiesbaden 
anti-human-Tpl2, polyclonal, rabbit Cell Signaling Technology, Inc., Danvers, 
USA 
anti-human-uPAR (FL-290), polyclonal, 
Rabbit 
Santa Cruz Biotechnology Inc., Santa Cruz, 
USA 
 
anti-human-Vinculin, clone hVIN-1, 
Mouse 
Sigma-Aldrich, Steinheim 
anti-human-α-Tubulin, clone B-5-1-2, 
Mouse 
Sigma-Aldrich, Steinheim 
anti-human-β-Catenin Antibody 
(Carboxy-terminal Antigen) polyclonal, 
Rabbit 
Cell Signaling Technology, Inc., Danvers, 
USA 
Anti-mouse Matrilin-2, affinity-purified, 
polyclonal Rabbit 
Dr. Raimund Wagener,  ( Piecha D et al. J 
Biol Chem 274:13353 (1999) ) 
anti-mouse-IgG, H&L-Chain, HRP-Conj., 
Goat 
Merck KGaA, Darmstadt 
anti-rabbit-IgG, H&L-Chain, HRP-Conj., 
Goat 
Merck KGaA, Darmstadt 
Goat-anti-Rabbit IgG - 
Tetramethylrhodamine isothiocyanante 
(TRITC) 
antibodies-online GmbH/Acris, Aachen 
  
 
2.7 Oligonucleotide primers, TaqMan®-probes, siRNAs, miR-10b and 
pEZX-MT01 plasmid 
Oligonucleotide primers 
Human MPP4 (Stöhr et al., 2005) 
A128 a forward (5’-TTA CGA AAT GAA TGG GCG-3’) 
A128 a reverse (5’AGG CTC TAG GTC CAT GAC-3’) 
 
Human β-Actin (Götte et al., 2007) 
forward: 5’-CAA AGA CCT GTA CGC CAA CAC-3’ 
reverse: 5’-CAT ACT CCT GCT TGC TGA TCC-3’ 
 
Human Sdc-1 (Götte et al., 2007) 
forward: 5’-AGGACGAAGGCAGCTACTCCT-3’  
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reverse:  5’-TTTGGTGGGCTTCTGGTAGG-3’ 
 
Mycoplasma-PCR Primer mix 1 (outer 
Primer) (Garner et al., 2000) 
Mycoplasma-PCR Primer mix 2 (inner 
Primer) (Garner et al., 2000)  
5’-Primer mix:  
CGC CTG AGT AGT ACG TTC GC 
CGC CTG AGT AGT ACG TAC GC 
TGC CTG AGT AGT ACA TTC GC 
CGC CTG GGT AGT ACA TTC GC 
CGC CTG AGT AGT ATG ATG CTC GC 
TGC CTG GGT AGT ACA TTC GC 
3’-Primer mix:  
GCG GTG TGT ACA AGA CCC GA 
GCG GTG TGT ACA AAA CCC GA 
GCG GTG TGT ACA AAC CCC GA 
 
5’-Primer mix:  
TGG TGC ATG GTT GTC GTC AG 
TGG TGC ACG GTT GTC GTC AG 
3’-Primer mix:  
GAA CGT ATT CAC CGC AGC ATA 
GAA CGT ATT CAC CGC GAC ATA 
GAA CGT ATT CAC CGT AGC GTA 
GAA CGT ATT CAC CGC AGC GTA 
GAA CGT ATT CAC CGC AGT ATA 
GAA CGT ATT CAC CGC AAC ATG 
GAA CGT ATT CAC CGC GAC ATG 
 
 
TaqMan®-probes 
The TaqMan probes for real-time PCR were manufactured by Applied Biosystems 
(Foster City, USA). Information on the primer location can be found under 
www.allgenes.com. 
 
18S Hs99999901_s1 
Actin gamma-2 Hs01123712_m1 
AML1/RUNX-1 Hs01021971_m1 
ATF-2 Hs00153179_m1 
BCL-2  Hs00153350_m1 
CDH1(E-cad) Hs00170423_m1 
COX-2 Hs00153133_m1 
F11R (JAM-A) Hs00170991_m1 
FAK Hs00178587_m1 
Fascin-1 Hs00602051_m1 
Materials 
 51 
HPSE Hs00180737_m1 
KLF4 Hs00358836_m1 
MMP-2 Hs00234422_m1 
MMP-9 Hs00234579_m1 
MYL-9 Hs00697086_m1 
PAI-1 Hs 01126607_g1 
PLAU Hs00170182_m1 
PTEN Hs00829813_s1 
SDC-1 Hs00174579_m1 
TIMP3 Hs00165951_g1 
TLR4 Hs 00152939_m1 
Transgelin (SM22) Hs00162558_m1 
 
Additional primers were used employing the QuantiTect SYBR Green PCR kit (Qiagen, 
Hilden) in a LightCycler (Roche,Indianapolis, IN, USA) 
 
Annexin A10 Hs_ANXA10_1_SG          
Annexin A3 Hs_ANXA3_1_SG           
CD44 Hs_CD44_1_SG                
CDC42 Hs_CDC42_2_SG             
Claudin-1 Hs_CLDN1_1_SG               
Inversin Hs_INVS_1_SG                
JHDM1D Hs_JHDM1D_1_SG        
MAP3K8 Hs_MAP3K8_1_SG         
RhoA Hs_RHOA_1_SG           
RhoB Hs_RHOB_1_SG          
RhoC Hs_RHOC_2_SG           
SERPINB2 (PAI-2) Hs_SERPINB2_1_SG 
Materials 
 52 
  
 
siRNAs 
siRNA Sdc-1 (ID: s12634) was purchased from Ambion Inc., Austin, USA.                                       
Sense                                                                              
5’-GCAGGUGCUUUGCAAGAUAtt-3’ 
Antisense 
5’-UAUCUUGCAAAGCACCUGCac-3’  
siRNA Silencer® Negative Control 
 
Pre-miR miRNA precursors 
hsa-miR-10b (ID: PM11108) was purchased from Ambion Inc., Austin, USA. 
Mature Sequence: ACAGAUUCGAUUCUAGGGGAAU  
Stem-loop Sequence: 
CCAGAGGUUGUAACGUUGUCUAUAUAUACCCUGUAGAACCGAAUUUGUG
UGGUAUCCGU 
AUAGUCACAGAUUCGAUUCUAGGGGAAUAUAUGGUCGAUGCAAAAACUU
CA 
 
pEZX-MT01 Plasmid 
The pEZX-MTO1 vector shown below uses the firefly luciferase reporter gene under the 
control of an SV40 promoter and Renilla luciferase as the tracking gene under the control 
of a CMV promoter. Firefly luciferase expression is regulated by binding of the targeting 
miRNA to the 3’ UTR target sequence and luciferase activity is quantified with a 
colorimetric assay (http://www.genecopoeia.com/product/mirna/pdf/). pEZX-MT01 
plasmid was purchased from GeneCopoeia, Inc., Rockville, MD, USA. 
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Fig. 2.1 Structure of the GeneCopoeia miTarget reporter vector, pEZXMT-01 
(http://www.genecopoeia.com/product/mirna/pdf/). 
 
2.8 Reaction system („Kits“) 
 
Affymetrix One Cycle cDNA synthesis  Affymetrix, Santa Clara, CA 
Diff-Quik® staining system for invasion 
filters  
Dade Behring, Düdingen, Switzerland 
JETSTAR 2.0 MAXI columns with lysate 
filtration unit (LFU) 
 
GENOMED GmbH, Löhne 
LUC-PairTM miR Luciferase Assay GeneCopoeia, Inc., Rockville, MD, USA 
Micro BCA™ Protein Assay Thermo Fisher Scientific Inc., Rockford, 
USA 
RNA-Preparation system basicrna-OLS OMNI Life Science GmbH, Hamburg 
RNA-Transcription system ”First strand 
cDNA Synthesis Kit” 
Fermentas GmbH, St. Leon-Rot 
Western Blot Detection system Super 
Signal West Pico Chemiluminescent 
Substrate” 
Thermo Fisher Scientific Inc., Rockford, 
USA 
 
2.9 Equipments and Materials 
 
Agarose gel chamber SUB-CELL® GT  Bio-Rad Laboratories Inc., Hercules, USA 
Autoclave Hiclav® HV-50 HMC Europa GmbH, Engelsberg 
BD Falcon® High-Clarity Polypropylene 
Conical Tube (15 mL, 50 mL) 
Becton & Dickinson Biosciences, 
Heidelberg 
BioDoc Analyze system Biometra GmbH, Göttingen 
Cell culture flasks BD Falcon® (25 cm², 75 
cm², 150 cm²)  
Becton & Dickinson Biosciences, 
Heidelberg 
Cell culture plates Multiwell® Falcon®, Becton & Dickinson Biosciences, 
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(6-Well, 24-Well, 96-Well)  Heidelberg 
Cell scraper Costar® Vitaris AG, Baar 
Centrifuge Biofuge fresco (Molecular 
biology)  
Kendro-Heraeus, Berlin 
Centrifuge Multifuge 3 S-R(cell culture)  Kendro-Heraeus, Berlin 
Cover slips (different sizes) Diagonal GmbH & Co. KG, Münster 
Cryo-freezing device (NU200) Nunc GmbH & Co. KG, Wiesbaden 
Cryotubes Brand GmbH & Co. KG, Wertheim 
ELISA-Reader VersaMax® Microplate 
Reader 
Molecular Devices, Sunnyvale, CA, USA 
Gel electrophoresis-voltage source 
PowerPac® 300 
Bio-Rad Laboratories Inc., Hercules, USA  
GeneChip Fluidics 450 station AFFYMETRIX, INC.Santa Clara, CA, 
USA 
GeneChip Hybridization Oven Manual Tissue Arrayer MTA-1, Beecher 
Instruments, Silverspring, USA 
Incubators BB6060 Kendro-Heraeus, Berlin 
Invasion Chamber BD BioCoat® Matrigel® Becton & Dickinson Biosciences, 
Heidelberg 
Inverted microscope Axiovert25 Carl Zeiss, Inc. Göttingen 
Labmixer Vortex Genie 2 Scientific Industries, Bohemia, NY, USA 
Laminar flow hood HS15 Kendro-Heraeus, Berlin 
Light microscope with camera 
Axiovert-100 
Carl Zeiss AG, Jena 
Magnetic stirrer Ikamag® Ret Ika-Werke GmbH & Co. KG, Staufen 
Microlumat plus LB 96V Berthhold technologies, Bad Wildbad 
Micropipets Eppendorf Research® variabel  Eppendorf, Hamburg 
Microwave Micromat  AEG-Electrolux, Nürnberg 
Migration assays, Costar® Transwell-Clear 
inserts, 8 µm pore size 
Corning Life Sciences, Schiphol-Rijk, NL 
Neubauer Haemocytometer Paul Marienfeld GmbH & Co. KG, 
Lauda-Königshofen 
Nitrocellulose membrane Hybond TM ECL  GE Healthcare, General Electric Company, 
Chalfont St. Giles, GB 
PCR-Reaction plate 96 Well Multiply® 
(real time PCR) 
Sarstedt AG & Co., Nümbrecht 
PCR-Reaction tube Multiply®-µStrip 
8-fold (conventional PCR) 
Sarstedt AG & Co., Nümbrecht 
PCR-Thermocycler Applied Biosystems 
7300 real-time PCR system (real time 
Applied Biosystems Foster City, CA, USA 
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PCR) 
PCR-thermocycler Biometra T1 
(conventional PCR) 
Biometra GmbH, Göttingen 
Pipette tips epT.I.P.S. Eppendorf, Hamburg 
Pippettes, serological (1 mL, 5 mL, 10 mL, 
25 mL, 50 mL) 
Becton & Dickinson Biosciences, 
Heidelberg 
Savant SpeedVac concentrator Thermo Fisher Scientific Inc., Rockford, 
USA 
SDS-PAGE chambers Minigel-Twin Biometra GmbH, Göttingen 
Sensitive balance TE 214S-oCE Sartorius, Göttingen 
Slides for IHC, SuperFrost® plus, 75 x 
25mm 
R. Langenbrinck Labor und 
Medizintechnik, Emmendingen 
Slides, normal 76 x 26 mm Diagonal GmbH & Co. KG, Münster 
Standard eppendorf tubes 1,5 mL, 2mL Eppendorf, Hamburg 
Sterile filters Millex® GP  Millipore, Bedford, MA, USA 
Thermomixer Eppendorf, Hamburg 
Ultracentrifuge avanti 30 compact Beckman Instruments, München 
UV-Spectrophotometer BioDoc Analyze Biometra GmbH, Göttingen 
Video cameras (Models XC-ST70CE and 
XC-77CE) 
Hamamatsu/Sony, Japan 
Water bath GFL-1004 GFL, Burgwedel 
X-ray films CL-XPosureTM   Thermo Fisher Scientific Inc., Rockford, 
USA 
 
2.10 Softwares 
 
Adobe Photoshop 7 Adobe Systems Inc., San Jose, USA 
AMIRA software TGS Inc., San Diego, CA, USA 
AxioVision 4.3 (evaluation of Migration 
and Invasion assays) 
Carl Zeiss AG, Jena 
HiPic and WASABI softwares Hamamatsu/Sony, Japan 
JAVA programs and the NIH ImageJ 
software 
http://rsb.info.nih.gov/ij/ 
MS Excel   Microsoft Corporation, Redmond, USA 
MS Power Point  Microsoft Corporation, Redmond, USA 
MS Word  Microsoft Corporation, Redmond, USA 
Sequence Detections Software (SDS) 
Version 1.4 (evaluation of real-time 
PCR-Analysis)  
Applied Biosystems Foster City, CA, USA 
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3 Methods 
3.1 Cell culture 
3.1.1 Culturing of breast cancer cell lines 
Different human breast cancer cell lines were cultured in cell culture flasks according to 
the conditions described in 2.1. At about 80% confluence, adherent growing cell lines 
were passaged. After removal of the old medium, the cells were washed by 5 - 10 ml PBS 
and then incubated for 5 min with 1 – 3 ml trypsin / EDTA solution at 37°C. The trypsin / 
EDTA solution was inactivated with 10 ml of pre-warmed PBS containing 10% FCS. The 
detached cells were centrifuged (5 min, 1500 rpm), resuspended in fresh medium and 
seeded again in such a dilution that the cells could be 80% confluence again after three 
days. For the different bioassays at each passage some of the cells were kept and 
accurately determined number of cells seeded. To determine the number of cells, an 
aliquot of cell suspension was diluted with trypan blue solution (1:1) and placed in a 
Neubauer counting chamber. The living cells (unstained) were counted via light 
microscopy, whereas necrotic cells, stained because of their permeable membrane, were 
not counted. The percentage of necrotic cells was also used as an indicator of the vitality 
of culture and if it exceeded 1%, the culture was discarded. 
 
3.1.2 Freezing and thawing the cells 
4 x 106 – 5 x 106 cells were suspended in 1.5 ml freezing media, which is consisting of 
70% cell culture medium, 20% FCS and 10% DMSO, and transferred into sterile 
cryogenic vials. With the help of a cryogenic freezing unit, the cell suspension was cooled 
at a cooling rate of 1°C/min to -80°C overnight and then transferred to liquid nitrogen 
(-196°C). For thawing the cells, the vials were transferred from the liquid nitrogen 
directly into a water bath (37°C). Immediately, the thawing vials content was pipetted 
into a surplus of cell culture medium, and centrifuged (5 min, 1500 rpm). The pellet was 
resuspended in complete growth medium for the cultivation in cell culture flasks. Thawed 
cells were only used in experiments after an acclimatization period of 7 - 12 days. 
 
3.1.3 Cell counting 
The cells were counted using a Neubauer hemocytometer. Equal volumes of cells and 
0.4% trypan blue solution (10 µl of cell suspension and 10 µl trypan blue) were mixed 
together. Trypan blue is a dye which stains dead cells blue, while the live cells remain 
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unstained. The chamber of the hemocytometer was filled with the stained cell suspension 
by capillary action. The total number of cells in the four marked squares (Fig. 3.1) was 
counted using a microscope. Each chamber of the hemacytometer is divided into sixteen 
1.0mm squares. A coverslip is forming the lid of these squares so that the total volume 
over each square is 0.0001 ml or 10-4 ml).  
The total number of the cells in 1 ml= Average number of the cells in large square x 
dilution factor x Volume of large square 
Average number of the cells = the total number of the cells in 4 large squares/4 
Volume of large square=0.1 cm x 0.1 cm x 0.01 cm= 10-4 cm3=10-4 ml 
Dilution factor=2 (10 µl cell suspension + 10 µl trypan blue) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.1 Counting cells with a Neubauer hemocytometer. Cells stained with trypan blue 
were loaded onto the hemocytometer and the total number of cells in the four big squares 
was counted. The number of cells/ml of cell suspension is then computed as described. 
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3.1.4 Monitoring Mycoplasma contamination 
In order to improve the cell culture conditions and avoid contamination, a regular test was 
performed on Mycoplasma specific DNA by conventional PCR, which is randomly 
performed on all cell lines present in all used incubators. For this purpose, 100µl of cell 
culture media were removed, heated for 3 min at 99°C, centrifuged and the collected 
supernatant was used for PCR I (see below). As a positive control, a sample was heavily 
contaminated with Mycoplasma was utilized and as a negative control was nuclease free 
water. The PCR products were separated by agarose gel electrophoresis and then made 
visible by ethidium bromide staining under ultraviolet (UV) light (for details see section 
3.2.5). In the case of massive Mycoplasma contamination, a band corresponding to 520 
bp is detected. In the case of a negative result, the products of PCR I were subjected to 
nested PCR (PCR II, see below). The primers of the PCR II are selected to be 
complementary to DNA segments of the products of PCR I. The logic behind this strategy 
is that if the wrong locus were amplified by mistake, the probability is very low that it 
would also be amplified a second time by a second pair of primers.The separation of PCR 
products was carried out as described for PCR I. When a band corresponding to 300 bp 
appeared, contaminated cells were discarded or treated with the antibiotic BMCyclin® 
according to the manufacturer’s instructions. The success of the treatment was verified by 
PCR as described before. 
 
Mycoplasma specific DNA – PCR I 
 
Reagent:  Temperature program: 
2.5 µl cell culture media 
2.5 µl 10X PCR-buffer  
1 µl Mycoplasma-PCR Primer mix 1 (10 pmol/µl 
each primer)  
0.5 µl dNTP 
0.125 µl Taq-Polymerase 
18.375 µl nuclease free water 
 
   5’ 94°C 
30’’ 94°C 
30’’ 67°C  35 Cycles 
30’’ 72°C 
   5’ 72°C 
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Mycoplasma specific DNA – PCR II (nested-PCR) 
 
Reagent:  Temperature program: 
10 µl PCR-Product of 1st PCR 
2.5 µl 10X PCR-buffer 
1 µl Mycoplasma-PCR Primer mix 2 (10 pmol/µl  
Primer) 
0.5 µl dNTP 
0.125 µl Taq-Polymerase 
10.875 µl nuclease free water 
   5’ 94°C 
30’’ 94°C 
30’’ 63°C  35 Cycles 
30’’ 72°C 
   5’ 72°C 
 
 
3.1.5 Stock solutions and diluent used for chemicals and chemokines 
used in vitro 
First we prepared chemicals and chemokines used in vitro as described by the 
corresponding manufacturer as a stock solution. Just before each experiment, an aliquot 
of the stock solution was diluted with an appropiate diluent to the desired concentration 
(Table 3.1). 
 
Table 3.1 Stock solutions and diluent used for chemicals and chemokines used in vitro 
Substance Stock solution Diluent 
PMA 250 µM in 20mM DMSO PBS 
Recombinant 
human HGF 
10 µg/ml in 1X PBS containing 0.1% 
BSA 
PBS 
Y27632 10 µM in PBS PBS 
 
3.1.6 In vitro invasion and migration assay 
Principle 
BD BioCoat Matrigel Invasion Chambers were used because they provide cells with the 
conditions that allow us to assess their invasive property in vitro. These chambers consist 
of 8 µm pore size PET (polyethylene terephthalate) membrane with a thin layer of 
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Matrigel basement membrane matrix. The Matrigel Matrix serves as a reconstituted 
basement membrane in vitro. The layer occludes the pores of the membrane, blocking 
non-invasive cells from migrating through the membrane. In contrast, invasive cells 
(malignant and non-malignant) are able to detach themselves from and invade through 
the Matrigel matrix and the 8 micron membrane pores. The membrane may be processed 
for light and electron microscopy and can be easily removed after staining. The Matrigel 
matrix is a solubilized basement membrane preparation extracted from 
Engelberth-Holm-Swarm (EHS) mouse sarcoma. It contains laminin, collagen type IV, 
HSPGs, entactin and growth factors, including TGF beta , bFGF and others which occur 
naturally in EHS tumor. It is used for assessment of the metastatic potential of tumor cells, 
altered expression of cell surface proteins or MMPs (Albini et al., 1987) (Fig. 3.2). For 
migration assay, the Boyden chamber assay, originally introduced by Boyden for the 
analysis of leukocyte chemotaxis, is based on a chamber of two medium-filled 
compartments separated by a microporous membrane. In general, cells are placed in the 
upper compartment and are allowed to migrate through the pores of the membrane into 
the lower compartment, in which chemotactic agents are present. After an appropriate 
incubation time, the membrane between the two compartments is fixed and stained, and 
the number of cells that have migrated to the lower side of the membrane is determined. 
Therefore, the Boyden chamber-based cell migration assay has also been called filter 
membrane migration assay, Trans-well migration assay, or chemotaxis assay (BOYDEN, 
1962; Chen, 2005). 
 
 
 
 
 
 
 
  
 
            Fig. 3.2 Schematic drawing of a BD BioCoat Matrigel invasion Chamber. 
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Procedure 
The needed number of Matrigel inserts was rehydrated by addition of pre-warmed culture 
medium to the interior of the inserts and bottom of wells for 2 h in a humidified tissue 
culture incubator at 37°C. Afterwards, the medium was removed without disturbing the 
layer of Matrigel Matrix on the membrane. 25 x 103 control and Sdc-1 siRNA-transfected 
cells (►3.2.1) in 0.5 ml DMEM/10% FCS were added 48 h after transient transfection in 
triplicates to the upper compartments of BioCoat Matrigel Invasion insert. After a 20 h 
adhesion phase, the media were removed and replaced by 500 µl serum free media. To the 
lower compartment (well of a 24-well plate), 0.75 ml DMEM ±40 ng/ml HGF or 10% 
FCS as a chemoattractant were added. The incubation time was varied from 20-72 h 
depending on the number of the cells, cell line type and chemoattractant used. After the 
incubation, the non-invading cells are removed from the upper surface of the membrane 
by inserting a cotton tipped swab into the insert and applying gentle but firm pressure 
while moving the tip over the membrane surface. The cells on the lower surface of the 
membrane were fixed and stained with Diff-Quik dye solutions by successively 
immersing in 500 µL fixative solution (fast green in methanol) for 3 min, 500 µl 
Diff-Quik I (Eosin Y in phosphate buffer) for 2 min, Diff-Quik II (Thiazine dye in 
phosphate buffer) for 5 min and finally the insert was washed twice in the beaker 
containing deionized water to remove excess stain and allowed to air dry. The dried 
membranes were excised from the inserts using a scalpel, placed on glass slides and 
mounted with mounting medium and coverslips. Three visual fields of each membrane 
were photographed and cells were counted using Zeiss Axiovert microscope with 
Axiovision software at 50X magnification. The total cell number per membrane were 
summed and averaged for triplicates of inserts. Relative invasiveness was expressed as 
percentage of the cell number on HGF or FCS-treated inserts compared to untreated 
control inserts (n>3). For migration assay, we used the same approach using non-coated 
Matrigel Trans-well migration inserts. 
 
3.1.7 Cell viability assay (MTT assay) 
Principle 
This is a colorimetric assay that measures the reduction of yellow MTT by mitochondrial 
succinate dehydrogenase (Mosmann, 1983). The MTT enters the cells and passes into the 
mitochondria where it is reduced to an insoluble, colored (dark purple) formazan product. 
The cells are then solubilized with an organic solvent (e.g. isopropanol) and the released, 
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solubilized formazan reagent is measured spectrophotometrically. Since reduction of 
MTT can only occur in metabolically active cells, the level of activity is a measure of the 
viability of the cells. 
 
Procedure 
48 h post control and Sdc-1 siRNA transfection, 5 × 103 cells/well in complete growth 
medium were seeded into a 96-well plate and incubated at 37°C overnight. The cells then 
were grown in serum-starved medium for another 24 h followed by treatment with ±40 
ng/ml HGF for 48 h. Subsequently, cells were incubated with 10 µl/ well of MTT dye 
solution for 4 h at 37Co. The number of viable cells was directly proportional to the 
production of formazan, which was dissolved in 100 µl/well stopping buffer for 20 h, and 
measured spectrophotometrically at 570/650 nm in a Softmax Microplate reader. 
 
3.1.8 In vitro scratch motility assay (In vitro wound healing assay) 
Principle 
The in vitro scratch assay is a straightforward and economical method to study cell 
migration in vitro (Liang, 2007; Todaro et al., 1965). This method is based on the 
observation that, upon creation of a new artificial gap, so called "scratch", on a confluent 
cell monolayer, the cells on the edge of the newly created gap will move toward the 
opening to close the "scratch" until new cell–cell contacts are established again. The basic 
steps involve creation of a "scratch" on monolayer cells, capture of images at the 
beginning and regular intervals during cell migration to close the scratch, and comparison 
of the images to determine the rate of cell migration (Etienne-Manneville and Hall, 2001). 
It mimics to some extent migration of cells in vivo. For example, removal of part of the 
endothelium in the blood vessels will induce migration of endothelial cells into the 
denuded area to close the wound. Furthermore, the patterns of migration either as loosely 
connected population (e.g., fibroblasts) or as sheets of cells (e.g., epithelial and 
endothelial cells) also mimic the behavior of these cells during migration in vivo. Another 
advantage of the in vitro scratch assay is its particular suitability to study the regulation of 
cell migration by cell interaction with ECM and cell–cell interactions. 
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Procedure 
2 x 105 MDA-MB-231 cells were plated in a 6-well plate, incubated overnight in normal 
growth medium and followed by transfection with control and Sdc-1 siRNA. 24 h post 
transfection, the cells were grown overnight in serum-containing media. Then, the cells 
were serum starved for 24 h. The monolayer was scratched with 200 µl pipette tip, 
washed with PBS to remove floating cells in serum-free media and photographed (0 h) 
using a Zeiss Axiovert microscope. Subsequently, cells were stimulated with ±40 ng/ml 
HGF for 6 h. The scratched area was photographed (6 h) and difference of the area before 
and after HGF addition was quantified as percentage by Axiovision software. 
 
3.1.9 In vitro cell adhesion assay 
Principle 
Cell adhesion is a complex process involved in embryogenesis, migration/invasion, tissue 
remodeling, and wound healing. To perform these processes, cells adhere to ECM 
components (via adhesion receptors), forming complexes with components of the 
cytoskeleton that ultimately affect cell motility, differentiation, proliferation, and survival 
(Beauvais and Rapraeger, 2004). We have performed a quantitative colorimetric method 
for evaluating cell adhesion. First, cells are seeded onto the coated substrate, where the 
adherent cells are captured. Next, unbound cells are removed with consecutive washes. 
Finally, the adherent cells are stained, lysed and subsequently detected by 
spectrophotometer. 
 
Procedure 
96-well plates were coated with 50 µg/ml laminin for 1 h at room temperature or 10 µg/ml 
fibronectin at 4°C overnight and washed two times with 0.1% BSA in DMEM without 
FCS. The plate was then incubated for 45 min with blocking buffer (0.5% BSA in DMEM) 
and washed once. 48 h post transfection, control and Sdc-1 siRNA-transfected cells were 
released with 2 mM EDTA in PBS and washed twice and resuspended in blocking buffer. 
25 x 103 cells were added to the coated wells and allowed to attach for 1 h at 37°C, 5% 
CO2. The cells were washed 3 times with PBS and subsequently fixed with 3.7% PBS 
buffered formaldehyde for 30 min. Attached cells were stained with 1% methylene blue 
in 0.01 borate buffer (pH 8.5) for 30 min. following 4 times washing with borate buffer, 
the cells were lysed in ethanol/0.1 M HCl (1:1) and the released stain was quantified by 
spectrophotometry at 620 nm. 
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3.2 Molecular biology 
3.2.1 Knockdown experiments 
Principle 
RNA interference (RNAi), also known as posttranscriptional gene silencing, is initiated 
by long double-stranded RNA (dsRNA) molecules that are homologous to a gene 
sequence (Fire et al., 1998). These long dsRNA molecules trigger a cascade of events that 
lead to the degradation of the corresponding mRNA, and subsequently to reduced levels 
of the corresponding protein. The long dsRNA is cleaved into 21–23 base pair small 
interfering RNAs (siRNAs) by a cytoplasmic enzyme called Dicer (Elbashir et al., 2001). 
The siRNA duplexes are unwound and assembled into a multi-component nuclease, 
RNA-induced silencing complex (RISC) (Preall and Sontheimer, 2005). The activated 
RISC targets the complementary mRNA for degradation (Fig. 3.3). RNAi can be used to 
suppress the function of a gene in a variety of organisms and cell lines, if the sequence of 
the gene is known. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
         Fig. 3.3 Strategy of the RNAi technology (modified from Shan, 2010). 
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Procedure 
For cell transfection, 2 x 105 cells were plated in a 6-well plate 1 day prior transfection. 
The next day, the cells were transfected with negative control siRNA and Sdc-1 siRNA 
using Dharmafect® transfection reagent to deliver siRNA into mammalian cells. The 
transfection was performed as follows per well: 1) Tube 1: 2 µl Dharmafect® was added 
to 78 µl transfection media (OPTI-MEM 1) and incubated 5 min at room temperature 
(RT).  2) Tube 2: 4 µl 40 nM siRNA was added to 76 µl OPTI-MEM 1.  3) The content of 
Tube 1 was added to Tube 2 and incubated for 20 min at RT. In exponentially growing 
cells (> 90% viability) culture medium was replaced with 840 µl OPTI-MEM 1. To avoid 
cytotoxicity caused by transfection, the transfection medium was replaced with complete 
medium after 24 h and the transfected cells were used in different bioassays to investigate 
the potential role of Sdc-1 silencing on breast cancer behaviour. To confirm the 
successful transfection, mRNA expression analysis was performed 48 h post transfection 
by qPCR (► 3.2.2, 3.2.3, 3.2.4, 3.2.6) and protein analysis after 72 h by Western blot (► 
3.3.1, 3.3.2, 3.3.3).  
 
3.2.2 Preparation of total cellular RNA 
Total cellular RNA was isolated using the basic rna-OLS kit (OMNI Life Science). After 
complete removal of culture medium, 400 µl RL buffer was pipetted into confluent 
control and Sdc-1 siRNA-transfected cells, incubated for 2 min at RT and then collected 
by scraping with a cell scraper. The cell lysates were transferred into the spin filter D. 
Then the filter was placed into a 2 ml receiver tube and centrifuged at 10.000 xg for 2 min. 
The spin filter D was discarded and the filtrate containing RNA was kept. The filtrate was 
up and down mixed with equal volume 70% ethanol to remove the protein contamination 
and transferred into a spin filter R that was placed into a receiver tube. The former 
centrifugation step was repeated. Then, the receiver tube was discarded and 500 µl WL-A 
buffer was added to the spin filter R for washing followed by centrifugation at 10.000 xg 
for 1 min. The washing step was repeated by adding 700 µl WL-C buffer and 
centrifugation at 10.000 xg first for 1 min, and then for 3 min to remove all ethanol traces. 
Finally the spin filter R was placed into 1.5 ml elution tube and RNA was eluted by 30-50 
µl nuclease free water and incubated at RT for 1 min followed by centrifugation at 6000 
xg for 1 min. 
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3.2.3 Spectrophotometric estimation of RNA concentration 
 Nucleic acids can absorb ultraviolet light, with an absorption peak at 260nm wavelength. 
The more light absorbed by the sample, the higher the nucleic acid concentration in the 
sample. Aromatic amino acid and phenol absorb at 280 nm. The ratio A260/A280 gives an 
estimation of RNA purity and is about 1.8-2.0. The ratio A260/A280 less than 2 means that 
RNA is contaminated with proteins. (Wilfinger et al., 1997). Purified RNA was diluted 
1:20 in nuclease free water to measure optical density at 260 nm (OD260) against 
nuclease free water as blank. RNA concentration can be estimated by the following 
formula: 
 
3.2.4 Reverse transcription of RNA into cDNA 
The following reagents were added into a nuclease-free tube on ice and gently mixed. 
After a brief centrifugation, they were incubated at 65°C for 5 min and then chilled on ice. 
 
Reagents 
 
Volume/Concentration 
Total RNA 1 µg 
 
Random hexamer 1 µl 
 
Nuclease free water to 11 µl 
 
Total volume 11 µl 
 
 
The following components were added afterwards: 
 
 
 
RNAFVOD
mL
µg
c ⋅⋅=



260  
OD260: Optical density (Absorption) at 260 nm 
V: Dilution factor 
F: Extinction coefficient 
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Reagents             
                                                                         
Volume 
5X reaction buffer 4 µl 
 
RiboLock™ RNase Inhibitor (20 U/µl)         1 µl 
 
10 mM dNTP mix 2 µl 
 
M-MuLV Reverse Transcriptase (20 U/µl) 2 µl 
 
 Total volume 20 µl 
 
 
The former components were mixed gently and centrifuged and the following program 
was applied: 5 min at 25°C followed by 60 min at 37°C. The reaction was terminated by 
heating at 70°C for 5 min and subsequently chilled on ice. The formed cDNA was 
brought to a volume of 100 µl with nuclease free water and stored at -20°C until further 
use. 
 
3.2.5 DNA amplification and conventional polymerase chain reaction 
Principle 
The polymerase chain reaction (PCR) is a thermal cycling method for amplification of a 
defined DNA fragment (Saiki et al., 1985). By using two pre-synthesized 
oligonucleotides (primer), which are complementary to the target DNA segment, certain 
genomic DNA or cDNA sequences can be selectively amplified. This reaction was used 
to detect quantitative changes in mRNA expression of selected genes in cells under the 
influence of certain substances or treatments. The sequences of the cDNA to be amplified 
corresponded therefore to a coding portion of the gene. The formed PCR products were 
then detected and quantified.  The amount of formed product is correlated to the 
expression level of the examined gene. Typically, PCR is repeated for 30 to 40 cycles and 
this is performed in an automated cycler, which can heat and cool the tubes with the 
reaction mixture in a very short time. PCR consists of the following steps: 
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1. Initial denatuartion: is a step consists of heating the reaction to a temperature of 
94–96°C for 3-5 min which is required for heat activation of DNA polymerases by 
hot-start PCR and initial complete denaturation of the target DNA. 
2. Denaturation: during the denaturation, the double strand melts into a single-stranded 
DNA (ssDNA) by disrupting the hydrogen bonds between complementary bases at 
94–98°C for 20–30 seconds (sec). 
3. Annealing or hybridization: the reaction temperature is lowered to 50–65°C for 
20–40 sec allowing annealing of the primers to the ssDNA template. Stable DNA-DNA 
hydrogen bonds are only formed when the primer sequence very closely matches the 
template sequence. The annealing temperature depends on the target sequence. 
4. Extension or elongation: at this step, the DNA polymerase synthesizes a new DNA 
strand complementary to the DNA template strand by adding dNTPs that are 
complementary to the template in 5' to 3' direction. Taq polymerase has its optimum 
activity temperature at 72°C.  
5. Final elongation: this a single step is occasionally performed at a temperature of 
70–74°C for 5–10 min after the last PCR cycle to ensure that any remaining 
single-stranded DNA is fully extended. PCR products were detected by agarose gel 
electrophoresis. 
 
Procedure 
The optimal reaction conditions and the number of reaction cycles were determined 
empirically based on the primers used and the expression level of the DNA segment to be 
amplified. For a PCR reaction, 22.5 µl master mixture and 2.5 µl cDNA were pipetted 
into a sterile reaction tube. For the negative control, 2.5 µl RNAase free water was 
pipetted instead of cDNA. The following amplification cycles program as an example 
was employed for dysregulated membrane protein palmitoylated 4 (MPP4) detection: 
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Mastermix Temperature program: 
2.5 µl fwd-Primer (10 pmol/µl) 
2.5 µl rev-Primer (10 pmol/µl) 
5 µl 5X-PCR-buffer 
0.5 µl dNTP-Mix 
0.125 µl Taq-Polymerase 
11.88 µl nuclease free Water 
   5’ 95°C 
30’’ 94°C 
30’’ 50°C  33 Cycles 
30’’ 72°C 
 10’ 72°C 
 
 
Agarose gel electrophoresis 
Negatively charged nucleic acids can be separated according to their size through an 
agarose matrix with an electric field where shorter molecules migrate faster than longer 
ones because of the sieving effect of the gel. The concentration of agarose varied (1-2%) 
depending on the size of the DNA fragments expected. To prepare 1.5% agarose gels, 1.5 
g agarose was dissolved in 100 ml 1X TBE electrophoresis buffer at 90-100°C in 
microwave oven for 1-2 min. After cooling down to 60°C, 5 µl ethidium bromide was 
added and the gel was poured into a tray with a comb to generate the sample wells. PCR 
products (3 µl) were loaded into the gels and run at 100 volt in 1X TAE buffer for 30 min. 
DNA molecular weight marker (100 bp DNA ladder: 100-1517 bp) was used to determine 
the size of DNA fragments. DNA fragments on the gel were visualized under UV light 
and were documented using a BioDoc Analyze system. 
 
3.2.6 Real time PCR 
Principle 
Real-time PCR, also known as kinetic PCR, qPCR, qRT-PCR and RT-qPCR, is a 
quantitative PCR method for the determination of the copy number of PCR templates 
such as genomic DNA or cDNA in a PCR reaction. Real-time PCR can be probe-based or 
intercalator-based. Both methods were conducted in present study. Real-time PCR 
detects PCR products as they accumulate. The intercalator-based system includes the 
intercalator dye SYBR green in each amplification reaction, an adapted thermocycler to 
irradiate the samples with light of the proper excitation wavelength, and detection of the 
resulting fluorescence with a computer-controlled cooled CCD camera. Amplification 
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produces increasing amounts of dsDNA, which binds SYBR green dye, resulting in an 
increase in fluorescence. By plotting the increase in fluorescence versus cycle number, 
the system produces amplification plots that provide a more complete picture of the PCR 
process than assaying product accumulation after a fixed number of cycles. For 
intercalator-based PCR, melting curve analysis and agarose gel electrophoresis have to be 
performed for control purposes to ensure that no unspecific products were amplified. 
 
TaqMan PCR (probe-based PCR), requires a pair of PCR primers as regular PCR does, 
and an additional fluorogenic probe, thus increasing specificity of the PCR reaction. 
Holland et al., (1991) were the first to demonstrate that cleavage of a target probe during 
PCR by the 5' nuclease activity of Taq DNA polymerase could be used to detect 
amplification of the target-specific product. The probe is an oligonucleotide with both a 
reporter fluorescent dye and a quencher dye attached. While the probe is intact, the 
proximity of the quencher greatly reduces the fluorescence emitted by the reporter dye by 
Förster resonance energy transfer (FRET) through space. The probe is subsequently 
degraded by the thermostabile DNA-polymerase, resulting in a separation of the reporter 
from the quencher, and thus in increased fluorescence, which is proportional to the 
amount of DNA synthesized during the PCR reaction (Fig. 3.4) (Higuchi et al., 1992; 
Higuchi et al., 1993). 
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Fig. 3.4 Principle of TaqMan-PCR. In addition to the two amplification primers, a third 
gene specific probe, carrying a reporter and a quencher, hybridizes to the amplified gene. 
During amplification, this probe is degraded by the exonuclease activity of the Taq 
polymerase, the reporter separates from the quencher and a fluorescent signal can be 
measured (modified from assay-manual of Applied Biosystems, Foster City, USA). 
 
 
Procedure 
As described under 3.2, the cells were lysed and 1µg RNA of the prepared total RNA was 
reverse transcribed into cDNA (► 3.2.2, 3.2.3, 3.2.4). cDNA (2.5 µL), diluted with 11.25 
µL nuclease free water was used as a template for subsequent real-time PCR. The reaction 
mixture, 1.25 µL of the desired gene TaqMan ® Gene Expression Assays (contains both 
primer and a TaqMan® probe with 6-carboxy-fluorescein (FAM) as reporter and 
6-Carboxytetramethyl-rhodamine (TAMRA) as quencher) and 12.5 µL TaqMan® 
Universal PCR Master Mix (containing the polymerase and dNTPs) were added. An 
additional reaction for the expression of an internal control or house keeping gene (a gene 
whose expression is not affected by the treatment, here is 18S) was determined. The 
initial activation of Taq polymerase was carried out at 95°C for 10 min. Then 40 cycles 
were run for 15 sec at 95°C (denaturation) and 1 min at 60°C (annealing / extension). 
Each sample was carried out in duplicate. 
 
The data were analyzed using the ∆∆Ct method (Livak and Schmittgen, 2001). This 
quantification method measures the relative change in the expression level of the target 
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gene in both control and transfected (treated) cells with respect to an endogenous 
(reference) gene. These quantifications are based on the increase of cDNA per cycle: 
 
(1)  nn EXX )1(0 +⋅=
   Xn: The number of target molecules at n cycle 
X0: The initial number of target molecules 
E: The efficiency of target amplification (0 ≤ E ≤ 1) 
n: Number of cycles 
 
For amplicons designed to be less than 150 bp and for PCR conditions have been properly 
optimized, the efficiency is close to one (E=1) so,  
 
(2)  nn XX 20 ⋅=  Xn: The number of target molecules at n cycle 
X0: The nitial number of target molecules 
n: Number of cycles 
 
The threshold cycle (CT) indicates the fractional cycle number at which the amount of 
amplified target reaches a fixed threshold. Thus, 
 
(3)  Ctt XX 20 ⋅=  Xt: The threshold number of target molecules 
X0: The initial number of target molecules 
Ct: The threshold cycle for target amplification 
 
A similar equation for the endogenous reference (internal control gene) reaction is 
 
                                 Rt = Ro .2
Ct  
 
Dividing Xt by Rt gives the expression: 
 
(4)  
R
X
Ct
Ct
t
t
R
X
R
X
2
2
0
0
⋅
⋅
=  
Xt: The threshold number of target molecules 
Rt: The threshold number of reference molecules 
X0: The initial number of target molecules 
R0: The initial number of reference molecules 
CtX: The threshold cycle for target amplification 
CtR:  The threshold cycle for reference amplification 
 
So, 
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(5)  Ctq
t
t X
R
X ∆⋅= 2  
Xt: The threshold number of target molecules 
Rt: The threshold number of reference molecules 
Xq = X0/R0: equal to the normalized amount of target 
∆Ct = CtX - CtR: equal to the difference in threshold 
cycles for target and reference  
 
For real-time amplification using TaqMan probes, the exact values of Xt and Rt depend on 
a number of factors including the reporter dye used in the probe, the sequence context 
effects on the fluorescence properties of the probe, the efficiency of probe cleavage, 
purity of the probe, and setting of the fluorescence threshold. Therefore, the constant K 
does not have to be equal to one: 
 
(6)  Ctq KX
∆−⋅= 2  K= Xt/Rt  
 
 
The final step is to divide the Xq for any sample q by the Xq for the calibrator (c). The 
simplest design is to use untreated control as the calibrator. Therefore, the amount of 
target, normalized to an endogenous reference and relative to a calibrator, is given by 
 
(7)  
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For relative quantification (RQ) = (Xq)TS / (Xq)C  und -∆∆Ct = - (∆CtTS - ∆CtC)  
 
(8)  CtRQ ∆∆−= 2   
 
Relative gene expression levels for each target gene were determined using the 2-∆∆Ct 
method of duplicate reactions after normalization to 18S. The analysis of the raw data 
(determining the Ct values) was performed using the Sequence Detection Software 
version 1.4 and the calculation of RQ (equation 8) was computed using MS Excel. 
 
 
 
 
 
Methods 
 74 
3.2.7 Microarray expression analysis 
Principle 
Gene Microarray technology allows the simultaneous measurement of the concentrations 
of RNA molecules (or transcripts). More precisely, this technology allows the 
measurements of the expression patterns of genes also known as expression profiles. For 
example, by comparing the expression profiles of disease and normal cells (Alizadeh et 
al., 2000), responses of cells to environmental conditions (Gasch et al., 2000), or during 
biological process such as cell cycle (Spellman et al., 1998) and development (Tomancak 
et al., 2002), the researchers can explore the dynamics of gene expression, to form 
hypotheses about regulatory and functional roles of genes, and to obtain molecular 
signatures of cell types and all this on a genome-wide scale. 
 
The main idea behind DNA microarrays is to exploit the fact that two complementary 
single stranded DNA molecules hybridize (Jain, 2001). For each gene of interest, a short 
sequence complementary to its sequence is select. These sequences are called probes and 
have lengths ranging from 20 to 60 bases. The probes should be selected in such a way 
that there is a low chance of hybridizing with sequence others than the target gene 
sequence. Then, with the aid of robotics or nano manufacture technologies, thousands of 
copies of a particular probe are placed in a tiny area of a hard surface, the array. 
Thousands of such probe spots can be placed side by side forming a grid on the array. 
Each spot contains probes designed to hybridize with RNA from a specific gene. In the 
end, one can have as many as 105 spots arranged in a 2 x 2 cm array. 
 
There are several distinct microarrays technologies such as cDNA microarrays (Schena, 
1996) and Affymetrix Gene Chips (also known as Oligonucleotide arrays) (Lipshutz et al., 
1995). They differ mostly by how the chips are manufactured and on methodologies for 
probe selection. The particular characteristics of such technologies are important for 
decisions concerning experimental design, experimental costs, measurements reliability 
and data pre-processing aspects. 
 
In double channel microarrays, such as cDNAs microarrays, two cell samples are poured 
in the same microarray: cells of interest (e.g., disease cells, treated cells) and reference 
cells (e.g., healthy cells, untreated cells). Each of these cell populations is dyed with a 
distinct marker, for instance, a red Cy3 dye versus a green Cy5 dye. Double channel 
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microarrays return a relative quantification of the RNA expression in relation to the 
reference cell, usually measured by taking the logarithm of the ratio between the red and 
green signals. In single channel arrays, only one RNA sample is poured in the array, and 
no reference sample is used.  
 
Affymetrix microarray, an example of single channel array applied in this study, return 
estimates on the number of copies of a particular transcript in a given sample. 20 to 40 
distinct probes, which are complementary to the sequence of a unique gene, are placed in 
distinct spots on the array in order to obtain reliable estimates of RNA quantities. 
Additionally, a mismatch spot (MM) containing a sequence, where a base in the middle of 
the original probe (perfect match (PM)) sequence is exchanged, is placed next to each PM 
spot. These reduce the effect of cross-hybridization, increase the signal to noise ratio and 
improve the accuracy of the RNA quantification. 
 
Procedure 
Preparation of biotin-labeled complementary RNA was performed using the Affymetrix 
One Cycle cDNA synthesis kit exactly as described by the manufacturer (Fig. 3.5). All 
incubation temperatures steps were done in themocycler. 
 
Preparation of poly-A controls 
Serial dilution of poly A control stock with dilution buffer was prepared as 1:20 (2 µl+38 
µl), 1:50 (2 µl+98 µl) and 1:10 (2 µl+18 µl). Consequently, 2 µL of the third dilution was 
added to 5 µg RNA. 
 
Preparation of first strand cDNA 
The following components were prepared as the following 
 
Reagents                                                                                     
 
Volume/Concentration 
Total RNA 
 
5 µg 
Third dilution of poly-A controls 2 µl 
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50 µM T7-Oligo(dT)-Primer 2 µl 
 
Nuclease free water to 12 µl 
 
 Total volume 12 µl 
 
 
Gently were mixed, centrifuged briefly and incubated at 70°C for 10 min then chilled on 
ice. The following first strand master mix was prepared, gently were mixed and added to 
the former reaction mixture afterwards: 
 
 
Reagents                                                                                     
 
Volume 
5X First strand reaction mix 4 µl 
 
0.1 M DTT 
 
2 µl 
 
10 mM dNTP 
 
1 µl 
 Total volume 7 µl 
 
 
Centrifuged briefly and incubated at 42°C for 2 min then chilled on ice. Then 1 µl 
SuperScript II reverse transcriptase (200 U/µL) was added, mixed well, briefly 
centrifuged and incubated at 42°C for 1 h then chilled on ice. 
 
Preparation of the second strand cDNA synthesis 
The following components were added to 20 µl of the synthesized first strand cDNA 
 
Reagents                                                                                     
 
Volume
5X  second strand reaction mix 30 µl 
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10 mM dNTP mix 3 µl 
 
E.coli DNA ligase (10 U/µl) 1 µl 
 
E.coli DNA polymerase (10 
U/µl) 
 
4 µl 
RNase H (2U/µl) 1 µl 
 
Nuclease free water  91 µl 
 
 Total volume 130 µl 
 
 
Gently were mixed, centrifuged briefly and incubated at 16°C for 2 h.  Consequently, 2 µl 
T4 DNA polymerase (10 U/µl) was added and incubated at 16°C for 5 min and then 
chilled on ice. Finally 10 µl 0.5 M EDTA was added. DNA was subsequently freeze-dried 
in a SpeedVac concentrator and shipped to Professor George Yip’s group (National 
University of Singapore) for further analysis as described previously (Nikolova et al., 
2009).  
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Total RNA 
 
First strand cDNA 
syntheis 
 
8 µl of 5 µg total 
RNA/nuclease free water + 2 
µl poly A control + 2 µl 
primer 
 
Incubation for 
10 min at 70°C 
 
Addition of 7 µl first strand 
master mix 
 
Incubation for 2 min at 42°C 
 
Second strand  cDNA 
synthesis 
Addition of 
130 µl second strand 
synthesis master mix 
Incubation for 
2 h at 16°C 
 
Addition of 2 µl T4 DNA- 
polymerase 
Incubation for 
5 min at 16°C 
 
Addition of 10 µl 0.5 M 
EDTA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Addition of 1 µl Superscript II 
reverse transcriptase 
 
Reverse transcription 
for 1 h at 42°C 
cDNA cleanup by 
GeneChip® Sample 
Cleanup Module 
cDNA 
       In vitro 
transcription (IVT) 
Addition of 
20 µl IVT-master mix 
Incubation for 16 h 
at 37°C 
cRNA cleanup by 
GeneChip® 
Sample 
Cleanup Module 
   cRNA 
Fragmentation 
15 µg cRNA + 
8 µl Fragmentation 
Buffer 
Heated up to 
94°C for 35 min 
Hybridization 
10 µg fragmented 
cRNA 
Hybridization at 
45°C for 16 h 
Washing & 
Staining 
Automated by 
Affymetrix Fluidics 
Station 400 
Scanning 
Fig. 3.5 Schematic representation of the            
Affymetrix work flow 
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3.2.8 Luc-Pair ™ miR Luciferase Assay 
Principle 
The study of transcriptional regulation using reporter gene expression is common in cell 
biology research and pharmaceutical discovery. In earlier years, research focused on the 
regulation of promoter activity. Recently, post-transcriptional regulations have been 
identified as another gene regulatory mechanism found in cells. For example, small 
inhibitory RNAs, such as siRNA and miRNA, have been implicated in a wide range of 
post-transcription cellular functions. 
 
Firefly (Photinus pyralis) luciferase has been proven to be an ideal reporter for 
monitoring both promoter activity and post-transcriptional regulations in the control of 
gene expression. It is a cytoplasmic enzyme with a molecular weight at about 61 kDa and 
catalyzes the following reactions: 
                                      Luciferase 
ATP + luciferin + O2                            Oxyluciferin + AMP + PPi + CO2 + light 
                                         Mg2+ 
The intensity of light emission is linearly related to the amount of luciferase and is 
measured using a luminometer and luminescence plate reader. Renilla (Renilla reniformis) 
luciferase is a 36 kDa protein. It is a monomeric protein and requires no posttranslational 
processing. It can function as a genetic reporter immediately upon translation. It catalyzes 
the following reaction: 
 
 
 
 
 
 
 
 
In general, it is relatively simple to monitor the upregulation of genetic elements with 
firefly luciferase assays. It has been more difficult to measure the down regulation of 
genes since assay windows are relatively small for down regulation and some 
non-specific events can reduce the luciferase activity, such as cell death. Therefore, 
normalizing the expression of an experimental reporter to the expression of an 
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independent control reporter can help differentiate between specific and nonspecific 
cellular responses. Normalization is also needed for adjusting differences in transfection 
efficiencies and cell viability. Firefly and Renilla luciferases have been widely used as 
co-reporters for normalization studies because both assays are quick, easy and sensitive. 
Firefly and Renilla luciferases are ideal co-reporters because they have distinct 
evolutionary origins and very different enzyme structures and substrates. The assay 
system by GeneCopoeia, Inc. was used in this study, as it measures the activities of firefly 
and Renilla luciferase sequentially from a single sample. The firefly luciferase 
luminescence is elicited by one reagent, while a second reagent simultaneously quenches 
the firefly luciferase and elicits Renilla luciferase luminescence 
(http://www.genecopoeia.com/product/mirna/pdf/). 
 
Procedure 
Plasmid pEZX-MT01 transformed E.coli was purchased from Genecopia. The 
transformed E. coli cells were plated out onto a LB agar plate containing Kanamycin and 
the cells were left to grow overnight. Thereafter, a single, well-grown bacterial culture 
was utilized to inoculate in 500 ml LB medium with Kanamycin antibiotic, and then the 
culture was grown for 14 – 16 h. Consequently, the bacterial cells from the E. coli culture 
were spun down for 3 min at 12.000 xg and the supernatant was removed quantitatively 
with a pipette. Following the resuspension of the cells in 20 ml buffer E1 containing 100 
µg/ml RNase avoiding cell clumps, the bacterial cells were lysed and mixed gently but 
thoroughly (e.g. by multiple inverting) with 20 ml buffer E2 until a homogeneous mixture 
was obtained. The bacterial cell lysate was incubated at RT for 5 min. The lysis mixture 
was neutralized with 20 ml buffer E3. The neutralization mixture with all the precipitated 
matter was applied into the lysate Filter Unit inserted into pre- equilibrated JETSTAR 2.0 
column with 30 ml of equilibration buffer E4. The lysate was let to run through by gravity 
flow until the flow stops. Residual bacterial lysate was washed out by applying 20 ml of 
buffer E5 into the filtration device. As soon as the JETSTAR column stopped dripping, 
the filtration device was discarded and the JETSTAR column was washed by applying 50 
ml of wash buffer E5. The DNA was eluted from the column into the clean tube with 15 
ml of elution buffer E6 and precipitated by mixing with 0.7 vols. of isopropanol. Lastly, 
the DNA was spun down for 30 min at 12.000 xg at 4°C, washed with 70-80% ethanol, 
briefly dried for 5 - 10 min and dissolved in 30 µl nuclease free water. The quantification 
was performed as described before (► 3.2.3). 
Methods 
 81 
To investigate transcriptional regulation of Sdc-1 expression by miR-10b, pre-miR-10b 
was co-transfected along with 1 µg of plasmid pEZX-MT01 expressing firefly luciferase 
under the control of the human Sdc-1 3′UTR, and Renilla luciferase under the control of 
the constitutively active cytomegalovirus (CMV) promoter. Luciferase assays were 
performed in quadruplets (n=3 experiments) in a 96-well format using the Luc-Pair miR 
Luciferase Assay exactly as described by the manufacturer. 2 x 105 MDA-MB-231 breast 
cancer cells were plated in a 6-well plate 1 day prior transfection. The next day, control 
miR-precursor or pre-miR-10b were co-transfected along with 1 µg of plasmid 
pEZX-MT01 expressing firefly luciferase under the control of the human Sdc-1 3′UTR, 
and Renilla luciferase under the control of the CMV using Dharmafect® transfection 
reagent. The transfection was performed as following per well: 1) Tube 1: 2 µl 
Dharmafect® was added to 78 µl transfection media (OPTI-MEM 1) and incubated 5 min 
at RT. 2) Tube 2: 4 µl control miR-precursor or 4 µl pre-miR-10b and 2.5 µl plasmid 
pEZX-MT01 expressing firefly luciferase under the control of the human Sdc-1 3′UTR 
was added to 73.5 µl OPTI-MEM 1. 3) The content of Tube 1 was added to Tube 2 and 
incubated for 20 min at RT. In exponentially growing cells (> 90% viability) culture 
medium was replaced with 840 µl OPTI-MEM 1. To avoid cytotoxicity caused by 
transfection, transfection medium was replaced with complete medium after 24 h. At 48 h 
after transfection, the growth media were removed and cell lysates were prepared by 
addition of 320 µl solution I and using a rubber policeman. 80 µl of the cell lysates were 
transferred into a black 96-well plate following by addition of 20 µl of the 5X working 
solution I (substrate I+ solution I, dilution 1:40), the absorbance was measured by 
luminometer. Quickly, 100 µl of the working solution II (substrate II+ solution II, 
dilution 1:200) was added to the same wells and the absorbance was measured again to 
normalize firefly to Renilla luciferase activity. Data were expressed as percent of the 
relative luciferase activity to control miR-transfected cells. 
 
3.3 Protein biochemistry 
3.3.1 Preparation of total cell extracts 
Cells were placed on ice and the medium was removed. Cells were washed once with 
ice-cold PBS. Appropriate volume of cold modified RIPA lysis buffer containing 
proteases inhibitors was added to the cells. Cells were scraped from the plate using a cell 
scraper and transferred to a fresh eppendorf tube. The sample was shaked for 40 min and 
centrifuged at 13.000 rpm for 10 min at 4°C. The total cell lysate was carefully 
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transferred to a fresh tube. A small aliquot of the lysate was used for protein 
quantification and the rest was stored at –20°C. 
 
3.3.2 Estimation of protein concentration using the Bicinchoninic acid 
method  
Principle 
Protein determination is one of the most common approaches performed in biochemical 
research. The principle of the Bicinchoninic acid (BCA) assay according to Smith, et al. 
(1985), is similar to the Lowry procedure in that both rely on the formation of a Cu2+ 
protein complex under alkaline conditions, followed by reduction of the Cu2+ to Cu1+. 
The amount of reduction is proportional to the protein present. It has been shown that 
cysteine, trytophan, tyrosine and the peptide bond are able to reduce Cu2+ to Cu1+. BCA 
forms a purple blue complex with Cu1+ in alkaline solutions with an absorbance 
maximum at 562 nm. The absorbance is directly proportional to the protein concentration. 
This provides a basis to monitor the reduction of alkaline Cu2+ by proteins and thus 
determine the protein concentration in a biochemical sample.  
 
Procedure 
Protein quantification with BCA was performed using the Micro BCA protein assay kit. 
BSA was used as a standard in this assay. BSA was diluted in PBS at a concentration 
ranging from 100 µg/ml to 1000 µg/ml and PBS used for preparing standards was used as 
a blank for constructing a standard curve (Fig. 3.6). 25 µl of each of the standards and the 
blank were pipetted into a 96-well plate at least in duplicates. 25 µl of the diluted sample 
(1:5 or 1:10) was in duplicates in the same 96-well plate. 200 µl of freshly prepared the 
working reagent (50 parts Reagent A and 1 part Reagent B) was added to each well 
containing the standards and the samples and the plate was mixed thoroughly on a plate 
shaker for 30 sec. Subsequently, the plate was covered and incubated at 37°C for 30 min 
and allowed to cool to RT before measuring the absorbance at 562 nm in a 
spectrophotometer. The amount of protein was quantified using the standard curve. 
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BSA concentration in µg/ml Volume of  1mg/ml BSA Volume of PBS 
 
1000 
 
1 ml 0 ml 
750 
 
750 µl 250 µl 
500 
 
500 µl 500 µl 
250 
 
250 µl 750 µl 
100 
 
100 µl 900 µl 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.6 Standard curve of the protein concentration using BSA as a standard protein 
according to BCA method. 
 
 
3.3.3 Polyacrylamide gel electrophoresis and Western blot 
Polyacrylamide gel electrophoresis (PAGE) is an analytical technique used to separate 
and characterize proteins. Polyacrylamide gels are composed of chains of polymerized 
acrylamide (linear polymers) that are cross-linked by the bifunctional agent 
bisacrylamide. The pore size is determined by the ratio of acrylamide to bisacrylamide, 
and by the concentration of acrylamide. Polymerization of acrylamide and bisacrylamide 
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monomers is induced by APS, which spontaneously decomposes to form free radicals. 
TEMED, a free radical stabilizer, is generally included to promote polymerization. 
 
SDS –PAGE 
Principle 
SDS-PAGE involves the separation of proteins based on their size. By heating the sample 
under denaturing and reducing conditions via treating the proteins with anionic detergents 
like SDS and β-mercaptoethanol respectively, proteins become unfolded and coated with 
SDS detergent molecules, acquiring a high net negative charge that is proportional to the 
length of the polypeptide chain. When loaded onto a gel matrix and placed in an electric 
field, the negatively charged protein molecules migrate towards the positively charged 
electrode and are separated by a molecular sieving effect (Laemmli, 1970). After 
visualization by a protein-specific staining technique, the size of a protein can be 
estimated by comparison of its migration distance with that of a standard of known 
molecular weight. 
 
Procedure 
Gel casting 
The gel casting stand was assembled and 12% polyacrylamide separating gel was 
prepared according to the volumes given below (enough for 4 gels). 
 
Stock solution 
 
Volume 
Acrylamid/Bis Solution 30% 
 
8.8 ml (12%) 
2.5X Separating gel buffer 
 
8.8 ml 
Deioinzed water 
 
4.4 ml 
10% APS 
 
200 µl (0.09%) 
TEMED 
 
20 µl  
 
Total volume 22.22 ml 
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The solution was mixed thoroughly and immediately transferred between the plates in the 
gel casting stand. The separating gel was pipetted up to the top of the glass plate leaving 
clear space one third at the top of the plate for the stacking gel. The solution was carefully 
overloaded with isobutanol saturated with water to prevent drying. The gel was allowed 
to polymerize for approximately 30 min. Once the separating gel polymerized, the 
isobutanol was removed and the stacking gel solution was poured on the separating gel 
till the chamber was filled. The desired comb was placed in between the plates in the 
stacking gel solution. The stacking gel was allowed to polymerize for almost 30 min. 
Polymerized gels were either immediately used for electrophoresis or stored at 4°C until 
further use. The stacking gel was prepared according to the volumes given below 
 
 
Stock solution 
 
Volume 
 Acrylamid/Bis Solution 30% 
 
1.12 ml (4%) 
5X stacking gel buffer 
 
1.32 ml 
Deionized water 
 
4 ml 
10% APS 
 
60 µl (0.01%) 
TEMED 
 
8 µl  
 
Total volume 
 
6.508 ml 
 
 
Sample preparation and electrophoresis 
30-60 µg total protein was mixed with 5X sample buffer (1:4) and boiled at 95οC for 5 
min. The boiled samples were briefly centrifuged and loaded onto the gel along with 5 µl 
pre-stained marker. Electrophoresis was performed at 15 mA/gel for the stacking gel for 
about 15 min. Then, the current was increased to 20 mA/gel for the separating gel until 
the marker reached the end of the gel. 
 
Methods 
 86 
Western blot 
Principle 
Western blot is an analytical method wherein protein samples in SDS-PAGE following 
electrophoresis can be transferred to a positively charged membrane (here nitrocellulose) 
by semi-dry electroblotting (Towbin et al., 1979). The gel and membrane are sandwiched 
between two stacks of filter paper that have been pre-wetted with transfer buffer. The 
membrane is placed near the anode (positively charged), and the gel is placed near the 
cathode (negatively charged). SDS-coated, negatively charged proteins are transferred to 
the membrane when an electric current is applied. The transfer of proteins was carried out 
at constant current 5.5 mA/cm2 for minigels for 1-3 h depending on the gel percentage. 
The transfer buffer is containing methanol to remove SDS and to increase the protein 
affinity to membrane.   
 
Procedure 
After gel running, the gels were removed from electrophoresis chamber and the stacking 
gel was cut with scalpel. The resolving gel was equilibrated in transfer buffer at 4Cο to 
remove SDS. At the meantime, the membrane was pre-wetted for 2 min in distilled water 
and then in transfer buffer at 4οC for 10 min. The safety cover of the Trans-Blot SD cell 
was removed and a gel sandwich was prepared in the following order: anode, soaked filter 
paper, membrane, gel, soaked filter paper (Fig. 3.7). Air bubbles between layers were 
rolled out using glass pipette. The cathode plate was added and 16 volt was applied for 
1-2 h. The membrane was subsequently removed and prepared for immunodetection. 
 
Immunodetection 
Principle 
The membrane bound proteins can be detected using specific antibodies. In the present 
study, we entirely used the indirect method using horseradish peroxidase (HRP) 
conjugated secondary antibodies. Before the addition of the primary antibody, the 
membrane first must be incubated with blocking buffer to prevent interactions between 
non-specific binding sites of the membrane and the antibodies. Secondly, the membrane 
can be probed with the primary antibody that will bind the corresponding epitope of the 
protein of interest. Excess primary antibody is removed by washing. Consequently, 
secondary antibody directed to the to the Fc portion of the primary antibody will be added. 
Enhanced chemiluminescent substrates produce light in proportion to the amount of 
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protein, which can be detected with the aid of X-ray films. HRP catalyzes the oxidation of 
luminol in the presence of hydrogen peroxide. The luminol, which is in an excited state 
immediately following the reaction, decays via a light-emitting pathway. This emission 
of light can be enhanced up to a 1000-fold by the addition of compounds, such as phenols. 
The image of the blot is visualized by exposing the blot to a film or a digital camera. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.7 Trans-Blot SD Semi-Dry Electrophoretic Transfer Cell showing the assembly of 
gel and membrane. 
 
 
Procedure 
After the transfer, the blot was stained Ponceau S stain for 2 min to determine the 
efficiency of protein transfer. The blot was destained in water for additional 5 min and 
directly used for antibody incubation. Blocking of the membrane was performed in 
blocking buffer for 1 hr at RT followed by incubation with the appropriate dilution (Table 
3.2) of primary antibody overnight at 4°C with gentle shaking. The membrane was 
washed 2X with washing buffer for 5 min each followed by 1X washing for 20 min. 
Consequently, the membrane was incubated with the corresponding HRP conjugated 
secondary antibody diluted in blocking buffer for 1 h at RT with gentle shaking followed 
by 3X washing for 5 min each. The blot was then incubated with appropriate amount of 
chemiluminescent substrate solution for 1 min. The excess substrate was drained and the 
membrane was put in a polythene sheet for detection. In a dark room, the signal was 
detected by exposing the membrane to an X-ray film and the film was developed by 
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briefly swirling in developer, acetic acid 1% and fixer, rinsed briefly in tap water and 
finally dried. 
 
Table 3.2  Dilution of primary and secondary antibodies utilized 
for detection by immunoblotting 
Antibody Dilution 
anti-goat-IgG, H&L-Chain, HRP-Conj., Rabbit 1:2000 
anti-human-Akt, polyclonal, Rabbit 1:1000 
anti-human-AML1, polyclonal, Rabbit 1:1000 
anti-human-Annexin A3, polyclonal, Rabbit 1:500 
anti-human-ATF-2 (20F1), monoclonal, Rabbit 1:1000 
anti-human-Cadherin11, clone 5B2H5, Mouse 1:500 
anti-human-CDK6 (DCS83), Mouse mAb 1:2000 
anti-human-COL1A2 (M-19), polyclonal, Goat 1:500 
anti-human-COX-2 (C-20), polyclonal, Goat 1:500 
anti-human-E-Cadherin, clone 36, Mouse 1:2000 
anti-human-EMP-2 (M-21), polyclonal, Rabbit 1:500 
anti-human-Fascin-1 (55K-2), monoclonal, Mouse 1:1000 
anti-human-GAPDH (V-18), polyclonal,Goat 1:500 
Anti-human-Met (C-12), polyclonal, Rabbit 1:500 
anti-human-MPP4 (H10), monoclonal, Mouse 1:2 
anti-human-p21 Waf1/Cip1 (12D1), monoclonal, Rabbit 1:1000 
anti-human-p38 MAP Kinase, polyclonal, Rabbit 1:1000 
anti-human-p44/42 MAP Kinase, polyclonal, Rabbit 1:1000 
anti-human-PAI-1 (3A120), monoclonal, Mouse 1:1000 
anti-human-phosho-Akt (ser473), polyclonal, Rabbit 1:1000 
anti-human-phospho -FAK (Tyr925), polyclonal, 
Rabbit 
1:1000 
anti-human-phospho p44/42 MAP Kinase 
(Thr202/Tyr204), polyclonal, Rabbit 
1:1000 
anti-human-phospho-Met (Tyr1234/1235), 
polyclonal, Rabbit 
1:1000 
anti-human-phospho-p38 MAP Kinase 
(Thr180/Tyr182), polyclonal, Rabbit 
1:1000 
anti-human-Phospho-Tyrosine (P-Tyr-100), 
monoclonal, Mouse 
1:2000 
anti-human-Rho A/B/C (H-70), polyclonal, Rabbit 1:200 
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anti-human-Rho B (119), polyclonal, Rabbit 1:500 
anti-human-Syndecan-1 (C-20), polyclonal, Goat 1:500 
anti-human-Syndecan-1 (DL-101), monoclonal 
Mouse 
1:500 
anti-human-Syndecan-1, polyclonal, Goat 1:500 
anti-human-uPAR (FL-290), polyclonal, Rabbit 1:500 
anti-human-Vinculin, clone hVIN-1, Mouse 1:2000 
anti-human-α-Tubulin, clone B-5-1-2, Mouse 1:4000 
anti-human-β-Catenin Antibody 
(Carboxy-terminal Antigen) polyclonal, Rabbit 
1:1000 
Anti-mouse Matrilin-2, affinity-purified, polyclonal 
rabbit 
1:500 
anti-mouse-IgG, H&L-Chain, HRP-Conj., Goat 1:10.000 
anti-rabbit-IgG, H&L-Chain, HRP-Conj., Goat 1:2000 
 
For total protein detection, membranes were stripped with stripping buffer 2X for 5 min 
each and once for 20 min at RT, washed 3X for 5 min, and reprobed with primary 
antibodies followed by the procedure described above. All other proteins were detected 
analogously with appropriate dilution of primary antibodies as mentioned above. 
 
3.3.4 Co-immunoprecipitation 
Principle 
Co-immunoprecipitation is most commonly used for identification of interacting partners 
of a target protein from the multitude of the proteins present in a cell lysate, and for 
investigating protein-protein associations in vivo. The procedure includes the following 
steps: 1) an antibody specific to the protein of interest is added to a cell lysate. 2) the 
antibody-protein complex is then precipitated by antibody-binding proteins usually using 
protein-G or protein-A sepharose. If there are any protein/molecules that bind to the first 
protein, they will also be precipitated. 3) the bound antibody-antigen complex is 
subsequently released from the antibody-binding molecule and the co-precipitated 
protein can then be analyzed by Western blot analysis or by sequencing a purified protein 
band (Harlow et al., 1986). 
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Procedure 
Preparation of precleared cell lysates 
3 x 106 MDA-MB-231 breast cancer cells were seeded in 10 cm dishes and incubated at 
37°C up to 90% confluency. Subsequently, cells were washed once with ice cold PBS and 
then 400 µl of cold modified RIPA buffer with protease inhibitors were added to the cells. 
Cells were scraped with a cell scraper and the cell lysates were collected in an Eppendorf 
tube. The tubes were centrifuged at 13.000 rpm at 4°C for 10 min to get rid of the debris. 
The clear lysate was then carefully transferred into fresh tubes. The cell lysates were 
precleared by addition of 1 µg IgG corresponding to host species of the primary antibody 
and 20 µl resuspended protein A/G plus agarose and incubated at 4°C for 30 min. 
following centrifugation at 2500 rpm for 5 min at 4°C to pellet the beads, the clear 
supernatant was carefully transferred into fresh tubes. The total protein concentration of 
the supernatant was estimated using the BCA method and at least 500 µg of total protein 
was used for the co-immunoprecipitation. 
 
Co-immunoprecipitation 
2 µg primary antibody (10 µl) were added to 500 µg protein in a 1.5 ml eppendorf tube 
and incubated at 4°C overnight with gentle rocking. On the next day, the mixture was 
incubated with 20 µl resuspended protein A/G PLUS-Agarose at 4ºC on a rocker platform 
overnight. Subsequently, the immunoprecipitate was collected by centrifugation at 2500 
rpm for 5 min at 4ºC. The pellet was washed 4 times with PBS with repeating the former 
centrifugation. Finally, the beads were resuspended in 40 µl sample buffer, boiled for 5 
min, 20 µl were loaded into 10% gel and the immnoblot was performed as described in 
the Western blot chapter (► 3.3.3). 
 
3.3.5 Separation of Cytosol and Membrane Fractions with Triton X-114 
2 x 105 MDA-MB-231 cells were plated in a 6-well plate, and incubated overnight in 
normal growth medium. On the next day, the cells were transfected with control and 
Sdc-1 siRNA. After 24 h, the transfection media were replaced with growth media 
containing 10% FCS. For separation of subcellular cytosolic and membrane fractions, 
after 48 h the cells were washed twice with ice-cold PBS and lysed in ice cold 100 µl 
fractionation lysis buffer/well  containing protease inhibitors. Cells were scraped with a 
cell scraper and collected in an Eppendorf tube. The cells were then disrupted by 6-7 
cycles of freezing in liquid nitrogen and thawing at 37°C. The crude lysate was subjected 
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to centrifugation at 100.000 ×g for 30 min at 4°C and the supernatant was collected as the 
cytosolic fraction. Pellets were resuspended, and membrane proteins were homogenized 
in 100 µl of lysis buffer containing 2% Triton X-114. The homogenate was centrifuged at 
800 ×g for 10 min. The supernatant was collected and is referred to here as the particulate 
fraction. Cytosolic and particulate fraction proteins were separated by SDS-PAGE and 
immunoblotted (► 3.3.3) 
 
3.3.6 Gelatin zymography 
Principle 
Since MMP-2 and MMP-9 have strong gelatinolytic activity, these secreted enzymes can 
be easily detected in the conditioned media of the cells by gelatin zymography. This 
approach is based on SDS-PAGE, which includes a substrate copolymerized with the 
polyacrylamide gel for the detection of enzyme activity. The samples should be prepared 
without reducing reagent or boiling to avoid destruction of the original structure and 
enzyme activity and electrophoresis should be performed at 4°C. Following 
electrophoresis, the SDS is removed from the zymogram by incubation in Triton X-100, 
followed by incubation in an appropriate digestion buffer overnight at 37°C. Total protein 
is detected by Coomassie Blue staining. Clear bands represent areas of proteolytic 
activity against blue background can be detected by staining followed by destaining of the 
gel (Toth et al., 1997). 
 
Procedure 
In vitro gelatin zymography was performed to detect MMP-2 and MMP-9 enzymatic 
activity in condtioned media of the MDA-MB-231 breast cancer cell line. Briefly, 2 x105 
MDA-MB-231 cells were plated in a 6-well plate, incubated overnight in normal growth 
medium, followed by transfection with control and Sdc-1 siRNA. 24 h post transfection, 
the cells were grown overnight in serum-containing media, followed by serum starvation 
for 24 h. The cells were stimulated with ±40 ng/ml HGF and the conditioned media were 
collected after 48 h. Equal amounts of protein were loaded onto 10% SDS 
polyacrylamide gels containing 1 mg/ml bovine gelatin and electrophoretically separated 
under non-reducing conditions at 4ºC. Subsequently, the gels were washed twice with 
2.5% Triton-X-100 solution for 15 min each, washed twice with water and incubated 
overnight at 37°C in developing buffer. Thereafter, gels were stained with 0.5% 
Coomassie brilliant blue R-250 in 50% methanol and 10% acetic acid for 1 h and then 
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de-stained in a 50% methanol and 10% acetic acid solution. Clear bands against dark blue 
background represent areas of proteolytic activity. Human recombinant ProMMP-2 and 
ProMMP-9 were loaded separately as positive controls. 
 
3.4 Immunofluorescence microscopy 
Principle 
This technique is based on antigen visualization with a fluorochrome-tagged molecule or 
chain of molecules; the fluorochrome is then excited and viewed with a special light 
source and a system of selective filters. Immunofluorescence localization can be direct or 
indirect. In the direct approach, antibodies or specific binding proteins (e.g. phalloidin) 
are linked to a fluorescent probe and used directly to localize antigen in the sample of 
interest. In the indirect method, the cell is probed with an unlabelled primary antibody 
and its location is in turn detected using a fluophore conjugated secondary antibody that 
recognizes primary antibody. The indirect method is commonly used for detection of low 
abundance antigens , as the primary antibody serves to amplify the final signal. 
Immunofluorescence staining of fixed adherent cells or tissues monitors the intracellular 
localization of multiple signaling or marker proteins. 
 
Procedure 
5 x 104 cells were seeded in a 6-well plate containing sterile round coverslips and allowed 
to settle overnight under culturing conditions. Then, the cells were washed once with PBS 
prior to fixation either by (a) ice cold methanol for 10 min at -20°C or (b) 3.7% 
PBS-buffered formaldehyde at RT for 10 min followed by twice washings with PBS 
before the cells were permeabilized with 0.1 % Triton-X100 in PBS for 5 min 
(formaldehyde-fixed cells only). Subsequently, the cells were washed twice with PBS 
and non specific antibody binding sites were blocked with 1% Aurion BSA in PBS for 1 h 
at RT. Afterwards, the coverslips were transferred to a moist chamber and incubated with 
240 µl of the appropriate primary antibody, diluted in 1% BSA in PBS overnight at 4°C. 
For a negative control, omission of primary antibody (1% BSA/PBS was used instead) 
was applied. Following 3X washing for 5 min with PBS, the samples were incubated for 1 
h in dark with ALEXA-Flour 568-labelled phalloidin for actin staining or 
fluorochrome-conjugated secondary antibody of the corresponding host of the primary 
antibody, diluted in 1% BSA in PBS. Slides were washed 3X with PBS and cell nuclei 
were counterstained with DAPI. After three additional washes with PBS, cells were 
Methods 
 93 
washed once with water and mounted on glass slides with VECTASHIELD® mounting 
medium and sealed with nail polish. Slides were analyzed with an LSM 510 META 
confocal microscope equipped with a Plan-Apochromat 63x/1.4 oil immersion objective. 
Appropriate dilutions of primary and secondary antibodies are listed in Table 3.3. 
 
Table 3.3 Dilution of primary and secondary antibodies utilized 
in immunofluorescence 
Antibody Dilution 
Alexa-Flour 488 anti-mouse IgG, Goat 1:600 
Alexa-Flour 555 anti-mouse IgG, Rabbit 1:400 
Goat-anti-Rabbit IgG - Tetramethylrhodamine 
isothiocyanante (TRITC) 
1:250 
anti-human-ATF-2 (20F1), monoclonal, Rabbit 1:100 
anti-human-AML1, polyclonal, Rabbit 1:50 
anti-human-Syndecan-1, clone BB4, monoclonal, 
Mouse  
1:100 
anti-human-E-Cadherin, clone 36, Mouse 1:100 
anti-human-MPP4 (H10), monoclonal, Mouse 1:2 
anti-human-Cadherin11, clone 5B2H5, Mouse 1:100 
anti-human-Cdc42, polyclonal, Rabbit 1:100 
 
 
3.5 Time lapse microscopy and cell motility 
Principle 
Nearly all cells in the human body are mobile at a given time during their life cycle. 
Embryogenesis, wound-healing, immune defense, and the formation of tumor metastases 
are well-known phenomena that rely on cell migration. Extensive experimental work 
revealed a precise spatial and temporal coordination of multiple components of the 
cellular migration machinery such as the actin cytoskeleton, cell-substrate and cell–cell 
interactions, and the activity of ion channels and transporters (Jalali et al., 2001; 
Lauffenburger and Horwitz, 1996; Rafelski and Theriot., 2004). These findings are the 
basis for detailed molecular models representing different microscopic aspects of the 
process of cell migration such as the protrusion of the leading edge of the lamellipodium, 
or actin dynamics (Mogilner and Edelstein-Keshet, 2002). Time lapse series show 
snapshots of a single cell, which are displayed at different times together with the 
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segmented cell boundary. Image segmentation was performed with Amira software 
(Visage Imaging/Mercury Computer Systems). The outlines of individual cells at each 
time step were marked throughout the entire image stack and taken for all further 
processing. Quantitative data analysis and calculation of parameters were performed with 
JAVA programs. The x and y coordinates of the cell center (in µm) were determined as 
geometric means of equally weighted pixel positions within the cell outlines as function 
of time. The combined trajectories of a cell population allow the calculation of the mean 
squared displacement that describes the mean of the squared distances between a 
common starting point at time t0 and the actual positions of a cell population at time t 
(Dieterich et al., 2008). 
 
Procedure 
To gain further insight into the relevant role played by Sdc-1 in the cell motility, 6 x 104 
(to avoid collisions between cells during the experiment) control and Sdc-1 
siRNA-transfected MDA-MB-231 breast cancer cells were seeded in 25 ml culture flasks 
(12.5 cm2, Falcon) cultured in complete grown medium. The culture flasks were put into 
heated chambers on stages of inverted microscopes. Cell migration was recorded in 10 
min intervals for 12 h at 37°C using video cameras and PC-vision frame grabber boards. 
Acquisition of images was controlled by HiPic and WASABI softwares. The 
circumferences of the cells were labeled applying the AMIRA software. The cell contours 
then served as the basis for further analysis. Parameters such as structural index (SI), 
migratory velocity (µm min-1) and translocation (µm) were analyzed using self-made 
JAVA programs and the NIH ImageJ software (Stock et al., 2005). Migration was 
determined as the movement of the cell center per time unit, the velocity was estimated 
from the 10 min time intervals applying a three point difference quotient and the cell area 
was measured as the number of pixels. The SI represents the cell shape. Values close to 
„1“correspond to a spherical cell shape whereas values close to „0“correspond to a 
spindle or a dendritic cell shape. SI was calculated as follows:  
SI = (4 π A) / p2 
where A is the area covered by the cell and p is the perimeter of A.  
To elucidate the Rho GTPase-dependent cell motility in Sdc-1-depleted cells, the 
transfected cells were grown in 2 ml complete media containing 10 µM Y27632 followed 
by the procedure as described before. 
Results 
 95 
4 Results  
4.1 siRNA-mediated knockdown of Syndecan-1 expression 
RNAi technology was employed targeting the coding region of Sdc-1. MCF-7, 
MDA-MB-468 and MDA-MB-231 breast cancer cells of different metastatic potential 
were transfected with 40 nM control or Sdc-1 siRNA using Dharmafect reagent 
according to Nikolova et al., (2009) and the manufacturer’s instructions. To confirm 
successful Sdc-1 silencing at mRNA level, quantitative real time PCR was performed, 
along with immunoflurescence and Western blot to substantiate Sdc-1 downregulation at 
the protein level as described in methods section. 
 
4.1.1 Quantitative real time PCR confirmation of Syndecan-1 siRNA 
knockdown 
48 h post transfection, the cells were harvested and total RNA was isolated and reverse 
transcribed into cDNA. cDNA was used as a template for qPCR to verify knockdown of 
Sdc-1. Sdc-1 mRNA expression was significantly downregulated by >90% (P<0.001), as 
confirmed by qPCR (Fig. 4.1). 
 
4.1.2 Confirmation of Syndecan-1 siRNA knockdown by 
immunofluorescence microscopy 
72 h post transfection, 5 x 104 control and Sdc-1 siRNA-transfected cells were seeded on 
coverslips in a 6-well plate overnight. The transfected cells were fixed with methanol and 
stained with monoclonal antibody against human Sdc-1. The expression level of Sdc-1 
was visualized by using Alexa-Flour 555 anti-mouse IgG. Fig. 4.2 shows markedly 
reduced expression level of Sdc-1 on the cell membrane of Sdc-1 siRNA-treated 
MDA-MB-231 cells compared to controls. 
 
4.1.3 Confirmation of Syndecan-1 siRNA knockdown by Western blot 
Control and Sdc-1 siRNA-treated cells were lysed 72 h after transfection. Cell lysates 
were subjected to Western blot as described in the methods section. The blotting 
membranes were probed for Sdc-1 with two different polyclonal antibodies against the 
Sdc-1 extracellular domain which show the heparan sulfate moieties and Sdc-1 (C-20) 
directed to C-terminus, respectively. 
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Fig. 4.1 qPCR analysis of Sdc-1 mRNA expression reveals a successful downregulation 
of Sdc-1 transcript 48 h post transfection. cDNA was prepared from 3 different replicates 
of control and Sdc-1 siRNA-transfected MDA-MB-231 cells and served as a template for 
qPCR. The 2-∆∆Ct method was used to determine relative gene transcript levels expressed 
as fold change (RQ) after normalization to 18S rRNA expression. n≥3, *** = p<0.001, 
error bars=SEM. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.2 Confocal immunofluorescence microscopic analysis of Sdc-1 protein expression. 
Control siRNA or Sdc-1 siRNA-transfected MDA-MB-231 cells were fixed in methanol 
72 h post transfection and immunostained with monoclonal antibody against human 
Sdc-1 (red fluorescent secondary antibody) as described in methods. Sdc-1 expression 
was clearly reduced in Sdc-1-silenced cells compared with controls. 
 
 
As depicted in Fig. 4.3., Sdc-1 expression at the protein level is downregulated following 
Sdc-1 siRNA transfection compared to controls. 
Collectively, our results revealed a successful downregulation of Sdc-1 mRNA and 
protein expression following transient transfection with Sdc-1 siRNA. Hence, these cells 
were employed for further approaches. 
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Fig. 4.3 Validation of Sdc-1 expression by Western blot analysis. Control and Sdc-1 
siRNA-treated MDA-MB-231 cells were lysed 72 h after transfection and 30 µg of the 
total protein were electrophoresed and immunoblotted using polyclonal antibody against 
the Sdc-1 extracellular domain (AF2780) or antibody (C-20) directed to C-terminus. 
Tubulin was used as a loading control. Data shown are triplicates from a single 
experiment representative of three independent experiments. 
 
 
4.2 Functional analysis of Syndecan-1-depleted breast cancer cell lines 
4.2.1 siRNA-mediated depletion of Syndecan-1 reduces HGF-dependent 
signaling via c-Met in breast cancer cells  
To characterize the potential role of Sdc-1 as a coreceptor for HGF/c-Met-dependent 
signaling, the human breast cancer cell lines MCF-7, MDA-MB-468 and MDA-MB-231 
were transfected with control or Sdc-1 siRNA for 24 h. The transfection media were 
exchanged for complete growth media containing 10% FCS on the next day. Afterwards, 
the transfected cells were serum-starved for 24 h. The control and Sdc-1-depleted cells 
were then stimulated with ±40 ng/ml in a 0-360 min time course. Cell lysates were 
prepared using modified RIPA buffer with proteinase inhibitors (Nikolova et al., 2009). 
30-60 µg of the total protein/lane was separated on 7.5-12% gels and electrotransferred to 
Hybond nitrocellulose membranes as described in the methods section. For detection of 
phosphorylated and total proteins, as well as loading controls, membranes were stripped 
with glycin buffer, washed, and reincubated with primary antibodies followed by the 
procedure described above. 
 
Western blot analysis revealed that Sdc-1 siRNA knockdown decreases the 
phosphorylation of c-Met, p44/42 MAPK, p38 MAPK, and AKT compared to control 
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cells. Peak activation of the c-Met receptor in control cells occurred within 10 min and 
sustained for 360 min in a biphasic pattern. Investigating pathways downstream of c-Met, 
p44/42 MAPK was phosphorylated within 10 min after HGF stimulation and maximal 
tyrosine phosphorylation was observed 60 min after HGF stimulation. p38 MAPK was 
activated after 10 min, showing sustained activation for at least 360 min. AKT acts 
downstream of PI3K and is a multifunctional regulator of cell survival, growth and 
invasion. In control cells, AKT was phosphorylated within 10 min after HGF stimulation, 
and the phosphorylation was maintained for 30 min (Fig. 4.4). As proof of principle, the 
prior approach was repeated for different breast cancer cell lines with different metastatic 
potential, MCF-7 (low invasive) and MDA-MB-468 (intermediate invasiveness). 
Knockdown of Sdc-1 attenuated the phosphorylation of p44/42 MAPK in MDA-MB-468 
cells, whereas in MCF-7 cells, HGF did not induce signaling which could possibly be 
ascribed to low expression of c-Met receptor in MCF-7 cells (Fig. 4.5) (Götte et al., 
2007).  
 
4.2.2 siRNA-mediated depletion of Syndecan-1 inhibits HGF-dependent 
breast cancer cell proliferation 
Since our data suggested a coreceptor role of Sdc-1 for HGF/c-Met-mediated signaling 
and since it has been reported that over expression of both full-length and truncated Sdc-1 
inhibited proliferation of the mesenchymal tumor cells (Zong et al., 2010), we next 
investigated the functional consequences of Sdc-1 depletion on HGF-dependent cell 
proliferation by MTT assay.  
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Fig. 4.4 siRNA-mediated knockdown of Sdc-1 expression attenuates HGF/c-Met 
signaling in MDA-MB-231 breast cancer cells. 2 x 105 serum starved control and Sdc-1 
siRNA-transfected MDA-MB-231 cells were stimulated with 40 ng/ml HGF for 0-360 
min and then total cell lysates were prepared. 30-50 µg of the total protein were subjected 
to immunoblot and probed with antibodies against the phosphorylated forms of c-Met, 
AKT, p44/42 MAPK and p38 MAPK. Blots were subsequently stripped and probed for 
total c-Met, AKT, p44/42 MAPK, and p38 MAPK. Data are a single experiment 
representative of three independent experiments. 
 
 
 
 
 
 
 
 
 
 
Fig. 4.5 Western blot analysis reveals that Sdc-1 silencing attenuates 
HGF/c-Met-mediated p44/42 MAPK downstream signaling in MCF-7 and 
MDA-MB-468 breast cancer cells. 2 x 105 control and Sdc-1 siRNA-transfected MCF-7 
and MDA-MB-468 breast cancer cells were serum-starved for 24 h and stimulated with 
40 ng/ml HGF for 10 min. Total cell lysates were prepared and 30 µg of the total protein 
were subjected to immunoblot with antibody against the phosphorylated forms of p44/42 
MAPK. Blots were subsequently stripped and probed for total p44/42 MAPK. Data are a 
single experiment representative of three independent experiments. 
 
 
Control and Sdc-1 siRNA-treated MDA-MB-231 cells were serum-starved for 24 h prior 
to stimulation with ±40 ng/ml HGF for 48 h. The MTT assay reveals that the proliferative 
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activity of Sdc-1 siRNA-treated cells is significantly higher than that of controls by 
19.6% (Fig. 4.6A). However, proliferation in response to HGF was increased by 11% in 
control cells, whereas HGF increased proliferation of Sdc-1-silenced cells by only 5% 
(p<0.05) (Fig. 4.6B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.6 Proliferative activity of control and Sdc-1-depleted MDA-MB-231 cells 
following stimulation with ±40 ng/ml HGF. (A) Sdc-1 knockdown enhances basal cell 
proliferation in the absence of HGF. (B) Sdc-1 siRNA treatment suppresses 
HGF-mediated MDA-MB-231 proliferation. 5 x 103 serum starved control and Sdc-1 
siRNA-transfected cells were treated ±40 ng/ml HGF for 48 h and the proliferation was 
assessed by MTT assay as described in the methods section. n≥3, * = p<0.05, error 
bars=SEM.  
 
 
4.2.3 siRNA-mediated depletion of Syndecan-1 inhibits HGF-dependent 
breast cancer cell migration 
The differential expression of Sdc-1 in cancer cells has been shown to modulate their 
malignant behavior (Nikolova et al., 2009). To reveal whether Sdc-1 is implicated in 
HGF-dependent cell motility, we assessed the wound closure following incubation ±40 
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ng/ml HGF in a scratch motility assay. Control and Sdc-1-depleted cells were serum 
starved for 24 h. The monolayer was scratched with a pipette tip, washed with PBS to 
remove floating cells in serum-free media and photographed (0 h) using a Zeiss Axiovert 
microscope. Subsequently, cells were stimulated with ±40 ng/ml HGF for 6 h. The 
scratched area was photographed (6 h) and difference of the area before and after HGF 
addition was quantified. Serum-starved Sdc-1-depleted MDA-MB-231 cells exhibit only 
a limited wound closure activity 6 h after HGF treatment. In contrast, HGF-treated 
control cells showed a significant acceleration of wound closure compared to 
Sdc-1-depleted cells (83.8% cell free area post HGF treatment vs 94.3% after Sdc-1 
depletion, p<0.05), confirming a functional role for Sdc-1 as a coreceptor for 
HGF/c-Met-dependent cell migration (Fig. 4.7A and B). 
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Fig. 4.7 (A) Delayed in vitro wound closure in Sdc-1-depleted MDA-MB-231 breast 
cancer cells post HGF stimulation compared to controls. (B) Representative image of the 
in vitro wound healing assay of untreated control and Sdc-1 siRNA-transfected cells at 0 
and 6 h, and stimulated control and Sdc-1 siRNA-transfected cells with 40 ng/ml HGF at 
0 and 6 h. n≥3, * = p<0.05, error bars=SEM.  
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4.2.4 Syndecan-1 depletion promotes breast cancer cell invasion via a 
HGF/c-Met-independent mechanism 
Since both c-Met and Sdc-1 have been shown to modulate breast cancer cell invasion and 
metastasis (Nikolova et al., 2009; Peruzzi and Bottaro, 2006), in vitro, Matrigel invasion 
chamber assays were employed to study a potential coreceptor role of Sdc1 for 
HGF-dependent breast cancer cell invasiveness. Control and Sdc-1-depleted 
MDA-MB-231 cells were exposed to chemoattractant gradient (±HGF); thereby invasive 
cells are able to invade through the reconstituted basement membrane (the Matrigel 
matrix and the 8 micron membrane pores. The Matrigel cell invasiveness was 
differentially affected by downregulated Sdc-1. HGF stimulation significantly promoted 
the invasion of the control cells by 62% compared to untreated controls. Notably, the 
invasiveness of Sdc-1-deficient cells was enhanced significantly by 366% even in the 
absence of HGF compared to control cells (Fig. 4.8A and B). HGF-stimulation of Sdc-1- 
depleted cells could not further augment the degree of invasiveness, suggesting that Sdc-1 
plays a critical role in mediating the ability of cells to invade the basement membrane 
matrix in a HGF-independent manner.  
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Fig. 4.8 In vitro invasion of control and Sdc-1-depleted MDA-MB-231 cells was 
demonstrated by Matrigel invasion assay. (A) Sdc-1 knockdown dramatically promotes 
in vitro invasiveness of MDA-MB-231 breast cancer cells in a HGF-independent manner. 
25 x 103 control and Sdc-1 siRNA-transfected cells were added to Matrigel invasion 
chambers and stimulated with ±40 ng/ml HGF for 48 h. n≥3, * =  p<0.05, error bars=SEM. 
(B) A representative image of Matrigel invasion filters stained with Diff-Quik dye. 
 
 
4.2.5 HGF treatment does not induce Syndecan-1 sheddding in 
MDA-MB-231 breast cancer cells  
Sdc-1 is known to be shed from cell surfaces through cleavage by endogenous proteases. 
Moreover, a variety of ligands can trigger such shedding, including EGF (Fitzgerald et al., 
2000; Subramanian et al., 1997). To assess whether HGF might elicit Sdc-1 shedding, 
MDA-MB-231 cells were incubated with 40 ng/ml HGF or 1 µM PMA for 30 min. 
Subsequently, the cells were fixed in methanol and the expression of Sdc-1 expression on 
the cell membrane was evaluated by immunostaining with monoclonal antibody and cells 
were examined by confocal immunoflourescence microscopy. Treatment of 
MDA-MB-231 cells with HGF did not result in induced cleavage of the cell membrane 
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Sdc-1, whereas Sdc-1 was shed following PMA treatment (Fig. 4.9). This finding 
substantiates that membrane-bound Sdc-1 is available as a coreceptor for 
HGF/c-Met-mediated signaling after HGF stimulation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.9 HGF does not induce Sdc-1 shedding in the MDA-MB-231 breast cancer cell 
line. 5 x 104 MDA-MB-231 cells were grown on coverslips for 16 h in a 6-well plate. 
Consequently, 40 ng/ml HGF or 1 µM PMA ( as positive control) was added to the cells 
for 30 min, then the cells were fixed, and processed for immunocytochemistry using 
antibody against Sdc-1 (red fluorescent secondary antibody). PMA entirely triggers 
Sdc-1 shedding from the cell membrane of MDA-MB-231 cells, whereas HGF doesn’t. 
 
 
4.2.6 Syndecan-1 depletion induces complex changes in gene expression 
in MDA-MB-231 cells 
Since Sdc-1 modulates both expression and function of a multitude of factors relevant to 
cancer cell invasion and metastasis (Nikolova et al., 2009; Yip et al., 2006), we 
performed an Affymetrix microarray analysis to screen for genes differentially expressed 
between control and highly invasive Sdc-1 siRNA-treated MDA-MB-231 cells. For this 
purpose, mRNA was prepared from multiple biological replicates of control and 
Sdc-1-silenced MDA-MB-231 cells, reverse transcribed into cDNA, and lyophilized 
prior to shipment to the Department of Anatomy, National University of Singapore. An 
analysis of the Affymetrix screening data by the group of Prof. Dr. George W. Yip 
revealed that, relative to controls, 238 genes were significantly upregulated and 304 
genes were downregulated in Sdc-1-depleted cells by at least a factor of 2 (Fig. 4.10). 
Differentially regulated genes were placed into categories based on their gene ontology 
annotations (Ashburner et al., 1999) (Fig. 4.10). Based on the data provided by the 
collaborators at the National University of Singapore, we performed a PubMed database 
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analysis to identify candidate groups of genes potentially involved in the proliferative, 
invasive and motile phenotypic changes in Sdc-1 siRNA-treated cells, which were 
subjected to further analysis (Appendix Table).  
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Fig. 4.10 Affymetrix microarray analysis for differential gene expression between 
control and Sdc-1 siRNA-transfected MDA-MB-231 cells. Gene Ontology groupings of 
up- and downregulated genes detected in the Affymetrix microarray screen that have 
known functions relevant to the observed phenotypic changes. mRNA was isolated from 
control and Sdc-1 siRNA cells, transcribed into cDNA and subjected to an Affymetrix 
microarray analysis as described in the methods section. Differentially expressed genes 
were selected based on the following criteria for the logged data: (Emean–Bmean) >1 or 
(Bmean–Emean) > 1 [where E = experiment (Sdc-1 siRNA), B = baseline (control)]; 
Present call % of E ≥ 0 and Present call % of B ≥ 100 or vice versa; unpaired t-test p < 
0.05.  (A) All regulated genes. (B) Upregulated genes. (C) Downregulated genes. 
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4.3 Validation of Syndecan-1-dependent target expression relevant to 
breast cancer progression 
4.3.1 Syndecan-1 depletion results in a differential expression of the 
transcription factors ATF-2, AML1/RUNX-1 and KLF4 
4.3.1.1 Syndecan-1 depletion results in upregulation of the transcription 
factor ATF-2 in a p38 MAPK-independent mechanism  
Among the Sdc-1-dependent candidate molecules with relevance to breast cancer 
progression, we first aimed at confirming the Affymetrix data for activating transcription 
factor-2 (ATF-2). ATF-2 is a sequence-specific DNA-binding protein that belongs to the 
bZIP family of proteins (Hai and Hartman, 2001). In response to stress stimuli, it 
activates a variety of gene targets including cyclin A, cyclin D and c-jun, which are 
involved in oncogenesis in various tissue types (Beier et al., 1999; Beier et al., 2000; De 
Cesare et al., 1995). ATF-2 expression has been correlated with maintenance of a 
malignant cell phenotype (Echlin et al., 2000; Ronai, 1998). ATF-2 has been correlated 
with proliferation, invasion and migration, as well as resistance to DNA-damaging agents 
in breast cancer cell lines (Vlahopoulos et al., 2008). In light of this information, we 
investigated the expression level of ATF-2 in control and Sdc-1 siRNA-transfected 
MDA-MB-231 breast cancer cells. 
 
ATF-2 was 2.6 fold upregulated in Sdc-1-depleted cells according to our Affymetrix data. 
In turn, total cellular RNA was independently isolated from control and Sdc-1 siRNA- 
transfected cells 48 h post transfection and reverse transcribed into cDNA which was 
utilized as a template for quantification relative gene expression after normalization to 
18S rRNA by the 2-∆∆Ct method as described in detail in methods section. Compared to 
the relative gene expression level of control cells (RQ=1), Sdc-1 silencing significantly 
upregulated ATF-2 expression level (RQ=1.25) (Fig. 4.11). 
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Fig. 4.11 Relative ATF-2 mRNA expression level as determined by real time PCR in 
Sdc-1-depleted cells.  Sdc-1 silencing upregulates the expression level of ATF-2 
transcript compared to controls. MDA-MB-231 breast cancer cells were treated with 
control or Sdc-1 siRNA for 24 h. Total cellular RNA was isolated 48 h post transfection 
and reverse transcribed into cDNA. The 2-∆∆Ct method was used to determine relative 
gene transcript levels after normalization to 18S rRNA. n≥3, * = p<0.05, error bars=SEM. 
 
 
We next aimed at confirming ATF-2 upregulation at the protein level by Western blot and 
immunofluorescence microscopy. Cell lysates of control and Sdc-1 siRNA-treated cells 
were prepared 72 h after silencing and subjected to Western blot for ATF-2. In 
accordance with our gene expression data, protein expression of ATF-2 was differentially 
upregulated (Fig. 4.12).  
 
 
 
 
 
 
 
 
Fig. 4.12 Western blot of cell lysates of control and Sdc-1 siRNA-transfected 
MDA-MB-231 cells revealed upregulation of ATF-2 following Sdc-1 silencing. Control 
and Sdc-1 siRNA-transfected cell lysates were collected and 30-50 µg protein/lane were 
immunoblotted and probed with ATF-2 antibody. Tubulin expression served as a loading 
control. Data shown are triplicates from a single experiment representative of three 
independent experiments. 
 
 
The expression level and localization of ATF-2 were additionally investigated by 
immunofluorescence microscopy. As depicted in Fig. 4.13, the expression level of ATF-2 
in Sdc-1-depleted cells is increased compared to controls. Notably, the nuclear 
localization is not affected by the Sdc-1 knockdown. 
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Fig. 4.13 Confocal immunofluorescence microscopy confirms the elevated expression 
level of ATF-2 in Sdc-1-silenced cells without alteration of nuclear localization. 5 x 104 
control and Sdc-1 siRNA-transfected MDA-MB-231 cells were grown on coverslips for 
16 h in a 6-well plate, fixed, and processed for immunocytochemistry using antibody 
against ATF-2 (red fluorescent secondary antibody). Top panel = merged ATF-2 and 
DAPI signal, central panel= ATF-2 signal, bottom panel = DAPI signal. 
 
 
Since it has been demonstrated that syndecan-4-null cells display higher levels of active 
p38 MAPK, thereby activating transcription factor ATF-2, as a direct p38 target 
(Saoncella et al., 2004), we compared both the phosphorylation state and expression of 
p38 in control and Sdc-1-depleted cells by Western blot. As shown in Fig. 4.14, 
knockdown of Sdc-1 did not have an impact on the activation of p38 MAPK. However, 
the expression level of total p38 MAPK was slightly higher following Sdc-1 depletion. 
These results suggest that upregulation of ATF-2 in Sdc-1 siRNA-transfected cells may 
be independent of activation of p38. 
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Fig. 4.14 Sdc-1 depletion does not induce p38 MAPK activation. Lysates of control and 
Sdc-1 siRNA-transfected cells were collected and 30-50 µg protein/lane were 
immunoblotted and probed with the indicated antibodies. Levels of total p38 MAPK are 
slightly increased in Sdc-1 siRNA-treated cells compared to controls. However, the levels 
of phosphorylated p38 are not differentially increased. Data shown are triplicates from a 
single experiment representative of three independent experiments. 
 
 
4.3.1.2 Syndecan-1 depletion results in downregulation of the 
transcription factor AML1/RUNX-1 
E-cadherin (E-cad) is an important tumor-suppressor gene. In cancer cells, loss of E-cad 
gene expression causes dysfunction of the cell-cell junction system; triggering cancer 
invasion and metastasis (Götte et al., 2007). Acute myeloid leukemia 1/ runt-related 
transcription factor 1 (AML1/RUNX1), a factor dysregulated in Sdc-1-depleted cells 
according to our Affymetrix screening, regulates the expression of E-cad (Liu et al., 
2005). This finding prompted us to investigate the expression level and localization of 
AML1/RUNX1 at the transcript level by qPCR and at the protein level by Western blot 
and immunofluorescence muicroscopy analogously to ATF-2. 
 
AML1/RUNX1 was 2.2 fold downregulated in Sdc-1-depleted cells according to our 
Affymetrix data. Real time PCR and Western blot results revealed significant 
downregulation expression of AML1/RUNX1 at the mRNA (RQ=0.68) and protein 
level, respectively, upon Sdc-1 knockdown (Fig. 4.15 and 4.16). AML1/RUNX1 
nuclear localization is not altered following Sdc-1 depletion (Fig. 4.17). 
 
 
 
 
 
 
Results 
 112 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.15 Relative AML-1 mRNA expression level as determined by real time PCR in 
Sdc-1-depleted cells.  Sdc-1 silencing downregulates the expression level of AML-1 
transcript compared to controls. The MDA-MB-231 breast cancer cell line was treated 
with control or Sdc-1 siRNA for 24 h. Total cellular RNA was isolated 48 h post 
transfection and reverse transcribed into cDNA. The 2-∆∆Ct method was used to determine 
relative gene transcript levels after normalization to 18S rRNA. n≥3, ** = p<0.01, error 
bars=SEM. 
 
 
 
 
 
 
 
 
 
 
Fig. 4.16 Western blot of cell lysates of control and Sdc-1 siRNA-transfected 
MDA-MB-231 cells reveals downregulation of AML1/RUNX-1 post Sdc-1 silencing. 
Control and Sdc-1 siRNA-transfected cell lysates were collected and 30-50 µg 
protein/lane were immunoblotted and probed with AML-1 antibody. Data shown are 
triplicates from a single experiment representative of three independent experiments. 
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Fig. 4.17 Confocal immunofluorescence microscopy confirms a reduced expression level 
of AML1/RUNX-1 in Sdc-1-silenced cells without alteration of nuclear localization. 5 x 
104 control and Sdc-1 siRNA-transfected MDA-MB-231 cells were grown on coverslips 
for 16 h in a 6-well plate, fixed, and processed for immunocytochemistry using antibody 
against AML1/RUNX-1 (red fluorescent secondary antibody). Top panel = merged 
AML1/RUNX-1 and DAPI signal, central panel= AML1/RUNX-1 signal, bottom panel = 
DAPI signal. 
 
 
4.3.1.3 Syndecan-1 depletion results in moderate upregulation of the 
transcription factor KLF4 
Krueppel-like factor 4 (KLF4) is a zinc finger protein that belongs to the Sp1/KLF family 
of transcription factors (Wieschaus et al., 1984). An earlier study has shown that ectopic 
expression of KLF4 in pancreatic cancer lines led to cell cycle arrest and marked growth 
inhibition in vitro (Wei et al., 2008). Furthermore, KLF4 can inhibit cell proliferation by 
blocking the G1/S progression of the cell cycle (Chen et al., 2001) and that it can directly 
repress the CyclinD1 promoter (Shie et al., 2000). Additionally, nuclear localization of 
KLF4 in breast cancer cells is a prognostic factor, identifying KLF4 as a marker of an 
aggressive phenotype in early-stage infiltrating ductal carcinoma (Pandya et al., 2004). 
Mechanistically, KLF4 simultaneously repressed p53 (which promotes cell proliferation) 
and induced p21Waf1/Cip1 (which inhibits cell proliferation) expression, suggesting a 
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paradoxical effect of KLF4 owing to a pro-mitogenic and anti-proliferative activity that is 
context-dependent. In normal cells, the p21Waf1/Cip1 induction by KLF4 represents the 
dominant response, resulting in cell-cycle arrest (Sur, 2009). According to our 
Affymetrix screening data, KLF4 was 2.3 fold downregulated in Sdc-1-depleted cells. In 
this regard, it was important to verify this finding by real time PCR. Our results revealed 
a mild, yet significant upregulation of KLF4 (RQ=1.12) in Sdc-1 siRNA-transfected cells 
compared to controls (P<0.01) as shown in Fig. 4.18. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.18 Relative KLF4 mRNA expression level as determined by real time PCR in 
Sdc-1-depleted cells. Sdc-1 silencing mild upregulates the expression level of KLF4 
transcript compared to controls. The MDA-MB-231 breast cancer cell line was treated 
with control or Sdc-1 siRNA for 24 h. Total cellular RNA was isolated 48 h post 
transfection and reverse transcribed into cDNA. The 2-∆∆Ct method was used to determine 
relative gene transcript levels after normalization to 18S rRNA. n≥3, ** = p<0.01, error 
bars=SEM. 
 
 
4.3.2 Syndecan-1 silencing results in enhanced basal tyrosine 
phosphorylation and alters the expression of apoptosis and cell cycle 
regulators 
As transcription factor expression depends on the activation of defined signal 
transduction pathways, we studied the effect of Sdc-1 depletion on basal cell signaling in 
the presence of FCS by Western blot. Tumor progression locus 2 (Tpl2/Cot or MAP3K8) 
is a serine/threonine protein kinase belonging to the family of MAP3 kinases. Activated 
Tpl2/Cot leads to induction of ERK1/2, JNK, NF-κB and p38MAPK pathways (Das et al., 
2005). In addition to a differential regulation in Sdc-1-depleted MDA-MB-231 cells, we 
had previously observed Sdc-1-dependent expression changes in MCF-7 cells 
overexpressing the soluble ectodomain of Sdc-1 (Nikolova et al., 2009). Hence, we 
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investigated the expression level of MAP3K8 at the mRNA and protein level. 
Consistently, qPCR and Western blot results unraveled downregulation expression of 
MAP3K8 at both the mRNA (Fig. 4.19) and protein level (Fig. 4.20) corroborating our 
Affymetrix data (2.4-fold downregulation). In contrast, overall tyrosine phosphorylation 
was enhanced in Sdc-1-deficient MDA-MB-231 cells compared to controls (Fig. 4.20). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.19 Relative MAP3K8 mRNA expression level as determined by real time PCR in 
Sdc-1-depleted cells.  Sdc-1 silencing downregulates the expression level of MAP3K8 
transcript compared to controls. The MDA-MB-231 breast cancer cell line was treated 
with control and Sdc-1 siRNA for 24 h. Total cellular RNA was isolated 48 h post 
transfection and reverse transcribed into cDNA. The 2-∆∆Ct method was used to determine 
relative gene transcript levels after normalization to 18S rRNA. n≥3, * = p<0.05, error 
bars=SEM. 
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Fig. 4.20 Western blot of cell lysates of control and Sdc-1 siRNA-transfected 
MDA-MB-231 cells reveals downregulation of Tpl-2 (MAP3K8) and enhanced 
phosphorylation of tyrosine following Sdc-1 silencing. Control and Sdc-1 siRNA- 
transfected cell lysates were collected and 30-50 µg protein/lane were immunoblotted 
and probed with Tpl-2 and phosphotyrosine antibodies. Data shown are triplicates from a 
single experiment representative of three independent experiments. 
 
 
The p21Waf1/Cip1 gene, coding for the cyclin-dependent kinase (CDK) inhibitor protein, 
has a role in several cellular processes, including cell cycle progression, apoptosis, DNA 
repair and differentiation (Lu et al., 2000; Marchetti et al., 2006; Secrist et al., 2003; Zhao 
et al., 2004). Interestingly, Sdc-1 siRNA knockdown resulted in reduced p21Waf1/Cip1 
expression by 2.2-fold as observed by Affymetrix screening. p21Waf1/Cip1 protein 
expression was substantially downregulated upon Sdc-1 knockdown as confirmed by 
Western blot (Fig. 4.21). 
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Fig. 4.21 Western blot of cell lysates of control and Sdc-1 siRNA-transfected 
MDA-MB-231 cells reveals downregulation of p21Waf1/Cip1 following Sdc-1 silencing. 
Control and Sdc-1 siRNA-transfected cell lysates were collected and 30-50 µg 
protein/lane were immunoblotted and probed with p21Waf1/Cip1-specific antibody. Data 
shown are triplicates from a single experiment representative of three independent 
experiments. 
 
 
The proliferation rate of normal and transformed epilthelial cells is modulated by the 
expression and/or the activity alterations of the cell cycle regulators in response to 
extraxellular signals (Hamel and Hanley, 1997; Sherr, 2000; Weinberg, 1995). Specific 
sets of cyclin/CDK protein complexes, which function at specific stages of the cell cycle, 
are key targets of these pathways (Morgan, 1995; van den Heuvel and Harlow, 1993). 
CDK6 regulates cell cycle events in the G1 phase of the cell cycle. Growth arrest and G1 
block in the cell cycle progression of MCF-7 cells is accompanied by a striking decrease 
in CDK6 mRNA and protein that accounts for the loss of total cellular CDK6 kinase 
activity (Cram et al., 2001). 
 
Since we elucidated the influence of Sdc-1 loss on the proliferative activity of 
MDA-MB-231 breast cancer cells and alterations of cell cycle regulators expression were 
observed according to our Affymetrix screening, CDK inhibitor 3 (2.8-fold up), CDK6 
(2.9-fold down) and Cyclin Y-like 1 (2-fold down), we decided to verify the expression 
level of CDK6 at the protein level post Sdc-1 loss. The expression of CDK6 in 
Sdc-1-depleted cells was completely abolished compared to controls as indicated by 
Western blot (Fig. 4.22). 
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Fig. 4.22 Western blot of cell lysates of control and Sdc-1 siRNA-transfected 
MDA-MB-231 cells reveals completely ablation of CDK6 expression post Sdc-1 
silencing. Control and Sdc-1 siRNA-transfected cell lysates were collected and 30-50 µg 
protein/lane were immunoblotted and probed with CDK6 antibody. Data shown are 
triplicates from a single experiment representative of three independent experiments. 
 
 
The proto-oncogene B-cell lymphoma/leukemia-2 (BCL2) gene (Reed, 1995) blocks a 
final common pathway leading to apoptosis and is expressed in more than half of human 
breast cancers. Invasive breast cancer has reduced BCL2 immunostaining compared with 
normal breast epithelia and pre-invasive breast lesions (Zhang et al., 1998). Since our 
results suggested that Sdc-1 silencing resulted in increased proliferative activity, we 
verified the expression gene level of BCL2 upon Sdc-1 siRNA knockdown. BCL2 gene 
expression was not significantly altered in Sdc-1 siRNA-treated cells (RQ=0.95) 
compared to controls (p>0.05) as shown in Fig. 4.23. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.23 Relative BCL2 mRNA expression level as determined by real time PCR.  Sdc-1 
silencing doesn’t significantly alter the expression level of BCL2 transcript compared to 
controls. The MDA-MB-231 breast cancer cell line was treated with control and Sdc-1 
siRNA for 24 h. Total cellular RNA was isolated 48 h post transfection and reverse 
transcribed into cDNA. The 2-∆∆Ct method was used to determine relative gene transcript 
levels after normalization to 18S rRNA. n≥3, error bars=SEM. 
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Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) is a dual 
protein/lipid phosphatase and its main substrate phosphatidyl-inositol 3,4,5 triphosphate 
(PIP3) is the product of PI3K (Maehama et al., 1998). Loss of PTEN function, either in 
murine embryonic stem cells or in human cancer cell lines, results in accumulation of 
PIP3, thus mimicking the effect of PI3K activation and triggering the activation of its 
downstream effectors, PDK1, AKT/PKB and Rac1/CDC42 (Stokoe, 2001). 
Tissue-specific deletions of PTEN usually provoke cancer. Moreover, an absence of 
PTEN cooperates with an absence of p53 to promote cancer. PTEN activity is lost by 
mutations, deletions or promoter methylation silencing at high frequency in many 
primary and metastatic human cancers (Parsons et al., 2005; Vivanco and Sawyers, 2002). 
Elimination of PTEN specifically in the mammary gland accelerated ductal extension and 
mammary tumors with metastatic properties (Deng and Brodie, 2001; Li G et al., 2002). 
Based on these findings, it was interesting to test whether reduced Sdc-1 expression 
influences PTEN gene expression by qPCR. Our data revealed that there is no a 
significant influence (RQ=0.96) following Sdc-1 knockdown on PTEN gene expression 
(P>0.05) as depicted in Fig. 4.24. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.24 Relative PTEN mRNA expression level as determined by real time PCR.  Sdc-1 
silencing doesn’t significantly alter the expression level of PTEN transcript compared to 
controls. The MDA-MB-231 breast cancer cell line was treated with control and Sdc-1 
siRNA for 24 h. Total cellular RNA was isolated 48 h post transfection and reverse 
transcribed into cDNA. The 2-∆∆Ct method was used to determine relative gene transcript 
levels after normalization to 18S rRNA. n≥3, error bars=SEM. 
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4.3.3 Syndecan-1 depletion results in a differential expression of a wide 
range of candidate molecules modulating breast cancer cell invasion 
and metastasis 
4.3.3.1 Dysregulation of the serine protease urokinase-type plasminogen 
system expression  
The serine protease urokinase-type plasminogen activator (uPA), its receptor, uPAR and 
its inhibitor, PAI-1 and PAI-2, are key players in a proteolytic cascade involved in 
physiological and pathophysiological degradation and remodeling of the ECM. uPA, 
when bound to uPAR efficiently converts plasminogen into the broad spectrum serine 
protease plasmin; its action on plasminogen is controlled by the serine protease inhibitors 
PAI-1 and PAI-2 (Conese and Blasi, 1995). The uPA system has a proteolytic potential, 
thereby playing a key role in tumor invasion and metastasis. To test whether Sdc-1 
deficiency may impact on the expression of uPA, uPAR and its inhibitors, PAI-1 and 
PAI-2, we performed qRT-PCR for uPA, PAI-1 and PAI-2 expression at the gene level 
and Western blot analysis of PAI-1 and uPAR at the protein level. 
 
Several members of the SERPIN family of protease inhibitors (SERPINs B2/PAI-2, B3, 
B4, B7, D1 and E1/PAI-1) were downregulated by a 19.7, 2.4, 7.9, 2.2, 7.2 and 2-fold 
change, respectively, as determined by Affymetrix screening data. qPCR results revealed 
that Sdc-1-deficient cells exhibited a significant downregulation of uPA (RQ=0.67) and 
massively downregulation of PAI-2 (RQ= 0.048) (p<0.01). However, we could not 
confirm a significant (p>0.05) downregulation of PAI-1 (RQ=0.88) upon Sdc-1 depletion 
(Fig. 4.25). Western blot analysis verified downregulation of PAI-1 and uPAR in Sdc-1 
siRNA-treated cells compared to controls (Fig. 4.26). This indicates that the enhanced 
invasive phenotype observed in Sdc-1-deficient cells could be mediated by 
downregulation of uPA/uPAR inhibitors. 
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Fig. 4.25 Relative uPA system expression levels as determined by by real time PCR.  
Sdc-1 silencing downregulates the expression level of uPA transcript and massively 
downregulates PAI-2 transcript compared to controls with no significant alteration of 
PAI-1 transcript expression. The MDA-MB-231 breast cancer cell line was treated with 
control and Sdc-1 siRNA for 24 h. Total cellular RNA was isolated 48 h post transfection 
and reverse transcribed into cDNA. The 2-∆∆Ct method was used to determine relative 
gene transcript levels after normalization to 18S rRNA. n≥3, ** = p<0.01, error 
bars=SEM. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.26 Western blot of cell lysates of control and Sdc-1 siRNA-transfected 
MDA-MB-231 cells reveals downregulation of PAI-1 and uPAR post Sdc-1 depletion. 
Control and Sdc-1 siRNA-transfected cell lysates were collected and 30-50 µg 
protein/lane were immunoblotted and probed with PAI-1 and uPAR antibodies. Data 
shown are triplicates from a single experiment representative of three independent 
experiments. 
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4.3.3.2 Dysregulation of MMP-2 and MMP-9 and their inhibitors 
expression upon Syndecan-1 deficiency 
MMPs are enzymes able to cleave collagen, gelatin, and other proteins of the ECM which 
belong to the family of multidomain, zinc-dependent proteins (Brinckerhoff and 
Matrisian, 2002). Owing to their ECM-degrading and modifying ability as well as their 
capability to cleave cell-ECM and cell-cell contacts, they facilitate detachment of 
epithelial cells from the surrounding tissue. Moreover, MMPs play key roles in 
embryonic development and mammary gland branching morphogenesis, but they are also 
upregulated in breast cancer, where they stimulate tumorigenesis, cancer cell invasion 
and metastasis (Radisky and Radisky, 2010). MMPs have been associated with EMT in 
cancer progression through three distinct mechanisms: (a) elevated levels of MMPs in the 
tumor microenvironment can directly induce EMT in epithelial cells, (b) cancer cells that 
undergo EMT can produce more MMPs, facilitating cell invasion and metastasis, and (c) 
EMT can generate activated stromal-like cells that drive cancer progression via further 
MMP production (Gilles et al., 1997; Martorana et al., 1998). Since ATF-2 is an essential 
transcription factor linked to MMP-2 upregulation (Song et al., 2006), we next 
questioned whether the enhanced invasiveness of Sdc-1-deficient cells, which show 
upregulated ATF-2 expression (►4.3.1), is MMP-2 and MMP-9-dependent. Hence, we 
employed qPCR and gelatin zymography to determine dysrgulation expression and 
gelatinolytic activity of MMP-2 and MMP-9. 
 
a) qRT-PCR of MMP-2 and MMP-9 
qPCR was performed independently for control and Sdc-1-depleted cell cDNA. qPCR 
results indicated a significant upregulation of MMP-2 (RQ=1.52) (p<0.01) and a 
significant downregulation of MMP-9 (RQ=0.24) (p<0.01) in Sdc-1-depleted cells 
compared to controls (Fig. 4.27).  
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Fig. 4.27 Relative matrix metalloproteases MMP-2 and MMP-9 mRNA expression level 
as determined by real time PCR. Sdc-1 silencing upregulates significantly the expression 
level of MMP-2 transcript and massively downregulates MMP-9 transcript compared to 
controls. The MDA-MB-231 breast cancer cell line was treated with control and Sdc-1 
siRNA for 24 h. Total cellular RNA was isolated 48 h post transfection and reverse 
transcribed into cDNA. The 2-∆∆Ct method was used to determine relative gene transcript 
levels after normalization to 18S rRNA. n≥3, ** = p<0.01, error bars=SEM. 
 
 
b) MMP-2 and MMP-9 gelatin zymography 
Since MMP-2 and MMP-9 have gelatinolytic activity, we conducted gelatin zymography 
to detect whether Sdc-1 depletion is accompanied by increased MMP activity. Briefly, 
±40 ng/ml HGF-treated conditioned media of control and Sdc-1-depleted cells were 
collected after 48 h and utilized for gelatin zymography. While gelatin zymography 
confirmed the presence of active form of MMP-2 (62 KDa) and proMMP-9 (92 KDa) 
activity in the conditioned media of MDA-MB-231 cells, no increase was observed of 
MMP-2 upon Sdc-1 depletion and HGF treatment. However, in support of the qPCR 
results, proMMP-9 activity was reduced in Sdc-1-deficient cells as depicted in Fig. 4.28. 
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Fig. 4.28 A representative zymogram from three independent experiments depicting 
gelatinolytic activity of proMMP-2 (72 kDa), MMP-2 (62 kDa) and proMMP-9 (92 kDa) 
in the MDA-MB-231 breast cancer cell line.  Samples were loaded equally according to 
protein content and separated on 10% SDS-PAGE containing 1% gelatin (w/v) under non 
reducing conditions as described in detail in the methods section. White bands indicate 
regions in which gelatin has been hydrolyzed by gelatinolytic activity of MMP-2 and 
MMP-9. Human recombinant proMMP-2 and proMMP-9 were loaded separately as 
positive controls. Zymographic analysis shows slightly decreased MMP-9 gelatinolytic 
activity in the media of Sdc-1-depleted cells compared to controls. HGF-treatment 
doesn’t alter MMP activity.  
 
 
c) Influence of Syndecan-1 deficiency on TIMP-3 expression in 
MDA-MB-231 breast cancer cells 
Tissue inhibitors of metalloproteinases (TIMPs) are natural MMPs inhibitors which 
impede the proteolytic activity of MMPs by forming noncovalent 1:1 stoichiometric 
complexes (Fassina et al., 2000). Disruption of the balance between MMPs and TIMPs 
may influence invasion and metastasis of cancer and may thus modify patient outcome 
(Freije et al., 2003). However, TIMPs exhibit several other biological functions in 
addition to the inhibition of active MMPs. These include the regulation of proMMP 
activation, tumor angiogenesis, cell growth and apoptosis (Jiang et al., 2002). As the 
suppression of the invasion potential of breast cancer cells by TIMP-3 suggests that the 
major matrix degradation proteinases required for the invasion of breast cancer cells in 
the Matrigel invasion assay are MMPs, and since their enzymatic activities can be 
inhibited effectively by TIMP-3 (Han et al., 2004), we investigated the expression level 
of TIMP-3 in Sdc-1-depleted cells and controls (Fig. 4.29). Our results revealed that 
TIMP-3 expression isn’t statistically significant altered (RQ=1.53) upon Sdc-1 silencing 
(P>0.05). 
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Fig. 4.29 Relative TIMP-3 mRNA expression level as determined by real time PCR.  
Sdc-1 silencing doesn’t significantly modulate the expression level of TIMP-3 transcript. 
The MDA-MB-231 breast cancer cell line was treated with control and Sdc-1 siRNA for 
24 h. Total cellular RNA was isolated 48 h post transfection and reverse transcribed into 
cDNA. The 2-∆∆Ct method was used to determine relative gene transcript levels after 
normalization to 18S rRNA. n≥3, error bars=SEM. 
 
 
4.3.3.3 Dysregulation of cell to cell adhesion promoting factors upon 
Syndecan-1 deficiency 
a) Dysregulation of cadherins in Syndecan-1-depleted cells 
Cadherins are transmembrane adhesion molecules that mediate calcium-dependent 
cell-cell adhesion. During oncogenesis, cell adhesion is disturbed by genetic and 
epigenetic changes, resulting in changes in signaling, loss of contact inhibition, and 
altered cell migration and stromal interactions. The prototypic member of the cadherin 
superfamily of cell-cell adhesion molecules is E-cad, which was characterized as a potent 
suppressor of invasion and metastasis (van Roy and Berx, 2008). Epithelial tumors 
including breast cancer often lose E-cad partially or completely as they progress toward 
malignancy (Strumane et al., 2004). In addition, most studies have shown both strong 
anti-invasive and anti-metastatic roles for E-cad (Perl et al., 1998). Cadherin-11 (Cad-11), 
or OB-cadherin, was originally identified in mouse osteoblasts (Okazaki et al., 1994); it 
was later found to be expressed in a variety of normal tissues of mesodermal origin, 
including areas of the kidney and brain (Hoffmann and Balling, 1995). On contrast to 
E-cad, it has been documented that Cad-11 expression may be well-correlated with the 
invasive phenotype in cancer cells and may serve as a molecular marker for the more 
aggressive, invasive subset of tumors. We could prove 2.4- fold upregulation of Cad-11 
by Affymetrix analysis. All of the above findings prompted us to investigate the 
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expression level of E-cad and Cad-11 in control and Sdc-1-deficient cells. As depicted in 
Fig 4.30, qPCR analysis revealed that Sdc-1 knockdown resulted in a highly significant 
downregulation of the expression of E-cad (RQ=0.62) (P<0.01). In addition, Western blot 
analysis confirmed the downregulation of E-cad and a slight upregulation of Cad-11 in 
Sdc-1-silenced cells compared to controls (Fig. 4.31). Interestingly, we could confirm a 
slight upregulation of Cad-11 by confocal immunofluorescence microscopy with a 
notable nuclear localization and downregulation of E-cad (Fig. 4.32A and B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.30 Relative E-cad mRNA expression level as determined by real time PCR.  Sdc-1 
silencing downregulates the expression level of E-cad transcript compared to controls. 
The MDA-MB-231 breast cancer cell line was treated with control and Sdc-1 siRNA for 
24 h. Total cellular RNA was isolated 48 h post transfection and reverse transcribed into 
cDNA. The 2-∆∆Ct method was used to determine relative gene transcript levels after 
normalization to 18S rRNA. n≥3, ** = p<0.01, error bars=SEM. 
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Fig. 4.31 Western blot of cell lysates of control and Sdc-1 siRNA-transfected 
MDA-MB-231 cells reveals downregulation of E-cad and a slight upregulation of Cad-11 
post Sdc-1 knockdown. Control and Sdc-1 siRNA-transfected cell lysates were collected 
and 30-50 µg protein/lane were immunoblotted and probed with E-cad and Cad-11 
antibodies. Data shown are triplicates from a single experiment representative of three 
independent experiments. 
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Fig. 4.32 Confocal immunofluorescence microscopy analysis shows (A) slight 
upregulation of Cad-11 with nuclear localization and (B) downregulation of E-cad in 
Sdc-1-depleted cells compared to controls. 5 x 104 control and Sdc-1 knockdown 
MDA-MB-231 cells were grown on coverslips for 16 h in a 6-well plate, fixed, and 
processed for immunocytochemistry using monoclonal antibodies against Cad-11 and 
E-cad (green fluorescent secondary antibody) and DAPI for nucleus staining as described 
in the methods, merged= Cad-11 and DAPI signal. 
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b) Influence of Syndecan-1 deficiency on inversin expression in 
MDA-MB-231 breast cancer cells 
A 125-kDa inversin protein isoform was found at cell-cell junctions. Two inversin 
isoforms, 140- and 90-kDa, were identified in the nuclear and perinuclear compartments. 
Plasma membrane location of inversin is dependent upon cell-cell contacts. It has been 
shown that the membrane-associated 125-kDa inversin forms a complex with N-cadherin 
and the catenins. The 90-kDa nuclear inversin complexes with β-catenin. These findings 
indicate that the inversin gene product functions in several cellular compartments, 
including the nucleus and cell-cell adhesion sites (Nürnberger et al., 2002). Since any 
data about expression of inversin in breast cancer are not well- defined, we sought to 
decipher the influence of Sdc-1 depletion on inversin expression.  Affymetrix data 
analysis displayed 2.2 fold downregulation of inversin in Sdc-1-depleted cells. In this 
regard, qPCR (Fig. 4.33) was employed to assess inversin gene expression following 
control and Sdc-1 siRNA treatment. The results revealed that inversin expression is 
statistically not altered upon Sdc-1 knockdown (RQ=0.66) (P>0.05). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.33 Relative inversin mRNA expression level as determined by real time PCR. 
Sdc-1 silencing doesn’t significantly modulate the expression level of inversin transcript. 
The MDA-MB-231 breast cancer cell line was treated with control and Sdc-1 siRNA for 
24 h. Total cellular RNA was isolated 48 h post transfection and reverse transcribed into 
cDNA. The 2-∆∆Ct method was used to determine relative gene transcript levels after 
normalization to 18S rRNA. n≥3, error bars=SEM. 
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4.3.3.4 Downregulation of annexin family members upon Syndecan-1 
deficiency 
The annexins (ANXs) are a superfamily of closely related calcium and membrane 
binding proteins, which show a cell type specific expression. They have a wide variety of 
cellular functions including vesicle trafficking, cell division, apoptosis, calcium signaling 
and growth regulation (Gerke and Moss, 2002; Gerke et al., 2005). There is merging 
evidence that the changes in ANXs expression and/or their subcellular localization 
contribute to the development and progression of cancer. Some ANXs are over-expressed 
in specific types of cancers, while others show consistent loss of expression (Hayes and 
Moss, 2004). Since it has been demonstrated that ANXA3 and ANXA10 are dysregulated 
in cancer and they related to invasion (Kim et al., 2009; Kim et al., 2010; Liu et al., 2002; 
Yan et al., 2010), qPCR and Western blot were utilized to confirm their dysregulation 
following control and Sdc-1 siRNA treatment. Sdc-1 siRNA treatment impairs the 
expression of ANXA3 and ANXA10. Real time PCR unraveled significantly 
downregulation of ANXA3 (RQ=0.27) and ANXA10 (RQ=0.43) upon Sdc-1 knockdown 
(P<0.01) as shown in Fig. 4.34. Further confirmation of ANXA3 downregulation was 
determined by Western blot performed in cooperation with the group of Prof. Dr. Volker 
Gerke, ZMBE Münster (Fig. 4.35). These results are in very good agreement with the 
Affymetrix analysis, which shows 2.9 and 2.7 fold decrease in transcript levels of 
ANXA3 and ANXA10 respectively after Sdc-1 silencing. 
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Fig. 4.34 Relative ANXA3 and ANXA10 mRNA expression level as determined by real 
time PCR. Sdc-1 silencing downregulates the expression level of ANXA3 and ANXA10 
transcript compared to controls. The MDA-MB-231 breast cancer cell line was treated 
with control and Sdc-1 siRNA for 24 h. Total cellular RNA was isolated 48 h post 
transfection and reverse transcribed into cDNA. The 2-∆∆Ct method was used to determine 
relative gene transcript levels after normalization to 18S rRNA. n≥3, ** = p<0.01, error 
bars=SEM. 
 
 
 
 
 
 
 
 
Fig. 4.35 Western blot of cell lysates of control and Sdc-1 siRNA-transfected 
MDA-MB-231 cells reveals downregulation of ANXA3 following Sdc-1 knockdown. 
Control and Sdc-1 siRNA-transfected cell lysates were collected and 30-50 µg 
protein/lane were immunoblotted and probed with ANXA3 antibody. Data shown are 
triplicates from a single experiment representative of three independent experiments. 
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4.3.3.5 Syndecan-1 deficiency downregulates tight junction protein 
claudin-1 and does not alter junctional adhesion molecule A expression 
Tight junctions are the most apical of intercellular junctions and appear as a network of 
continuous and anastomosing filaments on the protoplasmic face of the plasma 
membrane (Gonzales-Mariscal et al., 2003). They contribute to the transepithelial barrier 
that controls the transport of ions and small molecules through the paracellular pathway, a 
property referred to as the “barrier” function (Diamond, 1977; Tobioka et al., 2004). 
Tight junctions are also critical for the organization of epithelial cell polarity, separating 
the plasma membrane into apical and basolateral domains (Gumbiner, 1987; Itoh and 
Bissell, 2003). Moreover, they are also critical for the polarized location of ion channels, 
receptors, and enzymes to the membrane domains necessary for structurally and 
functionally developed epithelia, a function referred to as the “fence” function (Anderson 
et al., 1993; Diamond, 1977). 
 
The tight junction protein claudin-1 constitutes the backbone of the tight junction strand 
and is crucial for the epidermal barrier function (Furuse et al., 2002; Tsukita and Furuse, 
2002). Both an increase and a decrease in claudin-1 protein expression have been shown 
to be associated with tumorigenesis. In some cancers, including prostate (Sheehan et al., 
2007), breast (Tokes et al., 2005), and melanocytic neoplasia (Cohn et al., 2005), loss of 
claudin-1 has been associated with cancer progression and invasion, and the acquisition 
of the metastatic phenotype. Since our Affymetrix screening showed downregulation of 
claudin-1 with 2.6 fold in Sdc-1-silenced cells, we tested its expression at mRNA level by 
qPCR. As depicted in Fig. 4.36, Sdc-1 depletion resulted in a significant massive 
downregulation (RQ=0.26) of claudin-1 compared to controls (p<0.05). 
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Fig. 4.36 Relative claudin-1 mRNA expression level as determined by real time PCR. 
Sdc-1 silencing massively downregulates the expression level of claudin-1 transcript 
compared to controls. The MDA-MB-231 breast cancer cell line was treated with control 
and Sdc-1 siRNA for 24 h. Total cellular RNA was isolated 48 h post transfection and 
reverse transcribed into cDNA. The 2-∆∆Ct method was used to determine relative gene 
transcript levels after normalization to 18S rRNA. n≥3, * = p<0.05, error bars=SEM. 
 
 
Junctional adhesion molecule A (JAM-A or F11R), a tight junction protein, is a key 
negative regulator of cell migration and invasion. JAM-A is robustly expressed in normal 
human mammary epithelium, and its expression is downregulated in metastatic breast 
cancer tumor (Mandell et al., 2005). It has been shown that JAM-A acts as a key negative 
regulator of breast cancer cell invasion and possibly metastasis. Furthermore, loss of 
JAM-A could be used as a biomarker for aggressive breast cancer (Naik et al., 2008). We 
next reasoned if Sdc-1 knockdown may influence JAM-A expression, therefore we tested 
independently the expression level by real time PCR and Western blot analyis. qPCR (Fig. 
4.37) shows no significant difference in JAM-A expression between control and Sdc-1 
siRNA-transfected cells (RQ=0.95) (p>0.05). In addition, Western blot analysis (Fig. 
4.38) independently emphasized no alteration in expression level of JAM-A post Sdc-1 
expression ablation.  
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Fig. 4.37 Relative JAM-A mRNA expression level as determined by real time PCR.  
Sdc-1 silencing doesn’t alter the expression level of JAM-A transcript compared to 
controls. The MDA-MB-231 breast cancer cell line was treated with control and Sdc-1 
siRNA for 24 h. Total cellular RNA was isolated 48 h post transfection and reverse 
transcribed into cDNA. The 2-∆∆Ct method was used to determine relative gene transcript 
levels after normalization to 18S rRNA. n≥3, error bars=SEM. 
 
 
 
 
 
 
 
Fig. 4.38 Western blot of cell lysates of control and Sdc-1 siRNA-transfected 
MDA-MB-231 cells reveals no alteration of JAM-A expression post Sdc-1 depletion. 
Control and Sdc-1 siRNA-transfected cell lysates were collected and 30-50 µg 
protein/lane were immunoblotted and probed with JAM-A antibody. Data shown are 
triplicates from a single experiment representative of three independent experiments. 
 
 
4.3.3.6 Influence of Syndecan-1 deficiency on CD44 expression in 
MDA-MB- 231 breast cancer cells 
CD44, the major receptor for HA, is a family of transmembrane glycoproteins (Culty et 
al., 1992) that acts through several mechanisms to regulate breast carcinoma behavior 
(Diaz et al., 2005). Binding of CD44 to hyaluronan promoted breast cancer cell adhesion 
and inhibited invasion (Lopez et al., 2005). On the other hand, tumor cell invasion was 
increased when CD44 interaction with HA was inhibited by a CD44 blocking antibody 
(Ryś et al., 2003). The expression level of CD44 was suppressed in Sdc-1-depleted cells 
with 3.4 fold based on the Affymetrix screening data. Using qPCR, we analyzed 
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independently transcript levels of CD44 48 h after control and Sdc-1 siRNA transfection. 
mRNA level of CD44 wasn’t significantly (p>0.05) altered in Sdc-1- depleted cells 
(RQ=0.47) compared to controls (Fig. 4.39). 
 
 
 
 
 
 
 
 
 
 
Fig. 4.39 Relative CD44 mRNA expression level as analyzed by real time PCR.  Sdc-1 
silencing doesn’t significantly alter the expression level of CD44 transcript compared to 
controls. The MDA-MB-231 breast cancer cell line was treated with control and Sdc-1 
siRNA for 24 h. Total cellular RNA was isolated 48 h post transfection and reverse 
transcribed into cDNA. The 2-∆∆Ct method was used to determine relative gene transcript 
levels after normalization to 18S rRNA. n≥3, error bars=SEM. 
 
 
4.3.3.7 Syndecan-1 silencing upregulates heparanase expression in 
MDA-MB-231 breast cancer cells  
Heparanase (HPSE) is a β-endoglucuronidase, which acts via a hydrolytic mechanism to 
cleave glycosidic bonds in heparan sulfate (Vlodavsky et al., 1999). It is an essential 
modulator of breast cancer proliferation, invasion, and metastasis as well as a significant 
promoter of malignancy-associated angiogenesis. Analysis of the metastatic breast 
carcinoma cell lines MDA-MB-231 and MDA-MB-435 revealed upregulated expression 
of HPSE transcripts and heparanase enzyme activity compared with the non-metastatic 
MCF-7 breast cancer cell line (Vlodavsky et al., 1999). Tumors formed from MCF-7 cells 
transfected with HPSE cDNA that were injected into the mammary pad of nude mice 
showed enhanced growth, invasion, and survival together with a greater degree of 
vascularity compared with tumors produced by mock-transfected cells (Cohen et al., 
2006). In contrast, silencing HPSE in MDA-MB-435 cells significantly reduced their 
invasive ability (Edovitsky et al., 2004). It has been demonstrated that expression of 
Sdc-1 or presence of exogenous Sdc-1 inhibits HPSE-mediated invasive behavior of 
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melanoma cells (Reiland et al., 2004). The HPSE expression level was 2.2 fold 
upregulated in Sdc-1 siRNA-transfected cells compared to controls based on the 
Affymetrix expression profile. According to our data and the former a pivotal role of 
HPSE in breast cancer progression, we highlighted the potential influence of Sdc-1 
silencing on HPSE expression level by real time PCR. Our mRNA analysis (Fig. 4.40) 
independently unraveled that HPSE gene expression was significantly enhanced (RQ=1.5) 
in Sdc-1-depleted cells compared to controls (p<0.05). 
 
 
 
 
 
 
 
 
 
 
Fig. 4.40 Relative HPSE mRNA expression level as determined by real time PCR.  Sdc-1 
silencing significantly augments the expression level of HPSE transcript compared to 
controls. The MDA-MB-231 breast cancer cell line was treated with control and Sdc-1 
siRNA for 24 h. Total cellular RNA was isolated 48 h post transfection and reverse 
transcribed into cDNA. The 2-∆∆Ct method was used to determine relative gene transcript 
levels after normalization to 18S rRNA. n≥3, * = p<0.05, error bars=SEM. 
 
 
4.3.3.8 Syndecan-1 siRNA knockdown dysregulates expression level of 
TLR-4 and COX-2 gene expression in MDA-MB-231 breast cancer cells 
a) Syndecan-1 deficiency is associated with TLR-4 downregulation, and 
upregulates COX-2 in the MDA-MB-231 breast cancer cell line 
Toll-like receptors (TLRs) are a family of pattern recognition receptors that are best-known 
for their role in host defense against infection. In humans, 13 types of TLRs have been 
identified, which are mainly expressed by immune cells and epithelial cells (Yu and Chen, 
2008). TLR4 signaling in tumor cells can mediate tumor cell immune escape and tumor 
progression, and it is regarded as one of the mechanisms for chronic inflammation in 
tumorigenesis and progression. It has been recently demonstrated that knockdown of 
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TLR4 expression inhibits proliferation and inflammatory cytokine secretion in the 
MDA-MB-231 breast cancer cell line (Yang et al., 2010).  
 
Prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) 
and also known as cyclooxygenase-2 (COX-2) is a cytoplasmic enzyme involved in the 
conversion of PLA2-mobilized arachidonic acid into lipid signal transduction molecules 
known as prostaglandins and thromboxanes. The major product of the COX-2–catalyzed 
reaction is prostaglandin E2 (PGE2), an inflammatory mediator participating in many 
biological processes, including development, pain, immunity, and angiogenesis (Smith et 
al., 2000). In vitro studies have shown that COX-2 knockdown in the MDA-MB-231 
breast cancer cell line resulted in invasion inhibition and abolished the metastatic 
potential. Furthermore, loss of COX-2 resulted in the significant delay of tumor onset 
when the cells were injected in the mammary fat pad of severe combined 
immunodeficient mice (Stasinopoulos et al., 2007). COX-2 overexpression in the 
mammary glands of transgenic mice resulted in increased tumor formation (Liu et al., 
2001). Although an important link between TLR4 signaling and COX-2 expression has 
been described in the gut (Fukata et al., 2006), there is no report on this link in breast 
cancer. In this regard and according to our Affymetrix data analysis (4.9 fold 
downregulation of COX-2 and 2.3 fold downregulation of TLR4), we decided to analyze 
the influence of Sdc-1 suppression on the expression level of TLR4 and COX-2 in 
MDA-MB-231 cells using real time PCR. qPCR analysis (Fig. 4.41) independently 
demonstrated a significant drastic reduction of TLR4 gene expression (RQ=0.38) (p<0.01) 
and  enhanced COX-2 expression (RQ=1.4) (p<0.05) in Sdc-1-deficient cells in 
comparison to controls. To further validate the expression level of COX-2 at the protein 
level, Western blot was performed. Immunoblot analysis displayed a substantial 
increased expression of COX-2 in Sdc-1-depleted cells compared to controls (Fig. 4.42). 
These data suggest that upregulation of COX-2 upon Sdc-1 loss in MDA-MB-231 cells 
may be TLR4 expression-independent. 
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Fig. 4.41 Relative TLR4 and COX-2 mRNA expression level as determined by real time 
PCR.  Sdc-1 silencing drastically downregulates the expression level of TLR4 transcript 
and upregulates COX-2 transcript compared to controls. The MDA-MB-231 breast 
cancer cell line was treated with control and Sdc-1 siRNA for 24 h. Total cellular RNA 
was isolated 48 h post transfection and reverse transcribed into cDNA. The 2-∆∆Ct method 
was used to determine relative gene transcript levels after normalization to 18S rRNA. 
n≥3, * = p<0.05, ** = p<0.01, error bars=SEM. 
 
 
 
 
 
 
 
Fig. 4.42 Western blot of cell lysates of control and Sdc-1 siRNA-transfected 
MDA-MB-231 cells reveals upregulation of COX-2 following Sdc-1 knockdown. 
Control and Sdc-1 siRNA-transfected cell lysates were collected and 30-50 µg 
protein/lane were immunoblotted and probed with COX-2 antibody. Data shown are 
triplicates from a single experiment representative of three independent experiments. 
 
 
b) COX-2 upregulation upon Syndecan-1 depletion does not correlate 
with cytoplasmic β-catenin expression 
It is well-established that Wnt/β-catenin signaling leads to mammary tumorigenesis 
(Hatsell et al., 2003; Michaelson and Leder, 2001; Turashvili et al., 2006) and that 
aberrant activation of this signaling pathway can lead to the development of many human 
cancer types (Moon et al., 2004; van de Wetering et al., 2001). Moreover, it is well- 
established that Sdc-1 modulates Wnt/β-catenin signaling in an experimental in vivo 
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model of breast cancer (Alexander et al., 2000). It has been reported that COX-2 
overexpression correlated with cytoplasmic beta-catenin expression, but did not correlate 
with nuclear or membrane expression (Kawasaki et al., 2007). Based on this finding, and 
as we have demonstrated that Sdc-1 depletion resulted in upregulation of COX-2, we 
sought to test whether Sdc-1 loss may influence beta-catenin expression and localization. 
Control and Sdc-1 siRNA-transfected cells were lysed by freeze-thawing in ice cold lysis 
buffer and, cystosolic and membrane fraction were separated as described in detail in 
methods section. Next we conducted independently Western blot analysis of both 
fractions of control and Sdc-1-depleted cells. Immunoblot analysis data displayed no 
alteration in expression or localization of beta-catenin between control and 
Sdc-1-depleted cells (Fig. 4.43). 
 
 
 
 
 
 
Fig. 4.43 Western blot of cell lysates of control and Sdc-1 siRNA-transfected 
MDA-MB-231 cells reveals no alteration of beta catenin expression and localization 
following suppression of Sdc-1 expression. Control and Sdc-1 siRNA-transfected cell 
lysates were collected and then fractionated as described in the Methods. 30-50 µg 
protein/lane were immunoblotted and probed with beta catenin antibody. Data shown are 
a single representative experiment of three independent experiments. 1: cytosolic fraction 
of mock. 2: cytosolic fraction of Sdc-1 siRNA-transfected cells 3: membrane fraction of 
mock 4: membrane fraction of Sdc-1 siRNA-transfected cells. 
 
 
4.3.4 Syndecan-1 depletion results in a differential expression of a wide 
range of candidate molecules modulating breast cancer cell motility 
Cell migration in ECM is a multistep process involving changes in the cytoskeleton, 
cell-substrate adhesions and the ECM components. Cell migration is generally initiated in 
response to extracellular stimuli, which can be diffusible factors, signals on neighboring 
cells, and/or signals from the ECM (Hall, 1998; Van Aelst and D'Souza-Schorey, 1997). 
Cell migration process consists of five separate steps: 1. lamellipodium extension at the 
leading edge, 2. formation of new focal adhesions complexes, 3. secretion of surface 
proteases to ECM contacts, inducing localized proteolysis, 4. cell body contraction by 
actomyosin complexes and 5. tail detachment (Lauffenburger and Horwitz, 1996). These 
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processes are modulated by Rho proteins, which belong to the Ras superfamily. They are 
small (21-25 kDa) molecules that share structural homology and become activated only 
when bound to GTP. The best-characterized molecules are Rho, which controls the stress 
fibers and focal adhesion formation, and Rac and cell division cycle 42 (CDC42), which 
regulate membrane ruffling, and filopodium formation, respectively (Etienne-Manneville 
and Hall, 2002).  
 
4.3.4.1 Syndecan-1 loss dysregulates Rho family GTPase expression and 
induces actin stress fibers formation in MDA-MB-231 breast cancer 
cells  
Our Affymetrix data suggested a modulation of Rho GTPase–dependent pathways by 
Sdc-1: For example, the genes encoding the Rho GTPase activating proteins Rho GAP91 
and Rho GAP271 are significantly downregulated in Sdc-1-depleted cells (2.3 and 2.4 
fold respectively), whereas expression of CDC42 effector protein 31 is upregulated 2.1 
fold. Since Rho GTPases regulate multiple cellular responses, including cell motility, we 
examined the deregulation of expression level of RhoA, RhoB and RhoC upon Sdc-1 loss 
in the MDA-MB-231 breast cancer cell line. First we investigated their expression level 
at mRNA by real time PCR. qPCR analysis (Fig. 4.44) showed that RhoA expression was 
significantly (p<0.05) suppressed in Sdc-1-depleted cells (RQ=0.74) compared to 
controls. In addition, the expression levels of RhoB and RhoC were not significantly 
(p>0.05) altered (RQ=0.74 and 0.49 respectively) in Sdc-1-silenced cells in comparison 
to controls. In turn, we decided to validate the expression level of Rho GTPases at protein 
level by Western blot using a pan-Rho antibody recognizing Rho A, B and C. Our 
immunoblot (Fig.4.45) data demonstrated that Rho GTPases were upregulated in Sdc-1- 
deficient cells compared to controls. Consequently, we performed independently 
immunoblots using a specific antibody to detect the expression level of RhoB. Western 
blot data (Fig.4.45) indicated downregulation of RhoB in Sdc-1 knockdown cells 
compared to controls, suggesting a possible upregulation of RhoA and/or RhoC upon 
Sdc-1 siRNA knockdown. 
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Fig. 4.44 Relative Rho GTPases mRNA expression level as determined by real time PCR. 
Sdc-1 silencing significantly downregulates the expression level of RhoA transcript 
compared to controls. The MDA-MB-231 breast cancer cell line was treated with control 
and Sdc-1 siRNA for 24 h. Total cellular RNA was isolated 48 h post transfection and 
reverse transcribed into cDNA. The 2-∆∆Ct method was used to determine relative gene 
transcript levels after normalization to 18S rRNA. n≥3, * = p<0.05, error bars=SEM. 
 
 
 
 
 
 
 
 
 
 
Fig. 4.45 Western blot of cell lysates of control and Sdc-1 siRNA-transfected 
MDA-MB-231 cells reveals upregulation of RhoABC and downregulation of RhoB 
expression post Sdc-1 expression depletion. Control and Sdc-1 siRNA-transfected cell 
lysates were collected and 30-50 µg protein/lane were immunoblotted and probed with 
RhoABC and RhoB antibodies. Data shown are triplicates from a single experiment 
representative of three independent experiments. 
 
 
Recently, it has been reported that levels of CDC42, Rac1, and RhoA are elevated in 
many different human cancers, including human breast cancers (Fritz et al., 1999; Fritz et 
al., 2002; Pan et al., 2004). Activation of CDC42 and the recruitment of adaptor proteins 
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can promote actin polymerization. The directionality of cell movement is maintained by 
CDC42, which coordinates actin polymerization at the front of the cell with microtubule 
attachment and alignment (Etienne-Manneville and Hall, 2001; Ridley et al., 2003). 
Together, these events lead to the formation of an actin-rich protrusion. In respect of 
Affymetrix screening data analysis, CDC42 was elevated 3.2 fold in Sdc-1-depleted cells 
compared to controls. Therefore, it would be relevant to shed light on influence of Sdc-1 
loss on CDC42 gene expression. Compared to controls, real time PCR results (Fig. 4.46) 
indicated a non-significant alteration of CDC42 expression (RQ=0.5) in Sdc-1-deficient 
cells (p>0.05). However, we could affirm independently reduction of CDC42 expression 
by confocal immunofluorescence microscopy in Sdc-1-depleted cells compared to 
controls (Fig. 4.47).  
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.46 Relative CDC42 mRNA expression level as determined by real time PCR.  
Sdc-1 silencing doesn’t significantly alter the expression level of CDC42 transcript 
compared to controls. The MDA-MB-231 breast cancer cell line was treated with control 
and Sdc-1 siRNA for 24 h. Total cellular RNA was isolated 48 h post transfection and 
reverse transcribed into cDNA. The 2-∆∆Ct method was used to determine relative gene 
transcript levels after normalization to 18S rRNA. n≥3, error bars=SEM. 
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Fig. 4.47 Confocal immunofluorescence microscopy analysis shows downregulation of 
CDC42 expression in Sdc-1-depleted cells compared to controls. 5 x 104 control and 
Sdc-1 knockdown cells were grown on coverslips for 16 h in a 6-well plate, fixed, and 
processed for immunocytochemistry using monoclonal antibody against CDC42 (red 
fluorescent secondary antibody) as described in the methods.  
 
 
Activation of CDC42 leads to the formation of filopodia or microspikes (Mackay and 
Hall, 1998). Therefore, we next examined the effect of Sdc-1 siRNA knockdown in 
MDA-MB-231 cells on the actin cytoskeleton by fixation of the cells and visualization of 
actin filaments with rhodamine phalloidin staining. Sdc-1 depletion induced the 
formation of filopodia in MDA-MB-231 cells. Multiple thin actin stress fibers are present 
at the cell membrane; both in the intercellular region at areas of cell-cell attachment and 
at the free edges of the cell could be observed in Sdc-1-deficient cells compared to 
controls (Fig. 4.48). 
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Fig. 4.48 Sdc-1 silencing induces the formation of filopodia. MDA-MB-231 cells treated 
with control or Sdc-1 siRNA were subjected to immunofluorescence staining of F-actin 
with phalloidin (red). 
 
 
Fascin-1 is the 55kDa F-actin- binding cytoskeleton protein of general importance for a 
diverse set of cell protrusions with functions in cell adhesion, cell interactions, and cell 
migration (Adams, 2004; Rong et al., 2004). It plays an essential role in polarity of actin 
bundles in filopodia (Ishikawa et al., 2003). Sdc-1 is crucial in spreading and fascin spike 
formation by C2C12 myoblastic cells on TSP-1 (Adams et al., 2001). The upregulated 
expression of the fascin-1 gene may be correlated with the malignant transformation of 
human an immortalized esophageal epithelial cell line (Rong et al., 2004), whereas 
miR-145-dependent downregulation of fascin expression was shown to result in reduced 
motility of MDA-MB-231 breast cancer cells (Götte et al., 2010). In order to identify a 
quantitative value for gene expression of fascin-1 in the MDA-MB- 231 breast cancer cell 
line, qPCR was conducted independently to assess the expression level of fascin-1 gene 
in control and Sdc-1 siRNA-transfected cells (Fig. 4.49). Real time PCR unveiled that 
Sdc-1 knockdown had no a significant influence (p>0.05) on fascin-1 expression 
(RQ=0.85) compared to controls. Next we examined by Western blot the expression of 
fascin-1 at protein level upon Sdc-1 siRNA knockdown. No consistent expression change 
of fascin-1 is observed as indicated by immunoblot analysis (Fig. 4.50). 
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Fig. 4.49 Relative fascin-1 mRNA expression level as determined by real time PCR.  
Sdc-1 silencing doesn’t significantly influence the expression level of fascin-1 transcript 
compared to controls. The MDA-MB-231 breast cancer cell line was treated with control 
and Sdc-1 siRNA for 24 h. Total cellular RNA was isolated 48 h post transfection and 
reverse transcribed into cDNA. The 2-∆∆Ct method was used to determine relative gene 
transcript levels after normalization to 18S rRNA. n≥3, error bars=SEM. 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.50 Western blot of cell lysates of control and Sdc-1 siRNA-transfected 
MDA-MB-231 cells reveals no consistent change of fascin-1 expression following Sdc-1 
siRNA knockdown. Control and Sdc-1 siRNA-transfected cell lysates were collected and 
30-50 µg protein/lane were immunoblotted and probed with fascin-1 antibody. Data 
shown are triplicates from a single experiment representative of three independent 
experiments. 
 
 
4.3.4.2 Syndecan-1 siRNA knockdown leads to upregulated expression 
of the myosin regulatory light chain 9, transgelin and actin gamma 2 
smooth muscle enteric genes in MDA-MB-231 cells 
A number of myosins, the main motor protein in eukaryotic non-muscle cells, have been 
implicated in cell migration (Mermall et al., 1998). Myosin light chain phosphorylation is 
enhanced in the lamellipodial region of cells (Matsumura et al., 1998), which suggests a 
role for myosins in lamellipodium extension. Myosin regulatory light chain 9 (MYL-9) is 
critically involved in actomyosin contractility and stress fiber assembly (Licht et al., 2010) 
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and its expression is regulated by AML-1/RUNX1 (Sun et al., 2007). In accordance to our 
Affymetrix screening data, MYL-9 was 2.5 fold upregulated in Sdc-1-depleted cells 
compared to controls. Furthermore, the suppression of AML-1/RUNX1 expression was 
confirmed in Sdc-1-depleted cells. We verified the expression of MYL-9 at mRNA level 
by real time PCR. qPCR analysis (Fig. 4.51) showed that Sdc-1-depleted cells exhibited 
significantly elevated MYL-9 expression levels (RQ=1.72) compared to controls 
(p<0.05). 
 
Transgelin (TAGLN) also known as SM22, a 22 kDa protein is an actin stress 
fibre-associated protein (Lawson et al., 1997) and acts to promote formation and 
stabilization of actin gels in vitro. It is also associated with actin filaments in smooth 
muscle (Gimona et al., 2003). TAGLN may also be involved in cell migration. It has been 
shown to be associated with a specific sub-population of actin filament bundles that form 
podosomes (Gimona et al., 2003). TAGLN also acts to suppress expression of the MMP-9 
(Nair et al., 2006). Affymetrix screening data unveiled that TAGLN was increased (2.5 
fold) in Sdc-1-deficient cells compared to controls. To independently confirm the 
expression changes of TAGLN at the mRNA level, we conducted qPCR. Real time PCR 
results (Fig. 4.51) showed that Sdc-1-deficient cells displayed significantly higher 
TAGLN expression (RQ=2.13) compared to controls (p<0.01). 
 
Actin gamma 2 smooth muscle enteric (ACTG2) has been linked to cisplatin resistance in 
breast cancer cells (Watson et al., 2007). Affymetrix screening data revealed that ACTG2 
was upregulated (3 fold) in Sdc-1 knockdown cells compared to controls. Quantitative 
Real-time PCR expression analysis (Fig. 4.51) confirmed a significant enhanced 
expression level of ACTG2 (RQ=2.5) following Sdc-1 silencing (p<0.01). 
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Fig. 4.51 Relative MYL-9, TAGLN and ACTG2 mRNA expression level as determined 
by real time PCR.  Sdc-1 silencing enhances significantly the expression level of MYL-9, 
TAGLN and ACTG2 transcript compared to controls. The MDA-MB-231 breast cancer 
cell line was treated with control and Sdc-1 siRNA for 24 h. Total cellular RNA was 
isolated 48 h post transfection and reverse transcribed into cDNA. The 2-∆∆Ct method was 
used to determine relative gene transcript levels after normalization to 18S rRNA. n≥3, * 
= p<0.05, ** = p<0.01, error bars=SEM. 
 
 
4.3.4.3 Syndecan-1 siRNA knockdown induces upregulated expression 
of talin 1, and vinculin, and increases FAK tyrosine phosphorylation in 
MDA-MB-231 cells 
Formation of new focal adhesions complexes is localized in the lamellipodia of most 
migrating cells. Upon the attachment of the extending lamellipodium to ECM, integrins 
come into contact with ECM ligands and cluster in the cell membrane interacting with the 
FAK, α-actinin and talin. All these proteins can bind adaptor proteins through SH2, SH3 
or proline rich domains to recruit actin binding proteins (vinculin, paxillin and α-actinin) 
(Zamir and Geiger B, 2001; Zamir et al., 2000). Moreover, radixin, a member of the ERM 
cytoskeleton-associated protein family is a key signaling molecule that regulates cancer 
migration and invasion (Valastyan et al., 2010). 
 
Affymetrix screening data indicated enhanced expression level of talin-1 and radixin (2.8 
and 2.3 fold) respectively, in Sdc-1-depleted cells compared to controls. As we have 
previously shown (►4.3.2) that Sdc-1 knockdown induced a prominent tyrosine 
phosphorylation of several cellular proteins, which was particularly prominent for a 
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protein with a molecular weight of 125 kDa in MDA-MB-231 cells, we decided to 
decipher whether Sdc-1 lack influences the expression level of FAK and vinculin, and 
stimulation of FAK tyrosine phosphorylation. qPCR analysis (Fig. 4.52) revealed no 
significant difference (p>0.05) of the FAK mRNA expression level (RQ=0.97) between 
control and Sdc-1-silenced cells. However, Western blot analysis indicated that cells 
lacking Sdc-1 display higher FAK tyrosine phosphorylation at 125 kDa along with 
elevation of vinculin levels compared to controls (Fig. 4.53A). We confirmed higher 
FAK tyrosine phosphorylation in Sdc-1-depleted MDA-MB-468 breast cancer cells as 
well (Fig. 4.53B). 
 
 
 
 
 
 
 
 
 
 
Fig. 4.52 Relative FAK mRNA expression level as determined by real time PCR.  Sdc-1 
silencing doesn’t significantly alter the expression level of FAK transcript compared to 
controls. The MDA-MB-231 breast cancer cell line was treated with control or Sdc-1 
siRNA for 24 h. Total cellular RNA was isolated 48 h post transfection and reverse 
transcribed into cDNA. The 2-∆∆Ct method was used to determine relative gene transcript 
levels after normalization to 18S rRNA. n≥3, error bars=SEM. 
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Fig. 4.53 (A) Western blot of cell lysates of control and Sdc-1 siRNA-transfected 
MDA-MB-231 cells reveals enhanced expression of vinculin and higher FAK tyrosine 
phosphorylation following Sdc-1 silencing. Control and Sdc-1 siRNA-transfected cell 
lysates were collected and 30-50 µg protein/lane were immunoblotted and probed with 
vinculin and pFAK antibodies. (B) Western blot of cell lysates of control and Sdc-1 
siRNA-transfected MDA-MB-468 cells reveals higher FAK tyrosine phosphorylation 
post Sdc-1 silencing. Data shown are triplicates and duplicates from a single experiment 
representative of three independent experiments. 
 
 
4.3.4.4 FAK is physically associated with Syndecan-1 in MDA-MB-231 
breast cancer cells 
FAK is an important signaling partner of integrins, a role that includes the physical 
association of β1 integrin cytoplasmic tail and the N-terminal domain of FAK in vitro. 
(Lyman et al., 1997; Schaller et al., 1995). Epithelial membrane protein 2 (EMP2) is a 
tetraspan (4-transmembrane) protein belonging to the growth arrest specific-3/peripheral 
myelin protein-22 family (Wang et al., 2001). EMP2 expression is required for efficient 
integrin-mediated cellular responses, and EMP2 physically associates with certain 
integrin isoforms (Wadehra et al., 2002 and 2005). Moreover, it has been demonstrated 
that human full length Sdc-1 could be co-immuoprecipitated with ß5 integrin (McQuade 
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et al., 2006) and there is a positive effect of EMP2 levels on FAK phosphorylation which 
reflect a physical association between FAK and EMP2 (Morales et al., 2009). As we have 
shown increased phosphorylated form of FAK expression upon Sdc-1 lack and in regard 
of our Affymetrix screening, EMP-2 was upregulated 4 fold in Sdc-1-depleted cells in 
comparison to controls, we hypothesized that a physical association between FAK and 
EMP2 with Sdc-1 might exist. Indeed, we evaluated this idea by immuoprecipitation of 
Sdc-1 with polyclonal antibody and immunoblotted the precipitate with EMP-2 and FAK 
antibodies. Whereas we could not affirm the physical interaction between EMP-2 with 
Sdc-1, FAK could be co-immunoprecipitated with antibody directed against the 
cytoplasmic domain of Sdc-1, demonstrating a physical interaction of FAK and Sdc-1 in 
control cells (Fig. 4.54). 
 
 
 
 
 
 
 
 
 
Fig. 4.54 Co-immunoprecipitation of FAK with Sdc1. MDA-MB-231 cell lysates (500 
µg protein) were subjected to immunoprecipitation with a polyclonal antiserum directed 
against the cytoplasmic domain of Sdc-1 or a control antiserum as described in the 
methods. Western blot of immunoprecipitates reveals co-immunoprecipitation of FAK 
with Sdc-1. Data shown are from a single experiment that is a representative of two 
independent experiments. 
 
 
4.3.4.5 Syndecan-1 siRNA knockdown suppresses expression of the 
ECM components collagen type I A2 and matrilin-2 in MDA-MB-231 
cells 
It is known that the ECM is able to signal to cells and thereby directs or modulates the 
transcription of certain mRNAs. This signaling plays an important role in tumor invasion 
and metastasis, wound healing, remodeling of the ECM and cell differentiation (Christner 
and Ayitey, 2006). A study has demonstrated that decreased collagen production by 
tumorigenic cells correlates with faster cell growth, less adhesion to substratum and 
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increased tumorigenicity of the transformed cells (Rowe et al., 1978; Sandmeyer et al., 
1981). Collagen type I (COL1) is an integral structural component of the ECM and 
crucial for the formation of connective tissues. The functional role of the COL1A2 gene 
remains controversial. It has been reported as an oncogenesis-related molecule as well as 
a potential tumor suppressor gene (Lim et al., 1994; Yang et al., 2007). COL1A2 
downregulation through CpG hypermethylation of the promoter region has been shown to 
increase cell growth and migration activity in bladder cancer (Mori et al., 2009).  
 
Matrilin-2 encodes a member of the von Willebrand factor A domain containing protein 
family. This family of proteins is thought to be involved in the formation of filamentous 
networks in the ECM (Deák et al., 1997). Apparently, cell migration in response to 
wounding is enhanced in matrilin-2-depleted kerationcyte compared to controls 
(Ichikawa et al., 2008). 
 
Our Affymetrix screening data showed 2.3-fold downregulation of COL1A1, whereas 
matrilin-2 was 2.1-fold upregulated upon Sdc-1 suppression. In this regard and in 
agreement with these findings, we verified the expression level of COL1A2 and 
matrilin-2 expression by Western blot following Sdc-1 siRNA treatment in MDA-MB- 
231 cells. Immunloblot analysis (Fig. 4.55) showed that Sdc-1 siRNA knockdown 
apparently ablates the expression level of both COL1A2 and matrilin-2 in comparison 
with controls. These findings highlight that loss of Sdc-1 expression induced reduction of 
COL1A2 and matrilrin-2 which may have resulted in more motile phenotype. 
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Fig. 4.55 Western blot of cell lysates of control and Sdc-1 siRNA-transfected 
MDA-MB-231 cells reveals completely ablation of COL1A2 and matrilin-2 expression 
post Sdc-1 silencing. Control and Sdc-1 siRNA-transfected cell lysates were collected 
and 30-50 µg protein/lane were immunoblotted and probed with COL1A2 and matrilin-2 
antibodies. Data shown are triplicates from a single experiment representative of three 
independent experiments. 
 
 
4.3.4.6 Syndecan-1 depletion augments MDA-MB-231 cell motility via a 
Rho-GTPase-dependent mechanism 
 To determine the potential function of Sdc1 in cell motility, we used an RNA 
interference strategy to alter its expression. Based on our finding of differentially 
regulated Rho family GTPase expression, we analyzed the migratory behavior of control 
and Sdc-1-depleted MDA-MB-231 cells by performing time-lapse video microscopy. 
MDA-MB-231 mock and Sdc-1 siRNA-transfected cells were cultured in complete 
growth medium and cell migration was recorded for 12 h at 37°C at 10 min interval. 
Analysis of cell tracts revealed that control cells migrated poorly. In contrast, Sdc1 
siRNA-transfected cells had a significantly higher average cell velocity being 
approximately 4.5 fold greater than controls (Fig. 4.56A). The migratory speed of the 
mock cells was 0.19 µm/min (see Supplemental movie 1), whereas in Sdc-1 siRNA- 
treated cells was 0.86 µm/min (see Supplemental movie 2). The Sdc-1-deficient cells 
showed a significant increase in migratory distance compared to cells expressing 
wild-type levels of Sdc-1, the average distance covered by controls was 20 µm; whereas 
the distance in Sdc-1 siRNA-transfected cells was 66.1 µm (Fig. 4.56B). Control cells 
displayed a little movement and tend to form small radial membrane protrusions 
consisting of slowly forming and retracting lamellopodia and filopodia. However, Sdc1 
siRNA-treated cells moved at a higher average velocity with a fairly random course of 
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migration but rapidly emitted a complex set of protrusions consisting of multiple frontal 
filopodia followed closely behind by lamellopodia as they shuffled forward. Compared to 
the controls that usually showed a cobblestone epitheloid phenotype, the majority of Sdc1 
siRNA-transfected cells showed a polarized morphology with a distended fibroblastic 
shape as estimated by structural index (0.7 vs 0.57) (Fig. 4.56C). Rho-associated protein 
kinase (ROCK), a molecular switch, modulates cellular functions in breast cancer and 
additional tumor entities (Narumiya et al., 2009). To test whether the motile phenotype of 
Sdc-1 siRNA-transfected cells is RhoA/ROCK-dependent, the transfectants were 
incubated with Y27632, a selective inhibitor of Rho associated protein kinase (Liu et al., 
2009), for 12 h and cell migration was recorded at 10 min intervals. Post Y27632 
treatment, Sdc-1 siRNA-transfected cells exhibited slow migration compared to controls 
(see Supplemental movie 3 & 4) (0.17 µm/min vs 0.25 µm/min in controls) (Fig. 4.56A). 
Rock inhibitor treatment of control cells did not significantly affect the migratory speed 
compared to untreated control cells (0.25 µm/min vs 0.19 µm/min), whereas treated 
Sdc-1 siRNA transfectants showed a highly significant inhibition of migratory phenotype 
compared to untreated Sdc-1 siRNA transfectants (0.17 µm/min vs 0.86 µm/min) (Fig. 
4.56A). Moreover, post ROCK inhibitor treatment; control cells covered a distance of 
34.8 µm whereas the distance covered by Sdc-1 siRNA-transfected cells was 29.3 µm 
(Fig. 4.56B). Inhibition of ROCK rendered the control cells more spindle-shaped 
compared to Sdc-1 siRNA- transfected cells (structural index 0.38 vs 0.59) (Fig. 4.56C). 
Taken together, our data suggest that increased motility of Sdc-1-depleted cells depends 
on Rho GTPase activity. Representative cell tracks of untreated and Y27632-treated 
control and Sdc-1 siRNA- transfected cells are shown in Fig. 4.56D and E respectively. 
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Fig. 4.56 Sdc-1 silencing enhances MDA-MB-231 breast cancer cell motility dependent 
on Rho GTPase activity. Time lapse-video microscopy studies were performed on 6 x 104 
control and Sdc-1 siRNA-transfected cells for 12 h at 10 min intervals. (A) Sdc-1- 
depleted cells migrate significantly faster than mock-transfected cells. The ROCK 
inhibitor Y27632 significantly decreases Sdc-1 siRNA-transfected cell motility. (B) 
Sdc-1 siRNA -treated cells migrate over longer distances compared to controls. ROCK 
inhibitor treatment abolishes the Sdc-1 specific effect. (C) The structural index of the 
cells indicates that Sdc-1-depleted cells have a tendency to be more spindle-shaped, 
whereas control cells are more rounded. The ROCK inhibitor renders the control cells 
more spindle-shaped, but has no significant effect on Sdc-1-depleted cell shape. (D) and 
(E) representative cell tracks of control and Sdc-1 siRNA-treated cells ±Y27632 
incubation, respectively. n=3, * = p<0.05, ** = p<0.01, error bars=SEM. 
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4.3.4.7 A specific ROCK inhibitor impedes the expression of COX-2 
and p21 Waf1/Cip1 in control and Syndecan-1 siRNA-transfected cells 
RhoA and its effector protein ROCK promote the expression of the pro-inflammatory 
gene COX-2 at the transcriptional level in human epithelial cells (Benitah et al., 2003). 
To test if this finding also applies to our experimental context, control and Sdc-1 siRNA- 
transfected cells were incubated with Y27632 for 24 h and 48 h at 37οC. Cell lysates were 
prepared and utilized for immunoblotting to examine the influence of ROCK inhibitor 
treatment on COX-2 expression. Western blot analysis displayed a drastic reduction of 
COX-2 expression in control and Sdc-1-lacking cells post Y27632 treatment in a 
time-dependent manner (Fig. 4.57). COX-2 downregulation was more profound in 
Sdc-1-depleted cells, suggesting that Sdc-1 may modulate COX-2 expression in a 
RhoA/ROCK-dependent mechanism. 
 
 
 
 
 
 
Fig. 4.57 Western blot of cell lysates of control and Sdc-1 siRNA-transfected 
MDA-MB-231 cells treated with Y27632 reveals a dramatic reduction of COX-2 
expression in a time-dependent manner. Control and Sdc-1 siRNA-transfected cells were 
grown in a complete growth media and treated with 10 µM Y27632 for 24 h and 48 h. 
Total cell lysates were collected and 30-50 µg protein/lane were immunoblotted and 
probed with COX-2 antibody. Data shown are from a single experiment that is 
representative of three independent experiments. 
. 
 
RhoA has previously been reported to downmodulate p21 Waf1/Cip1 levels in cells 
transformed by oncogenic Ras (Olson et al., 1998). In addition, activation of RhoA by 
fibronectin suppresses p21 Waf1/Cip1 RNA levels during G1 cell cycle progression (Danen 
et al., 2000). To address a potential functional link to Sdc-1, control and Sdc-1 siRNA- 
transfected cells were incubated with Y27632 for 24 h and 48 h at 37Cο. Cell lysates were 
prepared and utilized for immunobloting to examine the influence of the ROCK inhibitor 
on p21 Waf1/Cip1 expression. Post Y27632 treatment, Western blot analysis displayed a 
reduction of p21 Waf1/Cip1 expression in control and in Sdc-1-silenced cells (Fig. 4.58). 
This finding suggests that RhoA/ROCK modulates p21 Waf1/Cip1 expression in the 
MDA-MB- 231 breast cancer cell line. 
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Fig. 4.58 Western blot of cell lysates of control and Sdc-1 siRNA-transfected 
MDA-MB-231 cells treated with Y27632 reveals a modulation p21 Waf1/Cip1 expression 
level in a time-dependent manner. Control and Sdc-1 siRNA-transfected cells were 
grown in a complete growth media and treated with 10 µM Y27632 for 24 and 48 h. Total 
cell lysates were collected and 30-50 µg protein/lane were immunoblotted and probed 
with p21 Waf1/Cip1 antibody. Data shown are from a single experiment that is representative 
of three independent experiments. 
 
 
4.3.4.8 Syndecan-1 siRNA treatment drastically downregulates MPP-4 
expression in MDA-MB-231 cells 
We analyzed the expression of the MAGUK / PDZ-domain scaffolding protein, 
membrane palmitoylated protein-4 (MPP4), which was found to be differentially 
regulated (3.2-fold downmodulated) in Sdc-1-deficient cells according to our Affymetrix 
screening data. MAGUK / PDZ domain proteins such as CASK and syntenin have been 
identified as important Sdc-1-dependent modulators of cell adhesion and migration 
(Lambaerts et al., 2009). To verify the expression level of MPP4 in control and Sdc-1 
siRNA-treated cells, conventional PCR, Western blot, and immunoflurescence were 
performed, which consistently revealed a massive downregulation of MPP4 expression in 
Sdc-1-depleted MDA-MB-231 cells compared to controls (Fig. 4.59A-C). To address the 
subcellular distribution of endogenous MPP4, immunostaining unveiled nuclear 
localization of MPP4, where it could have transcriptional activities (Fig. 4.59C). 
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Fig. 4.59 Analysis of MPP4 expression and localization in control and Sdc-1 
siRNA-treated MDA-MB-231 cells. (A) RT-PCR analysis. RNA was prepared from 
control and Sdc-1 siRNA-treated MDA-MB-231 cells, mRNA was reverse transcribed 
into cDNA and used as a template for PCR amplification of MPP4. 1.5% agarose gel 
electrophoresis indicates downregulation of MPP4 in Sdc-1-depleted cells compared to 
controls. PCR band intensities were normalized for actin expression as a house keeping 
gene. (B) Western blot analysis of control and Sdc-1 siRNA-transfected cells shows 
downregulation of MPP4 protein expression in Sdc-1-silenced cells compared to controls. 
(C) Confocal immunofluorescence microscopy analysis shows less immunolocalization 
of MPP4 in nucleus of Sdc-1-silenced cells compared to controls. 5 x 104 cells were 
grown on coverslips for 16 h in a 6-well plate, fixed, and processed for 
immunocytochemistry using monoclonal antibody against MPP4 (green fluorescent 
secondary antibody) top panel = merged MPP4 and DAPI signal, central panel= MPP4 
signal, bottom panel = DAPI signal. Data shown are from a single experiment that is 
representative of three independent experiments. 
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4.3.5 Syndecan-1 siRNA treatment represses JHDM1D gene expression 
in MDA-MB- 231 cells 
The control of gene expression in eukaryotes relies in part on the methylation status of 
histone proteins (Rea et al., 2000). Histone methylation on lysine and arginine residues 
contributes to the regulation of gene expression (Berger, 2002; Martin and Zhang, 2005). 
The JmjC domain-containing enzymes catalyze demethylation of histone through an 
oxidative reaction (Tsukada et al., 2006). Jumonji C domain-containing histone 
demethylase 1 homolog D (JHDM1D) demethylates either Lys9-or 27-trimethylated 
histone 3 (H3K9me2 or H3K27me2) (Horton et al., 2010). As our Affymetrix screening 
unveiled many repressed target genes upon Sdc-1 depletion that might be mediated by 
hypermethylation, we sought to substantiate the downregulation of JHDM1D transcript 
gene (2.2 fold) in the MDA-MB-231 breast cancer cell line as has been proved by 
Affymetrix screening. Hence, qPCR was carried out for cDNA of control and Sdc-1 
siRNA-transfected cells in cooperation with the group of Prof. Schüle, Department of 
Obstetrics and Gynecology, Freiburg University. JHDM1D mRNA expression was 
significantly (p<0.01) repressed in Sdc-1-silenced cells (RQ=0.6) compared to controls 
(Fig. 4.60). 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.60 Relative JHDM1D mRNA expression level as determined by real time PCR.  
Sdc-1 silencing significantly represses the expression level of JHDM1D transcript 
compared to controls. The MDA-MB-231 breast cancer cell line was treated with control 
or Sdc-1 siRNA for 24 h. Total cellular RNA was isolated 48 h post transfection and 
reverse transcribed into cDNA. The 2-∆∆Ct method was used to determine relative gene 
transcript levels after normalization to 18S rRNA. n≥3, ** = p<0.01, error bars=SEM. 
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4.4 Syndecan-1 silencing promotes in vitro MDA-MB-231 cell adhesion 
to fibronectin and laminin 
Emerging data indicate that Sdc-1 has roles in cell adhesion and signaling, possibly as a 
co-receptor with integrins and cell-cell adhesion molecules by binding to matrix ligands, 
including fibronectin and laminins (Beauvais and Rapraeger, 2004). Since we have 
proven increased phosphorylation of FAK and expression of vinculin in Sdc-1- depleted 
cells, which is a crucial step in cell adhesion-mediated assembly of signaling complexes, 
we next assessed the potential role of Sdc-1 on the cell adhesion to fibronectin and 
laminin. Control and Sdc-1 siRNA-transfected cells were added to the coated wells 
(either by fibronectin or laminin) and were allowed to attach for 1 hour in the incubator. 
Subsequently, the cells fixed with formaldhyde, and attached cells were stained with 1% 
methylene blue in borate buffer, followed by spectophotometry of the cell lysates. In vitro 
adhesion of Sdc1 siRNA-transfected cells compared to controls was significantly 
enhanced by 30.4% (fibronectin) and by 13% (laminin), respectively (Fig. 4.61). 
 
 
 
 
 
 
 
 
 
 
Fig. 4.61 Sdc-1 silencing promotes MDA-MB-231 cell adhesion to fibronectin and 
laminin. MDA-MB-231 breast cancer cells were transfected with control and Sdc-1 
siRNA for 24 h. Cells were seeded onto a 96-well plate coated with 10 µg/ml fibronectin 
and 50 µg/ml laminin 48 h after transfection. Adhesion was determined as described in 
detail in the methods section using a colorimetric assay.  n≥3, * = p<0.05, ** = p<0.01, 
error bars=SEM. 
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4.5 Investigation of nuclear localization of Syndecan-1 in MDA-MB-231 
cells 
Previous reports have indicated that Sdc-1 can at least partially localize to the nucleus in 
tumor cells, with possible implications for transcriptional regulation (Chen and 
Sanderson, 2009; Nikolova et al., 2009; Zong et al., 2009). To address the subcellular 
distribution of endogenous Sdc-1, control and Sdc-1 siRNA-transfected cells were 
investigated by immunofluorescence microscopy. Immunostaining showed perinuclear 
and/or nuclear localization for Sdc-1 of both transfectants with strongly reduced 
expression in Sdc-1-depleted cells (Fig. 4.62). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.62 Confocal immunofluorescence microscopy analysis shows perinuclear and/or 
nuclear localization of Sdc-1. 5 x 104 control or Sdc-1 siRNA-transfected MDA-MB-231 
cells were grown on coverslips for 16 h in a 6-well plate, fixed, and processed for 
immunocytochemistry using monoclonal antibody against Sdc-1 (green fluorescent 
secondary antibody) and DAPI for nucleus staining as described in the methods. top panel 
= merged Sdc-1 and DAPI signal, central panel = Sdc-1 signal, bottom panel = DAPI 
signal. 
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4.6 Syndecan-1 is a novel regulatory target of miR-10b in 
MDA-MB-231 cells 
miRNAs are a recently described class of genes, encoding small non-coding RNA 
molecules, which primarily act by downregulating the translation of target mRNAs 
(Götte, 2010; Grosshans and Slack, 2002). Many miRNAs have been implicated in 
several human cancers, including breast cancer. miR-10b was the first miRNA found to 
influence the metastatic potential of human cancer cells. miR-10b was highly expressed 
only in metastatic cancer cells and was found to stimulate RhoC upregulation, thereby 
promoting cell migration and invasion in vitro and initiating tumor invasion and 
metastasis in vivo (Ma et al., 2007). Paradoxically, a microarray study reported that 
miR-10b is among the miRNAs found to be downregulated in primary breast tumors 
(independent of their clinical aggressiveness) compared with normal breast tissue (Iorio 
et al., 2005). A DIANA miRGen database (Megraw et al., 2007) search identified 
miR-10b, as a potential regulator of Sdc-1 expression, as predicted by the TargetScanS 
(Lewis et al., 2005) and PicTar (4 way) (Krek et al., 2005) algorithms. It has been 
demonstrated by our group that ectopic expression of miR-10b generates a phenocopy of 
the effect of Sdc-1 siRNA knockdown on in vitro invasion in MDA-MB-231 cells (C. 
Weise and M. Götte, unpublished data). We transiently transfected MCF-7 cells with 
control miR-precursor and pre-miR-10b precursor and conventional PCR results revealed 
downregulation of syndecan-1 expression upon miR-10b overexpression (Fig. 4.63A). 
To investigate posttranscriptional regulation of Sdc-1 expression by miR-10b, control 
miR-precursor or pre-miR-10b was co-transfected along with 1µg of plasmid 
pEZX-MT01 expressing firefly luciferase under the control of the human Sdc-1 3′UTR, 
and Renilla luciferase under the control of CMV promoter. Cell lysates were prepared 
and assayed in a luminometer normalizing firefly to Renilla luciferase activity measured 
in the same well. pre-miR-10b transfection resulted in a significant 40% decrease in 
normalized firefly luciferase activity, indicating direct regulation of the 3′UTR of Sdc-1 
by miR-10b (Fig. 4.63B). Additional experiments by our group indicate that pre-miR-10b 
transfection of MDA-MB-231 and MCF-7 breast cancer cells results in downregulation 
of Sdc-1 expression at the mRNA and protein levels (C. Weise and M. Götte, 
unpublished). 
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Fig. 4.63 (A) RT-PCR analysis. RNA was prepared from control miR-precursor and 
pre-miR-10b precursor-treated MCF-7 cells, mRNA was reverse transcribed into cDNA 
and used as a template for PCR amplification of Sdc-1. 1.5% agarose gel electrophoresis 
indicates downregulation of Sdc-1 mRNA upon ectopic miR-10b expression in MCF-7. 
PCR band intensities were normalized for actin expression as a house keeping gene. (B) 
The 3′UTR of Sdc-1 is a target for transcriptional regulation by miR-10b. MDA-MB-231 
breast cancer cells were transfected with plasmid pEZX-MT01-Sdc-1-3′ UTR expressing 
firefly luciferase (hLuc) under the control of an SV40 enhancer and the 3′UTR of human 
Sdc-1, and Renilla luciferase (hRLuc) under constitutive control of the CMV promoter. 
Cells were co-transfected with a control pre-miR or pre-miR-10b and simultaneously 
assayed for activity of both luciferases 48 h after transfection. Significantly, miR-10b 
transfection induced 40% reduction in Sdc-1-specific normalized firefly luciferase 
activity. n=3, ** = p<0.01, error bars=SEM.  
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4.7 Ectopic expression of miR-10b leads to downregulated E-cadherin 
expression in the MCF-7 breast cancer cell line 
As we have previously confirmed that E-cad was downregulated upon Sdc-1 silencing, 
we tested whether ectopic expression of miR-10b may influence E-cad expression as a 
downstream target of Sdc-1. microRNA database analyses employing the TargetScanS 
(Lewis et al., 2005) and PicTar (4 way) (Krek et al., 2005) algorithms revealed that E-cad 
isn’t a direct predicted target of miR-10b, therefore, possible changes in E-cad expression 
could at least partially be attributed to Sdc-1 downregulation. We investigated the 
expression level of E-cad of control and pre-miR-10b-transfected MCF-7 breast cancer 
cells at the protein level. Western blot analysis showed that E-cad expression was 
downregulated upon ectopic miR-10b overexpression (Fig 4.64). 
 
 
 
 
 
 
 
Fig. 4.64 Western blot of cell lysates of control miR-precursor and pre-miR-10b- 
transfected MCF-7 cells reveals downregulation of E-cad post ectopic miR-10b 
overexpression. Control and miR-10b overexpressed cell lysates were collected and 
30-50 µg protein/lane were immunoblotted and probed with E-cad antibody. Data shown 
are triplicates from a single experiment representative of three independent experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results 
 164 
4.8 Ectopic expression of miR-10b upregulates TAGLN expression in 
the MDA-MB-231 breast cancer cell line 
TAGLN was identified as a putative target of miR-10b as predicted by the TargetScanS 
(Lewis et al., 2005) and PicTar (4 way) (Krek et al., 2005) algorithms. We confirmed 
upregulation of TAGLN upon Sdc-1 depletion in MDA-MB-231 cells, which might 
contribute to the enhanced invasive phenotype. Therefore, we sought to investigate the 
expression level of TAGLN at the mRNA level following miR-10b overexpression. We 
performed qPCR for cDNA of control and pre-miR-10b-transfected MDA-MB-231 
breast cancer cells. Real time PCR analysis (Fig. 4.65) revealed that TAGLN expression 
was significantly (p<0.05) upregulated in miR-10b-overexpressing cells compared to 
controls (RQ=3.3), which in line with our results of TAGLN expression in Sdc-1- 
silenced MDA-MB-231 breast cancer cells (►4.3.4.2). 
 
 
 
 
 
 
 
 
 
 
Fig. 4.65 Relative TAGLN mRNA expression level as determined by real time PCR.  
miR-10b overexpression significantly upregulates the expression level of TAGLN 
transcript compared to controls. The MDA-MB-231 breast cancer cell line was treated 
with control or pre-miR-10b for 24 h. Total cellular RNA was isolated 48 h post 
transfection and reverse transcribed into cDNA. The 2-∆∆Ct method was used to determine 
relative gene transcript levels after normalization to 18S rRNA. n≥3, * = p<0.05, error 
bars=SEM. 
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4.9 Ectopic expression of miR-10b generates a migratory phenocopy of 
Syndecan-1-depleted MDA-MB-231 breast cancer cells 
Since we have demonstrated that Sdc-1 is a direct potential target of miR-10b, we tested 
whether Sdc-1 acts as a functional target of miR-10b. For this purpose, we tested 
influence of overexpression of miR-10b on the migration potential of MDA-MB-231 
cancer cells. We performed an in vitro migration assay in the presence of 10% FCS as a 
chemoattractant. Our results revealed that miR-10b-overexpressing cells displayed 
enhanced migration by 3 fold compared to controls (p<0.05) and generated a migratory 
phenocopy of Sdc-1-silenced cells (Fig. 4.66). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.66 In vitro Trans-well migration assay of control and pre-miR-10b-transfected 
MDA-MB-231 cells. (A) miR-10b overexpression enhances in vitro migration of 
MDA-MB-231 breast cancer cells. 25 x 103 control or pre-miR-10b-transfected cells were 
added to migration Trans-well inserts for 24 h and 10% FCS was used as a 
chemoattractant. n≥3, * = p<0.05, error bars=SEM. (B) A representative image of 
migration inserts stained with Diff-Quik dye. 
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4.10 Syndecan-1 silencing drastically inhibits invasiveness of the MCF-7 
breast cancer cell line 
Since Götte et al., (2007) have been reported that the low metastatic potential MCF-7 
breast cancer cell line has low expression signature of c-Met and since we have 
previously demonstrated that there is no activation of the p44/42 MAPK signaling 
pathway in response to HGF stimulation in these cells (► 4.2.1), we performed an in 
vitro Matrigel invasion assay in the presence of 10% FCS as a chemoattractant to assess 
the potential role of Sdc-1 for MCF-7 invasiveness. Our data unveiled that Sdc-1 
siRNA-transfected MCF-7 cells displayed dramatically reduced invasiveness by 
approximately a factor of 6 compared to controls (p<0.01) (Fig. 4.67). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.67 In vitro invasion of control and Sdc-1-depleted MCF-7 was demonstrated by 
Matrigel invasion assay. (A) Sdc-1 knockdown dramatically suppressed in vitro 
invasiveness of MCF-7 breast cancer cells. 25 x 103 control or Sdc-1 siRNA-transfected 
cells were added to Matrigel invasion inserts for 72 h and 10% FCS was used as a 
chemoattractant. n≥3, ** = p<0.01, error bars=SEM. (B) A representative image of 
Matrigel invasion filters stained with Diff-Quik dye. 
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4.11 Validation of pre-confirmed dysregulated candidate genes linked 
to the invasion phenotype of Syndecan-1-depleted MCF-7 cells 
Since an alteration in invasive phenotype upon Sdc-1 repression in MCF-7 breast cancer 
cells exists, we sought to verify the expression changes in Sdc-1-depleted MCF-7 cells 
for sets of pre-confirmed genes, responsible for enhanced invasive phenotype of Sdc-1- 
depleted MDA-MB-231 cells. qPCR results (Fig. 4.68) indicated significant upregulation 
of both HPSE (p<0.01) and ACTG2 (p<0.05) (RQ=1.6 and 2.7 respectively), and 
significant downregulation (p<0.01) of TAGLN (RQ=0.7) in Sdc-1 knockdown cells 
compared to controls. Both E-cad and MYL-9 (RQ=1.2 and 1.8 respectively) were not 
significantly altered (p>0.05).  The expression of uPA was not detected at all in MCF-7 
breast cancer cells. Next, we validated the expression level of E-cad at the protein level in 
control and Sdc-1 siRNA-transfected MCF-7 cells. As shown in Fig 4.69, the expression 
level of E-cad was markedly reduced upon Sdc-1 deficiency. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.68 Relative TAGLN, E-cad, HPSE, MYL-9 and ACTG2 mRNA expression level 
as determined by real time PCR upon Sdc-1 silencing in MCF-7 breast cancer cells.  
Sdc-1 silencing significantly represses the expression level of TAGLN transcript and 
upregulates both HPSE and ACTG2 transcripts compared to controls. The MCF-7 breast 
cancer cell line was treated with control or Sdc-1 siRNA for 24 h. Total cellular RNA was 
isolated 48 h post transfection and reverse transcribed into cDNA. The 2-∆∆Ct method was 
used to determine relative gene transcript levels after normalization to 18S rRNA. n≥3, * 
= p<0.05, ** = p<0.01, error bars=SEM. 
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Fig. 4.69 Western blot of cell lysates of control and Sdc-1 siRNA-transfected MCF-7 
cells reveals downregulation of E-cad following Sdc-1 depletion. Control and Sdc-1 
siRNA-transfected cell lysates were collected and 30-50 µg protein/lane were 
immunoblotted and probed with E-cad antibody. Data shown are duplicates from a single 
experiment representative of three independent experiments. 
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5 Discussion 
With over 1 million new breast cancer cases each year, breast cancer is the most common 
malignancy among women worldwide including Germany and Egypt (Dey et al., 2010; 
Katalinic et al., 2009; Kluttig and Schmidt-Pokrzywniak, 2009). Recently, the attention 
was paid toward to proteoglycanomics not only for their structural functions but also for 
their multitude relevant functional roles, thereby modulating cancer progression via 
interaction with both ligands and cognate receptors that regulate neoplastic growth and 
neovascularization (Iozzo and Sanderson, 2010). Consequently, determining the potential 
functions of PGs in breast cancer became a major challenge in the proteoglycanomics 
field.  
 
Syndecans via their HS chains bind to numerous soluble molecules (e.g., cytokines, 
chemokines), thereby facilitating downstream signaling events (Götte, 2003; Tkachenko 
et al., 2005). Additionally, syndecans signal through their protein cores, largely by direct 
interaction with other molecules that mediate signaling cascades (Lambaerts et al., 2009). 
Syndecan-1 (Sdc-1) is highly expressed at the basolateral membrane of simple epithelial 
cells, where it promotes adhesion to the ECM and regulates cell shape by interacting with 
the actin cytoskeleton (Bernfield et al., 1999). Transformed epithelial cells often lose 
expression of Sdc-1. This likely explains why loss of syndecan-1 expression is associated 
with accelerated tumor progression and reduced patient survival in some types of 
carcinomas (Pulkkinen et al., 1997). Conversely, in other tumor types such as breast 
carcinoma and hematologic malignancies, Sdc-1 is often highly expressed and associated 
with increased tumor invasiveness and poor prognosis (Barbareschi et al., 2003), 
consistent with the potential predictive value of Sdc-1 expression in neoadjuvant 
chemotherapy (Götte et al., 2006). Interestingly, the copexpression of Sdc-1 and c-Met 
has been documented in DCIS (Götte et al., 2007). The precise molecular mechanisms for 
the regulatory role of Sdc-1 and may be effector partner molecule(s) including receptors 
and signaling pathways in breast cancer behavior have not been completely deciphered. 
Therefore, intriguing questions were raised regarding the functional interplay of Sdc-1 
and c-Met and the functional consequences of regulated Sdc-1 expression in breast cancer 
pathogenesis. 
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In this study, we employed an in vitro siRNA approach to knockdown the expression 
level of Sdc-1 using breast cancer cell lines of different metastatic potential MCF-7, 
MDA-MB-468 and MDA-MB-231 (Lacroix and Leclercq, 2004). The successful 
downregulation of Sdc-1 at mRNA level was confirmed by qPCR 48 h post transfection, 
which pointed to more than 90% downregulation compared to controls (Fig. 4.1). 
Additionally, at the protein level, Sdc-1 expression was dramatically reduced in the cell 
lysate and on the cell membrane 72 h after transfection as we assessed by confocal 
immunoflourescence microscopy and Western blot respectively (Fig. 4.2 and 4.3). As 
these data showed that a successful Sdc-1 knockdown could be achieved under these 
experimental conditions, Sdc-1-depleted cells were utilized for further functional 
approaches. 
 
To dissect the hypothesis that Sdc-1 might promote HGF signaling and tumor growth, 
control and Sdc-1 siRNA-transfected human breast cancer cell lines, MCF-7, 
MDA-MB-468 and MDA-MB-231 were stimulated with HGF and activation of the 
c-Met receptor and downstream signaling pathways were examined. In MDA-MB-231 
breast cancer cells, Sdc-1 siRNA knockdown did not only result in decreased activation 
of the c-Met receptor, but also inhibited activation of HGF-dependent downstream 
pathways, including HGF-induced AKT, p44/42 and p38 MAPK activation (Fig. 4.4). 
Knockdown of Sdc-1 attenuated the phosphorylation of p44/42 MAPK in MDA-MB-468, 
whereas in MCF-7, HGF did not induce signaling which could possibly be ascribed to 
low expression of c-Met receptor in MCF-7 cells (Fig. 4.5) (Götte et al., 2007). Sdc1 is 
the most important HSPG of the epithelial cell surfaces serving multiple roles in 
proliferation and cell repair (Floer et al., 2010). Hence, we investigated the influence of 
Sdc-1 suppression on the proliferative activity and viability by stimulation of serum 
starved control and Sdc-1-depleted MDA-MB-231 cells with HGF for 48 h and 
ultimately measuring the proliferative activity by MTT assay. Proliferation in response to 
HGF was increased by 11% in control cells, whereas HGF increased proliferation of 
Sdc-1-silenced cells by only 5% (p<0.05) (Fig. 4.6B). The inhibition of c-Met-dependent 
mitogenic signaling in Sdc-1-depleted cells strongly suggests a role for Sdc-1 as a 
coreceptor for HGF/c-Met mediated signaling, as Sdc-1 has previously been shown to 
bind to HGF (Ramani et al., 2011). In addition, downregulation of the serine/theronine 
kinase Tpl-2 in Sdc-1-depleted cells (Fig. 4.19 and 4.20) may have contributed to reduced 
downstream signaling, as Tpl-2 is known to activate MAPK signaling in breast cancer 
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(Sourvinos et al., 1999). Consistent with our findings, Tpl-2 is upregulated in MCF-7 
cells overexpressing Sdc-1 ectodomain (Nikolova et al., 2009). Additionally, we 
confirmed downregulation of TLR4 expression (Fig. 4.41), which may have contributed 
to reduced proliferation (Yang et al. 2010). Yang et al., (2010) could show that TLR4 
silenced-MDA-MB-231 cells displayed significantly decreased cytokines such as IL-6 
and IL-8, consistent with our findings in Sdc-1- depleted cells (Appendix Table).  At 
present, we speculate a functional interaction between Sdc-1 and TLR4 may exist. 
However, the exact mechanism should be elucidated in further study. This emerges as an 
intriguing and promising target in inflammatory breast cancer. 
  
The acquisition of migratory and invasive potential by tumor cells is crucial in the 
progression of a solid, local primary tumor to metastasis.  In a first step, transformed cells 
within the primary tumor need to loosen cell-cell and cell-matrix contacts in order to 
migrate through the surrounding tissue (Mego et al., 2010). This process is orchestrated 
by changes in the expression of cell surface molecules, for instance Sdc-1. 
HGF-dependent in vitro wound repair-readout of cell motility displayed 83.8% cell free 
area post HGF treatment in control vs 94.3% after Sdc-1 depletion (Fig. 4.7). 
Downstream activation of the PI3K/AKT and the Ras/Erk pathways mediate 
HGF-induced motility (reviewed in Peruzzi and Bottaro, 2006). PI3K can activate a 
GTP-GDP exchanger for the small GTPase Rac, which, in turn, controls the organization 
of the actin cytoskeleton (Park et al., 2005). Therefore, inhibition of HGF-dependent 
AKT and p44/42 MAPK signaling in the absence of Sdc-1 may be a contributing factor to 
the observed reduced cell motility in our in vitro wound repair assay. Of note, the 
decreased wound area observed in the scratching assay may not only be due to altered cell 
motility, but also due to changes in the proliferation activity of the cells. Therefore, an 
additional cause of the reduced closure of the created wound in Sdc-1-depleted cells 
stimulated with HGF appears to be their reduced proliferative activity. HGF didn’t result 
in induced shedding of the cell membrane Sdc-1 compared to PMA treatment (Fig. 4.9). 
This finding substantiates that the long-term signal transduction response elicited by HGF 
stimulation in control cells is very likely linked to the coreceptor function of membrane 
bound Sdc-1.  Taken together, these results substantiate the functional coreceptor role of 
Sdc-1 for HGF/c-Met signaling in breast cancer, which is in line with the coreceptor 
function of Sdc-1 for FGFR in breast cancer (Nikolova et al., 2009), in Caco 2 colon 
carcinoma cells (Floer et al., 2010) and for c-Met in multiple myeloma (Derksen et al., 
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2002). Our data indicate that low expression of Sdc-1 has the potential to halt cellular 
growth via targeting overlapping signaling cascades in HGF-stimulated cells (Fig. 5.1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.1 Syndecan-1 modulates breast cancer cell proliferation, motility and invasiveness 
via HGF-dependent mechanisms. Syndecan-1 acts as a coreceptor for HGF-dependent 
signaling events. HGF-dependent signal transduction via the p44/42 MAPK, p38 MAPK 
and AKT/PKB pathways modulate cell proliferation and motility. This pathway may be 
further regulated via TLR4/Tpl-2-dependent signaling. 
 
 
On the other hand, our in vitro invasion assay indicated that HGF stimulation 
significantly promoted the invasion of the control cells by 62% compared to untreated 
controls. Notably, the invasiveness of Sdc-1-deficient cells was massively enhanced by 
366% in absence of HGF compared to control cells and no further influence of HGF on 
invasion of Sdc-1-depleted cells (Fig. 4.8). While these findings do not exclude that 
Sdc-1 acts as a potential coreceptor for HGF mediated invasion, they indicate that loss of 
Sdc-1 augments breast cancer cell invasion largely in an HGF-independent manner, as the 
quantitative increase in invasiveness caused by Sdc-1 depletion alone by far exceeded 
HGF-mediated effects in control cells. This duality in the role of Sdc-1 in cancer behavior 
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indicates a complex regulatory mechanism, which may be partly dependent on 
deregulated pathways upon Sdc-1 depletion under incubation conditions in the presence 
of serum.  
 
Since our results indicate that Sdc-1 depletion enhanced in vitro invasiveness of breast 
cancer cells in HGF-independent manner, we employed time-lapse video microscopy to 
characterize the motile phenotype of control and Sdc-1-depleted cells in 10% FCS. 
Time-lapse video microscopy unraveled that Sdc1 siRNA-transfected cells had a 
significant higher average cell velocity being approximately 4.5 fold greater than controls. 
The average distance covered by Sdc-1 siRNA-transfected cells was massively higher 
than that by controls. Furthermore, Sdc-1 depletion renders the cells more spindle shape 
compared to epitheloid phenotype of controls as estimated by structural index. These 
results suggest that Sdc-1 loss augments in vitro breast cancer cell motility in agreement 
with our in vitro invasion data. An important modulator of cytoskeletal dynamics, the 
Rho family GTPases includes Rho, Rac, and CDC42 (Banyard et al., 2000). To explore 
the mechanistic clue(s) mediating the motile phenotype of Sdc-1-depleted cells, ROCK 
inhibitor experiments were applied.  Post Y-27632 treatment, Sdc-1 siRNA-transfected 
cells exhibited slower migration compared to controls. Inhibition of ROCK rendered the 
control cells more spindle-shaped compared to Sdc-1 siRNA-transfected cells (Fig. 
4.56A-D). These data suggested that increased motility of Sdc-1-depleted cells depends 
on Rho-GTPase activity. Taken together, these results were initially surprising, however, 
in view of the plethora of possible ligand-binding interactions mediated by the 
glycosaminoglycan chains of Sdc-1 and of additional core-protein mediated interactions, 
modulation of a single pathway by Sdc-1 appears highly unlikely, as reflected by our 
identification of >500 significantly differentially regulated gene products in 
Sdc-1-deficient cells.  
 
Activation of FAK is closely associated with a modulation of cell motility via Rho family 
GTPases (Couchman, 2010; Tang et al., 2008). Rho family of small GTPases is master 
regulator of actin cytoskeleton rearrangements (Spiering and Hodgson, 2011). 
Differential upregulation of Rho-GTPases in Sdc-1-depleted cells was demonstrated 
using an anti-RhoABC antibody, whereas RhoB expression was downregulated (Fig. 
4.45).  Notably, Sdc-1-dependent regulation of Rho pathway members (RhoB, RhoC, 
RhoD, Cdc42, RHOBTB3, RhoGEF, SLIT-ROBO Rho GAP) was previously observed 
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in MCF-7 cells overexpressing the soluble ectodomain of Sdc-1 (Nikolova et al., 2009). 
In accordance with the phenotype of Sdc-1-deficient cells, downregulation or knockout 
of RhoB expression results in increased invasiveness and motility of various cell types 
(Bousquet et al., 2009; Jiang et al., 2004; Wheeler and Ridley, 2007), involving a 
modulation of AKT signaling and cytoskeletal alterations. In contrast, upregulation of 
RhoA or RhoC is frequently observed in several tumor entities, including breast cancer, 
and results in increased invasiveness due to modulation of the cytoskeleton and activation 
of transcription factors (Benitah et al., 2004; Fiordalisi et al., 2006; Narumiya et al., 2009). 
Notably, siRNA-depletion of RhoA and RhoC reduces MDA-MB-231 invasiveness in 
vitro and in vivo (Pille et al., 2005). In fact, several cytoskeletal elements were 
significantly upregulated at the transcriptional level in Sdc-1-depleted cells (Fig. 4.51). 
MYL9, a modulator of cell motility, was recently shown to be necessary for successful 
lung colonization in an experimental in vivo model of metastasis (Medjkane et al., 2009). 
TAGLN, a shape change sensitive actin-binding protein associated with actin stress fibers, 
is involved in podosome formation (Gimona et al., 2003), suggesting that its upregulation 
may be linked to increased motility of Sdc-1-depleted cells. Finally, ACTG2 has been 
linked to cisplatin resistance in breast cancer cells (Watson et al., 2007). Our Affymetrix 
data suggest further modulation of Rho-GTPase–dependent pathways: For example, the 
genes encoding the Rho-GTPase activating proteins Rho GAP9* (* denotes differential 
regulation as found by Affymetrix analysis) and Rho GAP27* are significantly 
downregulated in Sdc-1-depleted cells, whereas expression of the CDC42 effector 
protein 3* is upregulated. While the former finding suggests that Rho-GTPases are 
potentially kept in a more active state in Sdc-1-deficient state, the latter finding may 
contribute to the increased filopodia formation in these cells (Fig. 4.48), loss of E-cad 
expression and redistribution of vinculin (Hirsch et al., 2001). In support of this notion, 
Affymetrix screening data displayed by approximately 2.3-fold upregulation of 
isoprenylcysteine carboxylmethyltransferase (Icmt) in Sdc-1-depleted cells, which is 
responsible for methylation of RhoA as the final step of prenylation pathway. Inhibition 
of Icmt significantly decreases the activation of Rho-GTPase in MDA-MB-231 cells 
(Cushman and Casey, 2009). Taken together, these findings suggest higher activity of 
Rho-GTPase in Sdc-1-depleted cells compared to controls that leads to increased 
Rho-GTPase-dependent motile phenotype of Sdc-1 knockdown cells. 
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Syndecans have been suggested to play a role in cell-cell adhesion based on the finding 
that several well-characterized cell-adhesion molecules bind to HS (Bernfield et al., 1999; 
Couchman et al., 2001). In vitro adhesion of Sdc1 siRNA-transfected MDA-MB-231 
cells compared to controls was significantly enhanced to fibronectin and to a lesser extent 
to laminin (Fig. 4.61). This finding is in line with increased HS-dependent adhesion to 
endothelial cells via ß2 integrin ligands in Sdc-1-deficient leukocytes (Floer et al., 2010; 
Kharabi Masouleh et al., 2009). This process was accompanied by increased FAK (Fig. 
4.53), general tyrosine phosphorylation (Fig. 4.20), as well as increased expression of 
vinculin (Fig. 4.53), talin and radixin as observed in Affymetrix screening (Appendix 
Table). We conclude that increased cell adhesion in the absence of Sdc-1 initiated 
matrix-dependent (Kornberg et al., 1992) rather than growth factor-dependent signal 
transduction. FAK co-immunoprecipitated with Sdc-1 (Fig. 4.54), suggesting a possible 
role for Sdc-1 in focal adhesion formation of MDA-MB-231 cells. Furthermore, several 
differentially regulated gene products identified in our screening are substrates for FAK, 
including ROCK, RhoA, talin and radixin, suggesting a functional relationship 
(Hildebrand et al., 1996; Matsui et al., 1998).  
 
Sdc-1-dependent modulation of Rho-GTPase-dependent cellular functions may also be 
the underlying cause of the increased proliferative potential of Sdc-1 siRNA-transfected 
MDA-MB-231 cells. Apart from increased FAK activation and tyrosine phosphorylation, 
this could be attributed to a downregulation of the p21WAF1/CIP1 protein (Fig. 4.21), a CDK 
inhibitor which plays a vital role in cell cycle arrest (Gartel and Radhakrishnan, 2005; 
Liberto et al., 2002). These data are consistent with a recent report on decreased cell cycle 
progression in Sdc-1-overexpressing mesenchymal tumor cells (Zong et al., 2010), 
considering the dedifferentiated, mesenchymal phenotype of MDA-MB-231 cells. 
Furthermore, we could demonstrate that the expression of p21 Waf1/Cip1 expression is 
regulated by RhoA/ROCK signaling (Fig. 4.58). Mechanistically, p21WAF1/CIP1 
downregulation in Sdc-1-depleted cells may be linked to increased expression and/or 
activation of RhoA (Liberto et al., 2002). The proliferation rate of normal and 
transformed epithelial cells is modulated by the expression and/or the activity alterations 
of the cell cycle regulators in response to extracellular signals (Hamel and Hanley, 1997; 
Sherr, 2000; Weinberg, 1995). Further alterations in cell cycle progression are suggested 
by our observation of significant expression changes of CDK inhibitor 3 (2.8-fold up), 
CDK6 (2.9-fold down) and Cyclin Y-like 1 (2-fold down) according to our Affymetrix 
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screening data. Our results revealed drastically inhibition of CDK6 expression in 
Sdc-1-depleted cells compared to controls (Fig. 4.22). In line with our result, previous 
study showed that a striking decrease in CDK6 mRNA and protein accounts for the loss 
of total cellular CDK6 kinase activity in MCF-7 cells (Cram et al., 2001). This seemingly 
challenges the influence of p21 Waf1/Cip1 protein loss on proliferation in Sdc-1-depleted 
cells. However, this could also explain the slightly higher basal proliferative activity of 
Sdc-1-depleted cells compared to controls in the presence of serum (Fig. 4.6A). 
 
Acute myeloid leukemia 1/ runt-related transcription factor 1 (RUNX1), also called 
AML1, is a member of the RUNX transcription factor family (Zhang and Zheng, 2010). 
AML1/RUNX-1 expression was significantly downregulated at the transcriptional level 
and at the protein level upon Sdc-1 depletion with no alteration of its nuclear localization 
(Fig. 4.15-17). Altered AML1/RUNX1-expression or function was previously shown to 
result in reduced E-cad (Liu et al., 2005), MYL9 (Sun et al., 2007), uPA (Kopf and 
Miskin, 2005) and p21WAF1/CIP1expression (Berg et al., 2008). These findings in other 
experimental systems nicely correlate to our data, and suggest that differential 
transcriptional regulation of these molecules in Sdc-1-depleted MDA-MB-231 cells may 
be a consequence of altered AML/RUNX1 expression.  In addition to RUNX-1/AML-1 
downregulation, we observed upregulation of an additional transcription factor, ATF-2. 
ATF-2 has been correlated with proliferation, invasion and migration, as well as 
resistance to DNA-damaging agents in breast cancer cell lines (Vlahopoulos et al., 2008). 
It is upregulated at the mRNA level by qPCR and at the protein level with no alteration of 
its nuclear localization in Sdc-1-depleted MDA-MB-231 cells (Fig. 4.11-13). This 
finding is similar to previous observations in Sdc-4-deficient fibroblasts, which show 
enhanced ATF-2 transcriptional activity, in addition to elevated p38 and Rac activation 
(Saoncella et al., 2004). Enhanced ATF-2 transcription depended on Sdc-4 expression 
and Rac1 activity, and was associated with increased lamellipodia formation. Our 
findings suggest that similar mechanisms appear to play a role in Sdc-1-deficient breast 
cancer cells. However, we could not confirm higher levels of active p38 MAPK in 
Sdc-1-depleted cells (Fig. 4.14).  
 
Loss of cell-cell contact is a pivotal step in the progression of breast cancer towards 
metastasis. The calcium-dependent cell-cell adhesion molecule E-cad is an established 
prognostic marker in breast cancer (Götte et al., 2007). Like Sdc-1, E-cad is mainly 
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present in epithelial cells, and is required for maintaining the epitheloid phenotype and 
inhibition of density-dependent cell growth (Cowin et al., 2005; Götte et al., 2007). 
Coordinated regulation of E-cad and Sdc-1 expression is seen during development, in 
mammary tumor cells subjected to antisense RNA-mediated downregulation of Sdc-1 or 
E-cad, and in DCIS of the breast (Götte et al., 2007). In MCF-7 cells overexpressing 
soluble Sdc-1, downregulation of E-cad expression is observed and linked to an invasive 
phenotype (Nikolova et al., 2009). Accordingly, we observed downregulation of E-cad in 
Sdc-1-depleted cells at the gene transcript and at the protein expression level (Fig. 
4.30-32B). Downregulation of E-cad expression post Sdc-1 loss appears to be a 
contributing factor of the highly invasive phenotype. The observation that E-cad 
co-immunoprecipitates with FAK in pancreatic carcinoma cells cultured on COL1 
(Koenig et al., 2006) and our finding of a co-immunoprecipitation of Sdc-1 with FAK 
raises the possibility that Sdc-1, E-cad and FAK may be capable of forming large signal 
transduction complexes. 
 
On the other hand, Cad-11, one of the classical type-2 cadherin family members, 
mediates homophilic cell-cell adhesion and is constitutively expressed in stromal and 
osteoblastic cells in bone marrow. Elevated cad-11 expression is also found in aggressive 
human breast cancers (Tamura et al., 2008). Additionally, Cad-11 is considered a marker 
of EMT and was found to be upregulated in 479 invasive breast carcinomas and 12 
carcinosarcomas (Sarrió et al., 2008). In this regard, our Affymetrix microarray analysis 
(2.3-fold upregulated) (Appendix Table) and Western blot analysis (Fig. 4.31) showed a 
significantly increased expression of Cad-11 in Sdc-1 siRNA-transfected cells in line 
with the expression of the two splice variants of cadherin-11 promoting invasiveness of 
breast cancer cells (Feltes et al., 2002). Intriguingly, our confocal immunoflourescence 
inspection uncovered Cad-11 nuclear localization in MDA-MB-231 breast cancer cells 
(Fig. 4.32A), which may suggest a possible transcriptional regulation role. 
 
MAGUK / PDZ domain proteins such as CASK and syntenin have been identified as 
important Sdc-1-dependent modulators of cell adhesion and migration (Lambaerts et al., 
2009). Notably, Sdc-1 and E-cad colocalize and co-immunoprecipitate with the 
transcriptional regulator β-catenin, and with the PDZ-domain scaffolding protein 
syntenin in epithelial cells, suggesting both a functional and physical association 
(Zimmermann et al., 2001). The MAGUK / PDZ-domain scaffolding protein, MPP4, was 
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downregulated at the transcriptional and protein level upon Sdc-1 depletion in 
MDA-MB-231 cells (Fig. 4.59). Interestingly, nuclear localization of both MPP4 (Fig. 
4.59C) and Sdc-1 (Fig. 4.62) could suggest a reciprocal regulatory and transcriptional 
interaction. 
 
The tight junction protein claudin-1 constitutes the backbone of the tight junction strand 
and is crucial for the epidermal barrier function (Furuse et al., 2002; Tsukita and Furuse, 
2002). Loss of claudin-1 has been associated with cancer progression and invasion, the 
acquisition of the metastatic phenotype and correlated with reduced disease-free survival 
in breast cancer patients with regional lymph node metastasis (Szasz et al., 2011). We 
could confirm significant transcriptional downregulation of the tight junction component 
claudin-1 in Sdc-1-depleted cells (Fig. 4.36). As reduced claudin-1 expression correlates 
with lymph node metastasis and recurrence status in breast cancer (Morohashi et al., 2007; 
Tokes et al., 2005), Sdc-1-dependent changes in claudin-1 expression may have further 
contributed to the invasive phenotype. On the other hand, the expression  level of JAM-A, 
a key negative regulator of breast cancer cell migration and invasion (Mandell et al., 
2005), did not change in our study post Sdc-1 knockdown (Fig. 4.37 and 4.38), strongly 
suggesting that decreased Sdc-1 expression may be associated with enhanced cell 
invasion possibly through a JAM-A-independent mechanism. 
 
Activated leukocyte cell adhesion molecule (ALCAM) is a glycoprotein that is involved 
in both homotypic and heterotypic (to lymphocyte cell-surface receptor CD6) adhesion 
(Swart, 2002). Burkhardt et al., (2006) demonstrated that both intraductal and invasive 
breast carcinomas had higher ALCAM expression than did normal breast tissue in a study 
on 162 primary breast carcinomas. High expression of activated ALCAM, which was 
upregulated 3-fold in Sdc-1-depleted cells according to our Affymetrix data, may 
therefore additionally facilitate the invasiveness phenotype caused by Sdc-1 siRNA 
knockdown. However, the role of ALCAM in breast cancer pathogenesis is not fully clear 
at this point, as controversial findings have been reported (Davies and Jiang, 2010). 
 
Cyclooxygenase-2 (COX-2) is a PGE2 synthesizing cytoplasmic enzyme (Smith et al., 
2000). COX-2 knockdown in MDA-MB-231 breast cancer cell line resulted in invasion 
inhibition and abolished the metastatic potential. Furthermore, loss of COX-2 resulted in 
the significant delay of tumor onset when the cells were injected in the mammary fat pad 
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of severe combined immunodeficient mice (Stasinopoulos et al., 2007). Not only beta 
catenin expression induces COX-2 expression in epithelial cells (Wang et al., 2008), but 
also beta catenin localization, where cytoplasmic beta catenin is correlated with COX-2 
upregulation in cancer (Kawasaki et al., 2007).  Our real time PCR and Western blot 
results uncovered upregulation of COX-2 in Sdc-1-depleted cells (Fig. 4.41 and 4.42). 
However, we could not prove a correlation between cytoplasmic beta catenin and COX-2 
expression (Fig. 4.43). Taken together, our data suggest that COX-2 is an invasion 
promoting additional candidate in Sdc-1-depleted cells and that cytoplasmic beta catenin 
may not be functionally linked to this process. Although, COX-2 expression is mediated 
by TLR4 signaling in intestine (Fukata et al., 2006; Moses et al., 2009), we could not 
prove a correlation link between expression of TLR4 and COX-2 in breast cancer, as 
TLR4 was downregulated upon Sdc-1 depletion (Fig. 4.41). However, our findings 
substantiate that RhoA/ROCK activation mediates the expression of COX-2, since 
massive downregulation of COX-2 expression was seen post ROCK inhibition (Fig. 
4.57). 
 
Annexins (ANXs) are calcium and membrane-binding proteins, whose expression 
changes and/or subcellular localization contribute to the development and progression of 
cancer (Gerke and Moss, 2002; Gerke et al., 2005). Our results point to downregulation of 
both ANXA3 and ANXA10 mRNA expression (Fig. 4.34) and ANXA3 protein (Fig. 4.35) 
upon Sdc-1 knockdown in agreement with numerous reports. Expression of ANXA10 is 
downregulated in gastric cancer (Kim et al., 2009; Kim et al., 2010) and hepatocellular 
carcinoma (Liu et al., 2002; Peng et al., 2005), and has been linked to vascular invasion, 
to the regulation of tumor cell proliferation, apoptosis resistance, and unfavourable 
clinical outcome. The role of ANXA3 in cancer progression is more controversial. 
Downregulation of ANXA3 is an independent adverse prognostic marker in prostate 
cancer (Köllermann et al., 2008). In contrast, high expression of ANXA3 is an 
independent prognostic marker in lung adenocarcinoma (Liu et al., 2009), and it has been 
linked to chemoresistance in ovarian cancer (Yan et al., 2010). Further studies are needed 
to establish the relevance of altered ANXA3 expression in breast cancer.  
 
Plasminogen activator, urokinase (uPA), its receptor, uPAR and its inhibitors, mediate a 
proteolytic cascade involved in physiological and pathophysiological degradation and 
remodeling of the ECM, thereby playing a key role in tumor invasion and metastasis 
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(Wolff et al., 2011). uPA, when bound to uPAR efficiently converts plasminogen into the 
broad spectrum serine protease plasmin; its action on plasminogen is controlled by the 
serine protease inhibitors PAI-1 and PAI-2 (Conese and Blasi, 1995). Previous studies on 
MCF-7 cells overexpressing-type, constitutively membrane-bound and soluble forms of 
Sdc-1 had demonstrated Sdc-1-dependent modulation of uPAR and TIMP-1 expression 
(Nikolova et al., 2009), contributing to protease-dependent modulation of 
Sdc-1-overexpressing breast cancer cells. In MDA-MB-231 cells, a complex 
dysregulation of protease and anti-protease expression was induced by Sdc1 knockdown: 
Several members of the SERPIN family of protease inhibitors (SERPINs E1/PAI-1, 
B2/PAI-2, D1*, B4*, B3* and B7*) (* denotes differential regulation as found by 
Affymetrix analysis) were downregulated by 19.7, 2.4, 7.9, 2.2, 7.2 and 2-fold change 
respectively as detected by Affymetrix screening data. qPCR results revealed that 
Sdc-1-deficient cells exhibited significant downregulation of uPA, massively 
downregulation of PAI-2 and non significant alteration of PAI-1 upon Sdc-1 depletion 
(Fig. 4.25). Western blot analysis verified downregulation of PAI-1 and uPAR in Sdc-1 
siRNA-treated cells compared to controls (Fig. 4.26). Taken together, our data suggest 
that the expression and/or the activity of uPA system inhibitors mechanistically overruled 
uPA and its receptor expression mediating the invasive phenotype in Sdc-1-depleted 
cells. 
 
Matrix metalloproteinase (MMPs) are upregulated in breast cancer, where they stimulate 
tumorigenesis, cancer cell invasion and metastasis via ECM degradation (Radisky and 
Radisky, 2010). Consequently, we investigated the expression level and activity of 
MMPs as a mechanistic clue for the invasive phenotype associated with Sdc-1 depletion. 
Our mRNA analysis showed significant upregulation of MMP-2 and a significant 
downregulation of MMP-9 in Sdc-1-depleted cells compared to controls (Fig. 4.27). 
Mechanistically, upregulation of MMP-2 could have been induced by COX-2 (Kurihara 
et al., 2009) and/or ATF-2 expression (Song et al., 2006). In contrast, as TAGLN is a 
repressor of MMP-9 expression (Nair et al., 2006), downregulation of MMP-9 in 
Sdc1-depleted cells may be linked to upregulated TAGLN. Furthermore, RhoA and 
RhoC have been implicated in the regulation of MMP-2 and MMP-9 expression and 
activity (Fromigue et al., 2008; Iiizumi et al., 2008) but the underlying mechanisms are 
complex and not easily applied to our experimental system. While gelatin zymography 
(Fig. 4.28) confirmed the presence of active form of MMP-2 (62 KDa) and ProMMP-9 
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(92 KDa) activity in the conditioned media of MDA-MB-231 cells, no increase was 
observed of MMP-2 upon Sdc-1 depletion and HGF treatment. As we observed no 
increase in gelatinolytic activity of MMP-2 and MMP-9 in Sdc-1-depleted 
MDA-MB-231 cells, upregulation of ADAMTSL4 (2.9-fold in Affymetrix Screening) 
and downregulation of MMP1 and ADAM 19 (5.7-fold and 2.5-fold respectively in 
Affymetrix Screening) (Appendix Table), we conclude that the increased cell motility in 
the absence of Sdc-1 may play a more important role for this phenotype than proteolysis. 
Alternatively, proteolytic activity towards alternative ECM substrates and direct 
downregulation of matrix substrates may have enhanced invasiveness in the absence of 
Sdc-1. Consistently, Affymetrix screening showed 2.3-fold downregulation of COL1A1 
(Appendix Table) in Sdc-1-depleted cells. In addition, the expression level of COL1A2 
and matrilin-2 (Fig. 4.55) were downregulated post Sdc-1 siRNA treatment in 
MDA-MB-231 breast cancer cells.  
 
Heparanase (HPSE) is involved in the degradation of HS of both cell-surface and ECM in 
normal tissues during development and tissue remodeling, and in neoplastic tissues. 
HPSE promotes breast cancer cell invasiveness in vitro and in xenograft models, and its 
expression correlates with breast cancer metastasis in clinical samples (Edovitsky et al., 
2004; Götte and Yip, 2006; Kelly et al., 2005; Vlodavsky et al., 2008). Sdc-1 inhibits the 
HPSE-1-mediated invasive effects in melanoma (Reiland et al., 2004). Additionally, 
colocalization of HPSE and Sdc-1 in the nucleus has been demonstrated, suggesting a 
simultaneous mechanism for turnover of HS: Intriguingly, Chen and Sanderson, (2009) 
could show that reduction in nuclear Sdc-1 following upregulation of HPSE expression 
lead to increased histone acetylation with an associated increase in gene transcription. 
Accordingly, we identified of >500 significantly differentially regulated gene products in 
Sdc-1-deficient cells. In support of these findings, our Affymetrix screening and real time 
PCR consistently showed upregulation of HPSE in Sdc-1-depleted cells compared to 
controls (Fig. 4.40). Taken together, upregulation of HPSE and the lack of the 
endocytosis receptor activity of Sdc-1 for HPSE (Gingis-Velitzki et al., 2004) may have 
driven the invasive phenotype and may have regulated transcription of many 
dysregulated genes as suggested by our Affymetrix gene expression profile. These results 
provide a plausible negatively reciprocal regulation between HPSE and nuclear Sdc-1, 
implying their important roles in tumor development and progression. A more detailed 
mechanistic analysis of this potential link is a worthwhile approach for future studies. 
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Histone methylation is the mechanism used by the cells to regulate the gene expression. 
Consistently, we identified JHDM1D, gene that demethylates trimethylated histone, 
downregulated in Sdc-1-depleted cells compared to controls (Fig. 4.60). At present, we 
can only speculate that JHDM1D may be linked to differential gene regulation in 
Sdc-1-depleted cells, or to a potential function of nuclear Sdc-1 (Fig. 4.62) (Chen and 
Sanderson, 2009; Zong et al., 2009).  
 
In this study, we have employed a siRNA approach to investigate the consequences of 
Sdc-1 depletion for breast cancer cell behavior in vitro. While this is an experimental 
approach, in vivo, microRNAs (miRs) may exert a mechanistically similar mode of 
regulation on Sdc-1 expression. miRs are small, approximately 22-nucleotide non-coding 
RNAs that post-transcriptionally decrease gene expression in a sequence-specific manner. 
Mammalian miRNAs predominantly act by binding to the 3' UTR of cognate mRNAs 
(Borchert et al., 2006; Lal et al., 2008). Among the miRs potentially regulating Sdc-1 
expression based on seed sequence homology to the 3’UTR of Sdc-1 according to 
searches in the DIANA miRGen databases (Megraw et al., 2007), miR-10b emerged as a 
candidate. As its expression is upregulated in metastatic breast cancer (Baffa et al., 2009; 
Ma et al., 2007), its upregulation in non-metastatic breast cancer cells initiates invasion 
and metastasis (Ma et al., 2007), and its silencing inhibits breast cancer metastasis in a 
mouse mammary tumor model (Ma et al., 2010), consistent with our invasive phenotype 
of Sdc-1-depleted cells. Ectopic overexpression of miR-10b in MCF-7 breast cancer cells 
resulted in downregulated Sdc-1 mRNA expression (Fig. 4.63A). To formally prove 
direct regulation of the Sdc-1 3'UTR by miR-10b, we employed luciferase activation 
assays, which revealed that pre-miR-10b transfection resulted in a significant 40% 
decrease in normalized firefly luciferase activity (Fig. 4.63B). Our data identify Sdc-1 as 
a novel target of miR-10b besides the previously identified targets HOXD10, RhoC and 
uPAR (Ma et al., 2007), suggesting a new physiological mechanism for Sdc-1 
downregulation in invasive breast cancer. These data also corroborate a recent study 
showing an inverse correlation between miR-10b and Sdc-1 expression in preinvasive 
breast cancer (Hannafon et al., 2011). Strikingly, we could confirm downregulation of 
E-cad expression at the protein level (Fig. 4.64) and upregulation of TAGLN mRNA 
expression (Fig. 4.65) following overexpression of miR-10b in breast cancer cells. These 
findings substantiate that miR-10b modulates the expression of E-cad and TAGLN in 
Sdc-1-dependent manner contributing in generation of invasive and migratory phenotype 
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of MDA-MB-231 cancer cells (Fig. 4.66), since TAGLN is a potential target of miR-10b 
as predicted by the TargetScanS (Lewis et al., 2005) and PicTar (4 way) (Krek et al., 2005) 
algorithms, and E-cad expression was downregulated upon Sdc-1 silencing (Fig. 4.30-32). 
To our knowledge, this is the first report to emphasize that Sdc-1 negatively modulates 
TAGLN expression, consistent with our finding, TAGLN is downregulated in MCF-7 
cells overexpressing Sdc-1 ectodomain (Nikolova et al., 2009). 
 
Lastly, we tested the influence of Sdc-1 silencing on the invasive phenotype of the 
MCF-7 breast cancer cell line, which has a low metastatic potential, and is less 
dedifferentiated compared to MDA-MB-231 cells (Lacroix and Leclercq, 2004). We 
employed our experimental system as previously mentioned in MDA-MB-231 using 10% 
FCS as chemoattractant, since Götte et al., (2007) have shown low expression of c-Met in 
this cell line, consistently with our HGF/c-Met mediated P44/42 MAPK downstream 
signaling data (Fig. 4.5). Our in vitro invasion assay data showed that Sdc-1 
siRNA-transfected MCF-7 cells displayed dramatically reduced invasiveness by 
approximately 6 fold compared to controls (Fig. 4.67). These data are surprising and 
contradict the invasive phenotype of Sdc-1-depleted MDA-MB-231 cells, suggesting a 
different regulatory mechanism of Sdc-1-driving invasion. 
 
When we next sought to verify some of Sdc-1 pre-confirmed regulated targets in MCF-7 
cells, the expression level of E-cad was found to be markedly reduced upon Sdc-1 
deficiency (Fig. 4.69) consistent with our observation in MDA-MB-231 and with 
synchronous regulation of Sdc-1 and E-cad in colon carcinoma, prostate cancer, and in 
breast cancer cell lines (Bernfield et al., 1999; Contreras et al., 2010; Nikolova et al., 
2009). Additionally, qPCR results indicated a significant upregulation of both HPSE and 
ACTG2, and a significant downregulation of TAGLN in Sdc-1-depleted cells compared 
to controls (Fig. 4.68). This paradoxical role of Sdc-1 is hard to understand, since the 
regulatory mechanism principally depends on the tumor type and/or grade and serum 
condition. However, it has to be considered that MCF-7 cells and MDA-MB-231 cells 
represent the more benign (MCF-7: hormone receptor positive, epithelial morphology, 
low invasive) and highly aggressive (MDA-MB-231: triple-negative, mesenchymal, 
migratory morphology, highly invasive) spectrum of breast cancer cell lines. Therefore, 
the spectrum of gene products influenced by loss of Sdc-1 in the two cell lines can be 
expected to differ considerably. Taken together, we could only speculate yet, that 
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inhibition of invasion of Sdc-1-depleted MCF-7 cells is mediated independently of 
upregulation HPSE, ACTG2 expression, downregulation of E-cad and is dependent on 
downregulation of TAGLN. At present, we can only speculate that the molecular basis of 
mechanisms underlying pleiotropic function of Sdc-1 in TAGLN expression is a cell 
type- and context-dependent. Moreover, downregulation of Sdc-1 in an early stage of 
tumor progression, as represented by MCF-7 cells, could be more amenable to be a 
therapeutic target compared to a later stage, as represented by MDA-MB-231 cells. 
Further study is required to better understand the precise regulatory mechanism of Sdc-1 
played in invasive and non-invasive tumor cells.  
  
In summary, we have demonstrated dual roles for Sdc-1 in modulating breast cancer cell 
behavior. Loss of Sdc-1 expression, in part mediated by upregulation of miR-10b, on the 
one hand leads to decreased responsiveness to mitogenic signal transduction via the 
c-Met receptor tyrosine kinase, suggesting only partial synergy of the Sdc-1 and c-Met 
signaling pathways (Fig. 5.1) (Menashe et al., 2010). On the other hand, Sdc-1 depletion 
initiated increased adhesion of MDA-MB-231 cells to fibronectin and laminin, and was 
associated with increased matrix-dependent signaling via FAK and Rho-GTPases. In turn, 
these signaling events lead to complex changes in transcription factor expression, a 
modulation of p21WAF1/CIP1 and basal cell proliferation, changes in the expression of 
E-cad, cad-11 and additional cell adhesion molecules, cytoskeletal elements, and of 
COX2 and HPSE, ultimately promoting breast cancer cell invasiveness (Fig. 5.2). Our 
data establish Sdc-1 as an important regulatory factor for a variety of key events in breast 
cancer progression. However, in accordance with our previous results demonstrating 
differential roles for membrane-bound and soluble forms of Sdc-1 (Nikolova et al., 2009), 
and studies by others (Maeda et al., 2004; Shao et al., 2009). our results also demonstrate 
that the multitude of Sdc-1 functions in breast cancer pathogenesis depend on the 
coexpression pattern of receptor tyrosine kinases, matrix substrates, proteases and HPSE, 
and the cell type (tumor vs stroma vs endothelial cells) expressing Sdc-1. Therefore, 
future therapeutic approaches targeting Sdc-1 (Yip et al., 2006) have to take into account 
this diversity, establishing a need for defining the stage and context in which targeting of 
Sdc-1 proves to be most efficient. Multitargeted approaches including Sdc-1 regulatory 
factors such as miR-10b (Ma et al., 2010), parallel targeting of the c-Met pathway 
(Menashe et al., 2010; Perizzi and Bottaro 2006), inhibition of HPSE (Götte and Yip, 
2006) and of Rho-GTPase function (Chang et al., 2009; Sparano et al., 2009) may prove 
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to be the safest and most efficient route of modulating dysregulated Sdc-1 function in 
breast cancer. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.2 Syndecan-1 modulates cell-matrix adhesion and signaling via FAK and 
Rho-GTPases, resulting in a modulation of cytoskeletal elements and cell motility, 
p21WAF1/CIP1 /CDK6-dependent cell proliferation and transcriptional regulation of 
proinvasive factors for instance, E-cad and MMP-2 via the transcription factors ATF-2 
and RUNX-1.  
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7 Appendix 
 
 
Table 7.1 Affymetrix microarray analysis of upregulated genes in Syndecan-1- 
depleted cells as compared to controls. 
 
Gene 
Symbol 
Gene Name Gene ID 
Fold 
Change 
P-value 
QKI 
quaking homolog, KH domain RNA 
binding (mouse) 
9444 6.044446 6.28E-06 
LSM14A 
LSM14A, SCD6 homolog A (S. 
cerevisiae) 
26065 5.5313864 6.87E-07 
NUDT15 
nudix (nucleoside diphosphate linked 
moiety X)-type motif 15 
55270 5.4657154 1.42E-05 
EMP2 epithelial membrane protein 2 2013 5.0181084 9.15E-06 
CPA3 carboxypeptidase A3 (mast cell) 1359 4.9634857 5.96E-06 
ILF3 
interleukin enhancer binding factor 
3, 90kDa 
3609 4.6541247 3.92E-05 
ILF3 
interleukin enhancer binding factor 
3, 90kDa 
3609 4.4698186 1.71E-05 
EMP2 epithelial membrane protein 2 2013 4.3497534 2.84E-05 
ANAPC10 
/// 
LOC72919
8 
anaphase promoting complex subunit 
10 /// hypothetical LOC729198 
10393//7291
98 
4.3284 1.25E-05 
- Clone 23774 mRNA sequence 9213 4.291026 1.19E-05 
HOMER1 homer homolog 1 (Drosophila) 9456 4.2575574 2.38E-05 
NR2F2 
nuclear receptor subfamily 2, group 
F, member 2 
7026 4.1756334 7.67E-04 
EMP2 epithelial membrane protein 2 2013 4.1737795 1.69E-05 
SCAMP1 secretory carrier membrane protein 1 9522 4.1612167 5.66E-05 
KRCC1 lysine-rich coiled-coil 1 51315 4.15166 5.81E-07 
THG1L 
tRNA-histidine guanylyltransferase 
1-like (S. cerevisiae) 
54974 4.1414375 3.07E-05 
SLC16A9 
solute carrier family 16, member 9 
(monocarboxylic acid transporter 9) 
220963 3.9835443 3.39E-05 
DHX40 
DEAH (Asp-Glu-Ala-His) box 
polypeptide 40 
79665 3.9666326 8.21E-06 
NEGR1 neuronal growth regulator 1 257194 3.9131126 5.68E-04 
KRCC1 lysine-rich coiled-coil 1 51315 3.8940413 2.45E-05 
CDC42 
cell division cycle 42 (GTP binding 
protein, 25kDa) 
998 3.8433998 3.68E-06 
CYFIP2 
cytoplasmic FMR1 interacting 
protein 2 
26999 3.6741714 6.43E-04 
HOMER1 homer homolog 1 (Drosophila) 9456 3.6679544 1.28E-06 
STEAP3 STEAP family member 3 55240 3.662003 0.00329 
SCAMP1 secretory carrier membrane protein 1 9522 3.6567774 1.82E-05 
TOP1MT 
topoisomerase (DNA) I, 
mitochondrial 
116447 3.6465342 2.94E-05 
ROD1 
ROD1 regulator of differentiation 1 
(S. pombe) 
9991 3.6283503 3.60E-06 
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SLC16A14 
solute carrier family 16, member 14 
(monocarboxylic acid transporter 14) 
151473 3.600755 1.80E-04 
STEAP3 STEAP family member 3 55240 3.5777762 4.72E-05 
PANK3 pantothenate kinase 3 79646 3.5017831 1.38E-04 
C1orf110 
chromosome 1 open reading frame 
110 
339512 3.4936714 1.85E-04 
GPNMB glycoprotein (transmembrane) nmb 10457 3.4647157 0.005646 
KIAA1946 KIAA1946 165215 3.4323857 1.24E-04 
NT5DC2 5'-nucleotidase domain containing 2 64943 3.366022 4.12E-06 
GPR137C G protein-coupled receptor 137C 283554 3.3129134 3.35E-05 
C4orf32 
chromosome 4 open reading frame 
32 
132720 3.305765 1.22E-05 
NRG1 neuregulin 1 3084 3.2636666 2.49E-05 
NSD1 
nuclear receptor binding SET 
domain protein 1 
64324 3.2570052 7.60E-04 
TBC1D30 TBC1 domain family, member 30 23329 3.2053792 7.85E-04 
CYB5R4 cytochrome b5 reductase 4 51167 3.203873 6.41E-06 
KRCC1 lysine-rich coiled-coil 1 51315 3.1920738 8.70E-06 
FAM135A 
family with sequence similarity 135, 
member A 
57579 3.1571848 2.78E-05 
TMEM50
B 
transmembrane protein 50B 757 3.1477468 3.34E-05 
PIAS2 
protein inhibitor of activated STAT, 
2 
9063 3.1357064 1.89E-04 
CTSH cathepsin H 1512 3.0790172 2.43E-04 
ALCAM 
activated leukocyte cell adhesion 
molecule 
214 3.0036256 5.76E-05 
ACTG2 
actin, gamma 2, smooth muscle, 
enteric 
72 3.0025263 5.32E-05 
DHX40 
DEAH (Asp-Glu-Ala-His) box 
polypeptide 40 
79665 2.995911 6.45E-06 
FAM13C1 
family with sequence similarity 13, 
member C1 
220965 2.9939213 0.00103 
NR2F2 
nuclear receptor subfamily 2, group 
F, member 2 
7026 2.9765341 0.003448 
SAR1B 
SAR1 gene homolog B (S. 
cerevisiae) 
51128 2.9534054 5.55E-05 
ANKRD13
C 
ankyrin repeat domain 13C 81573 2.946325 3.67E-05 
OSGIN2 
oxidative stress induced growth 
inhibitor family member 2 
734 2.9410803 3.04E-05 
SCAMP1 secretory carrier membrane protein 1 9522 2.9277499 1.86E-05 
CDKN3 
cyclin-dependent kinase inhibitor 3 
(CDK2-associated dual specificity 
phosphatase) 
1033 2.9193041 1.84E-05 
ADAMTS
L4 
ADAMTS-like 4 54507 2.9076867 9.78E-05 
OSGIN2 
oxidative stress induced growth 
inhibitor family member 2 
734 2.8988385 5.73E-04 
LSM14A 
LSM14A, SCD6 homolog A (S. 
cerevisiae) 
26065 2.8948083 6.24E-05 
IL10RB interleukin 10 receptor, beta 3588 2.8902943 1.53E-05 
OLFML2A olfactomedin-like 2A 169611 2.8761294 0.002957 
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YWHAH 
tyrosine 
3-monooxygenase/tryptophan 
5-monooxygenase activation protein, 
eta polypeptide 
7533 2.8732316 6.14E-05 
CDKN3 
cyclin-dependent kinase inhibitor 3 
(CDK2-associated dual specificity 
phosphatase) 
1033 2.8728757 8.41E-06 
NR2F2 
nuclear receptor subfamily 2, group 
F, member 2 
7026 2.8674886 2.82E-05 
NDUFA5 
NADH dehydrogenase (ubiquinone) 
1 alpha subcomplex, 5, 13kDa 
79664 2.8487964 5.87E-04 
SLC38A4 solute carrier family 38, member 4 55089 2.8337145 0.005098 
ALCAM 
activated leukocyte cell adhesion 
molecule 
214 2.8138685 1.24E-06 
SEPP1 selenoprotein P, plasma, 1 6414 2.8079605 0.003601 
TLN1 talin 1 7094 2.802124 0.001929 
PRKAR2B 
protein kinase, cAMP-dependent, 
regulatory, type II, beta 
5577 2.7898483 4.53E-05 
RTN1 reticulon 1 6252 2.781371 3.17E-04 
SPOPL speckle-type POZ protein-like 339745 2.7747183 3.93E-05 
SH3PXD2
A 
SH3 and PX domains 2A 9644 2.7715023 4.22E-05 
NOX5 
NADPH oxidase, EF-hand calcium 
binding domain 5 
79400 2.7623904 0.007197 
S100A2 S100 calcium binding protein A2 6273 2.7516065 4.29E-04 
VASH2 vasohibin 2 79805 2.750202 2.39E-04 
SCAMP1 secretory carrier membrane protein 1 9522 2.736714 9.70E-04 
KIAA0100 KIAA0100 9703 2.7301755 1.55E-04 
FECH ferrochelatase (protoporphyria) 2235 2.717047 2.72E-06 
ELOVL7 
ELOVL family member 7, 
elongation of long chain fatty acids 
(yeast) 
79993 2.7160857 1.66E-06 
CHRDL1 chordin-like 1 91851 2.7152321 5.15E-05 
SMAD2 SMAD family member 2 4087 2.7032208 3.82E-05 
ATP11C ATPase, class VI, type 11C 286410 2.6891744 2.17E-04 
NR2F2 
nuclear receptor subfamily 2, group 
F, member 2 
7026 2.6816008 1.08E-04 
RAP2B 
RAP2B, member of RAS oncogene 
family 
5912 2.679656 1.97E-05 
CDC42 
cell division cycle 42 (GTP binding 
protein, 25kDa) 
998 2.6775658 5.13E-05 
CRABP2 
cellular retinoic acid binding protein 
2 
1382 2.671978 2.02E-04 
STX2 syntaxin 2 2054 2.6672716 5.13E-06 
MDK 
midkine (neurite growth-promoting 
factor 2) 
4192 2.6671014 5.34E-05 
DCLK1 Doublecortin-like kinase 1 9201 2.664656 0.003541 
NR2F2 
nuclear receptor subfamily 2, group 
F, member 2 
7026 2.6604772 2.20E-05 
MFSD6 
major facilitator superfamily domain 
containing 6 
54842 2.6558676 3.08E-05 
C7orf41 
chromosome 7 open reading frame 
41 
222166 2.6503155 7.63E-04 
TAGLN transgelin 6876 2.6441803 1.40E-04 
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SCAMP1 secretory carrier membrane protein 1 9522 2.6432035 0.004193 
TncRNA trophoblast-derived noncoding RNA 283131 2.6403933 7.51E-04 
ATF2 activating transcription factor 2 1386 2.635938 5.13E-05 
DNMT1 
DNA 
(cytosine-5-)-methyltransferase 1 
1786 2.6357288 2.15E-06 
LSM14A 
LSM14A, SCD6 homolog A (S. 
cerevisiae) 
26065 2.6099768 1.77E-05 
LOC10013
2678 
similar to hCG1993567 100132161 2.6099756 0.011648 
SNRNP27 
small nuclear ribonucleoprotein 
27kDa 
11017 2.5976715 7.81E-06 
LOC28327
8 
hypothetical protein LOC283278 283278 2.581764 3.04E-05 
SIK2 salt inducable kinase 2 23235 2.5674062 5.15E-04 
SLC44A2 solute carrier family 44, member 2 57153 2.5670736 1.42E-05 
GLT8D4 
glycosyltransferase 8 domain 
containing 4 
727936 2.5609972 0.003277 
TK2 thymidine kinase 2, mitochondrial 7084 2.5572116 8.77E-04 
ALG13 
asparagine-linked glycosylation 13 
homolog (S. cerevisiae) 
79868 2.5493734 7.98E-04 
MYL9 myosin, light chain 9, regulatory 10398 2.5482059 6.78E-04 
SMAD2 SMAD family member 2 4087 2.5451324 4.19E-04 
TncRNA trophoblast-derived noncoding RNA 283131 2.542934 8.68E-05 
ANO10 anoctamin 10 55129 2.5346148 7.13E-07 
PHLDA1 
pleckstrin homology-like domain, 
family A, member 1 
22822 2.531166 2.81E-04 
HMGN4 
high mobility group nucleosomal 
binding domain 4 
10473 2.5311258 6.21E-05 
ARG2 arginase, type II 384 2.5272787 2.51E-04 
RDX radixin 5962 2.5163643 7.29E-07 
- 
MRNA; cDNA DKFZp434N2116 
(from clone DKFZp434N2116) /// 
CDNA FLJ37098 fis, clone 
BRACE2019004 /// CDNA clone 
IMAGE:5285282 
 2.5117583 0.002015 
CALML4 calmodulin-like 4 91860 2.5063298 4.03E-04 
TAGLN transgelin 6876 2.5044112 5.38E-04 
HMGN4 
high mobility group nucleosomal 
binding domain 4 
10473 2.4980984 3.03E-05 
FLJ41278 
/// 
TBC1D30 
TBC1 domain family, member 30 /// 
hypothetical gene supported by 
AK123272 
23329 /// 
400046 
2.4980402 2.65E-04 
IVNS1AB
P 
influenza virus NS1A binding 
protein 
10625 2.4919982 9.55E-05 
ZNF280D zinc finger protein 280D 54816 2.4871585 0.00356 
FAM102B 
family with sequence similarity 102, 
member B 
284611 2.4851358 6.78E-05 
SOCS4 suppressor of cytokine signaling 4 122809 2.4738061 8.05E-05 
USP6NL USP6 N-terminal like 9712 2.4694123 3.32E-05 
SH3PXD2
A 
SH3 and PX domains 2A 9644 2.4605572 1.89E-06 
CACHD1 cache domain containing 1 57685 2.4592047 1.65E-04 
SPOPL speckle-type POZ protein-like 339745 2.4591053 2.98E-04 
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WDR5B WD repeat domain 5B 54554 2.4535792 1.72E-04 
ICMT 
isoprenylcysteine carboxyl 
methyltransferase 
23463 2.4511395 3.36E-05 
C6orf155 
chromosome 6 open reading frame 
155 
79940 2.4508767 0.001323 
BRMS1L 
breast cancer metastasis-suppressor 
1-like 
84312 2.4496527 3.65E-05 
HADH 
hydroxyacyl-Coenzyme A 
dehydrogenase 
3033 2.4459686 1.26E-05 
DOPEY2 dopey family member 2 9980 2.4374912 3.80E-04 
EDIL3 
EGF-like repeats and discoidin I-like 
domains 3 
10085 2.4331443 2.41E-05 
PDCD2 programmed cell death 2 5134 2.4258506 2.18E-05 
RIT1 Ras-like without CAAX 1 6016 2.4232316 3.62E-04 
SSBP2 
single-stranded DNA binding protein 
2 
23635 2.415772 3.90E-04 
C12orf24 
chromosome 12 open reading frame 
24 
29902 2.4153528 3.11E-05 
REEP1 receptor accessory protein 1 65055 2.4088116 8.83E-04 
ICMT 
isoprenylcysteine carboxyl 
methyltransferase 
23463 2.3896525 2.91E-06 
HECTD2 HECT domain containing 2 143279 2.3860264 4.53E-06 
SAR1B 
SAR1 gene homolog B (S. 
cerevisiae) 
51128 2.3848355 3.08E-05 
SLITRK5 
SLIT and NTRK-like family, 
member 5 
26050 2.3844924 1.69E-05 
RY1 
putative nucleic acid binding protein 
RY-1 
11017 2.3790684 1.28E-05 
EDIL3 
EGF-like repeats and discoidin I-like 
domains 3 
10085 2.377286 0.00436 
FAM8A1 
family with sequence similarity 8, 
member A1 
51439 2.3772335 0.001338 
CDH11 
cadherin 11, type 2, OB-cadherin 
(osteoblast) 
1009 2.376483 0.002223 
HNRNPU
L1 
heterogeneous nuclear 
ribonucleoprotein U-like 1 
11100 2.3740063 2.06E-04 
TCFL5 
transcription factor-like 5 (basic 
helix-loop-helix) 
10732 2.372463 2.34E-07 
HERC4 hect domain and RLD 4 26091 2.3612726 1.43E-05 
ACPL2 acid phosphatase-like 2 92370 2.3539603 8.53E-04 
LSM7 
LSM7 homolog, U6 small nuclear 
RNA associated (S. cerevisiae) 
51690 2.346922 4.35E-06 
LMNB2 lamin B2 84823 2.340909 2.07E-04 
LOC40150
4 
Hypothetical gene supported by 
AK091718 
401504 2.3377545 1.39E-04 
CLN8 
ceroid-lipofuscinosis, neuronal 8 
(epilepsy, progressive with mental 
retardation) 
2055 2.330017 0.002614 
BICD1 bicaudal D homolog 1 (Drosophila) 636 2.3259935 4.84E-04 
ASH1L 
ash1 (absent, small, or 
homeotic)-like (Drosophila) 
55870 2.323448 4.65E-06 
SYNGR3 synaptogyrin 3 9143 2.3167505 0.012903 
CPS1 
carbamoyl-phosphate synthetase 1, 
mitochondrial 
1373 2.3139007 0.010777 
HIP1 huntingtin interacting protein 1 3092 2.3137407 4.85E-04 
SRPK2 SFRS protein kinase 2 6733 2.3132825 2.13E-05 
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FAM49A 
family with sequence similarity 49, 
member A 
81553 2.312478 1.59E-04 
LOC10012
8223 /// 
TARDBP 
TAR DNA binding protein /// 
hypothetical protein LOC100128223 
100128223 
/// 23435 
2.307729 2.44E-05 
LOC40150
4 
hypothetical gene supported by 
AK091718 
401504 2.3071146 0.001274 
C7orf58 
chromosome 7 open reading frame 
58 
79974 2.3046958 5.81E-05 
MALAT1 
metastasis associated lung 
adenocarcinoma transcript 1 
(non-protein coding) 
378938 2.3041105 0.003034 
GAMT 
guanidinoacetate 
N-methyltransferase 
2593 2.3009338 2.59E-05 
TMEM184
B 
transmembrane protein 184B 25829 2.3008907 1.93E-05 
SLC35D1 
solute carrier family 35 
(UDP-glucuronic 
acid/UDP-N-acetylgalactosamine 
dual transporter), member D1 
23169 2.2989151 1.10E-04 
SS18 
synovial sarcoma translocation, 
chromosome 18 
6760 2.2980838 0.002817 
NEGR1 neuronal growth regulator 1 257194 2.2969568 6.72E-04 
PAQR3 
progestin and adipoQ receptor family 
member III 
152559 2.2916842 1.51E-05 
SS18L1 
synovial sarcoma translocation gene 
on chromosome 18-like 1 
26039 2.2911232 2.86E-04 
CARS2 
cysteinyl-tRNA synthetase 2, 
mitochondrial (putative) 
79587 2.2877493 6.61E-07 
RAB4A /// 
SPHAR 
RAB4A, member RAS oncogene 
family /// S-phase response 
(cyclin-related) 
10638 /// 
5867 
2.2875693 3.91E-04 
F2R 
coagulation factor II (thrombin) 
receptor 
2149 2.2794774 5.08E-04 
ABCC6 
ATP-binding cassette, sub-family C 
(CFTR/MRP), member 6 
368 2.278768 0.001788 
RIPK2 
receptor-interacting serine-threonine 
kinase 2 
8767 2.2743561 0.001531 
THBS2 thrombospondin 2 7058 2.272448 8.95E-06 
IKZF5 
IKAROS family zinc finger 5 
(Pegasus) 
64376 2.2723038 0.0017 
MOBKL2
B 
MOB1, Mps One Binder kinase 
activator-like 2B (yeast) 
79817 2.2711108 5.51E-05 
TMEM48 transmembrane protein 48 55706 2.267336 1.91E-05 
TMEM5 transmembrane protein 5 10329 2.263722 4.14E-04 
CLMN 
calmin (calponin-like, 
transmembrane) 
79789 2.2551498 4.80E-04 
POLR3E 
polymerase (RNA) III (DNA 
directed) polypeptide E (80kD) 
55718 2.2545044 6.29E-05 
SBNO1 
strawberry notch homolog 1 
(Drosophila) 
55206 2.2468674 3.06E-04 
MALAT1 
metastasis associated lung 
adenocarcinoma transcript 1 
(non-protein coding) 
378938 2.2409656 0.011991 
HNRNPD 
heterogeneous nuclear 
ribonucleoprotein D (AU-rich 
3184 2.2393365 1.52E-06 
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element RNA binding protein 1, 
37kDa) 
POLR3E 
polymerase (RNA) III (DNA 
directed) polypeptide E (80kD) 
55718 2.22974 1.12E-04 
PGRMC2 
progesterone receptor membrane 
component 2 
10424 2.2264555 4.61E-04 
RPGRIP1L RPGRIP1-like 23322 2.2264304 3.09E-05 
HADH 
hydroxyacyl-Coenzyme A 
dehydrogenase 
3033 2.2243626 9.19E-05 
BDNF brain-derived neurotrophic factor 627 2.2186987 9.21E-05 
ZNF85 zinc finger protein 85 7639 2.21682 0.001603 
ZDHHC20 
zinc finger, DHHC-type containing 
20 
253832 2.2149458 3.81E-04 
CNOT3 
CCR4-NOT transcription complex, 
subunit 3 
4849 2.2099717 0.003253 
SHANK3 
SH3 and multiple ankyrin repeat 
domains 3 
85358 2.2096941 0.005743 
TACC2 
transforming, acidic coiled-coil 
containing protein 2 
10579 2.1985915 8.18E-05 
IL6ST 
interleukin 6 signal transducer 
(gp130, oncostatin M receptor) 
3572 2.1977377 0.001378 
C3orf23 
chromosome 3 open reading frame 
23 
285343 2.1960301 9.59E-04 
ASH1L 
ash1 (absent, small, or 
homeotic)-like (Drosophila) 
55870 2.1942487 4.38E-04 
C6orf174 
/// 
KIAA0408 
KIAA0408 /// chromosome 6 open 
reading frame 174 
387104 /// 
9729 
2.1927075 7.73E-04 
NARG2 NMDA receptor regulated 2 79664 2.1926477 0.001617 
TAF5L 
TAF5-like RNA polymerase II, 
p300/CBP-associated factor 
(PCAF)-associated factor, 65kDa 
27097 2.1926196 4.96E-04 
LOC10013
2798 
Similar to hCG1774772 100132798 2.1910253 0.024724 
HPS3 Hermansky-Pudlak syndrome 3 84343 2.1869512 0.001165 
FAM122B 
/// 
TMEM57 
transmembrane protein 57 /// family 
with sequence similarity 122B 
159090 2.186815 2.71E-04 
DISC1 disrupted in schizophrenia 1 27185 2.18583 0.001367 
ARP11 actin-related Arp11 653857 2.1857288 6.40E-05 
SMEK2 
SMEK homolog 2, suppressor of 
mek1 (Dictyostelium) 
57223 2.184011 0.00171 
TMED4 
transmembrane emp24 protein 
transport domain containing 4 
222068 2.182506 0.003188 
QKI 
quaking homolog, KH domain RNA 
binding (mouse) 
9444 2.178023 4.48E-06 
GDF11 growth differentiation factor 11 10220 2.1779082 0.011583 
LIMCH1 
LIM and calponin homology 
domains 1 
22998 2.1745772 2.51E-05 
ERMP1 
endoplasmic reticulum 
metallopeptidase 1 
79956 2.1698833 9.95E-04 
DIXDC1 DIX domain containing 1 85458 2.1654406 0.00245 
EDIL3 
EGF-like repeats and discoidin I-like 
domains 3 
10085 2.1651545 0.009099 
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CD24 CD24 molecule 100133941 2.1647034 5.37E-04 
MYO18A 
/// TIAF1 
TGFB1-induced anti-apoptotic factor 
1 /// myosin XVIIIA 
399687 /// 
9220 
2.1628206 6.06E-04 
HPSE heparanase 10855 2.1612854 4.24E-04 
TTC3 tetratricopeptide repeat domain 3 7267 2.1604052 0.001398 
ATE1 arginyltransferase 1 11101 2.160202 2.20E-05 
CERK ceramide kinase 64781 2.159501 9.69E-06 
EP400NL EP400 N-terminal like 347918 2.1570635 8.45E-05 
RC3H2 
ring finger and CCCH-type zinc 
finger domains 2 
54542 2.1570628 4.22E-04 
HNRNPD 
heterogeneous nuclear 
ribonucleoprotein D (AU-rich 
element RNA binding protein 1, 
37kDa) 
3184 2.1563058 1.57E-05 
TPM1 tropomyosin 1 (alpha) 7168 2.155895 0.001269 
SEMA4F 
sema domain, immunoglobulin 
domain (Ig), transmembrane domain 
(TM) and short cytoplasmic domain, 
(semaphorin) 4F 
10505 2.1525812 5.10E-04 
HNRNPD 
heterogeneous nuclear 
ribonucleoprotein D (AU-rich 
element RNA binding protein 1, 
37kDa) 
3184 2.144231 8.52E-05 
IVNS1AB
P 
influenza virus NS1A binding 
protein 
10625 2.1420524 4.22E-04 
PRKXP1 
protein kinase, X-linked, pseudogene 
1 
441733 2.1408112 0.001331 
ATMIN ATM interactor 23300 2.1403394 1.39E-04 
USP31 ubiquitin specific peptidase 31 57478 2.1371076 2.12E-04 
PDGFC platelet derived growth factor C 56034 2.1334963 3.12E-05 
QKI 
quaking homolog, KH domain RNA 
binding (mouse) 
9444 2.1311028 2.18E-05 
KIAA0114 KIAA0114 57291 2.1256242 1.31E-04 
SEC24A 
SEC24 related gene family, member 
A (S. cerevisiae) 
10802 2.1241128 1.39E-04 
MATN2 matrilin 2 4147 2.1208842 2.49E-04 
LOXL1 lysyl oxidase-like 1 4016 2.1206787 5.88E-04 
S100A4 S100 calcium binding protein A4 6275 2.120211 0.004227 
FAM122B 
family with sequence similarity 
122B 
159090 2.1197069 1.33E-04 
C11orf30 
chromosome 11 open reading frame 
30 
56946 2.1186595 0.002815 
SPAG16 sperm associated antigen 16 79582 2.1180754 4.09E-05 
TMEM56 Transmembrane protein 56 148534 2.117821 8.96E-05 
SLC25A4 
solute carrier family 25 
(mitochondrial carrier; adenine 
nucleotide translocator), member 4 
291 2.1165175 2.21E-06 
RNFT2 ring finger protein, transmembrane 2 84900 2.115981 1.64E-04 
RUNDC3
B 
RUN domain containing 3B 154661 2.1089764 0.005233 
PPFIA2 
protein tyrosine phosphatase, 
receptor type, f polypeptide 
(PTPRF), interacting protein (liprin), 
alpha 2 
8499 2.105969 0.005152 
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CENTA2 centaurin, alpha 2 55803 2.1045148 0.001582 
FLJ42709 
hypothetical gene supported by 
AK124699 
441094 2.1038868 7.32E-04 
IDH3A 
isocitrate dehydrogenase 3 (NAD+) 
alpha 
3419 2.1017122 7.62E-04 
ILF3 
interleukin enhancer binding factor 
3, 90kDa 
3609 2.099918 4.23E-06 
NR2F1 
Nuclear receptor subfamily 2, group 
F, member 1 
7025 2.099065 6.23E-04 
HIP1 Huntingtin interacting protein 1 3092 2.0984356 7.15E-05 
KIAA1737 KIAA1737 85457 2.098065 1.84E-05 
TTC3 tetratricopeptide repeat domain 3 7267 2.09637 8.66E-05 
XPR1 
xenotropic and polytropic retrovirus 
receptor 
9213 2.0962884 4.22E-05 
TMEM50
B 
transmembrane protein 50B 757 2.092871 3.09E-04 
GJA3 gap junction protein, alpha 3, 46kDa 2700 2.0884333 5.86E-05 
RBPJ 
recombination signal binding protein 
for immunoglobulin kappa J region 
3516 2.0877614 2.59E-05 
IAH1 
isoamyl acetate-hydrolyzing esterase 
1 homolog (S. cerevisiae) 
285148 2.0857012 9.05E-05 
RGS4 regulator of G-protein signaling 4 5999 2.0812385 0.00693 
SCRN2 secernin 2 90507 2.079881 7.41E-04 
SLAIN1 SLAIN motif family, member 1 122060 2.0788882 1.83E-04 
WHSC1 
Wolf-Hirschhorn syndrome 
candidate 1 
7468 2.0770938 2.50E-04 
NMU neuromedin U 10874 2.075148 7.63E-04 
CELSR2 
cadherin, EGF LAG seven-pass 
G-type receptor 2 (flamingo 
homolog, Drosophila) 
1952 2.0741785 1.29E-04 
C3orf23 
chromosome 3 open reading frame 
23 
285343 2.0731766 1.69E-06 
CDC42EP
3 
CDC42 effector protein (Rho 
GTPase binding) 3 
10602 2.0704653 1.88E-05 
KRT80 keratin 80 144501 2.0699482 9.12E-04 
ALG13 
asparagine-linked glycosylation 13 
homolog (S. cerevisiae) 
79868 2.0692372 0.00155 
FOXQ1 forkhead box Q1 94234 2.0683227 0.001252 
KIF11 kinesin family member 11 3832 2.0664093 6.12E-05 
ZFAND6 zinc finger, AN1-type domain 6 54469 2.0652814 5.40E-07 
CCDC149 coiled-coil domain containing 149 91050 2.0648746 2.93E-04 
HNRNPD 
heterogeneous nuclear 
ribonucleoprotein D (AU-rich 
element RNA binding protein 1, 
37kDa) 
3184 2.0641592 2.09E-05 
TFDP1 transcription factor Dp-1 7027 2.0608869 0.001101 
ZNF514 zinc finger protein 514 84874 2.0600436 8.73E-04 
RDX radixin 5962 2.059867 4.82E-04 
SURF4 surfeit 4 6836 2.0536325 7.00E-06 
CAMLG calcium modulating ligand 819 2.0522864 7.90E-04 
SURF4 surfeit 4 6836 2.0509257 2.29E-05 
HNRNPU heterogeneous nuclear 11100 2.049048 6.32E-05 
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L1 ribonucleoprotein U-like 1 
PREPL prolyl endopeptidase-like 9581 2.0486948 1.17E-04 
SSBP2 
single-stranded DNA binding protein 
2 
23635 2.0395331 6.41E-05 
LIMCH1 
LIM and calponin homology 
domains 1 
22998 2.0395088 1.27E-04 
DCXR dicarbonyl/L-xylulose reductase 51181 2.0373461 4.43E-04 
PMS1 
PMS1 postmeiotic segregation 
increased 1 (S. cerevisiae) 
5378 2.036774 0.001534 
CSF1 
colony stimulating factor 1 
(macrophage) 
1435 2.0358467 4.26E-06 
AKT1S1 AKT1 substrate 1 (proline-rich) 84335 2.0346282 0.009559 
PDK1 
pyruvate dehydrogenase kinase, 
isozyme 1 
5163 2.03422 3.77E-04 
ZNF280C zinc finger protein 280C 55609 2.0330582 0.006972 
MRPS6 mitochondrial ribosomal protein S6 64968 2.0276878 2.74E-05 
GOLGA4 
golgi autoantigen, golgin subfamily 
a, 4 
2803 2.0273786 2.73E-04 
RAB27A 
RAB27A, member RAS oncogene 
family 
5873 2.0245948 1.29E-05 
KIAA0515 KIAA0515 84726 2.0229757 9.62E-05 
CALML4 calmodulin-like 4 91860 2.022108 0.005313 
C6orf70 
chromosome 6 open reading frame 
70 
55780 2.0211155 7.67E-06 
AASS 
aminoadipate-semialdehyde 
synthase 
10157 2.0158226 0.001396 
KLHL2 kelch-like 2, Mayven (Drosophila) 11275 2.0155036 7.06E-05 
SMURF2 
SMAD specific E3 ubiquitin protein 
ligase 2 
64750 2.0153506 3.11E-04 
SLC41A1 solute carrier family 41, member 1 254428 2.014171 8.46E-04 
SP3 Sp3 transcription factor 6670 2.0132928 3.51E-05 
PDGFRL 
platelet-derived growth factor 
receptor-like 
5157 2.0132833 7.38E-04 
GALNTL1 
UDP-N-acetyl-alpha-D-galactosami
ne:polypeptide 
N-acetylgalactosaminyltransferase-li
ke 1 
57452 2.0080645 4.84E-04 
RBPJ 
recombination signal binding protein 
for immunoglobulin kappa J region 
3516 2.0055008 1.66E-04 
ASB8 
ankyrin repeat and SOCS 
box-containing 8 
140461 2.0051484 7.91E-04 
HIPK3 
homeodomain interacting protein 
kinase 3 
10114 2.0046983 0.010266 
CD24 CD24 molecule 100133941 2.0028467 3.39E-05 
STMN3 stathmin-like 3 50861 2.0023303 6.42E-04 
SLC5A3 
solute carrier family 5 (inositol 
transporters), member 3 
6526 2.0013106 2.40E-05 
ZNF93 zinc finger protein 93 81931 2.000992 6.81E-04 
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Table 7.2 Affymetrix microarray analysis of downregulated genes in Syndecan-1- 
depleted cells as compared to controls. 
 
Gene 
Symbol 
Gene Name Gene ID 
Fold 
Change 
P-value 
CXCL5 chemokine (C-X-C motif) ligand 5 6374 -33.195267 8.67E-04 
CXCL5 chemokine (C-X-C motif) ligand 5 6374 -24.857037 1.10E-04 
SERPINB2 
serpin peptidase inhibitor, clade B 
(ovalbumin), member 2 
5055 -19.714857 8.78E-05 
CCL20 chemokine (C-C motif) ligand 20 6364 -8.0971575 2.29E-04 
SERPINB4 
serpin peptidase inhibitor, clade B 
(ovalbumin), member 4 
6318 -7.881855 1.55E-04 
IFIT1 
interferon-induced protein with 
tetratricopeptide repeats 1 
3434 -7.5585546 7.88E-08 
SERPIND1 
serpin peptidase inhibitor, clade D 
(heparin cofactor), member 1 
3053 -7.273174 4.33E-04 
IFIT3 
interferon-induced protein with 
tetratricopeptide repeats 3 
3437 -7.0914955 5.13E-06 
CSF3 
colony stimulating factor 3 
(granulocyte) 
1440 -7.089965 0.00323 
IFIT3 
interferon-induced protein with 
tetratricopeptide repeats 3 
3437 -6.731651 3.40E-07 
SDC1 syndecan 1 6382 -6.5177665 3.96E-07 
SCG5 secretogranin V (7B2 protein) 6447 -6.3422427 0.00208 
IFIT2 
interferon-induced protein with 
tetratricopeptide repeats 2 
3433 -5.9899497 3.02E-05 
TBC1D7 TBC1 domain family, member 7 51256 -5.9098334 1.10E-07 
MMP1 
matrix metallopeptidase 1 
(interstitial collagenase) 
4312 -5.7016454 2.80E-04 
CXCL11 chemokine (C-X-C motif) ligand 11 6373 -5.4459934 3.44E-05 
ST8SIA4 
ST8 alpha-N-acetyl-neuraminide 
alpha-2,8-sialyltransferase 4 
7903 -5.428345 3.82E-05 
ST8SIA4 
ST8 alpha-N-acetyl-neuraminide 
alpha-2,8-sialyltransferase 4 
7903 -5.423559 3.16E-06 
IFIT2 
interferon-induced protein with 
tetratricopeptide repeats 2 
3433 -5.40353 2.61E-05 
HMGA2 high mobility group AT-hook 2 8091 -5.4021072 1.38E-06 
PTGS2 
prostaglandin-endoperoxide 
synthase 2 (prostaglandin G/H 
synthase and cyclooxygenase) 
5743 -5.361778 0.00139 
IL1A interleukin 1, alpha 3552 -5.3247647 2.88E-04 
ALOX5AP 
arachidonate 
5-lipoxygenase-activating protein 
241 -4.950923 6.68E-04 
EIF5A2 
eukaryotic translation initiation 
factor 5A2 
56648 -4.9466386 7.09E-06 
OASL 2'-5'-oligoadenylate synthetase-like 8638 -4.8864455 2.16E-07 
IL24 interleukin 24 11009 -4.830144 0.001326 
MXD1 MAX dimerization protein 1 4084 -4.7663536 1.67E-04 
SOD2 superoxide dismutase 2, 6648 -4.703162 8.55E-05 
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mitochondrial 
CXCL3 chemokine (C-X-C motif) ligand 3 2921 -4.613666 0.002999 
OASL 2'-5'-oligoadenylate synthetase-like 8638 -4.5914135 1.87E-05 
PGM2L1 phosphoglucomutase 2-like 1 283209 -4.554465 1.23E-05 
CEACAM1 
carcinoembryonic antigen-related 
cell adhesion molecule 1 (biliary 
glycoprotein) 
634 -4.5357637 1.26E-04 
ST8SIA4 
ST8 alpha-N-acetyl-neuraminide 
alpha-2,8-sialyltransferase 4 
7903 -4.5355883 4.01E-05 
EIF5A2 
eukaryotic translation initiation 
factor 5A2 
56648 -4.528002 1.44E-05 
PTGS2 
prostaglandin-endoperoxide 
synthase 2 (prostaglandin G/H 
synthase and cyclooxygenase) 
5743 -4.449729 7.40E-04 
SDC1 syndecan 1 6382 -4.4010415 6.44E-04 
MREG melanoregulin 55686 -4.304541 7.46E-06 
KPNA5 
karyopherin alpha 5 (importin alpha 
6) 
3841 -4.241921 2.71E-05 
SLC16A1 
solute carrier family 16, member 1 
(monocarboxylic acid transporter 1) 
6566 -4.1763415 6.65E-04 
IFI44 Interferon-induced protein 44 10561 -4.103973 3.84E-04 
CXCL2 chemokine (C-X-C motif) ligand 2 2920 -4.0828977 0.001476 
SELT selenoprotein T 51714 -4.0727925 1.49E-05 
KLHL28 kelch-like 28 (Drosophila) 54813 -4.04115 7.61E-06 
TNFRSF1
B 
tumor necrosis factor receptor 
superfamily, member 1B 
7133 -4.013819 4.83E-05 
IL1B interleukin 1, beta 3553 -3.9741292 4.78E-04 
TNIP3 TNFAIP3 interacting protein 3 79931 -3.9637513 9.11E-06 
CPEB3 
cytoplasmic polyadenylation 
element binding protein 3 
22849 -3.9594493 7.47E-04 
SELT selenoprotein T 51714 -3.9586146 5.49E-06 
SLC16A1 
solute carrier family 16, member 1 
(monocarboxylic acid transporter 1) 
6566 -3.944382 0.001314 
ISG20 
interferon stimulated exonuclease 
gene 20kDa 
3669 -3.88194 1.78E-05 
MGC15634 hypothetical protein MGC15634 84841 -3.8748178 2.12E-04 
ETS1 
v-ets erythroblastosis virus E26 
oncogene homolog 1 (avian) 
2113 -3.8683903 4.28E-05 
IL1B interleukin 1, beta 3553 -3.845237 3.90E-04 
WNK4 
WNK lysine deficient protein kinase 
4 
65266 -3.8282874 4.70E-04 
SSR3 
signal sequence receptor, gamma 
(translocon-associated protein 
gamma) 
6747 -3.825098 3.16E-06 
ISG20 
interferon stimulated exonuclease 
gene 20kDa 
3669 -3.8183334 3.02E-05 
KIAA0494 KIAA0494 9813 -3.7994688 7.41E-06 
IL8 interleukin 8 3576 -3.7667215 0.005075 
BCL2A1 BCL2-related protein A1 597 -3.7603767 1.02E-04 
STARD3N
L 
STARD3 N-terminal like 83930 -3.746834 1.05E-06 
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SERPINB3 
/// 
SERPINB4 
serpin peptidase inhibitor, clade B 
(ovalbumin), member 3 /// serpin 
peptidase inhibitor, clade B 
(ovalbumin), member 4 
6317 /// 
6318 
-3.6849325 3.62E-05 
KPNA5 
karyopherin alpha 5 (importin alpha 
6) 
3841 -3.6209848 1.20E-05 
FAM9B 
family with sequence similarity 9, 
member B 
171483 -3.5571325 5.81E-04 
IL6R interleukin 6 receptor 3570 -3.5536633 5.52E-05 
DDX60 
DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 60 
55601 -3.50298 8.70E-04 
IFIH1 
interferon induced with helicase C 
domain 1 
64135 -3.4938805 6.10E-05 
ATXN1 ataxin 1 6310 -3.4890397 1.70E-05 
RHEBL1 Ras homolog enriched in brain like 1 121268 -3.4866793 2.09E-05 
CMAS 
cytidine monophosphate 
N-acetylneuraminic acid synthetase 
55907 -3.472876 4.48E-06 
SIGLEC15 sialic acid binding Ig-like lectin 15 284266 -3.4592056 5.96E-05 
ATXN1 ataxin 1 6310 -3.4522288 3.37E-06 
C1orf62 
chromosome 1 open reading frame 
62 
254268 -3.4210289 6.50E-04 
CD44 CD44 molecule (Indian blood group) 960 -3.3818703 1.37E-04 
LOC10013
1096 
hypothetical protein LOC100131096 100131096 -3.3807707 9.77E-05 
REEP3 receptor accessory protein 3 221035 -3.3799343 0.004228 
ADRB1 adrenergic, beta-1-, receptor 153 -3.3776999 6.91E-06 
HERC5 hect domain and RLD 5 51191 -3.350188 1.43E-05 
PI3 
peptidase inhibitor 3, skin-derived 
(SKALP) 
5266 -3.344467 9.13E-04 
IL1F9 interleukin 1 family, member 9 56300 -3.3214993 0.003168 
KBTBD8 
kelch repeat and BTB (POZ) domain 
containing 8 
84541 -3.3057761 4.30E-04 
MGC5618 hypothetical protein MGC5618 79099 -3.2569332 1.88E-04 
TGFBR2 
transforming growth factor, beta 
receptor II (70/80kDa) 
7048 -3.2366056 5.71E-04 
MPP4 
membrane protein, palmitoylated 4 
(MAGUK p55 subfamily member 4) 
58538 -3.2304673 3.78E-05 
KPNA5 
karyopherin alpha 5 (importin alpha 
6) 
3841 -3.2233102 5.61E-04 
GBP4 guanylate binding protein 4 115361 -3.2172365 2.08E-04 
FAM73A 
family with sequence similarity 73, 
member A 
374986 -3.2104127 2.96E-04 
PI3 
peptidase inhibitor 3, skin-derived 
(SKALP) 
5266 -3.2101862 8.70E-04 
IFI44 interferon-induced protein 44 10561 -3.2088401 5.80E-07 
EIF5A2 
eukaryotic translation initiation 
factor 5A2 
56648 -3.2058444 1.65E-04 
ITGB2 
integrin, beta 2 (complement 
component 3 receptor 3 and 4 
subunit) 
3689 -3.200254 6.70E-05 
TET3 tet oncogene family member 3 200424 -3.1948123 1.17E-04 
PEAR1 
platelet endothelial aggregation 
receptor 1 
375033 -3.193465 1.07E-04 
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AREG /// 
LOC72773
8 
amphiregulin (schwannoma-derived 
growth factor) /// similar to 
Amphiregulin precursor (AR) 
(Colorectum cell-derived growth 
factor) (CRDGF) 
374 /// 
727738 
-3.1873872 1.68E-04 
KAP2.1B 
/// 
KRTAP2-1 
/// 
KRTAP2-4 
/// 
LOC64435
0 /// 
LOC72828
5 /// 
LOC72893
4 /// 
LOC73075
5 
keratin associated protein 2-1 /// 
keratin associated protein 2-4 /// 
keratin associated protein 2.1B /// 
hypothetical LOC644350 /// similar 
to keratin associated protein /// 
hypothetical LOC728934 /// similar 
to keratin associated protein 2-4 
644350 /// 
728285 /// 
728934 /// 
730755 /// 
81872 /// 
85294 /// 
85297 
-3.155209 0.01446 
CASP1 
caspase 1, apoptosis-related cysteine 
peptidase (interleukin 1, beta, 
convertase) 
834 -3.150084 4.68E-05 
SSR3 
signal sequence receptor, gamma 
(translocon-associated protein 
gamma) 
6747 -3.1437025 1.66E-05 
HERC6 hect domain and RLD 6 55008 -3.1391172 1.18E-05 
TBC1D9 
TBC1 domain family, member 9 
(with GRAM domain) 
23158 -3.13654 2.14E-06 
FAM73A 
family with sequence similarity 73, 
member A 
374986 -3.125261 4.56E-04 
SLC46A3 solute carrier family 46, member 3 283537 -3.1229675 5.41E-06 
CXCL11 chemokine (C-X-C motif) ligand 11 6373 -3.1063924 7.82E-05 
LOC72794
5 
similar to hCG1651100 727945 -3.079939 2.89E-04 
LOC20165
1 
similar to Arylacetamide deacetylase 
(AADAC) 
201651 -3.0769103 8.11E-04 
AKR1B10 
aldo-keto reductase family 1, 
member B10 (aldose reductase) 
57016 -3.0694435 4.19E-04 
TET1 tet oncogene 1 80312 -3.0576482 3.13E-04 
GBP5 guanylate binding protein 5 115362 -3.0456214 9.33E-05 
EBI3 Epstein-Barr virus induced gene 3 10148 -3.0431516 5.32E-04 
ST8SIA4 
ST8 alpha-N-acetyl-neuraminide 
alpha-2,8-sialyltransferase 4 
7903 -3.0422702 0.001025 
XPOT 
exportin, tRNA (nuclear export 
receptor for tRNAs) 
11260 -3.0418103 3.43E-05 
BSG basigin (Ok blood group) 682 -3.0406573 5.75E-04 
LOC10013
1096 
hypothetical protein LOC100131096 100131096 -3.0294127 4.51E-04 
POU3F2 POU class 3 homeobox 2 5454 -3.0260909 2.07E-05 
CLIP4 
CAP-GLY domain containing linker 
protein family, member 4 
79745 -3.0165043 1.52E-04 
MGC11082 hypothetical protein MGC11082 84777 -2.9699283 3.66E-04 
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SLC16A1 
solute carrier family 16, member 1 
(monocarboxylic acid transporter 1) 
6566 -2.968313 0.001233 
SFTPF surfactant associated protein F 207107 -2.9555547 6.48E-06 
CSNK1A1 casein kinase 1, alpha 1 1452 -2.9530673 4.24E-07 
C6orf58 
chromosome 6 open reading frame 
58 
352999 -2.937718 8.07E-05 
CDK6 cyclin-dependent kinase 6 1021 -2.9110062 2.08E-05 
VNN3 vanin 3 55350 -2.9094932 2.34E-05 
TTC27 tetratricopeptide repeat domain 27 55622 -2.909041 1.81E-05 
ZNF643 zinc finger protein 643 65243 -2.9025216 1.78E-04 
H2AFV H2A histone family, member V 94239 -2.902123 1.24E-06 
C1orf62 
chromosome 1 open reading frame 
62 
254268 -2.8946528 4.81E-04 
ARNT 
aryl hydrocarbon receptor nuclear 
translocator 
405 -2.8944483 5.39E-05 
TRIM6 tripartite motif-containing 6 117854 -2.8900096 1.85E-05 
EIF2S2 
eukaryotic translation initiation 
factor 2, subunit 2 beta, 38kDa 
8894 -2.8850095 2.26E-07 
KIAA0494 KIAA0494 9813 -2.8713558 2.32E-05 
PPP1R2 
protein phosphatase 1, regulatory 
(inhibitor) subunit 2 
5504 -2.8685646 1.37E-04 
CXCL1 
chemokine (C-X-C motif) ligand 1 
(melanoma growth stimulating 
activity, alpha) 
2919 -2.8628242 0.005711 
ANXA3 annexin A3 306 -2.859195 1.58E-06 
FAM43A 
family with sequence similarity 43, 
member A 
131583 -2.8567462 7.79E-04 
N4BP2 NEDD4 binding protein 2 55728 -2.84812 2.12E-04 
CDK6 cyclin-dependent kinase 6 1021 -2.8446815 0.003422 
OAS2 
2'-5'-oligoadenylate synthetase 2, 
69/71kDa 
4939 -2.8341162 1.43E-04 
NPL 
N-acetylneuraminate pyruvate lyase 
(dihydrodipicolinate synthase) 
80896 -2.8263485 1.38E-04 
NLRP3 
NLR family, pyrin domain 
containing 3 
114548 -2.8214953 0.001867 
SLC7A7 
solute carrier family 7 (cationic 
amino acid transporter, y+ system), 
member 7 
9056 -2.819709 2.84E-05 
ARMC8 armadillo repeat containing 8 25852 -2.818948 8.93E-05 
CDK6 cyclin-dependent kinase 6 1021 -2.8136487 1.91E-04 
IL13RA2 interleukin 13 receptor, alpha 2 3598 -2.8053112 0.003806 
SERPINB3 
serpin peptidase inhibitor, clade B 
(ovalbumin), member 3 
6317 -2.7973952 3.62E-04 
CASP1 
caspase 1, apoptosis-related cysteine 
peptidase (interleukin 1, beta, 
convertase) 
834 -2.7964926 8.56E-05 
LOC28573
5 
hypothetical protein LOC285735 285735 -2.794283 0.002468 
ISG15 ISG15 ubiquitin-like modifier 9636 -2.7941728 1.25E-06 
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TMPRSS3 transmembrane protease, serine 3 64699 -2.7939308 0.001374 
KLHL15 kelch-like 15 (Drosophila) 80311 -2.790627 6.38E-06 
YOD1 
YOD1 OTU deubiquinating enzyme 
1 homolog (S. cerevisiae) 
55432 -2.7890217 1.08E-04 
TLR4 toll-like receptor 4 7099 -2.7850344 2.79E-05 
OAS2 
2'-5'-oligoadenylate synthetase 2, 
69/71kDa 
4939 -2.7796533 1.11E-05 
RGS10 regulator of G-protein signaling 10 6001 -2.7776017 6.91E-06 
HINT3 
histidine triad nucleotide binding 
protein 3 
135114 -2.7721908 5.50E-04 
PAFAH2 
platelet-activating factor 
acetylhydrolase 2, 40kDa 
5051 -2.7673154 1.95E-04 
FMNL3 formin-like 3 91010 -2.7622924 1.43E-04 
LYPLA1 lysophospholipase I 10434 -2.760002 3.41E-04 
TLK1 tousled-like kinase 1 9874 -2.757787 1.95E-04 
TGFBR2 
transforming growth factor, beta 
receptor II (70/80kDa) 
7048 -2.75094 7.81E-06 
RHEBL1 Ras homolog enriched in brain like 1 121268 -2.7341359 1.76E-04 
ANXA10 annexin A10 11199 -2.717977 0.003001 
CLDN1 claudin 1 9076 -2.7056077 0.001738 
IL7R interleukin 7 receptor 3575 -2.7049818 8.29E-05 
MGC11082 Hypothetical protein MGC11082 84777 -2.7045128 0.003774 
LOC16207
3 
hypothetical protein LOC162073 162073 -2.6940184 9.27E-04 
RARRES3 
retinoic acid receptor responder 
(tazarotene induced) 3 
5920 -2.6921675 4.51E-04 
ARID3A 
AT rich interactive domain 3A 
(BRIGHT-like) 
1820 -2.682646 6.66E-04 
EPS15L1 
epidermal growth factor receptor 
pathway substrate 15-like 1 
58513 -2.6790237 2.17E-05 
ETS1 
v-ets erythroblastosis virus E26 
oncogene homolog 1 (avian) 
2113 -2.6783986 2.77E-04 
LOC28597
2 
hypothetical protein LOC285972 285972 -2.6672175 0.01197 
HYAL4 hyaluronoglucosaminidase 4 23553 -2.663533 5.49E-06 
DC2 DC2 protein 58505 -2.6633935 3.02E-05 
PPIC 
peptidylprolyl isomerase C 
(cyclophilin C) 
5480 -2.6544943 1.28E-05 
LYPLA1 lysophospholipase I 10434 -2.6360483 3.25E-05 
CLDN1 claudin 1 9076 -2.6279907 2.09E-04 
PDGFA 
platelet-derived growth factor alpha 
polypeptide 
5154 -2.624393 4.90E-05 
MXD1 MAX dimerization protein 1 4084 -2.6224456 2.64E-04 
ZFP106 
zinc finger protein 106 homolog 
(mouse) 
64397 -2.6076212 9.57E-06 
SCML1 
sex comb on midleg-like 1 
(Drosophila) 
6322 -2.6030312 1.89E-05 
ALG10B 
asparagine-linked glycosylation 10 
homolog B (yeast, 
alpha-1,2-glucosyltransferase) 
144245 -2.5992873 3.67E-04 
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IL6R interleukin 6 receptor 3570 -2.5913188 0.007024 
CSF2RA /// 
LOC10013
3516 
colony stimulating factor 2 receptor, 
alpha, low-affinity 
(granulocyte-macrophage) /// 
hypothetical protein LOC100133516 
100133516 
/// 1438 
-2.5886984 0.001496 
YOD1 
YOD1 OTU deubiquinating enzyme 
1 homolog (S. cerevisiae) 
55432 -2.5884612 0.010619 
MPZL3 myelin protein zero-like 3 196264 -2.5860264 5.08E-05 
MPZL2 myelin protein zero-like 2 10205 -2.5784004 0.001114 
TNFSF18 
tumor necrosis factor (ligand) 
superfamily, member 18 
8995 -2.5692601 0.005878 
GNB4 
guanine nucleotide binding protein 
(G protein), beta polypeptide 4 
59345 -2.5632007 3.10E-06 
IGSF10 
immunoglobulin superfamily, 
member 10 
285313 -2.5609574 6.82E-05 
H2AFV H2A histone family, member V 94239 -2.5588322 8.50E-05 
CDK6 cyclin-dependent kinase 6 1021 -2.5575116 0.005001 
LARP2 
La ribonucleoprotein domain family, 
member 2 
55132 -2.5568218 5.39E-04 
CYP3A5 
cytochrome P450, family 3, 
subfamily A, polypeptide 5 
1577 -2.5410478 0.003978 
NHLRC3 NHL repeat containing 3 387921 -2.540394 2.39E-04 
LMO2 
LIM domain only 2 (rhombotin-like 
1) 
4005 -2.538344 2.56E-04 
CDK6 cyclin-dependent kinase 6 1021 -2.5349507 1.48E-04 
ZC3HAV1 zinc finger CCCH-type, antiviral 1 56829 -2.5258071 1.05E-04 
TPRG1L tumor protein p63 regulated 1-like 127262 -2.5256128 1.12E-07 
CXorf56 
chromosome X open reading frame 
56 
63932 -2.5221033 5.93E-04 
CTHRC1 
collagen triple helix repeat 
containing 1 
115908 -2.521972 2.12E-04 
HACL1 2-hydroxyacyl-CoA lyase 1 26061 -2.5199203 7.87E-08 
PPIC 
peptidylprolyl isomerase C 
(cyclophilin C) 
5480 -2.5145342 8.56E-05 
ZFYVE26 
zinc finger, FYVE domain 
containing 26 
23503 -2.5143096 1.43E-05 
PTPN2 
protein tyrosine phosphatase, 
non-receptor type 2 
5771 -2.5133548 6.30E-07 
ZFYVE26 
zinc finger, FYVE domain 
containing 26 
23503 -2.5133517 3.43E-06 
CYP3A4 
cytochrome P450, family 3, 
subfamily A, polypeptide 4 
1576 -2.4956148 0.002249 
KIAA1324 KIAA1324 57535 -2.4942594 0.001103 
NLRP3 
NLR family, pyrin domain 
containing 3 
114548 -2.492214 0.001485 
LRP6 
low density lipoprotein 
receptor-related protein 6 
4040 -2.491776 1.47E-04 
ARHGAP9 Rho GTPase activating protein 9 64333 -2.4907546 7.39E-05 
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IL7R interleukin 7 receptor 3575 -2.4863422 3.79E-04 
ADAM19 
ADAM metallopeptidase domain 19 
(meltrin beta) 
8728 -2.4812682 6.69E-07 
H3F3A /// 
H3F3B /// 
LOC44092
6 
H3 histone, family 3A /// H3 histone, 
family 3B (H3.3B) /// H3 histone, 
family 3A pseudogene 
3020 /// 
3021 /// 
440926 
-2.4802673 3.83E-04 
PGM2L1 phosphoglucomutase 2-like 1 283209 -2.4779882 2.43E-04 
IL1R1 interleukin 1 receptor, type I 3554 -2.4749398 2.60E-05 
LOC16207
3 
hypothetical protein LOC162073 162073 -2.471419 0.00116 
CASP1 /// 
COP1 
caspase 1, apoptosis-related cysteine 
peptidase (interleukin 1, beta, 
convertase) /// caspase-1 
dominant-negative inhibitor 
pseudo-ICE 
114769 /// 
834 
-2.4695086 3.25E-05 
ZFAND2A zinc finger, AN1-type domain 2A 90637 -2.464204 2.76E-05 
KLF4 Kruppel-like factor 4 (gut) 9314 -2.4596603 1.59E-05 
GK5 glycerol kinase 5 (putative) 256356 -2.4590554 8.36E-04 
KYNU 
kynureninase (L-kynurenine 
hydrolase) 
8942 -2.441267 2.97E-04 
PPP1R3B 
protein phosphatase 1, regulatory 
(inhibitor) subunit 3B 
79660 -2.4412556 6.02E-06 
IL6 interleukin 6 (interferon, beta 2) 3569 -2.438826 0.003732 
KCNJ15 
potassium inwardly-rectifying 
channel, subfamily J, member 15 
3772 -2.4352503 5.78E-04 
PGM2L1 phosphoglucomutase 2-like 1 283209 -2.4295435 2.15E-05 
RUNX1 
runt-related transcription factor 1 
(acute myeloid leukemia 1; aml1 
oncogene) 
861 -2.4263077 9.38E-04 
MAP3K8 
mitogen-activated protein kinase 
kinase kinase 8 
1326 -2.4249542 0.001067 
YAP1 Yes-associated protein 1, 65kDa 10413 -2.4242854 6.37E-05 
HHLA3 HERV-H LTR-associating 3 11147 -2.4167774 8.58E-05 
TET3 tet oncogene family member 3 200424 -2.4141486 0.002254 
ABI3BP 
ABI gene family, member 3 (NESH) 
binding protein 
25890 -2.4114766 5.14E-05 
CPEB3 
cytoplasmic polyadenylation 
element binding protein 3 
22849 -2.4113634 0.00377 
CXADRP1 
coxsackie virus and adenovirus 
receptor pseudogene 1 
653108 -2.4097528 8.50E-04 
AMPD3 
adenosine monophosphate 
deaminase (isoform E) 
272 -2.3997955 9.69E-06 
FAM46C 
family with sequence similarity 46, 
member C 
54855 -2.3982105 0.002071 
LY96 lymphocyte antigen 96 23643 -2.397603 6.08E-05 
LOC28616
7 
hypothetical LOC286167 286167 -2.3957167 2.38E-05 
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SSX1 synovial sarcoma, X breakpoint 1 6756 -2.3846636 6.67E-05 
DCP1A 
DCP1 decapping enzyme homolog 
A (S. cerevisiae) 
55802 -2.3837328 1.16E-05 
LOC28326
7 
hypothetical LOC283267 283267 -2.3821054 1.71E-04 
H3F3A /// 
H3F3B /// 
LOC44092
6 
H3 histone, family 3A /// H3 histone, 
family 3B (H3.3B) /// H3 histone, 
family 3A pseudogene 
3020 /// 
3021 /// 
440926 
-2.3814585 3.92E-04 
CSF2RA /// 
LOC10013
3516 
colony stimulating factor 2 receptor, 
alpha, low-affinity 
(granulocyte-macrophage) /// 
hypothetical protein LOC100133516 
100133516 
/// 1438 
-2.3797965 4.69E-04 
ARNT 
aryl hydrocarbon receptor nuclear 
translocator 
405 -2.3752534 2.37E-04 
TRIML2 tripartite motif family-like 2 205860 -2.367616 2.55E-04 
LOC16207
3 
hypothetical protein LOC162073 162073 -2.3664224 2.67E-05 
MREG melanoregulin 55686 -2.3663194 4.61E-05 
IGF2BP3 
/// 
LOC64546
8 
insulin-like growth factor 2 mRNA 
binding protein 3 /// similar to 
putative RNA binding protein KOC 
10643 /// 
645468 
-2.365643 0.002027 
ARHGAP2
7 /// 
LOC20117
5 
hypothetical protein LOC201175 /// 
Rho GTPase activating protein 27 
201175 /// 
201176 
-2.3631263 3.10E-04 
HINT3 
histidine triad nucleotide binding 
protein 3 
135114 -2.3599286 7.17E-04 
GNB1 
guanine nucleotide binding protein 
(G protein), beta polypeptide 1 
2782 -2.3526793 1.75E-05 
GTDC1 
glycosyltransferase-like domain 
containing 1 
79712 -2.3506036 6.11E-07 
USP18 ubiquitin specific peptidase 18 11274 -2.3476036 1.47E-04 
OSMR oncostatin M receptor 9180 -2.3442333 0.0012 
H3F3A /// 
H3F3B /// 
LOC44092
6 
H3 histone, family 3A /// H3 histone, 
family 3B (H3.3B) /// H3 histone, 
family 3A pseudogene 
3020 /// 
3021 /// 
440926 
-2.3421183 4.12E-04 
JHDM1D 
jumonji C domain containing histone 
demethylase 1 homolog D (S. 
cerevisiae) 
80853 -2.3420317 6.44E-04 
CASP1 
caspase 1, apoptosis-related cysteine 
peptidase (interleukin 1, beta, 
convertase) 
834 -2.3397775 1.54E-04 
VEPH1 
ventricular zone expressed PH 
domain homolog 1 (zebrafish) 
79674 -2.337985 3.59E-04 
COL1A1 collagen, type I, alpha 1 1277 -2.3377388 9.86E-04 
DDX58 
DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 58 
23586 -2.3313994 6.55E-05 
PDZD2 PDZ domain containing 2 23037 -2.3280187 5.51E-05 
STCH 
stress 70 protein chaperone, 
microsome-associated, 60kDa 
6782 -2.3277621 0.001263 
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LOC16207
3 
hypothetical protein LOC162073 162073 -2.3259997 7.77E-04 
CX3CL1 chemokine (C-X3-C motif) ligand 1 6376 -2.3240929 0.002413 
C11orf17 
/// NUAK2 
chromosome 11 open reading frame 
17 /// NUAK family, SNF1-like 
kinase, 2 
56672 /// 
81788 
-2.3224726 2.40E-04 
RTP4 
receptor (chemosensory) transporter 
protein 4 
64108 -2.3205504 0.002176 
STAU2 
staufen, RNA binding protein, 
homolog 2 (Drosophila) 
27067 -2.315223 4.42E-06 
ZDHHC11 
zinc finger, DHHC-type containing 
11 
79844 -2.3129177 1.83E-05 
SCML1 
sex comb on midleg-like 1 
(Drosophila) 
6322 -2.3093011 6.05E-05 
CHM choroideremia (Rab escort protein 1) 1121 -2.3052354 0.002563 
LZTFL1 
leucine zipper transcription 
factor-like 1 
54585 -2.2995265 9.02E-06 
COP1 
caspase-1 dominant-negative 
inhibitor pseudo-ICE 
114769 -2.2984278 0.002715 
STX11 syntaxin 11 8676 -2.2939022 0.003327 
LCN2 lipocalin 2 3934 -2.2930005 0.004766 
ITGB2 
integrin, beta 2 (complement 
component 3 receptor 3 and 4 
subunit) 
3689 -2.2864842 7.11E-05 
CCL3 /// 
CCL3L1 /// 
CCL3L3 /// 
LOC72883
0 
chemokine (C-C motif) ligand 3 /// 
chemokine (C-C motif) ligand 3-like 
1 /// chemokine (C-C motif) ligand 
3-like 3 /// similar to C-C motif 
chemokine 3-like 1 precursor 
(Small-inducible cytokine A3-like 1) 
(Tonsillar lymphocyte LD78 beta 
protein) (LD78-beta(1-70)) (G0/G1 
switch regulatory protein 19-2) 
(G0S19-2 protein) (PAT 464.2) 
414062 /// 
6348 /// 
6349 /// 
728830 
-2.28634 4.21E-04 
HINT3 
histidine triad nucleotide binding 
protein 3 
135114 -2.2853966 3.10E-04 
SCML2 
sex comb on midleg-like 2 
(Drosophila) 
10389 -2.2852077 2.08E-04 
RUNX1 
runt-related transcription factor 1 
(acute myeloid leukemia 1; aml1 
oncogene) 
10413 -2.2850466 2.30E-04 
YAP1 Yes-associated protein 1, 65kDa 861 -2.2850466 4.39E-04 
STS 
steroid sulfatase (microsomal), 
isozyme S 
412 -2.2846243 3.08E-04 
SGK1 
serum/glucocorticoid regulated 
kinase 1 
6446 -2.2820203 0.008355 
KLHL28 kelch-like 28 (Drosophila) 54813 -2.2797384 0.001157 
RCSD1 RCSD domain containing 1 92241 -2.2773795 1.68E-04 
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DVL3 
dishevelled, dsh homolog 3 
(Drosophila) 
1857 -2.2767258 6.20E-04 
LETM2 
leucine zipper-EF-hand containing 
transmembrane protein 2 
137994 -2.276674 3.59E-05 
VEPH1 
ventricular zone expressed PH 
domain homolog 1 (zebrafish) 
79674 -2.2759085 3.38E-05 
CYP1B1 
cytochrome P450, family 1, 
subfamily B, polypeptide 1 
1545 -2.2724996 0.002895 
CSNK1A1 casein kinase 1, alpha 1 1452 -2.272256 9.98E-04 
KIAA0494 KIAA0494 9813 -2.2707818 6.08E-05 
MOCS2 molybdenum cofactor synthesis 2 4338 -2.2630377 1.43E-04 
SCN3A 
sodium channel, voltage-gated, type 
III, alpha subunit 
6328 -2.2614772 0.002083 
USP44 ubiquitin specific peptidase 44 84101 -2.2603757 4.17E-04 
ELL2 
elongation factor, RNA polymerase 
II, 2 
22936 -2.2586129 1.55E-04 
ALG10B 
asparagine-linked glycosylation 10 
homolog B (yeast, 
alpha-1,2-glucosyltransferase) 
144245 -2.2556176 0.00121 
RSAD2 
radical S-adenosyl methionine 
domain containing 2 
91543 -2.254609 8.92E-04 
GPR175 G protein-coupled receptor 175 131601 -2.2525055 6.70E-04 
EHD1 EH-domain containing 1 10938 -2.2477627 1.27E-05 
LOC28412
0 
hypothetical LOC284120 284120 -2.2431343 0.001512 
PLXNC1 plexin C1 10154 -2.2412212 2.37E-04 
NUPL1 nucleoporin like 1 9818 -2.240917 2.34E-07 
SOD2 
superoxide dismutase 2, 
mitochondrial 
6648 -2.2337618 0.001846 
CRLF2 cytokine receptor-like factor 2 64109 -2.2328224 6.92E-04 
INVS inversin 27130 -2.2327993 5.59E-06 
DDX58 
DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 58 
23586 -2.229235 2.08E-04 
TNFRSF11
B 
tumor necrosis factor receptor 
superfamily, member 11b 
(osteoprotegerin) 
4982 -2.2272263 1.01E-04 
C7orf44 
chromosome 7 open reading frame 
44 
55744 -2.225877 6.67E-04 
FLJ13611 hypothetical protein FLJ13611 80006 -2.2240584 6.95E-04 
USO1 
USO1 homolog, vesicle docking 
protein (yeast) 
8615 -2.2238736 1.19E-05 
EHD1 EH-domain containing 1 10938 -2.2193253 6.65E-05 
EDN1 endothelin 1 1906 -2.2188468 0.00815 
KLHL24 kelch-like 24 (Drosophila) 54800 -2.2156265 8.33E-04 
ENSA endosulfine alpha 2029 -2.2141438 7.83E-07 
EHD1 EH-domain containing 1 10938 -2.211867 1.17E-05 
RASA2 RAS p21 protein activator 2 5922 -2.2118397 4.07E-04 
EHD1 EH-domain containing 1 10938 -2.2110531 2.48E-04 
LOC10012 hypothetical protein LOC100129361 100129361 -2.2102213 3.94E-06 
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9361 
DKK3 
dickkopf homolog 3 (Xenopus 
laevis) 
27122 -2.2089493 0.00245 
NCF2 
neutrophil cytosolic factor 2 (65kDa, 
chronic granulomatous disease, 
autosomal 2) 
4688 -2.208771 7.68E-06 
SERPINB7 
serpin peptidase inhibitor, clade B 
(ovalbumin), member 7 
8710 -2.2078884 0.005868 
ARPC1A 
actin related protein 2/3 complex, 
subunit 1A, 41kDa 
10552 -2.2036903 8.31E-05 
TMED9 
transmembrane emp24 protein 
transport domain containing 9 
54732 -2.202698 2.77E-05 
KLF4 Kruppel-like factor 4 (gut) 9314 -2.2021074 1.74E-04 
DNAJB9 
DnaJ (Hsp40) homolog, subfamily 
B, member 9 
4189 -2.1971755 1.23E-05 
ABHD5 abhydrolase domain containing 5 51099 -2.1957016 5.68E-04 
GDF15 growth differentiation factor 15 9518 -2.1907172 1.30E-04 
TGFBR3 
transforming growth factor, beta 
receptor III 
7049 -2.1872585 2.34E-05 
PHLDB2 
pleckstrin homology-like domain, 
family B, member 2 
90102 -2.1819503 1.52E-04 
TMEM167 transmembrane protein 167 153339 -2.1813128 1.00E-05 
LIPH lipase, member H 200879 -2.1790488 1.06E-05 
TMEM156 transmembrane protein 156 80008 -2.1781814 2.25E-05 
BTN3A3 
butyrophilin, subfamily 3, member 
A3 
10384 -2.1781464 1.05E-04 
RGS10 regulator of G-protein signaling 10 6001 -2.1738906 2.17E-04 
CDKN1A 
cyclin-dependent kinase inhibitor 1A 
(p21, Cip1) 
1026 -2.1662939 1.29E-04 
POU2F2 POU class 2 homeobox 2 5452 -2.1659815 7.78E-04 
CYP3A5 
cytochrome P450, family 3, 
subfamily A, polypeptide 5 
1577 -2.1658769 0.003176 
SLC39A11 
solute carrier family 39 (metal ion 
transporter), member 11 
201266 -2.1641629 9.33E-05 
APOL6 apolipoprotein L, 6 80830 -2.1574228 7.86E-04 
PBLD 
phenazine biosynthesis-like protein 
domain containing 
64081 -2.156551 0.002058 
IRG1 
immunoresponsive 1 homolog 
(mouse) 
730249 -2.1561482 5.59E-05 
PAFAH2 
platelet-activating factor 
acetylhydrolase 2, 40kDa 
5051 -2.1505497 3.03E-05 
PSPC1 paraspeckle component 1 55269 -2.1495707 6.16E-04 
CTH 
cystathionase (cystathionine 
gamma-lyase) 
1491 -2.1461554 3.82E-04 
CYP1B1 
cytochrome P450, family 1, 
subfamily B, polypeptide 1 
1545 -2.1454077 1.06E-04 
SDCCAG8 
serologically defined colon cancer 
antigen 8 
10806 -2.142167 2.19E-04 
RUNX1 runt-related transcription factor 1 861 -2.1401253 0.001487 
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(acute myeloid leukemia 1; aml1 
oncogene) 
ARHGAP9 Rho GTPase activating protein 9 64333 -2.139467 0.005413 
COX4NB COX4 neighbor 10328 -2.1374226 6.05E-05 
MTMR9 myotubularin related protein 9 66036 -2.135492 2.67E-05 
FAIM3 Fas apoptotic inhibitory molecule 3 9214 -2.1343071 0.002212 
CCNYL1 Cyclin Y-like 1 151195 -2.133411 5.94E-05 
VNN3 vanin 3 55350 -2.1325643 0.002245 
SDCCAG8 
serologically defined colon cancer 
antigen 8 
10806 -2.1321428 1.95E-04 
SENP2 
SUMO1/sentrin/SMT3 specific 
peptidase 2 
59343 -2.125061 3.52E-06 
LOC10013
1053 
hypothetical LOC100131053 100131053 -2.1221378 0.008399 
CYP1B1 
cytochrome P450, family 1, 
subfamily B, polypeptide 1 
1545 -2.1203976 2.94E-04 
SERPINB3 
serpin peptidase inhibitor, clade B 
(ovalbumin), member 3 
6317 -2.1194618 8.24E-04 
STAM2 
Signal transducing adaptor molecule 
(SH3 domain and ITAM motif) 2 
10254 -2.11845 3.24E-04 
CTH 
cystathionase (cystathionine 
gamma-lyase) 
1491 -2.1175776 2.42E-04 
YY1 YY1 transcription factor 7528 -2.1063082 3.93E-05 
TLK1 tousled-like kinase 1 9874 -2.1061866 3.32E-05 
ABHD13 abhydrolase domain containing 13 84945 -2.1029577 8.80E-05 
PDCD10 programmed cell death 10 11235 -2.1022642 1.45E-05 
TMEM173 transmembrane protein 173 340061 -2.1018846 4.79E-05 
SLC37A1 
solute carrier family 37 
(glycerol-3-phosphate transporter), 
member 1 
54020 -2.1015816 1.44E-04 
NUFIP2 
nuclear fragile X mental retardation 
protein interacting protein 2 
57532 -2.1002572 4.08E-06 
F2RL1 
coagulation factor II (thrombin) 
receptor-like 1 
2150 -2.0969813 5.02E-04 
RASA2 RAS p21 protein activator 2 5922 -2.0953255 5.02E-05 
GNG11 
guanine nucleotide binding protein 
(G protein), gamma 11 
2791 -2.0944912 2.56E-05 
APOL6 apolipoprotein L, 6 80830 -2.0933409 1.19E-04 
CACNA2D
3 
calcium channel, voltage-dependent, 
alpha 2/delta subunit 3 
55799 -2.0903828 0.007788 
ZNFX1 zinc finger, NFX1-type containing 1 57169 -2.0902781 9.33E-05 
CASP7 
caspase 7, apoptosis-related cysteine 
peptidase 
840 -2.089764 5.90E-05 
SLPI 
secretory leukocyte peptidase 
inhibitor 
6590 -2.0896027 2.28E-04 
RNF4 ring finger protein 4 6047 -2.088129 3.84E-06 
IGF2BP3 
insulin-like growth factor 2 mRNA 
binding protein 3 
10643 -2.088121 1.27E-05 
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GBP5 guanylate binding protein 5 115362 -2.083597 0.001419 
COX4NB COX4 neighbor 10328 -2.08315 4.03E-05 
MAN2A1 
mannosidase, alpha, class 2A, 
member 1 
4124 -2.082885 6.37E-04 
HIVEP1 
human immunodeficiency virus type 
I enhancer binding protein 1 
3096 -2.082598 8.07E-04 
LOC38879
5 
similar to hCG2019498 388795 -2.0817206 3.18E-05 
REEP3 receptor accessory protein 3 221035 -2.0788155 3.35E-04 
EHD1 EH-domain containing 1 10938 -2.0773237 8.40E-05 
DNAJB9 
DnaJ (Hsp40) homolog, subfamily 
B, member 9 
4189 -2.075648 1.24E-05 
ATF3 activating transcription factor 3 467 -2.07391 1.85E-04 
CASP1 
caspase 1, apoptosis-related cysteine 
peptidase (interleukin 1, beta, 
convertase) 
834 -2.073451 1.11E-05 
TLR4 toll-like receptor 4 7099 -2.0690534 0.001032 
IGF2BP3 
insulin-like growth factor 2 mRNA 
binding protein 3 
10643 -2.0688944 2.35E-04 
WT1 Wilms tumor 1 7490 -2.0674443 0.008201 
CEACAM1 
carcinoembryonic antigen-related 
cell adhesion molecule 1 (biliary 
glycoprotein) 
634 -2.0640588 0.0015 
H3F3A /// 
H3F3B /// 
LOC44092
6 
H3 histone, family 3A /// H3 histone, 
family 3B (H3.3B) /// H3 histone, 
family 3A pseudogene 
3020 /// 
3021 /// 
440926 
-2.0616813 7.20E-05 
DOK3 docking protein 3 79930 -2.0614538 9.03E-04 
KLF9 Kruppel-like factor 9 687 -2.0585566 0.005693 
ZNF470 zinc finger protein 470 388566 -2.0581913 3.04E-04 
JHDM1D 
jumonji C domain containing histone 
demethylase 1 homolog D (S. 
cerevisiae) 
80853 -2.0580275 1.94E-04 
HSD11B1 
hydroxysteroid (11-beta) 
dehydrogenase 1 
3290 -2.0575109 0.002342 
NR4A2 
nuclear receptor subfamily 4, group 
A, member 2 
4929 -2.057349 0.002199 
FUT4 
fucosyltransferase 4 (alpha (1,3) 
fucosyltransferase, 
myeloid-specific) 
2526 -2.0544589 0.001414 
WDR69 WD repeat domain 69 164781 -2.0533092 7.43E-04 
SSX1 synovial sarcoma, X breakpoint 1 6756 -2.0515225 2.20E-05 
YY1 YY1 transcription factor 7528 -2.0504072 1.10E-04 
ENTPD7 
ectonucleoside triphosphate 
diphosphohydrolase 7 
57089 -2.0479481 0.003347 
BTN3A1 
butyrophilin, subfamily 3, member 
A1 
11119 -2.046104 0.003485 
TMEM2 transmembrane protein 2 23670 -2.0460851 1.35E-04 
MAP4K4 
mitogen-activated protein kinase 
kinase kinase kinase 4 
9448 -2.0438669 5.43E-06 
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TPP1 tripeptidyl peptidase I 1200 -2.0438511 5.32E-04 
PMAIP1 
phorbol-12-myristate-13-acetate-ind
uced protein 1 
5366 -2.0435097 0.001 
DCP1A 
DCP1 decapping enzyme homolog 
A (S. cerevisiae) 
55802 -2.0413349 4.78E-05 
CSF2RA 
colony stimulating factor 2 receptor, 
alpha, low-affinity 
(granulocyte-macrophage) 
1438 -2.0413039 6.75E-04 
RGS17 regulator of G-protein signaling 17 26575 -2.0408497 2.22E-04 
TMEM87A transmembrane protein 87A 25963 -2.0407155 8.07E-05 
TLR4 toll-like receptor 4 7099 -2.0384452 8.68E-05 
CYP1A1 
cytochrome P450, family 1, 
subfamily A, polypeptide 1 
1543 -2.036389 0.001173 
PXMP2 
peroxisomal membrane protein 2, 
22kDa 
5827 -2.0361001 1.27E-04 
FBXW7 
F-box and WD repeat domain 
containing 7 
55294 -2.0354886 1.86E-04 
FAM133A 
family with sequence similarity 133, 
member A 
286499 -2.0350342 2.21E-04 
THBD thrombomodulin 7056 -2.034315 4.35E-04 
DNAJB9 
DnaJ (Hsp40) homolog, subfamily 
B, member 9 
4189 -2.0334618 5.69E-05 
SERPINE1 
serpin peptidase inhibitor, clade E 
(nexin, plasminogen activator 
inhibitor type 1), member 1 
5054 -2.032918 0.003183 
RPS6KC1 
ribosomal protein S6 kinase, 52kDa, 
polypeptide 1 
26750 -2.0321417 3.40E-05 
TIPARP 
TCDD-inducible poly(ADP-ribose) 
polymerase 
25976 -2.030278 6.63E-07 
USO1 
USO1 homolog, vesicle docking 
protein (yeast) 
8615 -2.0302618 2.44E-04 
LOC15116
2 
hypothetical LOC151162 151162 -2.0302024 7.02E-06 
TMC8 transmembrane channel-like 8 147138 -2.0300815 3.44E-05 
LY6K 
lymphocyte antigen 6 complex, 
locus K 
54742 -2.0299702 1.04E-04 
KIAA0241 KIAA0241 23080 -2.0285606 2.56E-04 
C3orf59 
chromosome 3 open reading frame 
59 
151963 -2.0272117 2.55E-04 
PTX3 
pentraxin-related gene, rapidly 
induced by IL-1 beta 
5806 -2.0253627 4.35E-04 
LOC72943
6 
Hypothetical LOC729436 729436 -2.0237806 0.001308 
SLC10A7 
solute carrier family 10 (sodium/bile 
acid cotransporter family), member 
7 
84068 -2.02188 1.39E-04 
BRWD1 
bromodomain and WD repeat 
domain containing 1 
54014 -2.0216734 0.002296 
CHD7 
chromodomain helicase DNA 
binding protein 7 
55636 -2.0214705 6.75E-06 
RNF38 ring finger protein 38 152006 -2.0212114 8.26E-05 
ATP6V1B2 
ATPase, H+ transporting, lysosomal 
56/58kDa, V1 subunit B2 
526 -2.020993 2.32E-05 
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RGS10 Regulator of G-protein signaling 10 6001 -2.020435 0.002131 
AP2B1 
adaptor-related protein complex 2, 
beta 1 subunit 
163 -2.0199401 4.91E-06 
PMAIP1 
phorbol-12-myristate-13-acetate-ind
uced protein 1 
5366 -2.0188925 2.53E-05 
PHF7 PHD finger protein 7 51533 -2.018249 0.00142 
CFP complement factor properdin 5199 -2.0176094 1.27E-05 
SMARCA1 
SWI/SNF related, matrix associated, 
actin dependent regulator of 
chromatin, subfamily a, member 1 
6594 -2.0166655 4.02E-04 
SYTL3 synaptotagmin-like 3 94120 -2.0145478 6.10E-05 
CSF2RA 
colony stimulating factor 2 receptor, 
alpha, low-affinity 
(granulocyte-macrophage) 
1438 -2.0127256 0.001124 
TNFRSF10
A 
tumor necrosis factor receptor 
superfamily, member 10a 
8797 -2.0080738 3.23E-05 
LAPTM5 
lysosomal associated multispanning 
membrane protein 5 
7805 -2.0075712 6.25E-05 
CARD6 
caspase recruitment domain family, 
member 6 
84674 -2.006788 2.32E-04 
MLKL mixed lineage kinase domain-like 197259 -2.00602 3.09E-05 
tcag7.1228 hypothetical protein FLJ25778 254048 -2.0049212 1.00E-04 
LOC73043
2 /// STYX 
serine/threonine/tyrosine interacting 
protein /// similar to 
serine/threonine/tyrosine interacting 
protein 
6815 /// 
730432 
-2.002312 2.76E-05 
SSR3 
signal sequence receptor, gamma 
(translocon-associated protein 
gamma) 
6747 -2.001271 8.88E-05 
FKBP14 FK506 binding protein 14, 22 kDa 55033 -2.0012398 5.33E-04 
SYNPO synaptopodin 11346 -2.0010746 4.63E-04 
AFF3 AF4/FMR2 family, member 3 3899 -2.0004911 4.45E-05 
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8 Abbreviations 
 
µg Microgram 
µl Microlitre 
µM Micromolar 
µm Micrometer 
6-OST 6-O-Sulfotransferase 
A Absorbance 
ACTG2 Actin gamma 2 smooth muscle enteric 
ADAM17 A disintegrin-like and metalloproteinase 
AML1/RUNX1 Acute myeloid leukemia 1/ runt-related transcription factor 1 
AMP Adenosine monophosphate 
ANX Annexin 
APS Ammonium persulfate 
ATF-2 Activating transcription factor-2 
ATP Adenosine tri phosphate 
BCA Bicinchonic acid 
BCL2 B-cell lymphoma/leukemia-2 
BMPs Bone morphogenetic proteins 
bp Base pairs 
BRCA1 Breast cancer 1, early onset 
BSA Bovine Serum Albumin 
Cad-11 Cadherin-11 
CASK Calcium/calmodulin-associated serine kinase 
CCL5 Chemokine (C-C motif) ligand 5 
CDC42 Cell division cycle 42 
CDK Cyclin-dependent kinase 
cDNA Complementary DNA 
cm Centimeter 
CMV Cytomegalovirus 
COL1A2 Collagen type I A2 
COX-2 Cyclooxygenase-2 
cRNA Complementary RNA 
CS Chondroitin sulphate 
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DAPI 4', 6'-diamidino-2-phenylindole  
DCIS Ductal breast carcinoma in situ 
DMEM Dulbecco’s modified Eagle’s medium 
DMSO Dimethylsulfoxide 
DNA Deoxyribonucleic acid 
dNTP Deoxyribonucleotide triphosphate 
DPBS Dulbecco’s phosphate buffered saline 
DS Dermatan sulphate 
dsDNA Double-stranded DNA 
dsRNA Double-stranded RNA  
DTT 1,4-Dithiothreit 
E.coli
 
Escherichia coli 
E-cad E-cadherin  
ECM Extracellular matrix 
EDTA Ethylendiamintetracetic acid  
EGFR Epidermal growth factor 
EHS Engelberth-Holm-Swarm  
ELISA Enzyme-linked immunosorbent assay 
EMP2 Epithelial membrane protein 2 
EMT Epithelial mesenchymal transition 
ER Estrogen receptor  
Erk1/2 Extracellular signal-regulated kinase 1/2 
ERM Ezrin, Radixin, Moesin  
EXT Exostose  
FAK Focal adhesion kinase 
FCS Fetal calf serum  
FGF Fibroblast growth factor  
Fig Figure 
g Gram 
GAGs Glycosaminoglycans 
GAIP Gα-interacting protein  
 Gal Galactose  
GALT Galactosyltransferase  
GAP GTPase-activating factor protein  
Abbreviations 
 253 
GDI Guanine dissociation inhibitor 
GEF Guanine exchange factor  
GLCAT Glucuronyltransferase 
GlcNAc N-acetylglucosamine  
GPCs Glycosylphosphatidylinositol -anchored glypicans  
GPI Glycosylphosphatidylinositol 
h Hour(s) 
HA Hyaluronic acid 
HER2/ERBB2 human epidermal growth factor receptor  
HGF Hepatocyte growth factor 
HOXD10 Homeobox D10  
HPSE Heparanase  
HRP Horseradish peroxidase  
HS Heparan sulfate 
HSPG Heparan sulfate proteoglycan 
IVT In vitro transcription  
JAM-A Junctional adhesion molecule A  
JHDM1D Jumonji C domain-containing histone demethylase 1 homolog D 
JMD Juxtamembrane domain  
JNK c-Jun NH2-terminal kinase 
kDa Kilodalton 
KLF4 Krueppel-like factor 4 
KS Keratan sulfate 
l Litre 
LB Luria-Bertina  
M Molar 
mA Milliampere 
MAGUK Membrane associated guanylate kinase 
MAPK Mitogen-activated protein kinase 
mg Milligram 
min Minute(s) 
miRNA MicroRNA  
ml Millilitre 
mM Millimolar 
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MMP Matrix metalloproteinase 
MPP4 Membrane palmitoylated protein-4  
mRNA Messenger RNA 
MT1-MMP Membrane type 1 matrix metalloproteinase  
MTT 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl-tetrazoliumbromide  
MYL-9 Myosin regulatory light chain-9  
n.s Non significant 
NADPH Nicotinamide adenine dinucleotide phosphate 
NDST N-deacetylase/N-sulfotransferase 
NF-kappaB Nuclear factor kappaB  
nm Nanometer 
OD  Optical density 
PAGE Polyacrylamide gel electrophoresis  
PAI Plasminogen activator inhibitor 
PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
PDK1 Phosphoinositide dependent kinase 1  
PDZ PSD-95, a postsynaptic protein; Discs-large, a Drosophila septate 
junction protein; and ZO-1, a tight junction protein 
PGE2 Prostaglandin E2  
PGs Proteoglycans 
PI3K Phosphatidylinositol-3-kinase 
PIP3 Phosphatidyl-inositol 3,4,5 triphosphate  
PKB Protein Kinase-B 
PKCα Protein kinase Cα  
PLA2 Phospholipase A2 
PMA Phorbol 12-Myristate 13-Acetate 
PR Progesterone receptor  
PTEN Phosphatase and tensin homolog 
qPCR Quantitative PCR 
Rho Ras homologue gene family member  
RIPA Radio-Immunoprecipitation Assay 
RISC RNA-induced silencing complex  
RNA Ribonucleic acid 
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RNAi RNA interference  
ROCK Rho-associated protein kinase  
rpm Rotations per minute 
RPMI Roswell Park Memorial Institute 
RQ Relative quantification 
rRNA Ribosomal RNA 
RT Room temperature 
RTK Receptor tyrosine kinase 
RT-PCR Reverse transcription PCR 
s Second(s) 
Sdc Syndecan 
SDS Sodium dodecyl sulphate  
SEM Standard error of the mean 
SERPIN Serpin peptidase inhibitor 
SI Structural index  
siRNA Small interfering RNA  
SLRPs Small leucine-rich proteoglycans 
ssDNA Single-stranded DNA 
Sulfs Sulfatases  
TAGLN Transgelin  
Taq Thermus aquaticus 
TBS Tris buffered saline 
TEMED N,N,N,N-tetra methylene diamine  
TGF-β Transforming growth factor-β  
TIMP Tissue inhibitor of metalloproteinases  
TLR Toll-like receptor  
TNF-α Tumor necrosis factor-alpha  
Tpl2 Tumor progression locus 2  
TRITC Tetramethylrhodamine isothiocyanante 
TSP-1 Thrombospondin-1 
uPA (PLAU) Urokinase-type plasminogen activator  
uPAR Urokinase-type plasminogen activator receptor 
UTR Untranslated region  
UV Ultraviolet 
Abbreviations 
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v/v Volume/Volume 
VEGF Vascular endothelial growth factor 
w/v Weight/Volume 
οC Degrees centigrade 
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